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Chapter 1 - General introduction
1NRTIs have been linked to kidney dysfunction and cardiovascular disease, respectively22,37-40. The approval of the first integrase inhibitor (INSTI) in 2007, raltegravir, extended cART 
regimen options for PLHIV experiencing drug toxicity41. However, cART toxicity remains a 
concern upon this day39,40,42-44.
Thus, to offset drug toxicity, cART initiation was initially reserved for people with substantial 
immunosuppression indicated by CD4+ counts below 350 cells/µL45,46. The hallmark SMART-
trail in 2006 randomized PLHIV to continuous treatment after cART initiation or cART 
interruption based on CD4+ count guided therapy as such lowering cART exposure. The cART 
interruption group showed increased mortality and morbidity from AIDS but also from non-
AIDS related events such as cardiovascular disease and cancer47. These events were especially 
linked to persistent inflammation and immune dysfunction and not fully explained by the 
degree of immunosuppression (CD4 count)48. This resulted in a paradigm switch with a 
focus on sustained viral suppression with immune recovery, resulting in a reduction of 
inflammation. 
Moreover, the lowest CD4 count (CD4 nadir), was found to be linked to mortality and 
morbidity even when viral loads were continuously suppressed, suggesting that severe 
immune suppression caused ongoing perturbations48-51. While initiation of cART improved 
life expectance in 199616, the introduction of less toxic regimes in 2008 further enhanced 
prognosis52. However, PLHIV that started cART between 1997 and 2012 still had a six times 
higher risk to die compared to the general population52.
cART for all, HIV a chronic disease
Higher mortality risks for PLHIV on cART led to the START-trial investigating whether the 
prognosis of PLHIV could be improved when cART was given regardless of CD4+ counts53. 
The START trial indeed showed a beneficial effect of immediate initiation of cART in PLHIV 
with CD4+ counts above 500cells/µL53. These results aligned benefits for individual patients 
with public health benefit, as viral suppression due to cART also reduced the risk of HIV 
transmission to almost zero54. The results of the START study published in 2015 led to the 
recommendation by the World Health Organization (WHO), European Aids Clinical Society 
(EACS) and International Antiviral Society (IAS)-USA panel to expand the use of cART to all 
PLHIV55-57.  Currently, the WHO estimates 38 million people are living with HIV of which 25.4 
million receive cART58. 
In 2009 Timothy Brown was reported to be cured from HIV after a stem cell transplantation 
with a donor carrying a homozygote mutation in the CCR5 co-receptor for HIV (CCR5Δ32 
genotype), which was hailed with great excitement59. A second patient reported to be cured 
from HIV followed ten years later60. Apart from the excitement that HIV cure was possible 
Human immunodeficiency virus 1 (HIV-1) was recognized as the causal agent of the acquired 
immune deficiency syndrome (AIDS) in 19831,2. HIV infects cells that express the cluster 
differentiation (CD)4 receptor, including T cells (CD4+ T-cells)3, monocytes/macrophages4, 
and dendritic cells5.  C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4) 
are important co-receptors that HIV uses to infect cells expressing CD46-8.  
An acute HIV infection can be seen 2-4 weeks after exposure and mostly presents as a ‘flu-
like’ syndrome although some individuals experience no significant symptoms. This acute 
HIV infection is followed by clinical latency or chronic HIV infection for 3-20 years9,10. Without 
treatment, the natural course of HIV infection causes progressive depletion of CD4+ T cells, 
leading to severe immune suppression and subsequent development of opportunistic 
infections and viral induced cancers: a condition that was named AIDS in eighties11. AIDS was 
associated with a very poor prognosis, as the initial life expectancy of AIDS was reported to 
be between 6-12 months11. 
Antiretroviral therapy
In 1987, the Federal Drug Authority (FDA) in the United states approved zidovudine (AZT), 
a nucleoside reverse transcriptase inhibitor (NRTI), as the first antiretroviral drug to treat 
HIV12. The initial use as monotherapy resulted in rapid development of resistance, hampering 
long-term successful treatment. The discovery of other classes of antiretroviral drugs such 
as protease inhibitors13,14 (PI) and nonnucleoside reverse-transcriptase inhibitors15 (NNRTI) 
in the mid-nineties paved the way for the introduction of (highly effective) combination 
antiretroviral therapy (cART), that mostly consisted of 2 NRTIs in combination with either a 
PI or a NNRTI14. cART prevented the development of resistance, strikingly improving efficacy 
of HIV treatment14,16,17. The introduction of cART dramatically improved the prognosis of HIV 
and the term AIDS is therefore generally considered inappropriate these days to define the 
health status of people living with HIV (PLHIV)16,18.
Although cART had reduced morbidity and mortality for PLHIV, drug toxicity was a major 
concern19. Lifelong cART was associated with short-term and long-term adverse events19,20. 
Class specific adverse effects were noticed. For example, PI-use was linked to lipid and 
metabolic disturbances with a possible increased risk for myocardial infarction21-23 and 
NRTIs were linked to (severe) mitochondrial toxicity24-28 resulting in a wide variety of clinical 
syndromes, including lactic acidosis, lipodystrophy, peripheral neuropathy, myopathy, 
cardiomyopathy, and pancreatitis28-32. Instead, particular adverse effects were related to 
the use specific drugs, such as allergy and nevirapine33, neurotoxicity and efavirenz34,35 and 
AZT was especially known for hematological toxicity such anemia or neutropenia12,36. These 
adverse effects were reduced when older NRTIs stavudine, AZT and didanosine were replaced 
by newer NRTIs tenofovir (TDF) and abacavir at the turn of the millennium25. Still these new 
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1example, resident T-helper (Th) 17 cells in the gut, which are important for gut immunity and integrity, are depleted during HIV infection83 and are not fully restored after cART initiation84. 
CD8+ T-cell activation and dysfunction is a prominent feature of uncontrolled HIV infection, but 
remains present despite cART treatment81,82. In addition, residual B-cell dysfunction contributes 
to impaired vaccination responses in PLHIV85. Furthermore, all compartments of the immune 
system maintain homeostasis through a complex network of direct and indirect interactions in 
normal conditions. However, even after prolonged viral suppression, this complex balance is not 
fully restored in PLHIV86.
Finally, blood platelets are the second most numerous blood cell and traditionally known for 
their role in haemostasis and cardiovascular diseases. Increasing evidence indicates that platelets 
are key players in inflammation and host defence87. Despite lacking a nucleus, platelets harbour 
fully functional mitochondria and a full translation machinery for protein synthesis88. Platelets 
contain many different proinflammatory molecules, such as cytokines (e.g. IL-1α, IL-1β, IL-18) and 
chemokines (e.g. Chemokine (C-C motif) ligand 5 (CCL5), CD40L)87. Upon activation, platelets 
can release those chemokines and cytokines, but can also release plasma membrane platelet-
derived microparticles (PMPs) into the circulation. PMPs are in the submicron range and are 
involved in haemostasis. Both PMPs and platelets itself can directly interact with leukocytes to 
modulate leukocyte function87. Multiple studies have shown that PLHIV have more activated and 
reactive platelets89-93, while others report hyporeactive platelets94,95. Interference of cART with 
platelet function could partly explain these heterogenous findings. While abacavir (a NRTI) has 
been linked to platelet perturbations in multiple studies96-98, others could not confirm abacavir-
associated platelet dysfunction92,99. Additionally, our group previously found in a cross-sectional 
study that individuals on a raltegravir-based regimen had reduced platelet reactivity compared to 
those on a non-integrase inhibitor-based regimen92. 
Factors influencing inflammation
During an uncontrolled HIV infection, the level of inflammation is mostly linked to the 
dynamic of the HIV infection itself and viral suppression with cART significantly reduces 
inflammation80. Yet, the underlying causes of persistent inflammation after successful cART 
are much more complex. Several factors have been suggested to contribute to persistent 
inflammation in these circumstances. First of all, ongoing exposure to microbial products 
has been implicated to underly persistent inflammation in PLHIV, including the HIV viral 
reservoir, cytomegalovirus (CMV) co-infection and increases in circulating microbial products 
resulting from compromised intestinal integrity65,100-105. The establishment of the HIV 
reservoir occurs within days of infection and comprises of latently infected memory CD4+ 
T cells and a variety of functional T helper cells with replication competent virus as well as 
defective proviruses106. The duration of HIV infection and cART treatment, as well as CD4 
nadir and patient-specific traits are known to influence HIV reservoir size61.
after allogenic stem cell transplantation with a very specific genetic phenotype, researchers, 
clinicians and patients also realised that such intervention was only feasible in a very 
selected group of PLHIV. Still, the possibility of cure boosted research on the HIV reservoir. 
These studies revealed that HIV persists in multiple cell types and tissue sites, and in both 
quiescent and proliferating, long-lived, latently infected cells, which complicates the total 
eradication of the viral reservoir61-63.  This makes cure a distinct prospect for most.
Viral suppression and cART for all PLHIV has contributed to further improvements in the 
life expectancy of PLHIV. Whereas 30-years ago an HIV infection was considered a terminal 
illness and care mainly focused on palliative care, PLHIV now have near normal life 
expectancies51. Nonetheless, HIV cure remains a distant prospect and PLHIV still have to cope 
with challenges of chronic inflammation, such as increased risk for cardiovascular diseases 
and multi-morbidity comparable to people living with diabetes51,64. Apart from increased risk 
of cardiovascular disease (CVD), the risk for malignancies, osteoporosis and neurocognitive 
impairment is increased in HIV38,48,64,65. Factors influencing development of non-AIDS co-
morbidities are complex and include cART itself, coinfections (e.g. hepatitis C), nutritional 
status, life style factors such as smoking or timing of cART initiation38,48,66,67. Underlying 
mechanisms are incompletely understood, but hypotheses evolve around persistent 
inflammation, incomplete immune restoration but also increased coagulated state with 
platelet dysfunction and increased d-dimer levels65. Although early cART initiation reduces 
the risk for those comorbidities, PLHIV treated during acute HIV infection still experience 
persistent inflammation after prolonged viral suppression68,69.
Persistent inflammation and immune dysfunction
The human immune system can be divided in an innate and adaptive immune 
compartment. The innate immune system consists of monocyte, macrophages, dendritic 
cells and platelets. The innate immune cells react non-specifically upon external stimuli 
producing inflammatory mediators such as cytokines and chemokines causing (systemic) 
inflammation. Innate pro-inflammatory processes are also involved in atherosclerosis and 
cardiovascular disease70. Pro-inflammatory monocyte subsets are increased in PLHIV even 
after viral suppression is reached71,72 and increased circulating concentrations of markers 
of innate immunity and monocyte activation, such as soluble CD14 (sCD14), soluble CD163 
(sCD163), high-sensitive C-reactive protein (hsCRP), interleukin (IL)-6 have been linked to 
non-AIDS comorbidities and mortality48,65,73-80. 
The adaptive immune compartment mainly consists of T-cells and B-cells. These cells mount a 
specific response and harbour a classic immunological memory. Despite long-term suppressive 
cART, CD4 restoration is often incomplete causing long-term depletion, residual activation and 
senescence of CD4+ cells81,82. These perturbations are most prominent in lymphoid tissues. For 
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1Outline thesisIn Chapter 2-6, we used the HFGP methodology to answer specific questions related to HIV. 
In Chapter 2, we investigated the function and phenotype of peripheral blood mononuclear 
cells (PBMC) by using an integrative approach of functional and transcriptional analyses with 
a focus on the inflammatory properties of monocytes. We linked these monocyte properties 
to markers of persistent inflammation (e.g. IL-6, sCD14, sCD163, hsCRP). We also explored 
underlying mechanisms of this inflammatory monocyte profile, including the possible 
contribution of exposure to microbial translocation, CMV seropositivity and HIV reservoir 
size. 
The relation between changes in the adaptive immune system and the inflammatory 
response is explored in Chapter 3. We used flow cytometry to comprehensively assess the 
WBC composition of PLHIV and compared the architecture of circulating immune cells with 
data generated in uninfected healthy controls. We explored the contribution of demographic 
and lifestyle related factors, as well as more specific HIV-related factors such as the HIV 
reservoir. Finally, we explored functional consequences of alterations in circulating adaptive 
immune cells by measuring the ex vivo production capacity of T-cell derived cytokines (IL-17, 
IL-22, and interferon (IFN)-g). 
Clonal haematopoiesis, caused by somatic mutations, emerges as a new risk factor for 
cardiovascular disease and haematological cancers in the general population125,126. The 
incidence of these mutations is unknown in PLHIV. In Chapter 4, we analysed the occurrence 
of somatic mutations and clonal haematopoiesis in PLHIV and studied whether changes 
could be associated with HIV-specific traits, HIV reservoir size and activity, inflammation and 
coagulation. Furthermore, we explored possible mutational signatures specifically involved 
in the development of somatic mutations in PLHIV.
The interaction between inflammation and coagulation is well known127. In Chapter 5, 
we studied whether plasmatic coagulation capacity was different between PLHIV and 
uninfected controls.  Furthermore, we explored the effect of cART, most notably abacavir, and 
inflammation on these parameters.
Platelets play an important role in inflammation and development of CVD87. Platelets do 
not have a nucleus but possess mitochondrial DNA88. Mitochondrial toxicity is the main 
underlining mechanism behind NRTI toxicity27. In Chapter 6, we determined whether 
mitochondrial DNA levels, a measure of mitochondrial toxicity128, of platelets differ between 
PLHIV and healthy controls, what the possible functional consequences are and the possible 
role of prior antiretroviral therapy, more specifically AZT.
Even though early treatment mitigates a large part of the disturbances caused by HIV, 
inflammation remains. 68,69 Numerous interventions to reverse persistent inflammation 
and dysfunction in PLHIV have been explored, including cholesterol-lowering agents107-109, 
angiotensin-converting enzyme (ACE) inhibitors109, valganciclovir (treating asymptomatic 
CMV)110 and aspirin93. Even though some showed a decrease in inflammation, it is 
questionable that these interventions will be potent or targeted enough to reverse 
persistent inflammation and immune dysfunction. Furthermore, biomarkers (e.g. d-dimer, 
sCD14, sCD163, IL-6) that are currently used for assessment of immune activation and 
dysfunction, provide insight in only a selection of possible pathways65. This is likely an 
oversimplification of the complex nature of HIV-associated persistent inflammation and 
an unbiased exploration of involved pathways is required.
Human functional genomics project
The human functional genomics project (HFGP) aims to improve our understanding of the 
variability of immune responses in human population111. Exploring how this variability 
relates to susceptibility to immune mediated diseases and to the response to immune based 
therapies. Previous studies have assessed factors that are associated with the interindividual 
variability in human immune responses, but frequently, only a limited number of factors with 
a limited number of immunological responses were investigated in healthy HIV-uninfected 
individuals112,113 or PLHIV114-118. The HFGP integrates -omics-based data (e.g. genomics, 
microbiome metagenomics, metabolomics, transcriptomics) with functional immune 
assays, platelet function and coagulation capacity in large cohorts of healthy individuals 
and patients. Using biostatistical integration of these data allows the prediction of novel 
interactions and targets for possible treatments111. This approach has already proven to be 
successful in HIV-uninfected individuals. It provided new insights on the influence of host 
and environment factors119, genetic factors, or the gut microbiota on host individual cytokine 
responses and immune cell populations119-124. A similar approach may therefore unravel the 
determinants of persistent inflammation of PLHIV using cART and as such provide basis for 
new interventions targeting non-AIDS related comorbidities.
Aim of this thesis
We established a Dutch PLHIV cohort on long-term effective cART within the HFGP. The 
HFGP provides a methodological framework through which specific HIV related immune or 
nonimmune biological processes can be assessed. In this thesis we provide the first steps into 
this approach exploring alterations in plasmatic coagulation, platelet function and immune 
responses in PLHIV. Integrating and linking different (patho)physiological pathways in PLHIV 
and lay ground-work for larger -omics-based projects tackling new challenges in HIV care 
and cure, mirroring the improvements in the HIV landscape as a whole. 
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Introduction
Persistent inflammation and immune dysfunction play an important role in the 
development of non-AIDS related comorbidities in people living with HIV (PLHIV). Those 
include cardiovascular disease (CVD), neurocognitive dysfunction and cancer 1-4. Reducing 
inflammation is considered to be an attractive therapeutic target to reduce the burden of 
non-AIDS related events. However, immune dysfunction and persistent inflammation in 
PLHIV are complex processes that are still incompletely understood. These involve changes 
in the adaptive immune system, including dysfunction and senescence of T-cell lymphocytes 
5, as well as changes in the innate immune system. Mediators of the latter, including soluble 
(s)CD14, sCD163 and high-sensitive C-reactive protein (hsCRP) are indicative of persistent 
immune activation and are associated with non-AIDS related events 6-8. 
Ongoing exposure to microbial products, for example by cytomegalovirus virus (CMV), 
continuing HIV replication or microbial translocation, may be one of the drivers of persistent 
inflammation 2,9-12. Increased inflammation can also result from a functional adaptation 
of innate immune cells induced by epigenetic reprogramming; a process termed ‘trained 
immunity’ 13-16. Trained immunity is recognized to play an important beneficial role in host 
defense processes, but may also contribute to conditions like atherosclerosis or type 2 
diabetes mellitus 17,18. Whether trained immunity contributes to persistent inflammation in 
PLHIV is currently unknown. 
The Human Functional Genomics Project (HFGP) aims to investigate variation in the immune 
responses 19. Studies in HFGP cohorts in healthy individuals have yielded different novel 
insights in the genetic and non-genetic regulation of inflammatory cytokine responses 
in response to microbial ligands 20-23. We established a HFGP cohort of Dutch PLHIV and 
in this cohort we describe alterations in the function and phenotype of peripheral blood 
mononuclear cells (PBMC) by using an integrative approach of functional and transcriptional 
analyses. We also explored underlying mechanisms of the inflammatory monocyte 
profile, including the possible contribution of exposure to microbial translocation, CMV 
seropositivity and HIV reservoir size. 
Abstract
Chronic inflammation and immune dysfunction play a key role in the development of 
non-AIDS related comorbidities. The aim of our study was to characterize the functional 
phenotype of immune cells in people living with HIV (PLHIV). We enrolled a cross-sectional 
cohort study of PLHIV on stable antiretroviral therapy and healthy controls. We assessed 
ex vivo cytokine production capacity and transcriptomics of monocytes and T-cells upon 
bacterial, fungal and viral stimulation. PLHIV exhibited an exacerbated pro-inflammatory 
profile in monocyte-derived cytokines, but not in lymphocyte-derived cytokines. Particularly, 
the production of the IL-1β to imiquimod, E. coli LPS and Mycobacterium tuberculosis was 
increased, and this production correlated with plasma concentrations of high-sensitivity 
C-reactive protein and soluble CD14. This increase in monocyte responsiveness remained 
stable over time in subsequent blood sampling after >1year. Transcriptome analyses 
confirmed priming of the monocyte IL-1β pathway, consistent with a monocyte trained 
immunity phenotype. Increased plasma concentrations of β-glucan, a well-known inducer 
of trained immunity, were associated with increased innate cytokine responses. Monocytes 
of PLHIV exhibit a sustained pro-inflammatory immune phenotype with priming of the IL-
1β pathway. Training of the innate immune system in PLHIV likely plays a role in long-term 
HIV complications and provides a promising therapeutic target for inflammation-related 
comorbidities. 
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Table 1. Baseline characteristics
PLHIV (n=211) Healthy controls (n=56)
Sex (% Male) 193 (91.5) 34 (60.8)A
Age (years, mean (SD)) 51.4 (10.8) 39.9 (17.3)B
BMI (kg/m2, mean (SD)) 24.5 (3.6) 24.1 (3.1)
HIV infection duration (years, median [IQR]) 8.5 [4.9, 14.2]
Way of transmission (%)
 Heterosexual 9 (4.3)
 IDU 3 (1.4)
 MSM 159 (75.4)
 Other/unknown 40 (19.0)
CD4 nadir (10^6 cells/mL; median [IQR]) 250.0 [135.0, 360.0]
CD4 count (10^6 cells/mL; median [IQR]) 660.0 [480.0, 810.0]
HIV load below 200 copies/mL (n (%)) 211 (100)
HIV load below 50 copies/mL for >1yr (n (%)) 188 (89%)
CD4/CD8 ratio (median [IQR]) 0.8 [0.6, 1.1]
cART duration (years; median [IQR]) 6.6 [4.2, 11.8]
cART regimen
NRTI-use (%) 203 (96.2)
NtRTI-use (%) 99 (46.9)
NNRTI-use (%) 63 (29.9)
PI-use (%) 32 (15.2)
Maraviroc-use (%) 3 (1.4)
INSTI-use (%) 141 (66.8)
Active smoking, n/N (%) 63 (29.9) 2 (3.6)B
Heavy drinking (%)* 28 (13.3) 11 (19.6)
Regular substance use, (%)** 61 (28.9) 3 (5.4)B
Hypercholesterolemia (%) 58 (27.5)
Hypertension (%) 41 (19.4)
Diabetes Mellitus (%) 9 (4.3)
No cardiovascular risk factors (%) 50 (23.7)
Statins (%) 58 (27.5)
Aspirin (%) 19 (9.0)
Metformin (%) 9 (4.3)
BMI: body mass index. IDU: intravenous drug-use. MSM: men who have sex with men. cART: combination antiretroviral 
therapy. NRTI: Nucleoside reverse transcriptase inhibitor. NtRTI: nucleotide reverse transcriptase inhibitor. NNRTI: 
non-nucleoside reverse transcriptase inhibitor. PI: protease inhibitor. INSTI: integrase inhibitor. *Classified according 
to the CDC definition: for men, ≥15 drinks per week and for women, ≥8 drinks/week. http://www.cdc.gov/alcohol/faqs.
htm#heavyDrinking (page accessed April 22, 2020, Page last reviewed: January 15, 2020, Content source: Division of 
Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control 
and Prevention). **Defined as use of any psychoactive substance (with the exception of alcohol and tobacco) during 
periods ≥ 1 time per week including ≥ 1 time during the 30 days prior to the study visit. A Significantly different between 
cohorts using Students T-test. B Significantly different between cohorts using Chi-square test.
Results
Characteristics
A total of 211 PLHIV on combination antiretroviral therapy (cART) and 56 HIV-uninfected 
controls were included in the analyses. Baseline characteristics are shown in Table 1. 
Compared to the healthy controls, PLHIV were more often male (91.5% vs. 60.7%; p<0.001) 
and of older age (median [IQR] age of 52.5[13.2] vs 30.0 [27.1] years, p<0.0001). The median 
(IQR) duration of cART use in PLHIV was 6.6yr (4-12yr) and 89% were virally suppressed (HIV 
viral copies ≤50 copies/mL) for more than one year. 
Circulating inflammatory markers and innate cytokine responses
We first measured concentrations of circulating inflammatory markers. Compared to healthy 
controls PLHIV had significantly higher concentrations of sCD14, hsCRP, IL-18, IL-18 binding 
protein (IL-18BP) and IL-6 (Figure 1A-G). These differences remained after adjusting for age, sex, 
body mass index (BMI), or seasonality (Figure 1A). Concentrations of adipokines were similar 
between groups after correction  (Figure 1A). 
Next, we analyzed functional changes in the innate and adaptive immune response. PBMCs 
were incubated with 12 stimuli (4 bacterial, 3 fungal, 1 viral and 6 Toll like receptor (TLR) 
ligands), followed by measurement of different monocyte-derived (IL-6, IL-1β, TNFα) 
and lymphocyte-derived (IL-17, IL-22, IFNγ) pro-inflammatory cytokines, as well as anti-
inflammatory cytokines (IL-10, IL-1Ra) in the supernatant. We observed markedly increased 
monocyte-derived cytokine responses in PLHIV, especially IL-1β responses upon stimulation 
with LPS (TLR4), imiquimod (TLR7) and Mycobacterium tuberculosis (Figure 2A,C,D). Production 
of TNFα and IL-6 were also increased in PLHIV (Figure 2A,E), except for lower production in 
response to Staphylococcus aureus (TNF-α) and Candida albicans (IL-6; Figure 1F,G). This increased 
pro-inflammatory cytokine response in PLHIV was not associated with a concurrent increase in 
the anti-inflammatory cytokines IL-1Ra or IL-10. However, the release of IL-1Ra by unstimulated 
cells was higher in PLHIV (Figure 2H), which is consistent with increased basal IL-1β production 
(Figure 2A). The number of monocytes in the isolated PBMCs (Supplemental Figure 1A-B) 
may influence cytokine production, but adjusting for the monocyte fraction in PBMCs did not 
significantly alter the outcome (Supplemental Figure 1C. T-cell-derived cytokine responses 
were generally lower for most stimuli in the PLHIV cohort (Supplemental Figure 2), but these 
differences were abrogated following adjustment for age, sex and seasonality (Figure 1A), 
except for IFNy responses to M. tuberculosis and C. albicans hyphae (Figure 2A-B). There were no 
associations between cytokine production capacity and smoking or different HIV-specific traits, 
including recent CD4 cell count, CD4/8 cell ratio, CD4 nadir, cART-regimen or co-medication 
(metformin, statins or aspirin) (Supplemental Figure 3). 
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Figure 2. Cytokine production capacity in PLHIV vs uninfected healthy controls (HC). (A) Ex vivo cytokine production 
capacity between PLHIV and HC after 24hr (in case of IL-1β, TNFα, IL-6, IL-10 and IL-1Ra) and 7 days stimulation (IL-22, IL-
17 and IFNγ). FDR-corrected (Benjamini-Hochberg method) P values are depicted from an adjusted model included age, 
sex, seasonality as covariates. Red depicts significantly higher in PLHIV, blue depicts lower in PLHIV compared to HC. 
(B-H) boxplots depicting ex vivo cytokine production capacity stratified by cohort. PLHIV depicted in blue and uninfected 
controls in yellow. P values, depicted in boxplots were calculated using Student’s t test after log-transformation. All 
boxplots are depicted according to Tukey with median (line), interquartile range (edge of boxplot), range (whiskers) and 
outliers three times interquartile range are depicted as dots. All plots include data from PLHIV (n = 211) and HC (n = 56). 
LPS: lipopolysaccharide; oxLDL: oxidized low-density lipoprotein; Pam3Cys: synthetic Toll-Like-Receptor (TLR)2 ligand; 

















































































































Figure 1. Circulating factors in people living with HIV (PLHIV) vs uninfected healthy controls (HC). (A) Circulating 
factors in PLHIV and uninfected controls. Crude model is linear regression after inverse rank-based transformation. 
Adjusted model included age, sex, and seasonality as covariates. Red depicts the marker is significantly increased in 
PLHIV; blue depicts the marker is decreased in PLHIV compared to healthy controls. All P values are FDR corrected 
(Benjamini-Hochberg method). (B-G) Boxplots depicting circulating factors of inflammation stratified by cohort, PLHIV 
(blue), uninfected controls (yellow). P values are calculated using Student’s t test. Boxplots are depicted according to 
Tukey with median (line), interquartile range (edge of boxplot), range (whiskers) and outliers 3 times interquartile 
range are depicted as dots. All plots include data from PLHIV (n = 211) and HC (n = 56). hsCRP: high-sensitivity C-reactive 
protein; sC14: soluble CD14; sCD163: soluble CD163; IL-6: interleukin-6; IL-18: interleukin-18; IL-18BP: interleukin 18 
binding protein.
Next, we assessed associations between innate cytokine responses, circulating inflammatory 
markers, and monocyte phenotypes (Figure 2A-I). Increased ex vivo cytokine responses were 
associated with persistent inflammation. For example, we found positive associations between 
IL-6 responses and circulating hsCRP (Figure 2A,I), and between LPS induced IL-1β responses 
and plasma sCD14 and IL-18BP (Figure 2A,D). In addition, non-classical and intermediate 
monocyte subsets (Figure S4A-F), which are considered pro-inflammatory monocyte 
phenotypes, correlated with higher IL-1β and IL-6 production after LPS or imiquimod, 
respectively (intermediate monocytes vs LPS-IL-1β R=0.23, p<0.001; Figure 2A-C) 24. Taken 
together, we show that PLHIV have an altered innate immune profile with markedly elevated 
monocyte cytokine responses, particularly IL-1β, which correlates with blood biomarkers of 
persistent inflammation.
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Increased IL-1β production capacity of PLHIV is stable over time
We then assessed the longevity of the elevated monocyte-derived cytokine responses. 
We resampled 28 male PLHIV, aged >45yr after >1yr and stratified them on the basis of 
their initial IL-1β production capacity in a group of low (lowest quartile) and high (highest 
quartile) IL-1β producers. Fourteen age and sex-matched uninfected controls were enrolled 
concurrently (Supplemental Table 1). Upon resampling, those assigned to the high IL-1β 
producer group still exhibited higher IL-1β and IL-6 production compared to participants in 
the low IL-1β producer group and matched healthy controls, suggesting that the enhanced 
monocyte responsiveness is stable over time (Figure 4A-B). TNF-α followed a similar, but 
non-significant pattern (P = 0.075; Figure 4C). To examine if the presence of T-lymphocytes 
affected the outcome, we isolated monocytes using magnetic beads (purity >95%, 
Supplemental Figure 4G) and repeated the stimulation experiments. We found that IL-1β 
production remained increased, suggesting that the elevated monocyte-derived cytokine 
response is due to an enhanced functional state of the monocytes themselves. 
Enhanced pro-inflammatory functional state of monocytes
Based on the previous findings, we postulated that a trained immunity functional phenotype 
contributes to the enhanced monocyte responsiveness in PLHIV. Hence, we isolated 
monocytes from eight PLHIV and four age and sex matched uninfected controls and analyzed 
their transcriptomes by RNA sequencing. Using principal component analysis (PCA), we 
observed clustering of the PLHIV and controls (Figure 5A). This clustering was even more 
pronounced when monocytes were differentiated towards macrophage phenotype by culture 
for 24hr in serum-free medium (RPMI; Figure 5B) and was also observed using hierarchical 
clustering (Figure 5C). Gene ontology (GO) analysis of 303 upregulated and 30 downregulated 
genes (Supplemental data) showed that pro-inflammatory pathways were upregulated in 
PLHIV, including the ‘inflammatory response’, ‘regulation of innate immune response’ and ‘IL-
1β production’ pathways (Figure 5D-E). Among the upregulated genes in these pathways were 
intracellular signaling proteins and inflammasome related molecules (e.g. NLRP3, STAT1), 
cytokines (e.g. IL1B, CCL2, MMP9, IL1RN), and pattern-recognition receptors (e.g. TLR2, TLR4, 
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Figure 3. Cytokine production capacity vs circulating factors. (A) Correlation plot with adjusted p-value shown after 
correcting for age, sex, seasonality as covariates. Red depicts a significant positive correlation and blue depicts a 
negative correlation within people living with HIV (PLHIV). All P values were FDR corrected per circulating factor. (B-I) 
Correlation plot without cofactor adjustment. Pearson’s coefficient (r) with P value after log-transformation are shown. 
All plots include data from PLHIV (n = 211) and HC (n = 56). LPS: lipopolysaccharide; oxLDL: oxidized lipodensityprotein; 
Pam3Cys: synthetic Toll-Like-Receptor (TLR)2 ligand; Poly IC: TLR3 ligand; imiquimod (IMQ): TLR7 ligand. hsCRP: high-
sensitivity C-reactive protein; sC14: soluble CD14; sCD163: soluble CD163; IL-6: interleukin-6; IL-18: interleukin-18; IL-
18BP: interleukin 18 binding protein. *P < 0.05 after FDR-correction.
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Figure 5. Transcriptome analysis of monocytes. (A) Principal component (PC) analysis (PCA) plot of transcriptome 
of monocytes from people living with HIV (PLHIV) and healthy controls (HC) directly after isolation. (B) PCA plot of 
transcriptome of monocytes from PLHIV and HC after 24 hours macrophage differentiation in medium only. (C) 
Hierarchical clustering plot PLHIV vs HC. (D) Gene ontology of differentially expressed genes (PLHIV vs HC) including 
adjusted P value and gene count. (E) Top pathways of gene ontology plot after macrophage differentiation (GO 
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Figure 4. Ex vivo cytokine production capacity of monocytes in a validation cohort. (A) IL-1β production upon 24h 
stimulation with imiquimod (1ug/mL), lipopolysaccharide (LPS; 100ng/mL) or M. tuberculosis (1ug/mL) in PBMCs or 
monocyte only culture (magnetic beads CD14+ isolation). (B) IL-6 production upon imiquimod stimulation. (C) TNFα 
production upon imiquimod stimulation. All data are stratified by healthy controls (HC; n = 14), people living with HIV 
(PLHIV) low initial IL-1β producers (n = 13) and PLHIV high producers (n = 15). P- values in panel A-C were calculated by 
Student t test. All boxplots are depicted according to Tukey; median (line), interquartile range (edge of boxplot), range 
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E). The inflammasome promotes the proteolytic cleavage of proIL-1β into active IL-1β, 
resulting in reduced proIL-1β/active IL-1β ratios in situations with increased caspase-1 
activity 25. Instead, we observed a trend towards an increased ratio of intracellular proIL-1β 
and active IL-1β (Figure 6F) in the high IL-1β producing PLHIV, and no differences in levels of 
NLRP3 expression (Figure 6C). Together, these results demonstrate that the enhanced IL-1β 
transcription, rather than increased processing through caspase-1, is the biological process 
that primarily drives the increased IL-1β production in PLHIV. 
β-glucan exposure induces a pro-inflammatory monocyte phenotype
We next examined possible pathways underlying the pro-inflammatory monocyte phenotype 
in PLHIV. Persistent exposure to microbial ligands derived from gut microbes, CMV or HIV 
itself has been suggested to play a role in the persistent inflammation in PLHIV2,9-12. We 
postulated that these factors also play a role in the pro-inflammatory monocyte phenotype. 
We, therefore, first assessed whether innate cytokine responses were associated with 
parameters of the HIV viral reservoir. The HIV reservoir was assessed by analyzing CD4+ 
cell-associated HIV-1 DNA (CA-DNA) and CA-RNA. In virally suppressed patients, the CA-
DNA roughly equals the integrated HIV-1 DNA, being replication competent or not26, while 
CA-RNA is associated with recent HIV-1 transcriptional activity and serves as a proxy for the 
active proviral reservoir27. While cell associated HIV-1 CA-DNA levels in CD4+ T-cells were 
associated with plasma IL-6 concentrations (Figure 7A), there was no association between IL-
1β cytokine responses (Supplemental Figure 5) or plasma sCD14 concentrations and HIV-1 CA-
DNA or CA-RNA levels in our cohort (Figure 7B-H). 
Next, we assessed associations between cytokine responses and CMV seropositivity. In 
total 198/211 (93.8%) of participants were CMV seropositive. There were no differences in 
IL-1β cytokine responses,sCD14 concentrations or HIV-1 CA-DNA between CMV seropositive 
vs. seronegative individuals (Figure 7I-L, Supplemental Figure 5). Another source of 
chronic microbial ligand exposure in PLHIV is increased microbial translocation 9. Plasma 
concentrations of Intestinal fatty acid binding protein (IFABP), a marker for microbial 
translocation, were significantly increased in PLHIV compared to controls (Figure 7M). We 
found a modest negative correlation of IFABP concentrations with IL-1β cytokine responses 




















































































Figure 6. IL1B gene expression and intracellular (pro)IL-1β. (A) IL1B gene expression after imiquimod 1ug/mL 
stimulation depicted as fold change (FC) from medium (RPMI). (B) IL6 gene expression after imiquimod stimulation 
depicted as fold change from medium. (C) NLRP3 gene expression (by ΔCT) in RPMI. (D) Intracellular levels of proIL-1β 
protein after Imiquimod stimulation. (E) Intracellular mature IL-1β protein after imiquimod stimulation. (F) Ratio of 
intracellular proIL-1β vs IL-1β after imiquimod stimulation protein. All data are stratified by healthy controls (HC; n = 
14), people living with HIV (PLHIV) low initial IL-1β producers (n = 13) and PLHIV high producers (n = 15). All boxplots are 
depicted according to Tukey; median (line), interquartile range (edge of boxplot), range (whiskers) and outliers three 
times interquartile range are depicted as dots. P-values were calculated by ANOVA and subsequently by pair-wised 
Student’s t test.
Enhanced IL-1β gene expression in monocytes of PLHIV
The release of active IL-1β from blood monocytes involves a priming signal that is mostly 
transcriptionally driven, which results in the synthesis of the IL-1β precursor (proIL-1β). 
This precursor is subsequently processed via caspase-1 into active IL-1β 25.  Using qPCR 
on monocytes stimulated with IMQ, we found that the IL1B (gene encoding for proIL-1β) 
RNA expression was higher in monocytes from PLHIV compared to controls (Figure 3F, P = 
0.021). IL6 mRNA followed a similar trend (Figure 6A, P = 0.027), whereas TNFA expression 
did not (data not shown, P = 0.74). Additionally, we measured intracellular proIL-1β and 
active IL-1β protein by ELISA and both were significantly elevated in PLHIV (Figure 6D-
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Increased intestinal translocation may also increase circulating concentrations of β-glucan, 
which is a well-known inducer of trained immunity 28. We therefore determined serum 
β-glucan concentrations in the subsequent cohort of 28 PLHIV and 12 controls. Compared to 
controls (4/14; 29%), a significantly higher proportion of PLHIV (16/28; 57%), and especially 
those in the high IL-1β producer group (11/15; 73%), had detectable β-glucan in serum (Figure 
8A-B). Individuals with detectable serum β-glucan had elevated IL-1β production (Figure 8C-
D), showed increased IL1B gene expression (Figure 8E) and increased intracellular proIL-1β 
upon stimulation (Figure 8F). Concurrently, IL1ra production was increased in PLHIV with 
detectable β-glucan concentrations (Figure 8G). A similar, non-significant trend was observed 
for IL-6 and TNF responses (Figure 8H-I). A similar, non-significant trend was observed 
for IL-6 and TNF-α responses (Figure 8I-L). Next, using a well-established in-vitro training 
protocol of trained immunity 29, we confirmed that pre-stimulation of adherent monocytes 
with β-glucan resulted in a pronounced enhancement of IL-6 release upon re-stimulation 
with LPS at day 6 (Figure 8M). We also investigated the effects of pre-stimulation with LPS. 
As previously reported, pre-stimulation with LPS induced immune tolerance (Figure 8D) 15. 
Taken together, these findings suggest that circulating β-glucan is a possible driver of the 
pro-inflammatory immune phenotype of monocytes in PLHIV. 
Figure 4



























3.0 3 .5 4.0
IL−1β − LPS
B
r  = 0.016 , P = 0.82
1.5 2 .0 2.5 3 .0
IL−1β − IMQ
C









































1.5 2 .0 2.5 3 .0
IL-1β - IMQ
G





























1.5 2 .0 2.5 3 .0
IL-1β - IMQ
O































































r = -0.12, P = 0.081 r = -0.07, P = 0.32 r = 0.02, P = 0.73
r = -0.17, P = 0.012 r = -0.14, P = 0.046 r = 0.08, P = 0.25
CMV-      CMV+ CMV-      CMV+ CMV-      CMV+







Figure 7. Parameters of HIV reservoir, CMV seropositivity and microbial integrity. (A-D) Log10-transformed cell 
associated HIV-1 DNA (CA-DNA) in CD4+ cells correlation with: (A) circulating IL-6 levels, (B) IL-1β production after 
LPS (100ng/mL) stimulation, (C) IL-1β production after imiquimod (IMQ; 1ug/mL) stimulation and (D) soluble CD14 
plasma concentration. (E-H) Log10-transformed cell associated HIV-1 RNA (CA-RNA) in CD4+ cells correlation with: 
(E) circulating IL-6 levels, (F) IL-1β production after LPS stimulation, (G) IL-1β production after imiquimod stimulation and 
(H) soluble CD14 plasma concentration. (I-L) Stratified by Cytomegalovirus (CMV) seropositivity: (I) Log10-transformed 
cell associated HIV DNA (CA-DNA) in CD4+ cells, (J) IL-1β production after LPS stimulation, (K) IL-1β production after 
imiquimod stimulation and (L) soluble CD14 plasma concentration. (M) Intestinal fatty-acid binding protein (iFABP) 
in plasma, a marker of intestinal integrity, between healthy controls (HC; n = 56) and people living with HIV (PLHIV; 
n = 211). (N-P) Plasma iFABP concentration correlation with: (N) IL-1β production after LPS stimulation, (O) IL-1β production 
after imiquimod and (P) soluble CD14 plasma concentration. All boxplots are depicted according to Tukey; median (line), 
interquartile range (edge of boxplot), range (whiskers) and outliers three times interquartile range are depicted as dots. 
Pearson’s coefficient (r) after log-transformation is shown in correlation plots. Data in boxplots are analyzed using Student’s 
t test after log10-transformation. All plots depict data from PLHIV only (n = 211) unless otherwise stated.
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Discussion
In this study, we investigated the functional phenotype of circulating immune cells in 
a cohort of PLHIV on stable cART. We show that PLHIV exhibit a sustained elevation in 
monocyte cytokine responsiveness, whereas lymphocyte-derived cytokine responses were 
mostly unaffected. Our immune profiling data, which included transcriptome analysis of 
circulating monocytes, further showed an increased expression and activation of the IL-
1β pathway. HIV infection is associated with increased microbial translocation 9 and we 
identified a, so far unrecognized, role for elevated circulating β-glucan concentrations in the 













































































































































































































Figure 8. β-glucan induces a pro-inflammatory phenotype in monocytes. (A) β-glucan (βG) in serum stratified by 
healthy controls (control), people living with HIV (PLHIV) with low or high initial IL-1β response. (B) percentage 
of detectable levels of β-glucan in serum, stratified by control, PLHIV with high and low initial IL-1β response. (C-D) 
IL-1β production after 24h stimulation with imiquimod (C; 1ug/mL) or Mtb (D; 1ug/mL) in PLHIV stratified by detectable 
β-glucan levels. (E) IL1B gene expression after imiquimod stimulation depicted as fold change (FC) from medium 
(RPMI). (F) Intracellular levels of proIL-1β protein after Imiquimod stimulation. (G-H) IL1Ra production after 24h 
stimulation with imiquimod (G) or Mtb (H) in PLHIV stratified by detectable β-glucan levels. (I-J) IL-6 production after 
24h stimulation with imiquimod (I) or Mtb (J) in PLHIV stratified by detectable β-glucan levels. (K-L) TNFα production 
after 24h stimulation with imiquimod (K) or Mtb (L) in PLHIV stratified by detectable β-glucan levels. (A-L) PLHIV 
n = 28, healthy controls (HC) n = 14. All boxplots are depicted according to Tukey; median (line), interquartile range 
(edge of boxplot), range (whiskers) and outliers three times interquartile range are depicted as dots. Data were analyzed 
using Student’s t test after log10-transformation. (M) Initial training with either LPS (TLR4 ligand), β-glucan (10ug/mL) 
or medium only (RPMI + 10% serum) was performed for 24h at day 1. Thereafter a 5-day resting period in medium only 
(supplemented by 10% serum), at day 6 adherent monocytes were restimulated with LPS 10ng/mL. IL-6 was measured 
in the supernatant and fold change from training with medium only are depicted. Data shown are from three separate 






































































































































































































































































































































































































































































































































































































































Chapter 2 - Reprogramming of innate immune cells in HIV
2
reservoir. Although, we do not exclude a possible accessory role for these markers of 
microbial exposure, we did find an association of circulating β-glucan concentrations and 
IL-1β responsiveness. β-glucan is a component of the cell wall of fungi and is known to be 
a strong inducer of trained immunity 16. Furthermore, IL-1β signaling is reported to be 
important in β-glucan induced trained immunity in vivo 51. Our present data corroborate 
earlier reports that increased circulating β-glucan concentrations can be found in virally-
suppressed PLHIV 28,52,53. Acute HIV infection leads to an early and pronounced loss of 
mucosal  Th17  CD4+  T cells 54. This cellular compartment is critical for regulation of mucosal 
host defense against Candida and regulation of epithelial cell permeability 55. Increased levels 
of other microbial products, including LPS, have also been reported in PLHIV 28,56. However, 
in contrast to β-glucan, LPS generally induces immune tolerance, even at low concentrations 
15,16, a notion we confirmed in vitro. This notion is supported by our observation that microbial 
integrity, as measured by iFABP, is associated with decreased monocyte responsiveness. An 
HIV infection is associated with alterations in the bacterial gut microbiome composition and 
these changes play a role in the incidence of co-morbidities and inflammation 2,57,58. While 
studies on the mycobiome in PLHIV are limited, fungal dysbiosis with a high prevalence of 
Candida species has been found in stool samples of PLHIV 59. Furthermore, our data showed 
lower IL-6 and higher IL-10 production by monocytes upon Candida stimulation in PLHIV 
compared to uninfected controls, suggesting an altered fungal immune response. This 
defective immunity could contribute to fungal dysbiosis in virally suppressed PLHIV. Hence, 
our present data support the need for future studies exploring the role of the mycobiome in 
persistent inflammation in PLHIV, as well as possible strategies to reduce β-glucan exposure.
Reducing inflammation is considered an attractive therapeutic target to reduce the burden 
of cardiovascular diseases. The CANTOS (Canakinumab Anti-Inflammatory Thrombosis 
Outcome Study) trial that was carried out in HIV uninfected subjects who were at risk for a 
cardiovascular event.  The trial revealed that specific neutralization of IL-1β reduced in the 
incidence of subsequent cardiovascular events and death from lung cancer 60,61. Similarly, the 
anti-inflammatory drug colchicine reduced cardiovascular events in patients with coronary 
disease 62. In contrast, the immunosuppressive drug methotrexate did not reduce CVD, 
underlining the importance of IL-1β in CVD 63. Recent findings that canakinumab reduced 
atherosclerotic inflammation in PLHIV at high-risk for CVD are therefore promising 64 and 
support the importance of IL-1β pathway in HIV. Orally administrated drugs that inhibit the 
IL-1β pathway, such as inflammasome inhibitors, may form an attractive alternative 65. This 
also applies to epigenetic modifying drugs, such as histone deacetylase (HDAC) inhibitors. 
These drugs have been shown to reduce CRP concentrations, IL-1β expression in PBMCs 66 
and IL-1β production to LPS stimulation in whole blood from PLHIV 67. Taken together, our 
present data support the use of interventions targeting the IL-1β pathway or reduce B-glucan 
exposure as an adjunctive therapy to reduce non-AIDS related co-morbidities. 
These data corroborate findings from earlier, smaller studies in PLHIV, which reported an 
increased production of pro-inflammatory cytokines to stimulation with ligands of TLR4 30,31 
or TLR7 32,33, or M. tuberculosis 34. The increased monocyte-derived cytokine responsiveness 
in our PLHIV cohort was associated with increased plasma concentrations of different 
circulating inflammatory markers, such as hsCRP, sCD14, IL-18 and IL-6, suggesting a 
functional link between changes in the innate immune profile and systemic inflammation 
in PLHIV. Remarkably, HIV infection had little effect on lymphocyte-derived cytokine 
responses, despite the fact that alterations in T-cell immune phenotype have been described 
in long-term viral suppressed PLHIV35,36. Previous research in HFGP cohorts of HIV-uninfected 
individuals showed that age, environmental, microbial and genetic factors have a clear 
impact on the function of circulating T-cells 21-23,37.
The observed intrinsic pro-inflammatory phenotype of monocytes in PLHIV was stable over 
time and associated with upregulation of pro-inflammatory pathways, most notably the 
IL-1β pathway. This corroborates a recent study showing a pronounced pro-inflammatory 
phenotype, including upregulation of IL1B, of monocyte derived macrophages in PLHIV 
38. Long-term epigenetic reprogramming of monocytes in response to microbes has been 
termed ‘trained immunity’. This functional adaptation of monocytes enables a greater 
response when subjected with a secondary stimulus as protective mechanism against a 
secondary infection 14-16. Nonetheless, a trained immunity phenotype of monocytes has 
also been related to conditions such as cardiovascular diseases and diabetes 39-42. In PLHIV, 
altered epigenetic profiles such as DNA methylation have been reported 43,44{Zhang, 2016 #4465,45. 
Specific DNA methylation patterns in PLHIV were associated with progressive aging and 
non-AIDS related co-morbidities, such as insulin resistance, neurocognitive disorders and 
chronic kidney disease 17,46-48. Interestingly, HIV/Simian immunodeficiency virus (SIV) DNA 
vaccination was recently shown to induce a trained immunity phenotype in vivo through 
upregulation of IL-1β related genes 49. This upregulation correlated with protection against 
subsequent SIV infection in macaques. Furthermore, HIV-1 itself has also been shown to 
increase IL-6 production via epigenetic modification of STAT3 in microglial cells 50. Although 
epigenetic modification has been shown to underlie the trained immunity phenotype, we 
did not determine epigenetic changes in the current study. Future studies are warranted to 
investigate the epigenetic processes underlying the trained immunity phenotype reported 
here. 
Another question concerned the identification of the possible mechanisms responsible 
for the observed changes in innate immune responses.  CMV 10, microbial translocation 9, 
and HIV reservoir 11 have each been related to persistent inflammation in PLHIV. However, 
our data did not show a positive correlation between monocyte responsiveness and CMV 
seropositivity, levels of IFABP (microbial translocation marker), or parameters of the HIV 
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and uninfected controls were sampled every three months during the inclusion of PLHIV. 
In the follow-up measurement, we resampled 28 male PLHIV, aged >45yrs after >1yr and 
stratified them on the basis of their initial IL-1β production capacity in a group of low (lowest 
quartile) and high (highest quartile) IL-1β producers.  A control group of fourteen age-sex 
matched healthy controls was also included. These groups were used for monocyte-only, 
RNA expression and β-glucan measurements. All experiments were performed by the same 
personnel using the HFGP methodologies (http://www.humanfunctionalgenomics.org) 19. 
General information from all participants was recorded in an electronic case report form 
(CastorEDC, Amsterdam, The Netherlands). Clinical data were extracted from the electronic 
hospital information system and the ‘Stichting HIV Monitoring’ registry (Amsterdam, The 
Netherlands).
Ex vivo PBMC and monocyte stimulation
Venous blood was collected in sterile 10 mL EDTA and 8 mL serum BD Vacutainer® tubes 
and processed within 1-4h. Isolation of PBMCs was performed freshly collected blood by 
density centrifugation over Ficoll-Paque (VWR, Amsterdam, The Netherlands) as described 
previously 70. Monocytes were isolated by magnetic activated cell sorting using negative 
bead selection with the Pan Monocyte Isolation kit according to manufacturer’s instructions 
(Miltenyi Biotec, Leiden, the Netherlands). Cell counts, cell purity and composition were 
evaluated by XN-450 hematology analyzer (Sysmex Corporation, Kobe, Japan). Fresh isolated 
cells (monocytes 1.105 cells per well, PBMCs 5.105 cells per well) were incubated with different 
bacterial, fungal, viral stimuli (Table S2) at 37°C and 5% CO2 for either 24h or 7d. For the 7d 
stimulation, 10% human pooled serum was added to the wells. IL-1β, IL-6, IL-1Ra, IL-10 and 
TNF-α were determined in the supernatants of the 24hr PBMC or monocyte stimulation 
experiments, using enzyme-linked immunosorbent assays (ELISA; Duoset ELISA, R&D 
Systems, Minneapolis, MN, USA). IL-17, IL-22 and IFNγ were measured after 7d stimulation 
of PBMCs (PeliKine Compact or R&D Systems). For intracellular cytokine measurements of 
active IL-1β and pro IL-1β (Quantikine, R&D Systems), cell pellets were lysed using Triton 
X-100 (Sigma, Zwijndrecht, The Netherlands). 
Measurements of plasma markers and immunophenotyping
Intestinal fatty acid binding protein (IFABP), a marker of enterocyte damIage, resistin, 
adiponectin, leptin, IL-18 binding protein (IL-18BP), IL-18, hsCRP, sCD14 and sCD163 were 
measured using ELISA (Duoset or Quantikine, R&D Systems). IL-6, TNF-α, IL-10 and IL-1Ra 
were measured using SimplePlex Cartridges (Protein Simple, San Jose, CA, USA). 1,3-β-D-
glucan (β-glucan) levels were measured with Fungitell ((Associates of Cape Cod, Liverpool, 
UK) and CMV IgG by ELISA (Genway Biotech, San Diego, CA, USA). All assays were performed 
according to manufacturer’s recommendations, and samples of the different cohorts were 
measured simultaneously in the same plates or SimplePlex Cartridges. Monocyte subsets 
A particular strength of our study is that in-depth functional analysis of adaptive and innate 
immune cell function in a relatively large cohort of PLHIV. The same HFGP approach was 
successfully used to investigate genetic, environmental and microbial factors influencing 
the immune system in HIV-uninfected individuals 21-23,37. Limitations of our study include 
that PLHIV and control cohort differed in age and sex distribution. All analyses were 
therefore adjusted for these differences using multivariate analyses with sufficient sample 
size. Moreover, the primary findings were confirmed when we resampled a selection of 
age and sex matched PLHIV and controls. However, we could not correct for men who have 
sex with men (MSM), as this information was not available for the control group68. Second, 
the nature of our cross-sectional study does not allow to draw strong causal inferences, 
for example on the role of HIV or β-glucan in the observed immune changes. Third, the 
heterogeneity and activity of the HIV reservoir is not fully determined by HIV CA-DNA and 
HIV CA-RNA measurement only, residual viremia with single copy assay could quantify 
recent HIV activity.   Fourth, recently monocyte alterations in PLHIV were linked to cART 
induced oxidative stress 69. The enrolment in our cohort was limited to virally-suppressed 
PLHIV on cART and, therefore, a possible independent effect of cART on immune responses 
could not be assessed. However, an effect of different cART regimens appears unlikely, since 
no differences in cytokine responses were found across the different cART regimens. Finally, 
due to limited inclusion of women in our cohort, generalizability to women or sex-specific 
analyses were not feasible. 
In conclusion, we found that PLHIV on stable cART exhibit a marked and long-lasting increase 
in the production of IL-1β with subsequent downstream monocyte-derived cytokines, 
suggesting a trained immunity phenotype of monocytes. Increased translocation of β-glucan 
from the gastrointestinal tract was identified as a possible inducer of this innate immune 
phenotype. Our findings provide mechanistic insights and shed new light on the usefulness 
of interventions targeting the innate immune system, as well as the gut mycobiome, as an 
adjunctive therapy to reduce non-AIDS related co-morbidities. 
Methods 
Study population
A total of 211 PLHIV were recruited from the HIV clinic of the Radboud university medical 
center between December 2015 and February 2017 with a follow up measurement in 2018. 
Caucasian individuals age ≥ 18 years, on cART > 6mo with an HIV-RNA load <200 copies/mL 
and showed no signs of opportunistic infections or active hepatitis B/C were included. The 
control group consisted of 56 healthy individuals not using any medication at inclusion. 
Inclusion, sampling and sample processing of both cohorts were conducted simultaneously 
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(Westburg, Leusden, The Netherlands) with 30µl elution buffer. Total RNA was reversely 
transcribed to cDNA by qScript cDNA SuperMix according to manufacturer’s protocol 
(Quantabio, Beverly, MA, USA). Before PCR amplification, genomic DNA was restricted by 
EcoRI (Promega, Madison, WI, USA) and cycling conditions were implemented as described 
previously 74. Total HIV-1 DNA measurements were normalized by measuring the reference 
gene RPP30 (Table S4) in duplicate by ddPCR and expressed per million PBMCs. CA-RNA was 
normalized using three reference genes per patient, (B2M, ACTB and GADPH), which were 
measured with LightCycler 480 SYBR Green I Master mix (Bio-Rad). HIV-1 RNA copies were 
divided by the geometric mean of the reference genes and expressed per million PBMCs. 
Droplet classification and absolute quantification was performed using the ddpcRquant 
analysis tool with standard settings 75.
Statistics
Depending on normality, log- or inverse rank-based transformation was applied. Values 
outside the assay quantification limits were imputed at the respective limit. Parameters for 
which one of the detection limits contained > 50% of the measurements were excluded. 
Comparisons in baseline characteristics between groups were made using Student’s T-test 
or Mann-Whitney U test depending on data distribution. Differences in non-continuous 
data were analyzed by the Pearson’s Chi-square test or Fisher’s exact test in case of expected 
counts less than five. Data were analyzed using a linear regression model. The crude model 
included an  adjustment for sampling time and the primary analyses included age, sex and 
seasonality as co-variates. P-values less than 0.05 were considered statistically significant 
and correction for multiple testing was applied using the Benjamini-Hochberg method (FDR-
correction). Data were analyzed using R (R Core Team, 2015). 
Study approval
The study protocol was approved by the Medical Ethical Review Committee region Arnhem-
Nijmegen (CMO2012-550) and experiments were conducted in accordance with the principles 
of the Declaration of Helsinki. Written informed consent was obtained from all participants.
were measured in whole blood on a Navios flow cytometer (Beckman Coulter, Brea, CA, USA) 
as described elsewhere. Antibodies used are listed in Table S3 22.
RNA extraction and gene expression
For qPCR analyses, total RNA was extracted from monocyte cell pellets (5.105 cells), collected 
in TRIzol (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. 
Subsequently, cDNA was synthesized using iScript reverse transcriptase according to 
manufacturer’s instructions (Invitrogen) with 500ng RNA input in 10ul reaction mix. Relative 
expression of genes NLRP3, TNF, IL6, IL1B was measured using SYBR Green assays (Invitrogen, 
Carlsbad, CA, USA) on an Applied Biosciences Step-one PLUS qPCR machine (Thermo Fischer 
Scientific, Carlsbad, CA, USA). Reaction volumes of 10 µL with 2 µL cDNA input. Normalization 
was performed using ΔΔCq based on two (18S and B2M) reference genes which were stable 
after stimulation. Cycling conditions included: 95°C for 10mins, [95°C for 15 seconds, 60°C for 
1min seconds] (40 cycles), followed by dissociation curve analysis. Primers were designed to 
be intron-spanning and are listed in table S4.
For transcriptome analysis by RNAseq, total RNA was extracted from monocytes (5.105) 
using the QIAGEN RNeasy RNA extraction kit (Qiagen, Venlo, The Netherlands), using on-
column DNase treatment. Next, ribosomal RNA removal and library preparation for next 
generation RNA-sequencing was achieved utilizing KAPA RNA HyperPrep Kit with RiboErase 
(Roche, Basel, Switzerland), following the manufacturer’s protocol. The integrity and quality 
of prepared libraries were assessed using Agilent 2100 Bioanalyzer (Santa Clara, CA, USA). 
Sequencing was performed using Illumina NextSeq 500 machine (San Diego, CA, USA) in a 
paired end sequencing fashion. Sequencing reads obtained from RNA-seq measurement 
were aligned to the hg38 human genome reference using STAR 71. A lower cutoff of average 
50 reads among all samples was used to designate a gene as being expressed in our cohort. 
R software and DESeq2 differential analysis package 72 were used to normalize and assess 
differentially expressed genes, utilizing FDR 5% and log2(Fold change) > 1 as the significance 
cutoff. The network of genes connected to their corresponding gene ontology was generated 
using cytoscape 73. The processed RNA-seq data including normalized read counts can be 
accessed via GEO (GSE160184).
HIV Reservoir quantification
HIV-1 CA-DNA and CA-RNA were measured in triplicate by droplet digital PCR (ddPCR QX200 
– Bio-Rad, Hercules, CA, USA) (Table S3) in CD4+ T cells isolated using EasySep Human CD4+ 
T Cell Isolation Kit (Stemcell technologies, Vancouver, Canada) as described previously 74. 
Briefly, genomic DNA was extracted using the DNeasy Blood & Tissue kit (Qiagen) according 
to the manufacturer’s protocol with an additional step of adding 75µl elution buffer on 
the column heated at 56°C for 10 min. CA-RNA was extracted using the Innuprep RNA kit 
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Supplemental table S1. Baseline characteristics validation cohort.
Characteristic HIV (n=28) HC (n=14)
Male sex, no. (%) 28 (100) 14 (100)
Age, median (IQR) years 56.3 (9.6) 64.3 (12.5)
cART regimen, no. (%)
NNRTI 6 (21.4) -
PI 2 (7.1) -
INSTI 20 (71.4) -
DTG 16 (57.1) -
ELV 1 (3.6) -
RAL 3 (10.7) -
cART: combination antiretroviral therapy. NNRTI: non-nucleoside reverse transcriptase inhibitor. PI: protease inhibitor. 
INSTI: integrase inhibitor. DTG: dolutegravir. EVG: elvitegravir. RAL: raltegravir.
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Supplemental table S3. Antibodies for immunophenotyping.
Fluorochrome FITC PE ECD PE-Cy5.5 PC7 APC APC-AF700 APC-AF750 PB KO
mAb CD16 HLA-DR CD14 CD4 CD25 CD56 CD8 CD19 CD3 CD45
Distributor BC BC BC BC BD BC BC BC BC BC
10-color flow cytometry panel. Samples were analyzed by a 3-laser Navios (BC).mAb: monoclonal antibody; BC: Beckman 
Coulter, CA, USA, BD: Becton Dickinson biosciences, CA, USA
Supplemental table S4. Primers and probes.





















Supplemental table S2. Stimulations scheme for the ex vivo cytokine production assays.
Stimulus Final Concentration Strain/Manufacture
Stimulation of PBMCs for 24 hours
LPS 1 and 100 ng/mL E.coli/Sigma
Pam3Cys 10 μg/mL EMC microcollections
RPMI + serum 10% human serum Life Technologies
Poly I:C 100 μg/mL Sas Invivogen
Imiquimod (TLR7 ligand) 5 ug/mL Invivogen
Influenza + serum 1.25 x 106 PFU/mL + 10% human serum H1N1 (in house)
Mycobacterium tuberculosis 1 μg/mL H37Rv (in house)
E.Coli 1 x 106/mL ATCC 35218 (in house)
Candida albicans conidiae 1 x 106/mL UC820 (in house)
Candida albicans hyphae 1 x 106/mL UC820 (in house)
Staphylococcus aureus 1 x 106/mL ATCC 29213 (in house)
Cryptococcus gattii + serum 1 x 107/mL + 10% human serum A1M-R265, AFLP type 6 (clinical isolate)
Streptococcus pneumonia 1 x 107/mL TIGR4
Stimulation of PBMCs for 7 days*
RPMI  + serum 10% human serum Life technologies
Staphylococcus aureus 1 x 106/mL
Cryptococcus gattii 1 x 107/mL A1M-R265, AFLP type 6 (clinical isolate)
Candida albicans conidiae 1 x 106/mL UC820 (in house)
Candida albicans hyphae 1 x 106/mL UC820 (in house)
Streptococcus pneumonia 1 x 106/mL TIGR4
Mycobacterium tuberculosis 1 μg/mL H37Rv (in house)
Imiquimod (TLR7 ligand) 2.5 ug/mL Invivogen
PBMCs: peripheral blood mononuclear cells; LPS: lipopolysaccharide; TLR: Toll-like receptor.
*All 7-day PBMC stimulation experiments were supplemented with 10% human pool serum
5756
Chapter 2 - Reprogramming of innate immune cells in HIV
2
Supplemental figure S3. Adjusted P-value are depicted from a corrected linear regression model including age, sex, 
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Supplemental figure S1. Adjusted P-value are depicted from a corrected model including age, sex, seasonality and 
monocyte fraction (of PMBCs) as covariates. Red depicts significantly higher in PLHIV, blue depicts lower in PLHIV 
compared to controls. All p-values are FDR corrected.
Supplemental Figure S2. Crude values 24h and 7 days cytokine production. Circulating factors in PLHIV and uninfected 
controls. Crude model is linear regression after inverse rank-based transformation. Corrected model included age, sex, 
and seasonality as covariates. Red depicts the marker is significantly increased in PLHIV; blue depicts the marker is 
decreased in PLHIV compared to controls. All p-values are FDR corrected.
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Supplemental figure S5. HIV reservoir, CMV seropositivity and microbial integrity. P-value are depicted from linear 
regression. Red depicts a significant positive correlation; blue depicts negative correlation. All p-values are FDR corrected.
Supplemental figure S4. Monocytes. (A-C) Circulating monocyte subset concentrations determined by 
immunophenotyping. Classical monocytes (A): CD14++CD16-, Intermediate(B): CD14++CD16+, non-classical(C): 
CD14+CD16+. (D-F) subsets are depicted as % of total monocytes. (G) Monocyte purity after CD14-negative selection 
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Introduction
Combination antiretroviral therapy (cART) has drastically curtailed morbidity and mortality 
in people living with HIV (PLHIV)1. Still, PLHIV remain at an increased risk for pneumococcal 
infections, Mycobacterium tuberculosis (M. tuberculosis) reactivation and impaired vaccine 
responses2-7. Moreover, HIV infection predisposes to non-infectious comorbidities, such 
as cardiovascular disease and non-AIDS-related cancer8, which share an underlying 
pathophysiological pathway characterized by a persisting and inappropriate activation of 
innate and adaptive immune cells9. Together, these observations point towards a disbalance 
in the homeostasis of the immune system, characterized by immunodeficiency on the one 
hand, and chronic inflammation on the other hand8. 
HIV-1 preferentially infects and kills activated CD4+ T cells, leading to rapid and severe CD4+ 
T cell depletion in the gut and increased microbial translocation10. A small proportion of these 
cells remains latently infected with replication competent virus and defective proviruses, 
called the HIV-1 reservoir11. The HIV-1 reservoir and increased microbial translocation, 
together with lifestyle factors and co-infections such as cytomegalovirus (CMV), are 
considered important drivers of the disrupted immune homeostasis in PLHIV11-15. However, 
published data have shown inconsistent or even contradictory findings. Heterogeneity in 
study populations, limited sample sizes of study populations and differences in lifestyle 
factors, including use of tobacco and recreational drugs, may underlie these inconsistencies 
and emphasize the need for an integrative approach in evaluating the immune system in 
PLHIV on chronic cART. 
The Human Functional Genomics Project (HFGP) aims to disentangle variation in the 
immune system in different cohorts of healthy individuals and individuals with underlying 
conditions. It combines multiple levels of analyses and data integration, including 
demographic and lifestyle data, data from ‘omics technologies’, en functional immune data16. 
As part of this project, we previously identified relevant environmental and host factors for 
circulating white blood cell (WBC) populations in healthy individuals17. Embedded within 
the HFGP, we established a cohort of 211 virally suppressed PLHIV (200HIV) and showed 
that these individuals exhibited a sustained pro-inflammatory immune phenotype with 
priming of the interleukin (IL)-1β pathway18. In the present study, we used the same cohort 
to comprehensively assess the peripheral WBC composition during chronic treated HIV 
infection with a special focus on the adaptive immune system. We compared their WBC 
populations with those of healthy individuals and assessed associations with demographic 
and lifestyle factors, different HIV-specific factors, circulating cytokines, as well as ex 
vivo cytokine production capacity of peripheral blood mononuclear cells (PBMCs) after 
stimulation with different bacterial, fungal and viral antigens.
Abstract
Despite adequate combination antiretroviral therapy (cART), the immune system in people 
living with HIV (PLHIV) only partially recovers, predisposing them to non-AIDS-related 
comorbidities and impaired vaccination responses. Here, we compared the circulating white 
blood cell (WBC) architecture between long-term treated people living with HIV (PLHIV) 
and healthy controls, by characterizing 108 peripheral WBC subsets by flow cytometry. We 
next assessed the relation between WBC subsets and clinical factors, markers of the HIV-1 
reservoir (CD4-cell-associated HIV-1 DNA [CA-DNA] and CA-RNA), CMV IgG titers, circulating 
inflammation markers, and immunoglobulins. Lastly, we assessed lymphocyte function by 
measuring ex vivo cytokine production capacity of interleukin (IL)-17, IL-22, and interferon 
(IFN)-ɣ in response to different bacterial, fungal and viral stimuli. We included a total of 211 
virally suppressed adult PLHIV (n=211) on combination antiretroviral therapy (cART) for a 
median (IQR) of 6.6 (7.7) years and 56 healthy controls. PLHIV showed a loss of naïve T cells, 
an increase of T helper (Th) 17 cells and effector T cells, as well as dysregulated B cell memory 
responses. Th17 percentages were related with inflammation markers (IL-6 and soluble 
sCD14), gut homing chemokines (CCL20) and intestinal fatty acid binding protein (IFABP). In 
the innate arm, PLHIV exhibited an expansion of monocytes and a clear loss of natural killer 
(NK) cells. Levels of CA-DNA and CA-RNA were associated with higher percentages of central 
memory CD4+ cells, Th17, and regulatory T cells, whereas CMV seropositivity was associated 
with an expansion of effector T cells in PLHIV. Functionally, IL-22 and IL-17 responses did 
not differ between PLHIV and controls, whereas IFN-ɣ production was reduced in PLHIV, 
especially in those with higher CA-DNA levels. Together, our data show a generalized 
dysregulated pro-inflammatory circulating immune profile in long-term treated PLHIV. 
These changes in WBC cells related with markers the HIV-1 reservoir and translated into 
reduced IFN-ɣ responses, reinforcing the need for early cART initiation.
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Flow cytometry 
Supplementary Table 1 summarizes the antibody clones and the fluorochrome conjugates 
used for the different panel fluorescent staining mixes. Staining was performed on 100 μl/
well erythrocyte-lysed blood (panel 1-3,5) or 0.5 x 106 cells/well freshly isolated PBMCs (panel 
4). Cells were stained according to previously described procedures (see also Supplementary 
Methods)17. Samples were measured on a 10-color Navios flow cytometer (Beckman Coulter, 
Fullerton, CA, USA), equipped with three solid-state lasers (488 nm, 638 nm, and 405 nm) 17. 
Gating was conducted manually and verified by two independent specialists to prevent gating 
errors. Samples were analyzed within 4-5 hr after blood collection, using five distinct and 
complementary 10-color antibody panels: 1. general; 2. T cell; 3. B cell; 4. intracellular T cell/
Treg; 5. Chemokine receptors. Staining and gating strategies are summarized can be found in 
Supplementary Figure 1. Flow cytometry data were analyzed using Kaluza software version 1.3.
PBMC stimulation experiments
Freshly isolated PBMCs were incubated with different stimuli (Supplementary Table 2) 
including bacterial (Staphylococcus aureus, M. tuberculosis, Streptococcus pneumoniae [S. 
pneumoniae]), fungal (Cryptococcus gattii, Candida albicans [C. albicans] hyphae and yeast) and 
other relevant antigens (Imiquimod, TLR7 ligand), in round-bottom 96-well plates (Greiner 
Bio-One, Frickenhausen, Germany) with 0.5 x 106 cells/well at 37°C and 5% CO2 in the presence 
of 10% human pooled serum for seven days. Supernatants were stored at -20°C. Levels of 
the lymphocyte-derived cytokines IL-17, IL-22, and interferon (IFN)-γ were measured in the 
supernatants (PeliKine Compact or Duoset ELISA, R&D Systems).
Plasma markers
Serum levels of immunoglobulin (Ig)M and IgG were measured by immunonephelometry 
using a Beckman Coulter Imager and Beckman Coulter reagents. Measurements were 
standardized using certified European reference material 470 (ERM®-DA470). CMV IgG 
antibodies were measured in serum using ELISA (Genway Biotech Inc., San Diego, CA, USA) 
according to the manufacturer’s instructions. Markers of systemic inflammation, high-
sensitive C-reactive protein (hsCRP) and soluble CD14 (sCD14), and microbial translocation, 
intestinal fatty acid binding protein (IFABP), were measured by ELISA (Quantikine, R&D 
Systems) according to the manufacturer’s instructions. IL-6 was measured using a SimplePlex 
Cartridge (Protein Simple, San Jose, CA, USA). Circulating plasma CCL20, IL-17A, and IFN-ɣ 
were measured using the commercially available Olink Proteomics AB Inflammation Panel 
as described previously21,22. In this Proceek Multiplex proximity extension assay, proteins 
are recognized by pairs of antibodies coupled to cDNA strands, which bind when they are 
in close proximity and extend by a polymerase reaction. Detected proteins were normalized 




This study is part of the HFGP (www.humanfunctionalgenomics.org)16. Between 14 December 
2015 and 6 February 2017, individuals living with HIV were recruited from the HIV clinic of 
Radboud university medical center. Inclusion criteria were: Caucasian ethnicity, age ≥ 18 
years, receiving cART > 6 months, and latest HIV-RNA levels <200 copies/ml. Exclusion 
criteria were: signs of acute or opportunistic infections, antibiotic use <1 month prior to study 
visit, or active hepatitis B/C. The control population consisted of 56 healthy adult individuals 
(56P cohort) who were longitudinally sampled four times in three-month intervals. Inclusion, 
sampling and sample processing of both cohorts were conducted simultaneously and by 
the same personnel. The 56P participants were selected as a subset of a larger cohort of 534 
healthy individuals (500FG) which was phenotypically assessed two years earlier according to 
the same methods17,19. Given the larger sample size, differences in cell-cell associations were 
compared between 200HIV and the 500FG.17 General information from all participants was 
recorded in the Castor Electronic Data Capture program (Castor EDC, CIWIT B.V., Amsterdam, 
The Netherlands), using questionnaires on socio-demographic information, lifestyle and 
life-events. Clinical data were extracted from medical files and the ‘Stichting HIV Monitoring’ 
registry (Amsterdam, The Netherlands).
Ethics
The study protocols were approved by the Medical Ethical Review Committee region 
Arnhem-Nijmegen (ref. 42561.091.122) and conducted in accordance with the principles of 
the Declaration of Helsinki. All study participants provided written informed consent. 
Cell processing
Venous blood was collected in sterile 10 ml EDTA BD Vacutainer® tubes between 8 and 11 
am and processed within 1-4 hours. Cell counts were determined using a Sysmex XN-450 
automated hematology analyzer (Sysmex Corporation, Kobe, Japan). Erythrocyte-lysed whole 
blood samples were obtained after 10 minutes incubation of 1.5 ml EDTA-anticoagulated 
blood with lysis buffer containing 3.0 M NH4Cl, 0.2 M KHCO3 and 2 mM Na4EDTA. The 
remaining WBC were washed twice, by adding 25 ml phosphate-buffered saline 1x (PBS, 
Braun, Melsungen, Germany) and centrifuging at 452 x g for 5 min at room temperature. 
Before staining, cells were resuspended in 300 μl of PBS enriched with 0.2% bovine serum 
albumin (BSA, Sigma-Aldrich, Zwijndrecht, Netherlands). Isolation of PBMCs was performed 
by density centrifugation of EDTA-anticoagulated blood diluted 1:1 in pyrogen-free PBS over 
Ficoll-Paque (VWR, Amsterdam, The Netherlands) as described previously20. Cells were 
adjusted to 5.0 x 106 cells/ml. 
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cohorts, and to calculate associations between WBC and clinical and virological factors. All 
analyses were corrected for age, sex, time since January 2015 and seasonal effects. Cytokine 
analyses between cohorts were also corrected for CD4+ and CD8+ T cell percentages. 
Spearman correlations were used as the distance metric for unsupervised hierarchical WBC 
count clustering. Two-sided FDR-corrected p-values < 0.05 were considered statistically 
significant27. Effect sizes are reported as Spearman’s Rho or standardized beta coefficients 
(β). Data were analyzed using the statistical programming language R (version 3.4.3, R Core 
Team, 2012).
Results
General and HIV-specific characteristics 
Data from 211 PLHIV and 56 controls were analyzed in this study (Table 1). PLHIV were older 
(median [IQR] 52.5 [13.2] vs 30.0 [27.1] years, p<0.0001) and more often male (193/211 [91.5%] vs 
34/56 [60.7%], p<0.0001) than controls. PLHIV had received cART for a median of 6.6 (7.7) years 
and 205/210 (98%) had plasma HIV-1 RNA <50 copies/mL at time of study visit. Analyzing the 
HIV reservoir, we found detectable levels of total CA-DNA in 207/208 (99.5%) and CA-RNA in 
210/210 (100%); CA-DNA and CA-RNA levels were highly correlated (Supplementary Figure 2A; 
R=0.68, p<2.2·10-16). In general, PLHIV with higher CA-DNA and CA-RNA levels were older, had 
been living with and treated for HIV for a longer period, and had lower nadir CD4+ T cell counts 
(Supplementary Figure 2A). We observed no significant differences in CA-RNA and CA-DNA 
between PLHIV with plasma HIV-1 RNA <50 copies/mL (205/210 [98%]) and those with plasma 
HIV-1 RNA 50-200 copies/mL (5/210 [2%]; Supplementary Figure 2B). PLHIV with at least once a 
viral load of >50 copies/mL during year prior to study visit (23/210 [11.0%]) had higher levels of 
CA-RNA (p=0.0077), but no differences in CA-DNA (p=0.076; Supplementary Figure 2B).
Alterations in WBC composition and cell-cell associations in chronic HIV 
We analyzed 108 WBC populations, including 93/107 (87%) B and T cell subsets and 14/107 
(13%) innate cell subsets (neutrophils, monocytes, natural killer [NK] and natural killer T 
cells [NKT]). Figure 1, Supplementary Figure 3 and Table 2 show the differences in WBC 
composition between PLHIV and controls. 
Principal component analysis (PCA) of all WBC populations showed clear differences in 
clustering between PLHIV and controls (Figure 1A). As expected, PLHIV had an expansion 
of CD8+ cells and a reduction of CD4+ T cells (Table 2). Functionally, CD4+ T cells comprise 
a diverse population of cells including T helper (Th) cells, which fulfill essential roles 
for viral (Th1, CCR6-CXCR3+CCR4-), parasitic (Th2, CCR6-CXCR3-CCR4+), and mucosal 
(Th17, CCR6+CXCR3-CCR4+) immunity28, and Tregs, which are essential for controlling 
Cell-associated HIV-1 DNA and cell-associated HIV-1 RNA quantification in CD4+  
T cells 
The HIV reservoir was assessed by analyzing CD4+ cell-associated HIV-1 DNA (CA-DNA) 
and CA-RNA. In virally suppressed patients, the CA-DNA roughly equals the integrated 
HIV-1 DNA, being replication competent or not23, while CA-RNA is associated with recent 
HIV-1 transcriptional activity and serves as a proxy for the active proviral reservoir24. CA-
DNA and CA-RNA were measured in triplicate by droplet digital PCR (ddPCR – Bio-Rad) in 
CD4+ T cells isolated using EasySep Human CD4+ T Cell Isolation Kit (Stemcell technologies, 
Vancouver, Canada) as described previously25. CA-DNA was extracted by  the DNeasy 
Blood & Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol 
with the addition of 75µl elution buffer on the column heated at 56°C for 10 minutes. CA-
RNA was extracted using the Innuprep RNA kit (Westburg, Leusden, The Netherlands) 
with 30µl elution buffer. Total RNA was reversely transcribed to cDNA by qScript cDNA 
SuperMix according to manufacturer’s protocol (Quantabio, Beverly, MA, USA). CA-DNA 
was normalized by measuring the reference gene RPP30 (Supplementary Table 3 and 
Supplementary Methods) in duplicate by ddPCR and expressed per million PBMCs. CA-RNA 
was normalized using three reference genes per patient, (B2M, ACTB and GADPH), which 
were measured with LightCycler 480 SYBR Green I Master mix. HIV-1 RNA copies were 
divided by the geometric mean of the reference genes and expressed per million PBMCs. 
ddPCR data analysis was performed using the ddpcRquant tool with standard settings for 
thresholding and absolute quantification26.
Statistical analyses
A detailed description of the statistical methods can be found in the Supplementary 
Methods. Given the impact of cohort differences in the frequency of main WBC types (e.g. 
CD4+) on the frequencies of their subsets (e.g. CD4+ regulatory T cells [Tregs]), results were 
primarily reported as WBC percentages, unless stated otherwise. WBC percentages were 
calculated by dividing the cell count of each subpopulation by its respective parent (one level 
up) or, where relevant, grandparent (two levels up; Supplementary Table 4). Data curation 
of cytokine, soluble marker, and immunoglobulin data was done according to previous 
methods19. For comparisons between cohorts, we used all four longitudinally collected data 
points from the 56P cohort as independent measurements. Because of the known seasonality 
effects on WBC, this approach was considered preferable over selecting one of the data 
collection points or summarizing the data points. Data were normalized using an inverse 
rank transformation algorithm. 
Comparisons in baseline characteristics between groups were made using Student’s t-test 
(or Mann-Whitney U test) for continuous variables, and Pearson’s Chi-square test (or Fisher’s 
exact) for categorical variables. Linear regression was used to compare WBC between 
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inflammation29. Despite reduced CD4+ T cell counts, Th frequencies (CD4+ CD45RA- CD25-) 
were markedly increased in PLHIV compared to controls (Table 2). Within the Th pool, Th2 
percentages were reduced in PLHIV compared to controls, whereas Th1 percentages did 
not differ. Remarkably, Th17 percentages and frequencies were increased in PLHIV (Figure 
1B, Table 2). While Treg percentages (of CD4+ cells), including highly suppressive Tregs co-
expressing the transcription factors FoxP3 and Helios, were also increased in PLHIV, Treg 
frequencies were reduced,(Figure 1B, Table 2), suggesting that this relative increase of Tregs 
mainly results from a loss of other CD4+ subsets30. Among Tregs, we found no differences in 
the percentage of activated (HLA-DR+) and effector Tregs (CD45RA-). 
The relationship between pro-inflammatory Th17 cells and Treg must remain balanced to 
preserve functional immunity. Altered ratios have been described in untreated HIV (lower 
Th17/Treg), autoimmune disease and cancer (higher Th17/Treg)10,31,32. Here, we found increased 
Th17/Treg ratios among virally suppressed PLHIV, irrespective of the Treg identification marker 
used (Figure 1B and Supplementary Figure 4). Furthermore, out of the Treg population, the 
percentage of Th17-like CCR6+ Tregs was increased in PLHIV, further contributing to a pro-
inflammatory state. Developmentally, T cells evolve from naive T cells to antigen experienced 
central memory (CM), effector memory (EM), and effector cells33,34. HIV not only differentially 
affects functional subpopulations, but also disrupts these developmental stages. While naïve 
CD4+ and CD8+ T cells were reduced, memory and effector cells were expanded in PLHIV (Figure 
1B, Table 2). Likewise, we found higher percentages of proliferating (Ki67+) CD4+ and CD8+ T 
cells in PLHIV, indicating increased cell turnover. These results suggest a shift from naive cells 
towards terminally differentiated cells in HIV, even if viral replication is under control35, which 
cannot be explained by age, sex, or season as we corrected our models for these factors.
Changes in the B cell compartment have also been described in PLHIV, including loss of CD27+ 
memory B cells36,37. Furthermore, viremia and low CD4+ T cell counts have been associated 
with the expansion of terminally differentiated B cells and immature B cells respectively36,37. 
In our study, we observed clear differences in B cell development in PLHIV illustrated by 
increase of naïve B cells (IgD+IgM+CD27-) and plasmablasts (IgD- IgM- CD38++) and a loss of 
memory B cells (IgD+IgM+CD27+), transitional B cells (CD24++CD38++) and natural effector B 
cells (CD24+CD38+IgD+IgM+, Figure 1B, Table 2). Adequate B cell maturation further requires 
optimal communication between B and T cells. We therefore sought to identify differences 
in WBC co-regulation between PLHIV and HIV-uninfected individuals by comparing cell-cell 
associations between PLHIV and participants from the 500FG cohort. Details of this 500FG 
cohort have been reported previously (500FG, n=534)17. Using the same immunophenotyping 
techniques, we observed weaker correlations between naïve, CM and EM CD4+ T cells and 
several B cell subpopulations (including class-switch memory B cells) within PLHIV than in 
participants of the 500FG cohort, suggesting altered B/T cell interactions (Figure 1C). These 
Figure 1. Differences in WBC percentages between PLIV and healthy individuals. Differences in WBC percentages 
(n=108 WBC subsets) between PLHIV (n=211) and healthy controls (n=56). (A) Principal component biplot showing 
standardized variance for the two principal component of all WBC subsets. The ovals represent the different cohorts. 
(B) Boxplots showing examples of cohort differences in cell percentages and Th17/Treg ratios (Treg identification marker 
CD25++). Inverse-rank transformed data were analyzed using linear regression and adjusted for age, sex, sampling time, 
and season. (C) Exploratory analysis depicting cell-cell associations between a total of 77 available WBC subsets that 
were significantly stronger (red) or weaker (blue) in PLHIV compared to healthy controls (n=534). FDR-adjusted p-values 
are obtained after 10 000 permutations and adjusted for age, sex, sampling time and season. HC: healthy control; 
PLHIV: people living with HIV; WBC: white blood cells.
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i.e. higher counts were associated with higher percentages of naïve CD4+ T cells (β=0.45, 
p=1.2·10-9) and memory B cells (β=0.18, p=0.034). In contrast, we observed no effects of the 
duration of HIV infection or cART (regimen) on the WBC composition (Supplementary Tables 
5 and 6). 
Second, we explored the relationship with markers of the HIV reservoir. CA-DNA was negatively 
associated with CD4+ T cell percentages (β=-0.33, p=9.8·10-5) and positively with CD8+ T cell 
percentages (β=0.34, p=7.0·10-5). Within the CD4+ T cell pool, CA-DNA correlated with higher 
percentages of CM and Th17 cells (β=0.21, p=0.026 and β=0.24, p=0.0081 respectively; Figure 3 
and Supplementary Tables 7 and 8) Higher CA-DNA was also associated with more CD4+ T cell 
proliferation (Ki67+, β=0.35, p=3.3·10-5) and Treg activation (HLA-DR+, β=0.23, p=0.0081 ). We 
found similar, generally weaker, associations between T cells and CA-RNA, but no relation with 
the relative HIV transcription level (CA-RNA/CA-DNA ratios; Supplementary Table 7 and 8). Lastly, 
we observed several associations between CA-DNA and B cells: higher CA-DNA levels correlated 
with reduced percentages of IgD+ only memory B cells (β=-0.27, p=0.00068) and, albeit non-
significantly, with reduced percentages of natural effector B cells (CD24+CD38+IgD+IgM+, β=-
0.18, p=0.056), and class unswitched memory B cells (IgD+IgM+CD27+, β=-0.18, p=0.053). 
Third, like in untreated PLHIV, CMV remains a major pathogen in immune suppressed PLHIV. 
As CMV is known to affect WBC populations in healthy controls39, we explored the association of 
CMV serostatus with WBC composition. 198 of the PLHIV (93.8%) were seropositive for CMV. In 
line with findings in healthy individuals39, CMV seropositivity correlated with higher percentages 
of effector, EM T cells (e.g. with CD8+ effector cells β=0.43, p=1.7·10-9 and CD4+ EM cells β=0.30, 
p=0.00011; Figure 3 and Supplementary Table 7 and 8) and NKT cells (β=0.29, p=0.00029), yet 
with lower percentages of Th17 cells (β=-0.26, p=0.00065). B cells were not directly affected by 
CMV. 
Microbial translocation, inflammation and Th17 differentiation in chronic HIV 
infection
One of our key findings is the shift of naïve cells into Th17 in PLHIV compared to healthy 
controls, which related with lower nadir CD4+ T cells counts and higher levels of CA-DNA. To 
further assess the potential underlying mechanisms, we explored the relationship between 
these WBC subsets, markers of chronic inflammation, and markers of microbial translocation. 
As discussed above, naïve T cells are able to differentiate into different Th subsets depending 
on the cytokine environment40. We previously showed that PLHIV in our cohort exhibited a 
pro-inflammatory profile with increased levels of hsCRP (p=0.00022) and sCD14 (a marker of 
monocyte activation, p=0.0025; Figure 4A) as well as markedly elevated monocyte-derived 
cytokine responses, particularly IL-1β 18. Such a pro-inflammatory cytokine environment may 
push the differentiation of naive CD4+ cells into Th17 cells 40. Indeed, we observed positive 
differences were not attributable to the influence of age, sex, or season as these factors were 
regressed out of the analysis. 
Apart from changes in the adaptive cell compartment, we observed clear changes in the 
innate WBC compartment in PLHIV reflected by an expansion of monocytes and NKT cells 
and a clear loss of NK cells, specifically the cytokine-producing NK bright cells (Table 2) 
Together, these data show a widespread functional and developmental dysregulation of the 
immune system in virally suppressed PLHIV. This dysregulation encompasses both the innate 
and the adaptive compartment and results in a pro-inflammatory immune environment with 
an expansion of monocytes, pro-inflammatory Th and effector T cells, and dysregulated B cell 
memory responses. 
Age, sex, and smoking influence the WBC composition during chronic HIV 
infection
Apart from the effects of HIV, demographic and lifestyle-related factors may influence the 
composition of the circulating WBC populations. Indeed, we found that older age was 
associated with an increase of innate immune cells and differential effects on B and T cell 
populations, for example with lower percentages of naïve T cells (CD4+ T cells β=-0.29, 
p=0.00020; CD8+ T cells β=-0.29, p=0.00020) and B memory cells (β=-0.39, p=1.5·10-7) and 
higher percentages of memory T cells (e.g. CD8+ CM β=0.22, p=0.00064) and mature naïve 
B cells in PLHIV (β=0.25, p=0.00087, Figure2 and Supplementary Tables 5 and 6). Sex-
dependent influences of the WBC composition, reflected by more effector and EM cells and 
fewer naïve (B and T) cells in males in HIV infection, resembled those observed previously 
observed in healthy individuals19,38. 
Lifestyle risk behaviors such as smoking (63/211 [29.9%]), heavy drinking (28/211 [13.3%]), 
and regular drug use (61/211 [28.9%]) were highly prevalent in PLHIV (Table 1). We found 
that packyears (reflecting total tobacco exposure) were associated with higher frequencies of 
neutrophils (β=0.22, p=0.033), Treg (β=0.22, p=0.033), CD8+ subsets (e.g. CCR6-CXCR3-CCR4+ 
β=0.24, p=0.025), and class switched memory B cells (β=0.20, p=0.042, Supplementary Table 
6). Active smoking correlated with higher proportions of Th17 (β=0.21, p=0.031) and CCR6+ 
Tregs (β=0.26, p=0.0028, Figure 2, Supplementary Table 5). Neither heavy drinking, nor 
regular drug use affected the WBC composition. 
HIV-1 reservoir and CMV affect the WBC composition in chronic HIV infection
We further assessed the effects of relevant clinical and virological factors on the WBC 
composition in PLHIV. First, we explored associations with the history of immune suppression 
and treatment-related factors. We found that nadir CD4+ cell counts were closely associated 
with both B and T cell percentages in PLHIV (Figure 2 and Supplementary Tables 5 and 6), 
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associations between Th17 percentages and circulating IL-6 (β=0.21, p=0.014) and sCD14 (β 
=0.17, p=0.035; Figure 4B,C). Notably, Th17 cells fulfill an essential role in mucosal defense 
and gut Th17 cells are known to be severely depleted during acute HIV10. 
To test whether gut integrity might have been compromised in our cohort, we measured 
levels of the microbial translocation marker IFABP and found increased levels in PLHIV 
compared to healthy controls (p=7.6·10-5; Figure 4D), suggesting ongoing microbial 
translocation in chronic treated HIV, especially in those with higher CA-RNA and CA-DNA 
(CA-RNA β =0.18, p=0.0091 and CA-DNA β=0.21, p=0.0025, Figure 4E). Higher levels of IFABP 
were associated with an expansion of peripheral blood Th17 (β=0.17, p0.043; Figure 4B). 
Homing of Th17 to the gut (and other tissues, such as the skin) is directed by the chemokine 
CCL20, which is produced by tissue and immune cells (neutrophils and monocytes) and binds 
uniquely to the CCR6+ receptor41. Correspondingly, we found strong associations between 
CCL20 and Th17 percentages (β=0.22, p=0.0037), CCL20 and Th17/Treg (β=0.26, p=0.00081 for 
Th17/FoxP3+ Treg, β=0.27, p=0.00081 for Th17/CD127low Treg, and β=0.19, p=0.013 for Th17/
CD25++ Treg), CCL20 and circulating IL-17A levels (β=0.47, p=1.2·10-11) and CCL20 and IFABP 
(β=0.24, p=0.0011; Figure 4F) . Together, these results suggest that the pro-inflammatory 
environment in chronic HIV may promote the differentiation of circulating naïve CD4+ T cells 
into Th17 cells and that these changes may be associated with changes in gut permeability 
and gut homing. 
Functional consequences of changes in adaptive immune cells in chronic HIV
As our results indicated significant changes in circulating immune cell populations in PLHIV, 
we next analyzed the possible functional consequences. First, we measured the cytokine 
production capacity of PBMCs after ex vivo stimulation with different stimuli. We found 
strong correlations between NK and T-cell percentages and IFN-g, IL-17, and IL-22 production 
capacity (Figure 5A and Supplementary Tables 9 and 10 ): IFN-g responses correlated with 
percentages of NK dim, CD4+ and CD8+ EM cells, whereas IL-22 responses correlated with 
CCR6+ CM CD4+ cell percentages. As expected, Th17 percentages were associated with 
increased circulating IL-17A (β=0.16, p=0.029) and ex vivo IL-17 responses to C. albicans 
(β=0.19, p=0.047) and with reduced IFN-ɣ responses (Figure 5A, E and Supplementary Tables 
9) Despite the expansion of Th17 cells among PLHIV compared to controls, ex vivo production 
capacity of IL-17 or IL-22 did not differ, suggesting that the functional capacity of these cells 
may be compromised. In contrast, IFN-g production upon stimulation with C. albicans hyphae 
(p=0.012) and M. Tuberculosis (p=0.0025) was reduced in PLHIV (Figure 5B). Among PLHIV, 
lower ex vivo IFN-g production to stimulation with Imiquimod ((β =-0.21, p=0.0020) and S. 
pneumoniae (β=-0.22, p=0.0011) and lower circulating IFN-g concentrations (β=-0.18, p=0.014) 
were associated with higher CA-DNA levels (Figure 5C, D). No associations were found 
between ex vivo cytokine production and CMV seropositivity. 
Figure 2. Clinical determinants of WBC percentages in PLHIV . (A) Heatmap of WBC percentages (n= n=108 WBC subsets) 
that were significantly associated with any of the clinical determinants tested in 211 PLHIV; WBC subsets that showed no 
significant correlations with any of the parameters (n=37) have been removed from the figure. (B) Examples of WBC subsets 
that were significantly associated with age, sex, smoking, or CD4 nadir. Inverse-rank transformed data were analyzed using 
linear regression and adjusted for age, sex, sampling time, and season. For color coding of the FDR-adjusted p-values see 
legend. PLHIV: people living with HIV; WBC: white blood cells.
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Figure 4. Inflammation, microbial translocation, and Th17 cells in PLHIV. (A) Boxplots showing differences in hsCRP 
and sCD14 between PLHIV (n=211) and healthy controls (n=56). (B) Heatmap showing associations between Th17 
percentages, Th17/Treg ratios and sCD14, hsCRP, IFABP, and CCL20. (C) Associations between Th17 percentages and 
sCD14 and circulating IL-6 in PLHIV. (D) Levels of the microbial translocation marker IFABP in PLHIV and healthy controls. 
(E) Associations between IFABP and CA-RNA and CA-DNA in PLHIV. (E) Associations between CCL20 and circulating 
IL-17A and IFABP. Inverse-rank transformed data were analyzed using linear regression analyses and corrected for 
sampling time. CA-DNA: CD4-cell-associated HIV-1 DNA; CA-RNA: CD4-cell-associated HIV-1 RNA; CCL20: Chemokine 
(C-C motif) ligand 20; HC: healthy control; hsCRP: high-sensitivity CRP; IFABP: intestinal fatty-acid binding protein; 
IL-6: interleukin 6; IL-17A: interleukin 17A; Mem Tc: CD4+ memory T cell; PLHIV: people living with HIV; sCD14: soluble 
CD14; Th17 percentages: T-helper 17 cell percentages (Mem Tc CCR6+ CXCR3-CCR4+ as percentage of CD4+ Mem Tc); 
Treg: regulatory T cells; WBC: white blood cells.
Figure 3. The HIV-1 reservoir, CMV serostatus and WBC percentages in PLHIV. (A) Heatmap of significant associations 
between WBC percentages (total n=108), CMV co-infection (serostatus and IgG titers in 198 seropositive PLHIV) and 
markers of the HIV-1 reservoir (CA -DNA and CA- RNA) in 211 PLHIV; WBC subsets that showed no significant correlations 
with any of the parameters (n=41) have been removed from the figure. (B) Examples of WBC percentages that were 
significantly associated with the viral reservoir or CMV IgG titers. Inverse-rank transformed data were analyzed using 
linear regression and adjusted for age, sex, sampling time, and season. For color coding of the FDR-adjusted p-values 
see legend. CA-DNA: CD4-cell-associated HIV-1 DNA; CA-RNA: CD4-cell-associated HIV-1 RNA; CMV: cytomegalovirus; 
PLHIV: people living with HIV; WBC: white blood cells.
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Second, we measured serum immunoglobulins and found significant correlations between 
serum IgM and IgM+ B cell populations (Figure 5F), but no cohort differences in IgM levels 
(10.04 [3.27] g/L in PLHIV versus 9.10 [3.79] g/L in controls, p= 0.12) or IgG levels (median [IQR] 
0.76 [0.49] g/L in PLHIV versus 0.82 [0.56] g/L in controls, p= 0.22). These results indicate that 
while some of the alterations in adaptive immune function may be reversed by long-term 
cART42,43, others, such as impaired IFN-g responses, remain.
Discussion
In this study we show that, despite suppressive cART, the circulating innate and adaptive 
immune cell composition in PLHIV differs from that of HIV-uninfected individuals. We 
confirm that PLHIV exhibit a WBC profile characterized by proliferating memory and effector 
CD4+ and CD8+ T cells. While untreated HIV infection has been associated with a loss of 
circulating Th17 cells10, we observed an expansion of circulating Th17 cells and increased 
Th17/Treg ratios during stable suppressive treatment, which was associated with plasma 
concentrations of IL-6, CCL20 and the microbial translocation marker IFABP. Furthermore, 
PLHIV showed clear changes in B cell maturation with reduced proportions of memory B 
cells and increased frequencies of plasmablasts. In the innate compartment, we observed 
an expansion of monocytes together with a loss of NK cells, specifically NK bright cells. 
In addition to age, sex, smoking, and CMV, we found strong associations between WBC 
populations and markers of the HIV-1 reservoir (CA-DNA and CA-RNA). Functionally, Th17 
responses seemed to be preserved, whereas IFN-g responses were compromised, especially 
in those with higher CA-DNA, which may affect host defense against some important 
bacterial pathogens (including M. Tuberculosis) as well as the HIV-1 reservoir.
Prior studies have shown that untreated HIV infection results in a massive depletion of Th17 
cells from the peripheral blood and the mucosa10, a process that may partially be reversed 
by cART44,45. We recently showed in the same cohort that PLHIV have a pro-inflammatory 
profile with increased monocyte-derived cytokines, particularly IL-1β18. IL-1β and IL-6 are 
among the critical cytokines driving differentiation of Th1740, and we postulate that these 
cytokines may have contributed to the higher circulating Th17 numbers. Th17 cells in the 
peripheral blood poorly reflect mucosal Th17 numbers 46 and we cannot exclude that mucosal 
Th17 depletion with increased microbial translocation and altered Th17 recruitment occurs 
in the participants of our study. Concurrently to increased Th17 cells and pro-inflammatory 
Th17-like (CCR6+) mTregs, PLHIV showed increased peripheral blood Th17/Treg ratios. 
Increased Th17/Treg ratios have been linked to cardiovascular disease and atherosclerosis31, 
cancer32, and major depressive disorder47, which are all highly prevalent in long-term treated 
PLHIV. Th17-mediated auto-immune diseases like psoriasis are also common among PLHIV, 
although they mostly occur during periods of severe immunosuppression and resolve upon 
Figure 5. Functional consequences of WBC alterations in PLHIV. (A) Heatmap of NK(T) and T cell percentages (total 
n=71) that were significantly associated with the ex vivo production of IFN-ɣ, IL-17, and IL-22 upon ex vivo stimulation of 
PBMCs with seven different stimuli in 211 PLHIV; WBC subsets that showed no significant correlations with any of the 
parameters (n=44) have been removed from the figure.  (B) Boxplot showing differences in ex vivo production capacity 
of IFN-ɣ upon seven days stimulation between PLHIV (n=211) and healthy controls (n=56). (C) Association between CA-
DNA and ex vivo IFN-ɣ production capacity in PLHIV.(D) Association between CA-DNA and circulating IFN-ɣ in PLHIV. 
(E) Association between Th17 percentages and circulating IL-17A in PLHIV. (F) Heatmap of B cell percentages (total n=28) 
that were significantly correlated with IgM or IgG levels in PLHIV; WBC subsets that showed no significant correlations 
with any of the parameters (n=21) have been removed from the figure. Inverse-rank transformed data were analyzed 
using linear regression analyses and corrected for sampling time. For cohort comparisons, data were corrected for age, 
sex, sampling time, season and the proportion of CD4+ and CD8+ cells. For color coding of the FDR-adjusted p-values see 
legend. CA-DNA: CD4-cell-associated HIV-1 DNA; HC: healthy control; IFN-ɣ: interferon gamma; Ig: immunoglobulin; 
IL-17(A): interleukin 17(A); IL-22: interleukin 22; Mem Tc: CD4+ memory T cell; NK(T) cells: natural killer (T) cells; PBMC: 
peripheral blood mononuclear cell; PLHIV: people living with HIV; sCD14: soluble CD14; Th17 percentages: T-helper 17 
cell percentages (Mem Tc CCR6+ CXCR3-CCR4+ as percentage of CD4+ Mem Tc); WBC: white blood cell
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Several limitations should be considered when interpreting our data. First, the observational 
study design limits causal inferences. Second, generalizability of our findings to women, 
children and non-European populations requires further studying. Third, individuals in our 
control group were younger and more often female. However, we controlled for these cohort 
differences in our statistical models. Fourth, we used a predefined set of flow cytometry 
panels. While this standardized approach enhances validity and reproducibility and enabled 
us to compare our results with those of a large cohort of healthy controls, some interesting 
WBC subsets and markers for HIV have not been included (e.g. Tfh cells and PD-1/CD57 
expression in the context of B/T cell interactions and immune cell exhaustion respectively). 
Finally, our WBC data are limited to the peripheral blood and we have no data on tissue-
specific WBC composition (e.g. lymph nodes or the gut).
In summary, we show that the circulating innate and adaptive immune cell composition is 
altered in a large group of long-term treated PLHIV. Furthermore, our findings suggest that 
some of the adaptive immune responses (Th17) are preserved while IFN-g responses are 
compromised. Our comprehensive approach provides new insight into the changes in the 
immune cell architecture and functional immunity in long-term treated HIV and highlights 
associations with the HIV-reservoir, underlining the need for early cART initiation. Our 
results are currently validated and extended in a multi-omics study including 2000 virally 
suppressed PLHIV (clinicaltrials.gov identifier: NCT03994835).
Supplementary data
All supplementary figures, the supplementary methods, and  supplementary table 1-3 can be 
found at the end of this manuscript. Supplementary tables 4-10  are digitally available at the 
website of the published article..
cART initiation48. Despite these changes in Th17, IL-17 and IL-22 cytokine responses did not 
differ between PLHIV and healthy controls. In contrast, we observed reduced ex vivo IFN-g 
responses in PLHIV. IFN-g is predominantly produced by NK(T) cells, Th1, and CD8+ cells42. 
Given that CD8+ cells were increased in PLHIV and Th1 cells did not differ between PLHIV and 
controls, we postulate that the reduced IFN-g responses may have resulted from the loss of 
NK cells, which has been reported previously in both untreated and treated PLHIV49,50. In line 
with prior data, we observed an inverse relationship between IFN-g responses and CA-DNA, 
suggesting that the failure to restore the NK cell compartment after cART initiation may be 
important for the containment of the HIV-1 reservoir51.Moreover, IFN-g is a key cytokine in the 
immune response against M. tuberculosis which remains an important pathogen in treated 
PLHIV .52. Improving NK-derived IFN-g responses, may therefore be relevant in the context of 
M. Tuberculosis and HIV cure. 
Different factors may contribute to the variation in T-cells repertoire in PLHIV. First, the 
effects of demographic factors such as age, sex, and smoking resembled those observed 
previously in healthy individuals17,39. Second, PLHIV in our study were almost universally 
coinfected with CMV, and CMV seropositivity was associated with the expansion of effector 
and EM T cells 39,53. Of note, high CMV IgG levels may reflect frequent CMV reactivations or 
result from a stronger immune response (including adequate B/T cell interactions and B 
cell responses) and, consequently, fewer activations54. Importantly, higher CMV IgG titers 
have been linked to the development of non-AIDS-defining events such as cardiovascular 
disease55. Third, we found substantial associations WBC subsets and CD4+ nadir and markers 
of the HIV-1 reservoir. We found detectable levels of CA-RNA and CA-DNA in almost all 
participants. Overall, CA-DNA showed more and stronger correlations with WBC subsets than 
did CA-RNA, which can be explained by the fact that CA-RNA reflects transcriptional activity, 
which is more variable than CA-DNA, which equals integrated DNA11,56. 
Next to T cell dysfunction, HIV is characterized by aberrant B cell responses and 
B cell dysfunction. Using a different set of B cell markers than earlier studies in 
PLHIV 57,58, we confirm their observations that proportions of naïve B cells are increased and 
memory B cells are reduced in PLHIV. Moreover, adequate B cell maturation requires optimal 
communication between T and B cells, which, according to our data, might be compromised 
in chronic stable PLHIV. B/ T cell interactions take place in the germinal centers in lymph 
nodes and are orchestrated by follicular Th cells (Tfh)59. As these cells are known to be highly 
permissive to HIV infection and serve as reservoirs during chronic infection, they could 
potentially explain these disrupted B/T cell interactions59,60. Clinically, compromised B/T 
cells interactions may contribute to impaired immune responses to vaccination as well as 
increased risks for infections, such as invasive pneumococcal disease61. 
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Age, years 52.5 (13.2) 30.0 (27.1) <0.0001
Sex, female, n/N (%) 19/211 (9.0) 22/56 (39.3) <0.0001
BMI, kg/m2 24.1 (4.0) 23.6 (3.6) 0.41
Time since HIV diagnosis, years 8.5 (9.5) - -
Way of transmission, n/N (%) - -
MSM 159/211 (75.4) - -
Heterosexual contact 9 (4.3) - -
IDU 3 (1.4) - -
Other or unknown 40 (19.0)
Nadir CD4+ cell count, cells/μl 250 (230) - -
CD4+ count, cells/μl 660 (330) - -
Zenith HIV-RNA, copies/mL 100 000 (341 182) - -
HIV-RNA >50 copies/mL ≤1 yr. prior to inclusion, n/N (%) 23/210 (11.0) - -
CA-DNA (copies per million CD4+ cells) 1547 (2270)
CA-RNA (copies per million CD4+ cells) 157 (224)
cART-naive, n/N (%) 30/211 (14.2) - -
Time on cART, years 6.6 (7.7) - -
ARV classes, n/N (%)
NNRTI 63/211 (29.9) - -
PI 32/211 (15.2) - -
INSTI 141/211 (66.8) - -
Co-medication, n/N (%)
Cholesterol lowering drugs 58/211 (27.5) - -
Antihypertensive drugs 50/211 (23.7) - -
Metformin 9/211 (4.3) - -
Active smoking, n/N (%) 63/211 (29.9) 2/56 (3.6) <0.0001
Heavy drinking, n/N (%)* 28/211 (13.3) 11/56 (19.6) 0.29
Regular substance use, n/N (%)† 61/211 (28.9) 3/56 (5.4) <0.0001
Data depicted as median (IQR) unless stated otherwise. Data analyzed using Mann-Whitney U or χ2 (or Fisher’s exact) 
where applicable. 
* Classified according to the CDC definition: for men, ≥15 drinks per week and for women, ≥8 drinks/week. 
† Defined as use of any psychoactive substance (with the exception of alcohol and tobacco) during periods ≥ 1 time per 
week including ≥ 1 time during the 30 days prior to the study visit.
ARV, antiretroviral drug; BMI, body mass index CA-DNA: CD4-cell-associated HIV-1 DNA; CA-RNA: CD4-cell-associated 
HIV-1 RNA; HC: healthy control; cART, combination antiretroviral therapy; INSTI, integrase inhibitor; IDU, intravenous 
drug use; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; PLHIV: people 
living with HIV; PI, protease inhibitor
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Chapter 3 - Circulating immune cells in HIV
Supplementary Figure 1. Flow cytometry gating strategies of the B cell (C) and Treg panels
Supplementary Figure 1. Flow cytometry gating strategies of the general (A) and T cell (B) panels
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Chapter 3 - Circulating immune cells in HIV
Supplementary Figure 2. (A) Spearman’s correlations between CA-DNA and CA-RNA and clinical factors (B) Differences 
in CA-RNA and CA-RNA between PLHIV with (205/210 [98%]) and without HIV-1 RNA 50 <copies/mL (5/210 [2%]) at study 
visit and between PLHIV with (23/210 [11%]) and without plasma HIV-RNA>50 copies/mL (187/210 [89%]) in the year 
prior to study visit.CD-DNA: CD4-cell associated HIV-1 DNA; CA-RNA CD4-cell associated HIV-1 
Supplementary Figure 1. Flow cytometry gating strategies of the chemokine receptor (CCR) panel (E)
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Chapter 3 - Circulating immune cells in HIV
Supplementary Figure 4. Differences in Th17/Treg ratios with different markers. (A) Th17/Treg ratio based in 
which Tregs were identified using FoxP3 and Helios. (B) Th17/Treg ratio based in which Tregs were identified 
using CD25 and CD127. Results are comparable with results reported in Figure 1B Th17: T-helper 17 (Mem Tc CCR6+ 







































































































































































































































Chapter 3 - Circulating immune cells in HIV
Supplementary table 2. Stimulation scheme for the ex vivo cytokine production assays
Stimulus Final Concentration Strain/Manufacture
RPMI  + serum 10% human serum Life technologies
Staphylococcus aureus 1 x 106/mL ATCC 29213 (in house)
Cryptococcus gattii 1 x 107/mL A1M-R265, AFLP type 6 (clinical isolate)
Candida albicans conidiae 1 x 106/mL UC820 (in house)
Candida albicans hyphae 1 x 106/mL UC820 (in house)
Streptococcus pneumonia 1 x 106/mL TIGR4
Mycobacterium tuberculosis 1 μg/mL H37Rv (in house)
Imiquimod (TLR7 ligand) 2.5 ug/mL Invivogen
PBMCs: peripheral blood mononuclear cells; TLR: Toll-like receptor.
*All 7 day PBMC stimulation experiments were supplemented with 10% human pool serum.
Supplementary table 3. Primers and probes to determine CA-DNA and CA-RNA
Assay Oligo Modification Sequence 
Total HIV-1 DNA
and cell-associated HIV-1 RNA
Forward 5’-GCCTCAATAAAGCTTGCC-3’
Reverse 5’-GGCGCCACTGCTAGAGATTTT-3’
Probe 6FAM/MGB Eclipse 5’-AAGTRGTGTGTGCCC-3’
Reference gene RPP30 Forward 5’-AGATTTGGACCTGCGAGCG-3’
Reverse 5’-GAGCGGCTGTCTCCACAAGT-3’
Probe HEX/ZEN/3’ IBFQ 5’-TTCTGACCTGAAGGCTCTGCGCG-3’
Reference gene B2M Forward 5’-TGTCGGATGGATGAAACCCAGA-3’
Reverse 5’-TGCTCGCGCTACTCTCTCTTT-3’
Reference gene ACTB Forward 5’-CCGATCCACACGGAGTACTT-3’
Reverse 5’-TGGACATCCGCAAAGACCTG-3’













































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 - Circulating immune cells in HIV
Panel 1 (general) identified granulocytes, lymphocytes (both by FSC, side scatter [SSC]) and 
monocytes (CD14+). Lymphocytes were further characterized into T cells (CD3+CD56-), NK 
cells (CD3-CD56+), NKT cells (CD3+CD56+ ), and B cells (CD19+HLA-DR+). Cell subsets were 
determined for T cells (CD4 and CD8), NK cells (CD56 and CD16) and monocytes (CD14 and 
CD16). Panel 2 (T cell) covered CD4+ regulatory T cells (Treg; CD4+CD25+CD127 low) and 
maturation stages of CD4+ and CD8+ T cells (using CD45RA/CD27 and CD45RO/CD27). Panel 
3 (B cell) explored CD19+ B cell maturation stages by the expression of IgM/IgD and/or CD24/
CD38 and B cell subsets by differential CD19/CD20 and IgD/CD5 expression, as previously 
described 17. In panel 4 (intracellular T cell/Treg), the major T cell populations (CD4, CD8 and 
Treg) were identified and analyzed for proliferation status by intracellular Ki67 expression. 
Tregs (CD4+CD25+CD127low FoxP3+) were analyzed for expression of Helios, CD45RA, and 
HLA-DR. Absolute cell counts in this panel were calculated as described above by subtracting 
the granulocyte number (determined by panel 1) from the PBMC WBC counts (Sysmex XN-
450). In panel 5 (chemokine), monocytes and T cell populations (CD8, CD4 including memory 
T cells [Mem Tc; CD45RA-CD25-] and Treg [CD45RA-CD25++]) were analyzed for the expression 
of different cc-chemokine receptors (CCR): CXCR3 (CD183), CCR4 (CD194), and CCR6 (CD196).
Statistical methods
Linear regression analysis
The following regression formula was used:
Y1 ~  X1 + age + sex + sin(2 * pi * numDaysFromJan2015/365) + cos(2 * pi * numDaysFromJan2015/365) 
+ numDaysFromJan2015
where sin(2 * pi * numDaysFromJan2015/365) and cos(2 * pi * numDaysFromJan2015/365) 
capture seasonality patterns with a periodicity of one year19. The cell count data showed 
some slight drift over time which was corrected using the linear term numDaysFromJan2015, 
indicating after how many days after Jan 1st 2015 the sample was collected.
Analysis of correlation structures between 200HIV and 500FG
Correlations were performed on absolute WBC counts instead of WBC proportions.
To properly ascertain cell count correlations, we first corrected the IRT-normalized cell counts 
for age, sex, and seasonal effects, by regression out these factor using a model similar to 
the one described above. We calculated inter-cohort differences in strength of cell count 
associations using the following method. First, we defined the test statistic: 
D_real=correlation_X1_Y1_cohort1 - correlation_X1_Y1_cohort2=C1-C2
With hypotheses: H0: c1=c2 and H1: c1≠c2
Supplementary Methods
HIV-1 DNA and cell-assicioated HIV-1 RNA quantification in CD4+ T cells
See Methods for the description of the HIV-1 DNA and RNA extraction. Before PCR 
amplification, 8.65µl of genomic DNA was restricted by EcoRI (Promega) in a total volume 
of 10µl restriction digest for a minimum of 1 hour at RT. Total HIV-1 DNA and HIV-1 RNA were 
measured by adding respectively 2µl and 4µl in triplicates to ddPCR mix containing 10µl 2x 
ddPCR Supermix for Probes, 500nM primers and 300 nM probe (Table X). DNA was amplified 
by PCR with an initial denaturation step of 10min at 95°C, followed by a denaturation step 
for 30 sec at 95°C, an annealing/elongation step for 1 min at 56°C for 40 cycles, and a final 
step of 10min at 98°C. Total HIV-1 DNA was normalized by measuring the reference gene 
RPP30 (Table X) in duplicate by ddPCR and expressed per million PBMCs. Droplets were 
read by QX200 droplet reader (Bio-Rad) and automatic threshold setting was done using 
ddpcRquant software26. For HIV-1 RNA normalization, three reference genes per patient, 
B2M, ACTB and GAPDH (Supplementary Table S3) were measured with LightCycler 480 SYBR 
Green I Master mix. HIV-1 RNA copies were divided by the geometric mean of the reference 
genes and expressed per million PBMCs.
Immunophenotyping
Staining
For surface staining, cells were incubated in 25 μl surface staining master mix for 20 min 
at RT and washed twice in PBS + 0.2% BSA. Before acquisition, whole blood-derived cells 
were resuspended in 100 μl PBS + 0.2% BSA. For intracellular staining, surface-stained 
PBMCs were fixed and permeabilized using Fixation/Permeabilization solution (eBioscience, 
Vienna, Austria) for 30 min at 4°C protected from light. After washing the cells twice 
in permeabilization buffer (eBioscience, Vienna, Austria), cells were stained with 25 μl 
intracellular staining master mix for 30 min at 4°C protected from light. After a second 
washing step with permeabilization buffer, cells were resuspended in 100 μl PBS + 0.2% BSA 
for acquisition.
Flow cytometry
For each panel, single cells within the leukocyte (CD45+) population were identified by plotting 
the forward scatter (FSC) against FSC time of flight (FSC TOF), followed by characterization of the 
major myeloid or lymphoid lineages 17. The absolute number of WBC per ml of blood determined 
by the Sysmex XN-450 hematology analyzer was used to calculate absolute numbers of leukocyte 
(CD45+) cell subsets as measured by flow cytometry.
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where X1 and Y1 refer to the different cell types. Within each cohort the ID-labels were 
shuffled 10,000 times for each WBC type and the correlation between the cell types in both 
cohorts were calculated for all 10,000 permutations, yielding 10,000 unique correlation 
differences. 
D_permuted = correlation_X1_Y1_cohort1 - correlation_X1_Y1_cohort2
P-values were obtained using two different methods. First, P-values were calculated by 
dividing the number of times the absolute shuffled test statistics were higher than the real 
absolute test statistic. 
(number of times abs(D_permuted) >= abs(D_real)) + 1)/number of permutations
Second, p-values were obtained by applying a half-normal distribution to the absolute D_
permuted values. P-values were calculated out of the percentage of the area with absolute 
permuted values higher than the real correlation. This second approach yielded more precise 
p-values without increasing the number of permutations (as for the discrete permutation 
analysis the lowest possible p-value is 1/number of permutations). Here, the p-values from the 
fitted distribution are reported. Using the p-values from the discrete method (first method) 
showed very similar pattern, and therefore selecting one method over the other does not 
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Chapter 4 - Clonal hematopoeisis in HIV
Introduction
People with HIV (PLHIV) are at risk for non-AIDS related comorbidities such as 
atherosclerotic cardiovascular disease (CVD) and cancer1,2. This risk is associated with 
persistent inflammation, increased coagulation, accelerated aging, CD4 nadir and certain 
antiretroviral drugs1.
Recently, clonal hematopoiesis (CH), a common age-related phenomenon marked by 
expansion of cells with clonal hematopoiesis driver mutations, has been associated with all-
cause mortality, cancer and CVD3-5. Aside from age, chronic infection6 and inflammation7,8 
have also been implicated in the development of clonal hematopoiesis. As PLHIV experience 
persistent inflammation and are at increased risk for accelerated aging and CVD9,10, a role for 
CH in PLHIV is therefore hypothesized. Indeed, a recent study observed increased prevalence 
of CH as detected by whole exome sequencing (WES) in PLHIV as compared to controls11. 
However, associations with HIV-related factors and risk factors of CVD and cancer in PLHIV, 
such as the viral reservoir, CD4 nadir or inflammation were not shown. As the clinical course 
and treatment of HIV infection and CH possibly converge on hematopoietic stem cell biology, 
a potential correlation deserves investigation. Additionally, alike many other large-scale 
CH studies, the study used WES and as such could only detect mutations of considerable 
size (≥2%, also called clonal hematopoiesis of indeterminate potential (CHIP) mutations), 
whereas the use of targeted sequencing techniques improves the sensitivity for the detection 
of smaller CH driver mutations12. 
The aim of our study was to determine clonal hematopoiesis prevalence in PLHIV as 
compared to controls, and to assess possible associations with HIV-related clinical 
parameters, and markers of HIV reservoir, coagulation and inflammation.
Abstract 
Clonal hematopoiesis, a common age-related phenomenon marked by expansion of cells 
with clonal hematopoiesis driver mutations, has been associated with all-cause mortality, 
cancer and cardiovascular disease. People with HIV (PLHIV) are at risk for non-AIDS related 
comorbidities such as atherosclerotic cardiovascular disease and cancer. In a cross-sectional 
cohort study, we compared clonal hematopoiesis prevalence in PLHIV on stable antiretroviral 
therapy, with prevalence in a cohort of overweight individuals and a cohort of age- and 
sex-matched population controls. The prevalence of clonal hematopoiesis adjusted for age 
was increased and clone size was larger in PLHIV compared to population controls. Clonal 
hematopoiesis is associated with low CD4 nadir, increased residual HIV-1 transcriptional 
activity and coagulation factors in PLHIV. Future studies on the effect of clonal hematopoiesis 
on the HIV reservoir, and non-AIDS related comorbidities are warranted.
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– CH mutations with a variant allele frequency ≥2%, an arbitrary threshold established in the 
current literature historically chosen for methodological reasons21 and 2) small clones – CH 
mutations with a variant allele frequency <2%.
Circulating factors
Circulating factors of inflammation IL-18, high-sensitivity C-reactive protein (hsCRP), sCD14 
and sCD163 were measured using ELISA (Duoset or Quantikine, R&D systems). D-dimer 
was measured by ELISA according manufacturer’s instructions (Abcam, Cambridge, UK). 
IL-6, TNFa, IL-10 and IL-1Ra in serum were measured using Simple Plex Cartridges (Protein 
Simple, R&D systems, USA). All assays were performed according to manufacturer’s 
recommendations. Von Willebrand factor (vWF) concentrations were performed with an in-
house sandwich ELISA assay (DAKO, Agilent, Santa Clara, USA)22.
HIV-1 reservoir quantification
HIV-1 CA-DNA and CA-RNA in CD4+ T cells isolated using EasySep Human CD4+ T Cell 
Isolation Kit (Stemcell technologies, Vancouver, Canada), were measured in triplicate by 
droplet digital PCR (ddPCR QX200 – Bio-Rad) as described previously23. Genomic DNA 
was extracted using the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s protocol with an additional step of adding 75µl elution buffer on 
the column heated at 56°C for 10 min. CA-RNA was extracted using the Innuprep RNA kit 
(Westburg, Leusden, The Netherlands). RNA was reversely transcribed to cDNA by qScript 
cDNA SuperMix (Quantabio, Beverly, MA, USA). Before PCR amplification, genomic DNA 
was restricted by EcoRI (Promega)23. Total HIV-1 DNA measurements were normalized by 
measuring the reference gene RPP30 in duplicate by ddPCR and expressed per million 
CD4+ cells. CA-RNA was normalized using three reference genes, (B2M, ACTB and GADPH) 
determined by LightCycler 480 SYBR Green I Master mix. HIV-1 RNA copies were divided 
by the geometric mean of the reference genes and expressed per million CD4+ cells. 
Droplet classification and absolute quantification was performed using the ddpcRquant 
analysis tool with standard settings24. Primers and probes are shown in Supplementary 
Table S3.
Statistical analysis
All analyses were performed in R version 3.6.1 (R Core Team, CRAN-project). P-values <0.05 
were considered statistically significant. General characteristics were compared by means 
of Wilcoxon-rank sum tests for continuous parameters and Chi-square tests for categorical 
parameters. In addition, we computed standardized mean differences where appropriate 
using the R-package stddiff.
Materials and Methods
Study subjects
Samples were obtained from the 200HIV cohort (PLHIV cases, n = 219)13 on antiretroviral 
therapy (cART) with plasma HIV-RNA <200copies/mL, 300-Obese cohort (HIV-uninfected, 
overweight controls (BMI>27kg/m2), n = 302)14, and Nijmegen Biomedical Study (NBS, HIV-
uninfected, population controls, n = 437)15. The 200HIV and 300-Obese cohort are both 
part of the Human Functional Genomics Project (www.humanfunctionalgenomicsproject.
org) enrolled at the Radboud University Medical Center, Nijmegen, the Netherlands. These 
studies were approved by the local ethics committee (CMO Arnhem-Nijmegen, 200HIV: 
NL3235709110; 300-Obese: NL4684609113) and conducted in accordance to the Declarations 
of Helsinki. Samples for DNA extraction and plasma measurement were obtained after 
written informed consent. Clinical data were extracted from the electronic medical records 
and/or from the Dutch HIV registry (Stichting HIV-monitoring). The NBS is a population-
based study of 9,350 individuals, based on age- and sex-stratified random sample from the 
register of municipality of Nijmegen, the Netherlands15.
Clonal Hematopoiesis mutation identification
Clonal Hematopoiesis (CH) mutations were analyzed in DNA isolated from whole blood in 
PLHIV and 300-Obese cohorts, using ultra-sensitive single-molecule Molecular Inversion 
Probe (smMIP) sequencing, as previously described16. In short, a total of 300 MIP-probes 
were designed covering CH-related hotspots in 24 genes, including ASXL1, TET2 and DNMT3A 
(Supplementary Table S1 and Supplementary Table S2). In addition, we selected 437 age- and 
sex-matched population control samples, and used the previously generated sequencing 
data for CH mutation identification, but due to subtle technical (probe density) differences 
excluded DNMT3A mutations from this direct comparison 15. For each individual, two technical 
(PCR) replicates were sequenced, after which two independent data processing strategies were 
applied followed up by a targeted quality control (Supplementary Figure S1). Raw sequencing 
data were converted to fastQ-files, which were 1) aligned to the reference genome (hg19) 
using BWA-MEM17 and 2) imported into the commercially available NGS software package 
Sequence Pilot (JSI Medical Systems), using the optimized smMIP analysis module as described 
previously18,19. The latter allows for a consensus calling per probe, enabling somatic calls 
down to 0.001% (depending on locus specific coverage) by using a majority vote of Unique 
Molecular Identifier duplicates. The resulting variant calls were then subjected to a stringent 
quality filtering pipeline (Supplementary Figure S1C), in which (likely) false positive calls 
were excluded. The final variant allele frequency was calculated using samtools mpileup20 on 
the aligned bamfiles from 1). PLHIV and 300-Obese samples with an average coverage over 
the entire panel, and population control samples over all non DNMT3A genes, of >500x were 
included for analysis. We classified all detected CH mutations in two categories: 1) large clones 
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ranging from 24 to 69 and an average of 51.9 years, and majority of individuals were male 
(n = 365, 91.5%).
CH mutation prevalence in PLHIV versus uninfected controls
We identified 51 candidate CH mutations in 46 PLHIV individuals (21.2%), five individuals 
presenting with two different mutations. General characteristics for PLHIV CH mutation 
carriers versus non-carriers are shown in Table 1. The variant allele frequency of all CH 
mutations ranged from 0.05% to 32.94%, with a median clone size of 1.01%. Out of 51 
mutations, 20 (39.2%) were categorized as large clones (≥2%), highlighting the sensitivity of 
our assay to detect somatic mutations below the arbitrary allele frequency cutoff for CHIP3,15. 
For a complete list of all identified candidate CH mutations see Supplementary Table S5.
In our HIV-uninfected overweight controls (300-Obese), we identified 110 candidate CH 
mutations in 85 individuals (28.6%). We were unable to detect a significant difference 
in either CH mutations or CHIP prevalence between PLHIV and overweight controls 
(Supplementary Table S6). Yet, after correcting for the most important known risk factor 
age in a logistic model, we identified that the probability of CHIP in PLHIV is significantly 
higher as compared to HIV-uninfected overweight controls (OR cohort = 2.21 95% CI [1.03-
4.77]), an effect that did not reach statistical significance when smaller clones (variant 
allele frequency <2%) were included (Supplementary Table S7). Most observed clones in 
PLHIV were mutations in DNMT3A, representing roughly half of the CH mutations per 
age category (Figure 1A). Comparing the gene occurrence in PLHIV age ≥55 to controls 
age ≥55, we observed that the proportion of CH mutations in genes other than DNMT3A, 
specifically JAK2, STAT3, and TP53, was larger in PLHIV (Figure 1B), whereas on average CH 
mutation size was not different (Figure 1C). Considering only non-DNMT3A mutations in 
our age- and sex-matched population controls, we identified 55 candidate CH mutations 
in 42 individuals (10.5%), as compared to 25 in 23 individuals (10.6%) in PLHIV. Even 
though there was no significant difference in raw prevalence (p=1), logistic regression 
revealed that the effect of age on CH mutation prevalence was significantly smaller in 
PLHIV as compared to population controls, suggesting that non-age related factor(s) 
“drive(s)” the prevalence of CH in PLHIV (Supplementary Table S7). Finally, non-DNMT3A 
CH mutations were significantly larger in size in PLHIV as compared to population controls 
(p=0.004, Figure 1D).
CH mutation prevalence in PLHIV versus 300-Obese was assessed first by means of Chi-
square tests, and second in a logistic regression model correcting for the known risk factor 
age and cohort (a variable indicating whether an individual is in the PLHIV or 300-Obese). 
Prevalence of non DNMT3A CH mutations in PLHIV versus population controls was assessed 
in the same way. Logistic model fit was evaluated by means of a givitiCalibrationBelt-plot 
using the package givitiR, and are shown in Supplementary Figure S2.
In order to assess whether different mutational processes contribute to CH mutations in 
PLHIV as compared to controls, we performed a mutational signature analysis studying all 
48 single base substitutions (SBS) in their three-nucleotide context (see Supplementary 
Table S4)25. Fitting all identified somatic mutations into existing SBS signatures for which 
mutational processes of both  endogenous and exogenous origin have been characterized, 
may allow the identification of differential mutation processes for different sets of 
mutations. The contribution of the single base substitution (SBS) signatures was inferred 
using the R package DeconstructSigs26 and Mutational Signatures V3.1 available at the 
Catalogue of Somatic Mutations in Cancer (COSMIC release v91, June 2020).
Within PLHIV differences in categorical parameters were assessed by means of Chi-square 
tests, whereas continuous parameters by means of Wilcoxon-rank sum tests. In addition, 
to explore possible factors that are correlated with clonal hematopoiesis in PLHIV, we 
performed stepwise logistic regression with a selection of clinically relevant parameters as 
independent variables, CH mutation prevalence as dependent variable using the stepAIC() 
function with direction=”both” from the MASS package.
All figures were likewise generated in R using a variety of packages (dplyr, reshape2, ggplot2, 
ggpubr, tidyverse, ggpmisc, rcompanion, ggbeeswarm), after which they were optimized in 
Adobe Illustrator version 23.1.1 (Adobe Inc.).
Results
A total of 217 PLHIV on combination antiretroviral therapy, 297 uninfected 300-Obese 
control, and 399 age- and sex-matched population control individuals passed our quality 
control and coverage threshold of 500x (Supplementary Figure S3), and were included 
in our analyses. The age of PLHIV individuals ranged from 24 to 74, with an average age 
of 51.3 years, and the majority were male (n = 199, 91.7%). HIV-uninfected overweight 
controls (300-Obese) were generally older, (age range 54-81, average age 67.1 years), 
and sex was more evenly distributed (male n = 134, 45.1%). The age and sex distribution 
of our included population controls was comparable to PLHIV individuals, with an age 
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Figure 1. Clonal Hematopoiesis (CH) mutations in people with HIV (PLHIV), HIV-uninfected overweight controls 
(300-Obese), and HIV-uninfected age- and sex-matched population controls (NBS). (A) CH mutation prevalence 
is increased with age in PLHIV. The stacked bars represent the percentage of PLHIV carrying a CH mutation per age 
category (the CH mutation with highest variant allele frequency is plotted for individuals carrying multiple mutations). 
(B) The proportion of CH mutations in genes other than DNMT3A in PLHIV age ≥55 (n = 90) is larger as compared to 
HIV-uninfected overweight controls (n = 296). (C) CH mutation size is non-significantly increased in PLHIV as compared 
to HIV-uninfected overweight controls. (D) CH mutation size is significantly larger in PLHIV as compared to population 
controls. In (C) and (D) each dot represents a CH mutation (the number of mutations is annotated on the x-axis and 
the size on the y-axis), with a horizontal line and number to the right indicating the mean CH mutation size and the 
Wilcoxon-rank sum test P-value annotated at the top.
Table 1. General characteristics of PLHIV without clonal hematopoiesis (CH) mutations (non-carriers) as compared to 
PLHIV in which one or more CH mutations were identified (CHDM-carriers). 
non-carriers (n=171) CH-carriers (n=46) p
Sex Female - n (%) 13 (7.6%) 5 (10.9%) 0.68
Age - mean [IQR] (years) 50.0 [44.0-58.0] 57.0 [48.0-62.2] 0.006
BMI - mean [IQR] (kg/m2) 24.2 [22.0-26.5] 23.7 [22.4-25.8] 0.48
Known duration of HIV infection - mean [IQR] (years) 7.5 [4.7-12.7] 10.6 [6.8-16.9] 0.03
Way of transmission 0.44
   Heterosexual - n(%) 8 (4.7%) 1 (2.2%)  
   IDU - n(%) 2 (1.2%) 1 (2.2%)  
   MSM - n(%) 132 (77.2%) 32 (69.6%)  
   Other/unknown - n(%) 29 (17.0%) 12 (26.1%)  
CD4 nadir - mean [IQR] (cells/uL) 270.0 [150.0-380.0] 195.0 [72.5-290.0] 0.001
Current CD4 T-cell count- mean [IQR] (cells/uL) 660.0 [490.0-805.0] 635.0 [472.5-755.0] 0.58
Current CD4/CD8 T-cell ratio - [IQR] 0.8 [0.6-1.1] 0.8 [0.6-1.2] 0.37





HIV-RNA >50copies/mL <1 yr prior to inclusion, n (%) 14 (8.2%) 9 (19.6%) 0.05
cART duration - mean [IQR] (years) 6.1 [3.7-10.2] 9.1 [4.4-16.8] 0.05
ARV classes  
   NRTI - n (%) 165 (96.5%) 44 (95.7%) 1
   NtRTI - n (%) 79 (46.2%) 23 (50.0%) 0.77
   NNRTI - n (%) 50 (29.2%) 13 (28.3%) 1
   PI - n (%) 21 (12.3%) 11 (23.9%) 0.08
AZT ever - n (%) 39 (23.2%) 18 (39.1%) 0.048
Cardiovascular risk factors No - n (%) 45 (26.3%) 6 (13.0%) 0.09
MHCVD Yes - n (%) 42 (24.6%) 16 (34.8%) 0.23
Prior MI/CVA Yes - n (%) 11 (6.4%) 5 (10.9%) 0.48
Active smoking - n (%) 44 (25.7%) 17 (37.0%) 0.19
Packyears 12.0 [0.0, 27.0] 18.5 [1.9, 35.1] 0.18
Hypercholesterolemia - n (%) 45 (26.3%) 13 (28.3%) 0.94
Hypertension - n (%) 33 (19.3%) 10 (21.7%) 0.87
Diabetes Mellitus - n (%) 9 (5.3%) 1 (2.2%) 0.62
Family history CVD 1st degree - n (%) 81 (47.4%) 26 (56.5%) 0.35
BMI: body mass index. IDU: intravenous drug-use. MSM: men who have sex with men. cART: combination antiretroviral 
therapy. NRTI: Nucleoside reverse transcriptase inhibitor. NtRTI: nucleotide reverse transcriptase inhibitor. NNRTI: 
non-nucleoside reverse transcriptase inhibitor. PI: protease inhibitor. INSTI: integrase inhibitor. AZT: zidovudine. MI: 
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signature) to contribute uniquely to CH mutations in PLHIV, whereas SBS6 and SBS21 (both 
involved in DNA mismatch repair) contribute uniquely to CH mutations in HIV-uninfected 
overweight controls (Figure 2A). Remarkably, SBS18, a signature predominantly characterized 
by C>A mutations was likewise identified to contribute to CH mutations in PLHIV with prior 
exposure to AZT, whereas it was absent in unexposed individuals (red dashed square in 
Figure 2A and Figure 2B). However, as the number of CH mutations in this last sub-group 
analysis is low, the corresponding cosine value indicates these results should be interpreted 
with caution.
Low CD4 nadir, markers of coagulation and HIV reservoir are associated with CH 
mutation prevalence in PLHIV
Subsequently, we explored the clinical correlates of PLHIV with their CH mutation carrier 
status. In these exploratory analyses, CH mutation carriers were older (p=0.006, Table 1), 
duration of known HIV infection was longer (p=0.026, Table 1), and CD4 nadir was lower 
(p=0.001; Figure 3A). There was no difference in CH mutation prevalence with regard to 
combination antiretroviral therapy (cART) regimens, CD4/CD8 T-cell ratio or current CD4 
T-cell count. In a logistic regression model, older age (OR (+5yr): 1.21 [CI:1.01-1.45], p=0.04), 
lower CD4 nadir (OR (+50cells/mm2): 0.794 [CI:0.687-0.907], p=0.001), increased CD4/
CD8 ratio (OR: 2.85 [CI:1.33-6.39], p=0.008) were independently correlated to CH mutation 
prevalence, whereas HIV-duration and current CD4 T cell count were not (Supplementary 
Table S7).
PLHIV with a CH mutation were more likely to have at least once a viral load of >50 copies/mL 
prior to study visit (19.6% vs 8.2%, p=0.052), suggesting a more active HIV reservoir. In virally 
suppressed PLHIV, the HIV-1 CA-DNA roughly equals total integrated proviral DNA, while 
HIV-1 CA-RNA is associated with HIV-1 transcriptional activity27. Although these parameters of 
HIV reservoir strongly intercorrelate, HIV CA-RNA was increased in CH mutation carriers and 
HIV CA-DNA was not (Figure 3B). The discrepancy between CA-RNA and CA-DNA suggests 
an effect on transcriptional activity27. As a result, PLHIV with viral load between 50 and 200 
copies/ml (viral blip) 1 year prior to study visit (10.6%) had higher levels of CA-RNA (p<0.01), 
but no differences in CA-DNA. Although the CA-RNA difference disappeared after correction 
for CD4 nadir and age (Supplemental Table S7), the ratio of HIV-1 CA-RNA to CA-DNA, which 
represent relative viral transcription level27, was increased in CH mutation carriers (OR: 5.56 
[CI:1.77-45.97], p=0.017; Supplementary Table S7), independent of CD4 nadir, age and CD4/
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Figure 2. PLHIV present with a distinct mutational signature profile. (A) shows the contribution of different SBS 
signatures to Clonal Hematopoiesis (CH) mutations in PLHIV (top) and HIV-uninfected overweight controls (bottom). 
SBS1 and SBS18 contribute uniquely to CH mutations in PLHIV, whereas SBS6 and SBS21 are unique to controls. For raw 
results see Supplementary Table S8A. (B) shows that SBS18, a signature predominantly characterized by C>A mutations 
that is involved in reactive oxygen species (ROS) production, uniquely contribute to CH mutations in PLHIV with prior 
exposure to AZTs. For raw results see Supplementary Table S8B. Proposed etiology of SBS signatures: SBS1 - Spontaneous 
deamination of 5-methylcytosine (clock-like signature); SBS5 - Unknown (clock-like signature); SBS6 - Defective DNA 
mismatch repair; SBS10b - Polymerase epsilon exonuclease domain mutations; SBS12 - Unknown; SBS17a - Unknown; 
SBS18 - Damage by reactive oxygen species; SBS21 - Defective DNA mismatch repair; SBS29 - Tobacco chewing; 
SBS30 - Defective DNA base excision repair due to NTHL1 mutations; SBS31 - Platinum chemotherapy treatment. 
Annotation: Mutations (n) shows the number of CH mutations analyzed in each group; Cosine represents the cosine 
similarity value (range 0-1) - a correction applied on mutations prior to fitting to SBS signatures - values <0.8 are 
considered low.
CH mutations in PLHIV individuals are possibly driven by different mutational 
processes
To understand the mutational processes contributing to CH mutations, we explored 
mutational signatures, i.e. base substitutions in a tri-nucleotide context25. Our mutational 
signature analysis identified the signatures SBS1 (clock-like signature) and SBS18 (ROS-
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Discussion
In the current study, we show that clonal hematopoiesis driver mutations in PWH on long-
term successful cART are common and are independently associated with older age, low CD4 
nadir, increased CD4/CD8 T-cell ratio, as well as with markers of coagulation. Furthermore, 
we show that clonal hematopoiesis is linked to increased relative HIV-1 transcription level 
(e.g. increased HIV-1 CA-RNA to HIV-1 CA-DNA ratio).
Age is a known clonal hematopoiesis predictor in the general population3,4,16, as well as 
in the current study, supporting the validity of our data. CH may be important in PWH as 
their presence has been associated with hematological (pre)malignancies, as well as with 
CVD and all-cause mortality in HIV uninfected individuals3. Recently, a large-scale clonal 
hematopoiesis study by Bick et al. reported increased prevalence of large clones, or CHIP, in 
PWH as compared to control individuals11. In line with this, the probability of large clones 
adjusted for age was increased in PWH as compared to HIV-uninfected overweight controls, 
and the probability of all non-DNMT3A clones (small and large) was intriguingly driven by 
something other than age in PWH as compared to population controls in present study. 
Consistent with the latter, and the hypothesis that time is needed for a clone to grow, clone 
size was significantly increased in PWH as compared to age- and sex-matched population 
controls. The absence of this in our PWH versus overweight controls comparison is most 
likely due to the differences in age and BMI, as we have recently shown that clone size may be 
increased in obese individuals 16.
Our observation that something other than age drives CH prevalence in PWH, was 
substantiated by the fact that the mutational processes underlying the identified CH mutations 
may be different between PWH and controls. Only in PWH, a ROS mutational signature could 
be assigned to some of the observed CH mutations. ROS production is indeed increased in 
PWH and, interestingly, has been linked to nucleoside reverse transcriptase inhibitor (NRTI) 
induced mitochondrial toxicity3,4. The enhanced ROS-signature found in CH mutations from 
PWH compared to HIV-uninfected overweight controls could therefore mirror increased 
mitochondrial dysfunction in PWH. We could not assess whether either HIV or cART-use relates 
to CH mutation development, as all PWH were on cART and with plasma HIV RNA levels <200 
copies/ml. However, our data indicate that the ROS-signature may contribute to mutations 
in PWH with prior exposure to zidovudine, whereas it was absent in unexposed individuals. 
Zidovudine, an NRTI, has been extensively linked to hematological toxicity28.
The fact that our data suggest that in PWH other processes significantly reduce the 
correlation of CH prevalence with age is intriguing. Associations between clonal 














































































PWH: CH mutation carrier
PWH: non-carrier
Legend
Figure 3. PLHIV Clonal Hematopoiesis (CH) mutation carriers present with significantly lower CD4 nadir, and 
higher cell-associated HIV-RNA and coagulation markers. (A) Carriers (n = 46) present with significantly lower CD4 
nadir as compared to non-carriers (n = 171). (B) Carriers (n = 45) show significantly increased RNA levels as compared 
to non-carriers (n = 169), and non-significantly increased DNA levels as compared to non-carriers (n = 167). (C) Carriers 
(n = 46) present with significantly increased coagulation markers D-dimer and von Willebrand Factor (vWF) as compared 
to non-carriers (n = 171). (D) Carriers (n = 45) show comparable high-sensitivity C-reactive protein (hsCRP) as compared 
to non-carriers (n = 167) and carriers (n = 46) show comparable soluble CD14 (sCD14) levels as compared to non-carriers 
(n = 170). In each plot the mean of non-carriers and CH mutation carriers is annotated with a horizontal bar and value, at 
the top the Wilcoxon-rank sum test P-value is depicted.
Additionally, we studied associations between CH mutation carriership, coagulation and 
inflammation. No correlation was found with circulating inflammation markers (hsCRP, 
sCD14, sCD163, IL-6), while coagulation markers (d-dimer and vWF) were increased in CH 
mutation carriers (Figure 3C, 3D and Supplementary Figure S4), independent of age, CD4 
nadir and CD4/CD8 T-cell ratio (vWF: OR (+5000ng/mL): 1.053 [CI:1.014-1.097], p=0.009; 
d-dimer: OR (+50mg/mL): 1.076 [CI:1.004-1.163], p=0.044; Supplementary Table S7).
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AIDS related comorbidities, further examine signature analyses or perform sex-specific 
analyses. Furthermore, although the reported associations are interesting, the data do not 
allow us to draw causal inferences. The purpose of this study was exploratory and as such 
the reported independent correlations should be interpreted as hypothesis generating and 
require confirmation in future, ideally longitudinally designed, studies. And finally, our 
targeted sequencing technique limits unbiased genome wide CH mutation assessment3, 
due to only targeting previously described CH mutation hotspots and genes. Although, this 
is outweighed by the advantages of this technique - the use of high-sensitivity targeted 
sequencing including molecular barcoding allows for technical replication, comparable 
sensitivity, reliable quantification and overlapping probes ruling out sequencing errors or 
artefacts15.
In conclusion, clonal hematopoiesis in PWH using long-term cART is associated with low 
CD4 nadir, increased CD4/CD8 T-cell ratio, altered coagulation and signs of increased HIV 
transcriptional activity. Future studies on the effect of clonal hematopoiesis on the HIV 
reservoir, and non-AIDS related comorbidities are warranted.
Supplementary material
All supplementary figures, the supplementary methods, and  supplementary tables 1A, 2-7 
can be found at the end of this manuscript. Supplementary table 2 is available online or upon 
request in a separate excel file.
recently reported11. Yet, no correlations with other HIV-related parameters such as CD4 
T-cell count, HIV medication, HIV reservoir parameters were reported. We identified various 
other HIV-related parameters correlated with CH independently of age, such as CD4 nadir 
and CD4/CD8 T cell ratio. CD4 nadir is a marker for the severity of prior immunosuppression 
and HIV infection course. The link with CD4 nadir suggests prior immunosuppression due 
to HIV infection is associated with an increased CH prevalence in PWH. Recent studies have 
also linked CH to chronic infection and infection risk28,29. Longitudinal studies are needed to 
further investigate the link between HIV infection and CH. While in HIV-uninfected controls a 
link between clonal hematopoiesis and inflammation has been shown3,30, no association was 
found between clonal hematopoiesis and general inflammation parameters in our cohort of 
PWH. Our sample size restricted our ability to dissect whether inflammation independent 
of CD4 nadir has an effect. In contrast, new factors such as HIV reservoir and markers of 
coagulation – d-dimer and vWF - were independently associated with clonal hematopoiesis. 
Besides inflammatory markers, these coagulation factors have also been linked to mortality 
and CVD and are increased in PWH27,31. The interplay between coagulation, inflammation 
and CH requires future mechanistic studies.
The link with HIV reservoir is interesting, considering that several of the most important 
clonal hematopoiesis driver genes encode for epigenetic modifiers - genes that modify 
the epigenome through e.g. DNA methylation - with suggested downstream effects of 
altered gene expression and increased inflammation30. HIV transcription is known to rely on 
epigenetic modification, cell differentiation and activation but also low-grade inflammation1. 
It is intriguing to speculate, that increased relative HIV-1 transcription in individuals with CH 
could be the result of an aberrant epigenetic profile, causing alterations in the transcriptional 
program and cell differentiation15. Future studies using single cell transcriptome analyses in a 
longitudinal setting, could provide mechanistical insight into clonal hematopoiesis and HIV 
reservoir dynamics on single cell level. These studies could elucidate new mechanisms for 
(deep) HIV latency and influence future shock and kill strategies in HIV cure 32.
Limitations of the current study include the chosen control populations. The 300-Obese 
control individuals were processed with the exact same assay and in parallel with PWH, 
preventing possible confounding due to assay or batch differences, but they were generally 
older and showed an increased BMI. Although at the same time, the inclusion of these 
controls with additional cardiovascular risk factors and older age could underestimate 
the effect of HIV infection itself on clonal hematopoiesis, since both age and obesity has 
been found associated to increased prevalence of CH16. The comparisons between PWH 
individuals and population controls are more appropriate due to age- and sex-matching, but 
the assay is slightly different and as such we could only validate findings for non-DNMT3A 
mutations. Additionally, our limited sample size restricted the ability to link CH to non-
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A. B.
Supplementary Figure S3. smMIP coverage PLHIV and controls. (A) shows the average coverage depth for PWH in blue (n=217) and 
HIV-uninfected overweight controls in red (300-Obese, n = 297) over the entire Clonal Hematopoiesis (CH) panel, the blue and red 
diamonds represent the mean coverage depth for all individuals of the respective cohort. (B) shows the average coverage depth for PWH 
in blue (n=217) and HIV-uninfected population controls in red (NBS, n = 399) over all non DNMT3A genes in the CH panel, the blue and 







































Supplementary Figure S3. smMIP coverage PLHIV and controls. (A) shows the average coverage depth for PLHIV (n=217) 
and HIV-uninfect d controls i  ed (300-Obese, n-297)over the enti e Clonal hematopoeisis anel, the blue and red di mon s 
represent the mean coverage depth for all indivi uals of the respective c rt. (B) shows the average coverage depth for 
PLHIV (n=217) and HIV-uninfected population controls (n=399) over all non-DNMT3A genes in the Clonal hematopoeisis 
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Supplementary Table S1. Gene regions sequenced
Gene CHR BPstart BPstop Hotspot(s)
GNB1 chr1 1747219 1747281 K57
NRAS chr1 115256481 115256578 Q61
NRAS chr1 115258695 115258772 G13
DNMT3A chr2 25457097 25457337 R882; F868
DNMT3A chr2 25458534 25458737 W860
DNMT3A chr2 25459766 25459898  
DNMT3A chr2 25461963 25462122 P777
DNMT3A chr2 25463116 25463351 R771; G762; Y735
DNMT3A chr2 25463462 25463661  
DNMT3A chr2 25464379 25464623  
DNMT3A chr2 25466728 25466891  
DNMT3A chr2 25466975 25467236  
DNMT3A chr2 25467371 25467573  
DNMT3A chr2 25468094 25468246  
DNMT3A chr2 25468860 25468966  
DNMT3A chr2 25468999 25469230  
DNMT3A chr2 25469451 25469670  
DNMT3A chr2 25469890 25470072  
DNMT3A chr2 25470425 25470644 R326
DNMT3A chr2 25470847 25471147  
DNMT3A chr2 25497766 25497976  
DNMT3A chr2 25498336 25498443  
DNMT3A chr2 25505264 25505647  
DNMT3A chr2 25522970 25523163  
DNMT3A chr2 25536724 25536884  
SF3B1 chr2 198266793 198266879 K700
SF3B1 chr2 198267310 198267375 K666
MYD88 chr3 38182285 38182347 L265
MYD88 chr3 38182614 38182677 L273
PIK3CA chr3 178916710 178916775 R38
FGFR3 chr4 1803523 1803588 S249
FGFR3 chr4 1806082 1806145 G380
FGFR3 chr4 1807841 1807923 K650
TET2 chr4 106156676 106156762 L532; R550
TET2 chr4 106157359 106157422 Q764

















































Supplementary Figure S4. (A) Clonal 
Hematopoiesis (CH) mutation carriers 
(n=46) are significantly older as compared 
to non-carriers (n=171). (B) CH mutation 
carriers (n=45) present with comparable 
soluble CD163 (sCD163) levels as 
compared to non-carriers (n=170). (C) CH 
mutation carriers (n=44) show non-signifi-
cantly increased Interleukin(IL)-6 as 
compared to non-carriers (n=168). In each 
plot the mean of non-carriers and CH 
mutation carriers is annotated with a 
horizontal bar and the mean to the right, at 
the top the Wilcoxon-rank sum test P-value 
is depicted. 
Supplementary Figure S4. (A) Clonal hematopoeisis mutation carriers (n=46) are significantly older as compared to 
non-carriers (n=171). (B) CHDM-carriers (n=45) present with comparable soluble CD163 (sCD163) levels as compared to 
non-carriers (n=170). (C) CHDM-carriers (n=44) show non-significantly increased interleukin (IL)-6 as compared to non-
carriers (n=168). In each plot the mean of non-carriers and CHDM-carriers is annotated with a horizontal bar and the 
mean to the right, at the top the Wilcoxon-rank sum test  P-values is depicted.
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Supplementary Table S3.  
Probes and Primers for HIV-1 cell-associated RNA and DNA
Assay Oligo Modification Sequence 




Probe 6FAM/MGB Eclipse 5’-AAGTRGTGTGTGCCC-3’
Reference gene RPP30 Forward 5’-AGATTTGGACCTGCGAGCG-3’
Reverse 5’-GAGCGGCTGTCTCCACAAGT-3’
Probe HEX/ZEN/3’ IBFQ 5’-TTCTGACCTGAAGGCTCTGCGCG-3’
Reference gene B2M Forward 5’-TGTCGGATGGATGAAACCCAGA-3’
Reverse 5’-TGCTCGCGCTACTCTCTCTTT-3’
Reference gene ACTB Forward 5’-CCGATCCACACGGAGTACTT-3’
Reverse 5’-TGGACATCCGCAAAGACCTG-3’
Reference gene GAPDH Forward 5’-GAAGATGGTGATGGGATTTC-3’
Reverse   5’-GAAGGTGAAGGTCGGAGTC-3’
TET2 chr4 106157712 106157776 Q888
BRAF chr7 140453103 140453168 V600
BRAF chr7 140481373 140481439 G469
BRAF chr7 140494133 140494201 R362
JAK2 chr9 5073728 5073801 V617
PTEN chr10 89692869 89692955 R130
FGFR2 chr10 123279627 123279726 P253
HRAS chr11 534241 534335 G12
CBL chr11 119148879 119149040 C381; C396; C404
CBL chr11 119149194 119149295 F418
KRAS chr12 25398233 25398313 G12
PTPN11 chr12 112888146 112888211 Y63
IDH2 chr15 90631915 90631981 R140
TP53 chr17 7577460 7577612 I255; G187; R248
TP53 chr17 7578157 7578226 Y220
TP53 chr17 7578374 7578461 R175
TP53 chr17 7579327 7579393 R110
STAT3 chr17 40474385 40474451 D661
SRSF2 chr17 74732933 74733004 P95
ASXL1 chr20 31021185 31021291 R404; R417
ASXL1 chr20 31022246 31022314 Y591
ASXL1 chr20 31022573 31022637 Y693
ASXL1 chr20 31022891 31022956 Q803
GNAS chr20 57484390 57484467 R844
U2AF1 chr21 44524436 44524500 S34
BRCC3 chrX 154305462 154305526 R81
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Chapter 4 - Clonal hematopoeisis in HIV
Logistic Model IV :: PLHIV CH mutation yes/no~ age + CD4 nadir + CD4/CD8 ratio [n=216]
Estimate p-value OR Lower Upper Increment
(Intercept) -3,175 4,04E-03
age 0,037 4,09E-02 1,205 1,013 1,450 5
CD4 nadir -0,005 0,001 0,794 0,687 0,907 50
CD4/CD8 ratio 1,047 0,008 2,850 1,334 6,391 1
Logistic Model V :: PLHIV CH mutation yes/no~ age + CD4 nadir + CD4/CD8 ratio + log(DNA) [n=211]
Estimate p-value OR Lower Upper Increment
(Intercept) -3,062 0,077
age 0,043 0,023 1,240 1,036 1,503 5
CD4 nadir -0,005 2,09E-03 0,796 0,684 0,916 50
CD4/CD8 ratio 1,044 9,89E-03 2,842 1,308 6,487 1
log(DNA) -0,132 0,754 0,876 0,385 2,033
Logistic Model VI :: PLHIV CH mutation yes/no~ age + CD4 nadir + CD4/CD8 ratio + log(RNA) [n=213]
Estimate p-value OR Lower Upper Increment
(Intercept) -4,567 3,63E-03
age 0,041 0,031 1,225 1,025 1,483 5
CD4 nadir -0,004 0,011 0,824 0,705 0,954 50
CD4/CD8 ratio 1,077 0,007 2,937 1,364 6,645 1
log(RNA) 0,462 0,308 1,588 0,661 3,949
Logistic Model VII :: PLHIV CH mutation yes/no~ age + CD4 nadir + CD4/CD8 ratio + RNA/DNA ratio [n=209]
Estimate p-value OR Lower Upper Increment
(Intercept) -3,575 1,82E-03
age 0,040 3,40E-02 1,221 1,021 1,480 5
CD4 nadir -0,005 1,55E-03 0,795 0,684 0,911 50
CD4/CD8 ratio 1,008 0,012 2,740 1,265 6,210 1
RNA/DNA ratio 1,716 0,017 5,563 1,768 45,970
Supplementary Table S6. Baseline characteristics  of  PLHIV  vs  controls.  
Parameter PLHIV (n=217) Control (n=297) P-value
Sex Female - n (%) 18 (8.3%) 163 (54.9%) <0.01
Age - mean [IQR] (years) 51.3 [46-59] 67.1 [63-71] <0.01
BMI - mean [IQR] (kg/m2) 24.5 [22.1-26.2] 30.7 [28.3-31.9] <0.01
Smoking - n (%) 61 (28.1%) 29 (9.8%) <0.01
CHDM - n 51 110 na
CHDM carriers - n (%) 46 (21.1%) 85 (28.6%) 0.07
CHIP - n 20 37 na
CHIP carriers - n (%) 19 (6.4%) 33 (11.1%) 0.47
The column  P- value represents the X-square test P-value for categorical variables, and the Wilcoxon- rank-sum test P-value in the case of 
continuous variables. IQR = Interquartile range.
Supplementary Table S7. Logistic regression models
Logistic Model I :: CH mutation yes/no ~ age + cohort [n=514]
Estimate p-value OR Lower Upper
(Intercept) -3,952 2,78E-05 0,019 0,003 0,122
cohort - PLHIV 0,259 0,359 1,296 0,745 2,253
age 0,045 0,001 1,046 1,018 1,075
Logistic Model II :: CHIP yes/no ~ age + cohort [n=514]
Estimate p-value OR Lower Upper
(Intercept) -7,511 5,67E-07 0,001 2,88E-05 0,010
cohort - PLHIV 0,793 0,043 2,211 1,025 4,769
age 0,080 2,21E-04 1,083 1,038 1,130
Logistic Model III :: CH mutation yes/no ~ age + cohort [n=616]
Estimate p-value OR Lower Upper
(Intercept) -7,511 5,67E-07 0,001 2,88E-05 0,010
cohort - PLHIV 0,793 0,043 2,211 1,025 4,769
age 0,080 2,21E-04 1,083 1,038 1,130
133132
4
Chapter 4 - Clonal hematopoeisis in HIV
Supplementary Table S6. Mutational  Signature Analysis  Results. 
(A) (B)

































































































(A) PLHIV versus Control. (B) PLHIV with history of Zidovudine use (PLHIV_yesAZT) versus PLHIV without history of Zidovudine use (PLHIV_
noAZT).
Logistic Model VIII :: PLHIV  CH mutation  yes/no~ age + CD4 nadir + CD4/CD8 ratio + vWF [n=216]
Estimate p-value OR Lower Upper Increment
(Intercept) -3,636 1,55E-03
age 0,032 8,40E-02 1,176 0,983 1,424 5
CD4 nadir -0,005 1,33E-03 0,794 0,685 0,909 50
CD4/CD8 ratio 1,179 0,004 3,251 1,501 7,440 1
vWF 1,03E-05 0,009 1,053 1,014 1,097 5000
Logistic Model IX :: PLHIV  CH mutation  yes/no~ age + CD4 nadir + CD4/CD8 ratio + d-dimer [n=216]
Estimate p-value OR Lower Upper Increment
(Intercept) -3,099 4,96E-03
age 0,027 1,47E-01 1,146 0,957 1,387 5
CD4 nadir -0,005 9,09E-04 0,790 0,683 0,903 50
CD4/CD8 ratio 1,077 0,007 2,937 1,364 6,647 1
D-dimer 0,001 0,044 1,076 1,004 1,163 50
Logistic regression model of clonal hematopoeisis (CH) mutation prevalence as predicted by age in PLHIV as compared 
to HIV-uninfected overweight controls (Logistic Model I). CHIP (clones with VAF >2%) prevalence as predicted by age in 
PLHIV as compared to HIV-uninfected overweight controls (Logistic Model II).  Logistic regression model of non-DNMT3A 
mutation prevalence as predicted by age in PLHIV as compared to HIV-uninfected population controls (Logistic Model III). 
Logistic regression model of CHDM prevalence as predicted by age, CD4 nadir (cells/uL) and CD4/CD8 ratio (Logistic Model 
IV). This model was determined after a backward elimination model including multiple clinical parameters (Body mass 
index, known duration of HIV infection, current CD4 count, HIV RNA zenith, treatment duration, smoking (packyears), 
high sensitive C-reactive protein). Logistic regression model including parameters from model IV with log(DNA) (Logistic 
Model V). Logistic regression model including parameters from model III with log(RNA) (Logistic Model VI). Logistic 
regression model including parameters from model III with RNA/DNA ratio (Logistic Model VII). Logistic regression 
model including parameters from model III with von willebrand factor (vWF) (Logistic Model VIII). Logistic regression 
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Introduction
Successful combination antiretroviral treatment (cART) has nearly normalized life 
expectancy of people living with HIV (PLHIV), although treatment is not able to fully reverse 
immune activation and persistent inflammation1-3. This inflammation may increase the risk 
for thrombotic events 4. While increased risk for venous thrombosis PLHIV appears to be 
limited to those with incomplete CD4 recovery or with continuing viral replication 5,6, data on 
arterial thrombosis risk show an increased cardiovascular risk in well-treated PLHIV 7-9. There 
is an ongoing debate on the effect of cART, especially abacavir, on cardiovascular risk 10-15.
D-dimers, which are soluble fibrin degradation products, are a marker of coagulation 
activity in the body. HIV infection is associated with elevated D-dimer concentrations 
even in those with viral suppression 16-18. D-dimer concentrations are independently 
associated with overall mortality and the incidence of cardiovascular disease and cancer 
in PLHIV 9,16,19. D-dimer concentrations are influenced by activation of the coagulation 
cascade itself, as well as signals that provoke coagulation such as inflammation and 
endothelial activation 4. Indeed, the inflammatory markers sCD14, high-sensitive 
C-reactive protein (hsCRP) and sCD163 have been associated with D-dimer in 
PLHIV 17,20, suggesting a link between inflammation and in vivo coagulation activity in PLHIV.
The capacity of plasma to form thrombin is a critical determinant of in vivo plasmatic 
coagulation 21. Thrombin generation (TG) can be measured ex vivo to determine coagulation 
capacity in a standardized setting and has been used as a diagnostic tool for hypo- and 
hypercoagulability states 22. In contrast to elevated D-dimer concentrations in PLHIV 16-18, 
available data on ex vivo TG in PLHIV are contradictory 23-25. This also applies to the possible 
roles of inflammation and cART on TG. 
Hence, we measured TG, as well as different coagulation markers, in a cross-sectional cohort 
of cART treated, virally suppressed PLHIV and HIV-uninfected controls and related TG to 
markers of inflammation and cART. We hypothesized that TG is influenced by both persistent 
inflammation and cART. 
Abstract
D-dimer concentrations in people living with HIV (PLHIV) on antiretroviral therapy (cART) 
are increased and have been linked to mortality. D-dimer is a biomarker of in vivo coagulation, 
In contrast to reports on D-dimer, data on coagulation capacity in PLHIV are conflicting. 
Here, we assessed the effect of cART and inflammation on coagulation capacity. We explored 
coagulation capacity using calibrated thrombin generation (TG) and linked this to persistent 
inflammation and cART in a cross-sectional study including PLHIV with viral suppression 
and uninfected controls. We used multivariate analyses to identify independent factors 
influencing in vivo coagulation (D-dimer) and ex vivo coagulation capacity (TG). Among 208 
PLHIV, 94 (45%) were on an abacavir containing regimen. D-dimer levels (219.1 vs 170.5 ng/
mL, p=0.001) and inflammatory makers (sCD14, sCD163 and hsCRP) were increased in PLHIV 
compared to controls (n=56). PLHIV experienced lower thrombin generation (reflected by 
endogenous thrombin potential; ETP) compared to controls, after correction for age, sex 
and antiretroviral therapy. Abacavir-use was independently associated with increased ETP. 
Prothrombin concentrations were strongly associated with ETP and were lower in PLHIV 
on a non-abacavir containing regimen compared to controls, suggesting consumption as 
a possible mechanism for HIV-associated reduction in TG. D-dimer concentrations were 
associated with inflammation, but not TG. Abacavir-use was associated with increased 
TG and could serve as an additional factor in the reported increase in thrombotic events 
during abacavir use. Increased exposure to triggers that propagate coagulation, such as 
inflammation, likely underlie increased D-dimer concentrations found in most PLHIV.
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Plasma markers of coagulation and inflammation
Inflammatory markers sCD163 (Quantikine), sCD14 (Quantikine) and hsCRP (Duoset) were 
determined in EDTA plasma by ELISA (all R&D system, Minneapolis, USA). D-dimer was 
measured by ELISA according manufacturer’s instructions (Abcam, Cambridge, UK).
The measurement of plasmatic fibrinogen was performed using the Clauss-method on a 
Start4 analyzer (Dignostica Stago, Asnières, France) with a known fibrinogen reagent (Dade® 
Fibrinogen Determination Reagents, Siemens, Munich, Germany).  Prothrombin (sheep anti-
human prothrombin polyclonal antibody and HRP-conjugated sheep anti-human prothrombin 
polyclonal antibody; Affinity Biologicals, Ancaster, Canada), protein S (sheep anti-human 
protein S IgG antibody and HRP-conjugated sheep anti-human protein S antibody from Affinity 
Biologicals and von Willebrand factor (vWF; Rabbit anti-human vWF and HRP-conjugated 
rabbit anti human vWF; DAKO, Agilent, Santa Clara, USA) concentrations were performed 
with an in-house sandwich ELISA assay. Briefly, 96 wells microtiter plates (NUNC Maxisorp, 
Thermo Fisher Scientific, Waltham, USA) were coated overnight at 4°C with capture antibody 
in a carbonate-bicarbonate coating buffer (pH 9.6) and blocked with 2% BSA in phosphate-
buffered saline (PBS) for 45 minutes at room temperature (RT) before adding diluted plasma 
samples and incubated at RT for 1.5 hour. The wells were then incubated with in detection 
antibody in PBS/2%BSA for 2 hours at room temperature after washing. Plates were washed 
before addition of SIGMAFAST OPD (Sigma). After 30 minutes the reaction was stopped with 
3 M sulfuric acid (H2SO4, Sigma). Optical densities (OD) were measured at 490 nm using an 
ELx808 Absorbance Microplate Reader (Biotek, Bad Friedrichshall, Germany). A calibration 
curve of serial diluted NPP was added to each plate 27,28. Consequently, the concentrations of 
prothrombin and protein S were expressed as the percentage (%) of the normal NPP.
Statistical analysis
R version 3.5.1 (CRAN-project) was used for analyses. Comparison between groups was done 
by Mann-Whitney U test, Student’s T-test or Chi Square test depending data distribution. 
The primary outcome for TG used in our analyses was ETP. Other TG parameters were 
treated as exploratory parameters. Benjamini-Hochberg procedure was performed on 
circulating markers and ETP comparisons (Figure 2, Table 2). For univariate and multivariate 
linear regression data of the dependent variable was transformed by log- or inverse rank 
transformation depending distribution. All multivariate linear regression models include 
a parameter to correct for possible storage degradation or time of inclusion bias. The 
correlation matrix was performed using spearman’s correlation coefficient. Missing data for 
all parameters was below <2.5% and comparisons were done pairwise. 
Materials and Methods
Study procedures
This cross-sectional, prospective study was performed at the Radboud university medical center, 
a tertiary teaching hospital in The Netherlands. The study was conducted in accordance with the 
Declaration of Helsinki after approval of the ethics committee (CMO Arnhem-Nijmegen, The 
Netherlands; NL42561.091.12, 2012/550). This study was embedded in the Human Functional 
Genomics Project (HFGP; www.humanfunctionalgenomicsproject.org). Adult HIV-1 infected 
individuals and controls were concurrently enrolled after a written informed consent was 
obtained. Inclusion criteria included suppressed viral load (<200copies/mL) after cART use for at 
least six months. Exclusion criteria were the use of coumarin derivates or direct anticoagulant 
therapy, as well as active hepatitis B or C infection, and/or signs of an infection other than HIV-1. 
Plasma thrombin generation measured with and without thrombomodulin
TG in platelet poor plasma (PPP) was measured with the “MidiCAT” technique, which is a 
modified calibrated thrombin generation (CAT) for the measurement of samples with low 
plasma volume. 22,26 This technique maintains the plasma dilution ratio while requiring only 
half of the volume (i.e. 40 versus 80 μL per well) needed than the regular CAT technique. PPP 
was stored at -80oC until thawed at 37oC for 10 min before measurement. TG was triggered 
with 5 pM tissue factor (TF; Innovin, Seimens Healthcare Diagnostics, Marburg, Germany), 
4 μM phospholipids (PL; Avanti Polar Lipids Inc., Alabaster, AL, USA) and in the presence 
and absence of 7 nM thrombomodulin (TM; Synapse research institute, Maastricht the 
Netherlands). The concentration of TM was chosen to inhibit the ETP by 50% in normal 
pooled plasma (NPP). TG parameters were calculated using specialized software from 
Thrombinoscope B.V. (Maastricht, the Netherlands). TG parameters (supplemental figure 
1) including Lagtime (LT; min), time-to-peak (TTP; min), Peak (nM), endogenous thrombin 
potential (ETP; nM×min) and velocity index (VI; nM/min) were chosen for further analysis. 
The ETP, Peak and VI of tested subjects were normalized as the percentage of that of normal 
pooled plasma (NPP) tested without TM in the same run.26 
The sensitivity of the TG parameters to TM reflects the function of the anticoagulant protein 
C pathway. The TM sensitivity ratio of ETP (ETP-TMsr) was calculated as the ratio of the ETP in 
the presence of TM and ETP in the absence of TM. The normalized TM sensitivity ratio of ETP 
(nETP-TMsr) was calculated by dividing the ETP-TMsr of subject by that of NPP in the same 
run. The nPeak-TMsr and nVI-TMsr were calculated similarly. A nTMsr value less than 1 means 
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Table 1. Baseline characteristics
Characteristics










Sex (Female) (%) 13 (11.4) 5 (5.3) 22 (39.3) 0.192 <0.001
Age (years) 53.0 [47.0, 60.0] 50.0 [41.5, 58.0] 30.0 [25.8, 53.0] 0.086 <0.001
BMI (kg/m2) 24.2 [22.4, 26.0] 23.8 [21.8, 26.2] 23.8 [21.5, 25.6] 0.469 0.518
HIV infection duration (years) 10.0 [6.2, 16.8] 6.5 [4.3, 10.3] <0.001
Way of transmission (%) 0.245
Heterosexual 3 (2.6) 5 (5.3)
IDU 2 (1.8) 1 (1.1)
MSM 82 (71.9) 75 (79.8)
Other/unknown 27 (23.7) 13 (13.8)
CD4 nadir (cells/µL) 205.0 [120.0, 347.5] 275.0 [185.0, 377.5] 0.044
CD4 count (cells/µL) 645.0 [482.5, 827.5] 665.0 [492.5, 800.0] 0.754
Viral load <40 copies/mL (%) 111 (97.3) 94 (100%) 0.317
CD4-CD8 ratio 0.8 [0.5, 1.1] 0.8 [0.6, 1.1] 0.954
cART duration (years) 7.9 [4.9, 15.4] 5.5 [3.7, 8.6] <0.001
NNRT (%) 44 (38.6) 17 (18.1) 0.002
PI (%) 26 (22.8) 6 (6.4) 0.002
INSTI (%) 67 (58.8) 73 (77.7) 0.006
NRTI FTC (%) 91 (79.8) 0 (0.0) <0.001
NRTI 3TC (%) 14 (12.3) 91 (96.8) <0.001
NRTI AZT (%) 3 (2.6) 1 (1.1) 0.755
NtRTI TDF (%) 92 (80.7) 1 (1.1) <0.001
Prior myocardial infarction (%) 6 (5.3) 4 (4.3) 0.99
Prior stroke (%) 2 (1.8) 1 (1.1) 1
VTE/pulmonary embolism (%) 3 (2.6) 1 (1.1) 0.755
Smoking (%) 33 (28.9) 24 (25.5) 0.694
Hypercholesterolemia (%) 33 (28.9) 23 (24.5) 0.57
Hypertension (%) 23 (20.2) 15 (16.0) 0.546
Diabetes Mellitus (%) 6 (5.3) 2 (2.1) 0.419
Family history of CVD 1st degree 
(%)
59 (51.8) 44 (46.8) 0.568
cholesterol lowering drugs (%) 35 (30.7) 21 (22.3) 0.232
Antihypertensive drugs (%) 27 (23.7) 20 (21.3) 0.805
ASA (%) 10 (8.8) 8 (8.5) 1
ABC: abacavir; IDU: intravenous drug-use; MSM: man who have sex with man; HIVRNA blib: viral load of 40-500 copies/mL after 
previous viral suppression and direct subsequent suppressed viral load; NRTI: nucleoside reverse transcriptase inhibitor; NtRTI: 
nucleotide reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; INSTI: 
integrase inhibitor; FTC: emtricitabine; 3TC: lamivudine; AZT: zidovudine; TDF:  Tenofovir difumarate; ASA: acetyl salicylic acid; 
CVD: cardiovascular disease. Data are presented as median with interquartile range and were analyzed using either chi-square 
test or Mann-Whitney U-test depending data distribution. 
Results
A total of 208 virally suppressed PLHIV on stable cART and 56 uninfected controls were 
concurrently measured and included in the analysis. Baseline characteristics can be found in 
table 1. PLHIV were more often male (91.3% vs 60.7% p<0.001) and older (52 [46-59] vs 30 
[26-53] years p<0.001) compared to HIV uninfected controls. An abacavir containing regimen 
was used by 94 PLHIV (45%) and 140 PLHIV (67%) used an integrase inhibitor (INSTI)-based 
regimen. 
First, in vivo coagulation activity, determined by D-dimer, was increased in PLHIV compared 
to controls (219.1 vs 170.5 ng/mL respectively p=0.001; table 2), as were all markers of 
inflammation (hsCRP, sCD14, sCD163) and the microbial translocation marker IFABP (data 
shown in table 2). D-dimer was independently associated with age (B= 7.44, p<0.001) and 
after correction for age and sex, the difference in D-dimer between PLHIV and uninfected 
controls disappeared (B= 0.154, p=0.878;supplemental table 1). The markers of inflammation 
and microbial translocation remained significantly increased in PLHIV compared to controls 
after correction for age and sex (supplemental table 1). D-dimer concentrations correlated 
with markers of inflammation, IFABP, and endothelial activation (plasma vWF; see Figure 1). 
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Ex vivo coagulation capacity by thrombin generation
Next, ex vivo coagulation capacity was determined by ex vivo calibrated thrombin generation 
in plasma. Overall, calibrated thrombin generation showed lower thrombin generation, 
most notably reduced endogenous thrombin potential (ETP), our primary outcome 
regarding TG, in PLHIV compared to uninfected controls (table 2, FDR-corrected). In 
addition PLHIV experienced reduced peak thrombin formation and increased lag time 
PLHIV compared to HIV-negative controls (data shown in table 2). This difference in ETP 
persisted (FDR-corrected) only in a subgroup analysis of participants aged 40 years and above 
(Supplemental table 2), but disappeared in the subgroup of only men (supplemental table 
3). However, after correction for age and sex, none of the thrombin generation parameters 
were significantly different between both cohorts (supplemental figure 1). Most women 
used oral contraceptive during sampling, which may account for the strong changes in TG 
parameters when stratifying for sex in the uninfected cohort 29. Within the PLHIV cohort, no 
clear association was found between ETP and CD4 nadir, HIV duration or current CD4 count 
(Figure 1; supplemental table 5). Higher current CD4 count, and CD4-recovery were correlated 
with increased peak thrombin and ETP (data shown in supplemental table 5), whereas 
HIV-RNA zenith and HIV duration were associated with decreased protein C activity (nETP-
TMsr; supplemental table 4). With the exception of nETP-TMsr, we found no associations 
between smoking and TG parameters (supplemental table 5).
Inflammation and ex vivo coagulation capacity
While inflammatory markers and D-dimer correlated positively, ETP did not correlate 
with any of the included inflammatory markers. Only lag time and time-to-peak 
correlated with sCD14, sCD163 and hsCRP (data shown in figure 1). Moreover, sCD163 
showed a negative correlation with Protein C activity (nETP-TMsr; R -0.2, P<0.05, 
figure 1). 
Increased TG in abacavir- vs non-abacavir-treated PLHIV
Next, we explored whether different antiretroviral drugs were associated with TG. There 
was no association between the use of a protease inhibitor (PI), integrase inhibitor (INSTI) or 
non-nucleoside reverse transcriptase inhibitor (NNRTI; figure 2) with ETP or any of the other 
TG parameters. In contrast, abacavir-use was associated with an increased ETP (non-abacavir: 
83.7% [74.7, 97.6] vs 90.2% [82.7, 101.6], p= 0.001; figure 2 and table 2). Also, there was a trend 
towards higher peak thrombin concentrations in the abacavir-group (79.9% [65.2, 96.0] vs 
85.8% [76.1, 95.7] p= 0.083; table 2). This effect of abacavir on ETP was independent of age, sex 
and inflammation (ETP: B= 8.00, p=0.006; Supplemental table 5). Tenofovir difumarate (TDF) 
use was the most prescribed alternative for abacavir. As a consequence, TDF was associated 
with a reduced ETP in our cohort (B=-7.86, p=-0.006). However, in multivariate analysis, the 
effect of abacavir appeared to be larger than TDF on ETP. Therefore, we attributed the effect 
Table 2. Markers of inflammation and thrombin generation.
PLHIV HC PLHIV  
vs HC
PLHIV- no ABC PLHIV - ABC non-ABC 
vs ABC
n 208 56 P-value 114 94 P-value
d-dimer 219.1 [160.6, 334.8] 170.5 [122.0, 307.2] 0.002# 213.4 [158.6, 335.5] 221.9 [162.6, 334.2] 0.673
Fibrinogen 3.4 [2.8, 4.0] 3.2 [2.8, 4.1] 0.746 3.4 [2.8, 4.0] 3.3 [2.8, 4.0] 0.632
Prothrombin 109.0 [89.3, 135.1] 135.1 [102.4, 162.5] <0.001# 106.0 [87.1, 135.1] 113.4 [94.8, 134.8] 0.305
Protein S 91.4 [80.7, 110.3] 86.9 [72.7, 112.4] 0.121 91.7 [81.7, 109.4] 91.4 [78.2, 110.4] 0.937
vWf 42.7 [31.8, 59.4] 32.5 [24.4, 43.9] <0.001# 42.3 [31.6, 61.6] 43.0 [32.4, 57.3] 0.623
iFABP 499.6 [263.0, 717.1] 242.5 [112.9, 376.9] <0.001# 576.2 [287.4, 897.2] 400.6 [240.5, 619.2] 0.004#
hsCRP 1446 [608, 2735] 651 [205, 1179] <0.001# 1558 [624, 3285] 1192 [594, 2249] 0.337
sCD14 2139 [1778, 2625] 1789 [1502, 2071] <0.001# 2063 [1745, 2591] 2236 [1830, 2684] 0.193
sCD163 716.2 [525.6, 898.8] 517.3 [410.7, 578.1] <0.001# 765.8 [581.6, 916.1] 634.5 [487.8, 858.3] 0.019
Thrombin generation
ETP 86.6 [78.6, 99.6] 93.0 [83.3, 105.0] 0.011# 83.7 [74.7, 97.6] 90.2 [82.7, 101.6] 0.001#
Lag time 2.0 [1.7, 2.3] 2.0 [1.7, 2.0] 0.382 2.0 [1.7, 2.3] 2.0 [1.7, 2.3] 0.557
TTP 4.4 [4.0, 5.0] 4.3 [3.5, 5.0] 0.035 4.3 [4.0, 5.0] 4.4 [4.0, 5.0] 0.566
Peak 82.6 [70.0, 95.8] 88.1 [72.3, 101.5] 0.031 79.9 [65.2, 96.0] 85.8 [76.1, 95.7] 0.083
VI 78.1 [56.2, 102.7] 97.3 [64.0, 123.5] 0.001 76.4 [53.6, 102.5] 78.3 [61.2, 102.5] 0.566
Protein C activity
LagT-TM 1.7 [1.4, 2.0] 1.7 [1.4, 2.0] 0.704 1.7 [1.4, 2.3] 1.7 [1.7, 2.0] 0.645
TTP-TM 3.7 [3.3, 4.0] 3.7 [3.3, 4.0] 0.641 3.7 [3.3, 4.0] 3.7 [3.3, 4.0] 0.982
ETP-TM 40.6 [27.9, 52.0] 50.1 [32.8, 76.2] <0.001 41.0 [28.0, 51.1] 39.7 [26.3, 52.6] 0.706
PEAK-TM 49.6 [31.8, 62.4] 57.1 [39.8, 82.5] 0.002 50.9 [33.2, 61.6] 47.9 [29.9, 62.5] 0.553
VI-TM 59.8 [38.6, 82.5] 71.9 [51.8, 112.5] <0.001 62.1 [39.8, 85.4] 59.6 [33.2, 77.5] 0.509
nETP-TMSR 0.9 [0.7, 1.2] 1.2 [0.8, 1.5] 0.001 0.9 [0.7, 1.2] 0.9 [0.6, 1.2] 0.183
nPEAK-TMSR 0.9 [0.8, 1.1] 1.1 [0.9, 1.3] <0.001 1.0 [0.8, 1.1] 0.9 [0.8, 1.1] 0.185
nVI-TMSR 1.0 [0.9, 1.2] 1.1 [0.9, 1.2] 0.43 1.1 [0.9, 1.2] 1.0 [0.9, 1.2] 0.366
High sensitive CRP (hsCRP), soluble CD14, soluble CD163. Marker of micriobial translocation: plasma IFABP. Marker of endothelial 
activation: plasma von willebrand factor (vWf). Calibrated thrombin generation (TG)  was triggered with 5 pM tissue factor, 4 μM 
phospholipids and in the presence and absence of 7 nM thrombomodulin (TM). Lag time (LagT), Time to peak (TTP), endogenous 
thrombin production (ETP). Normalized Protein C activity (NSR). P-values were calculated using Mann-Whitney U test. Circulating 
factors and ETP as the primary outcome for TG were corrected for multiple testing using Benjamini-Hochberg procedure (FDR). 
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In most analyses on abacavir-associated cardiovascular risk in treated PLHIV, there was 
a discrepancy between current use, past use (>6 months) and cumulative abacavir-use 
(reviewed by Llibre et al 30). Current-use of abacavir was more strongly associated to ETP 
in our cohort than cumulative use. When analysis was restricted to current abacavir users, 
cumulative exposure (in days) was not correlated with ETP (B=0.597, p=0.552). 
When restricting the analysis to non-abacavir users, PLHIV had a decreased ETP, with 
increased lag time and a more pronounced protein C activity (table 2 and supplemental 
table 6) compared to uninfected controls. In summary, our data show that abacavir-use 
is associated with an increase in ex vivo coagulation capacity reflected by increased TG, 
whereas overall, PLHIV on a non-abacavir regimen showed a decreased coagulation capacity 
measured by TG.
Mechanisms of decreased TG
Decreased TG and increased D-dimer concentrations suggest consumption of coagulation 
factors. Indeed, prothrombin concentrations were decreased in PLHIV (figure 3c), even after 
correction for age and sex (PLHIV: 109.0% [89.3, 135.1], HC: 135.1% [102.4,162.5], p<0.001; 
supplemental table 1). While prothrombin concentrations were decreased in PLHIV 
compared to controls, fibrinogen concentrations (PLHIV: 3.4mg/mL [2.8,4.0], HC: 3.2mg/mL 
[2.8, 4.1], p=0.746) did not differ between groups (figure 3a,c). Furthermore, prothrombin 
was strongly correlated with ETP parameters in both PLHIV and uninfected controls (figure 
3d and supplemental table 6) suggesting that the reduced concentration of prothrombin 
may underlie the observed decrease in TG in PLHIV. Reduced production of prothrombin and 
other coagulation factors (by the liver) was deemed unlikely due to similar concentrations 
of protein S (PLHIV: 91.7% [81.7, 109.4], HC: 86.9% [72.7,112.4], p=0.163, figure 3e) and 
fibrinogen. No difference in prothrombin or fibrinogen could be observed when PLHIV were 
stratified based on abacavir-use (Table 2).
of NRTIs on ETP to abacavir in this study. To a similar extent, we could not clearly discriminate 
between lamivudine and abacavir in this cohort, as this was the most prescribed combination 
of NRTIs (all data from multivariate analyses are shown in supplemental table 4). 
As INSTI-use was high in the abacavir-group and showed a trend towards lower ETP, we 
corrected for INSTI use (B=-5.79, p=0.061) and the effect of abacavir on ETP became more 
pronounced (ETP: B=8.85, P=0.002). 
The abacavir-associated increase in ETP was not due to decreased protein C activity, a known 
inhibitor of plasmatic coagulation, as nETPsr was comparable between groups even after 
correction for age, sex and inflammation (abacavir: B=-0.895, p=0.37). 
Figure 1. Spearman correlation matrix. Spearman’s Correlation coefficients are shown in color and size of circles. 
Parameters are clustered using hierarchal clustering based on coefficients. Markers of inflammation: High sensitive 
CRP (hsCRP), soluble CD14, soluble CD163. Marker of micriobial translocation: plasma IFABP. Marker of endothelial 
activation: plasma von willebrand factor (vWf). Calibrated thrombin generation  was triggered with 5 pM tissue factor, 4 
μM phospholipids and in the presence and absence of 7 nM thrombomodulin (TM). Lag time (LagT), Time to peak (TTP), 
endogenous thrombin production (ETP). Normalized Protein C activity (NSR).
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Figure 3. Coagulation factors in PLHIV and healthy controls. (A) Fibrinogen concentration (mg/mL) in PLHIV and 
HC. (B) Correlation between inverse rank-based transformed (IRT) Endogenous thrombin potential (ETP; % of normal 
pooled plasma (NPP)) and fibrinogen (C) Prothrombin concentrations (% of NPP) in PLHIV and controls. (D) Correlation 
plot for IRT prothrombin and IRT ETP. (E) Protein S concentrations (% of NPP) in PLHIV and controls. (F) IRT Protein S and 
IRT ETP correlation plot. PLHIV: people living with HIV, HC: healthy controls. ETP: Endogenous thrombin production. 
Correlations coefficients are Pearson’s coefficients after inverse-rank based correction (IRT) for normalization. 
Comparisons between cohorts were done using Mann-Whitney U-test.
Figure 2. Endogenous thrombin potential stratified per cART-use. Endogenous thrombin potential (ETP; nM×min) were 
normalized as the percentage (%) of that of normal pooled plasma (NPP) tested in the same run. ABC: abacavir, INSTI: 
Integrase inhibitor, PI: Protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor, RAL: raltegravir, DTG: 
Dolutegravir Values were compared using Mann-Whitney U test. Data are depicted according to Tukey. Comparisons are 
corrected for multiple testing using Benjamini-Hochberg procedure. ETP remained significantly higher in ABC users 
compared to non-ABC after FDR correction.
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reflects actual hemostatic potential of the plasmatic coagulation pathways 22. We confirmed 
that D-dimers indeed correlated with endothelial activation (e.g. vWF) and inflammation (eg. 
sCD163), but found no such relation with TG parameters in PLHIV. This suggests that increased 
D-dimer concentrations are primarily influenced by increased provoking signals for coagulation, 
such as endothelial activation and inflammation during HIV infection. However, increased 
plasmatic coagulation capacity could still play a role in cardiovascular disease in PLHIV, as was 
shown by a case-control study using in silico TG 42. A significant role for plasmatic coagulation 
and increased TG has been shown in clinical studies including uninfected patients at risk for 
cardiovascular disease 31. As PLHIV are known for increased inflammation and endothelial 
activation, an abacavir-associated potentiation of the plasmatic coagulation capacity could 
therefore still result in increased risk for arterial thrombosis.
Interestingly, protein C activity was higher in PLHIV and correlated with inflammation 
(sCD163) thereby reducing the overall plasmatic coagulation capacity. This rebalancing of the 
anti- and procoagulant pathway during HIV infection mimics the rebalancing of hemostasis 
seen in liver disease 43. Monocyte and macrophage activation (sCD14 and sCD163) correlated 
with lag time and TTP. These parameters are mostly influenced by an increase in Tissue factor 
pathway inhibitor (TFPI) 44. This TFPI is known to be increased in PLHIV 45.  Even though 
endothelial cells and platelets mainly produce TFPI, monocytes are known producers of TFPI 
too and could increase production upon activation 44. 
Limitations and strengths
The cross-sectional design of our study does not allow to draw causal inferences. 
Furthermore, the independent increase in TG seen in abacavir treatment could be affected 
through indication bias whereby treatment selection is influenced by patient characteristics. 
Yet, in our case abacavir was preferably given to people with a decreased cardiovascular risk 
profile, which was reflected in our cohort with a trend towards lower CVD risk factors in the 
abacavir-treated group. Second, as TDF was the most prescribed alternative to abacavir, 
we cannot fully rule out that TDF has an inhibitory effect on TG. Yet, it will not change the 
conclusions that abacavir is associated with increased TG compared to non-abacavir users. To 
similar extent we cannot exclude the possibility that lamivudine is involved in this difference 
as lamivudine was prescribed concurrently to abacavir in the majority of patients. Third, 
we could not correlate TG parameters with clinical outcomes as was performed in the study 
reporting on in silico TG. While in silico TG can be calculated from plasma markers measured 
in (long-term) stored EDTA plasma, our functional assay of calibrated TG (CAT) requires 
citrated plasma, which is not regularly collected in large-scale cohorts. Actual measurement 
of thrombin formation using the CAT method is more precise than the modeling of the in silico 
TG method, because CAT also includes possible unknown confounders such as cART-use or 
other unknown factors. Therefore, CAT better reflects actual hemostatic potential in complex 
Discussion
In a cohort of virally suppressed PLHIV on chronic cART, we show that abacavir-use was 
associated with increased TG compared with non-abacavir regimens. Overall, PLHIV 
exhibited reduced TG compared to HIV-uninfected controls, which was associated with lower 
plasma concentrations of prothrombin. PLHIV had higher concentrations of inflammatory 
markers, which correlated with D-dimer concentrations, but not with TG parameters.
TG is a diagnostic tool for hypercoagulability states. This is not limited to venous thrombosis, 
and may also include arterial thrombosis31. The use of abacavir has been linked to an 
increased risk for acute cardiovascular events in different studies 10-13, but not in all 14,15. In 
contrast, abacavir use does not appear to be associated with an increased incidence of venous 
thrombosis5. Increased platelet activation was suggested to underlie the excess cardiovascular 
risk in users of abacavir 32-34, even though increased platelet activation was not observed in 
all studies 35. A recent study found that abacavir led to an inflammatory and prothrombotic 
endothelial phenotype promoting in vivo platelet activation via endothelial microparticles 
(EMP) 36. The increased TG in abacavir-use could also be caused by endothelial dysfunction 
and possible prothrombotic EMPs36,37. In addition, thrombin directly activates platelets, so our 
finding of increased TG capacity in abacavir users may as such contribute to increased platelet 
activation and CVD 38. In contrast to our results, a study by Jong et al 24 showed no difference in 
TG for abacavir-use, but only with a limited sample size of  27 individuals in the abacavir-group. 
While inflammation was increased in PLHIV, we found no increase in TG. Moreover, the 
subgroup analysis of non-abacavir users showed a slight decrease in TG in PLHIV compared to 
uninfected controls. This observation is in line with earlier observations showing decreased 
TG in long-term treated PLHIV 25. In this study, we confirm these results using a cohort 
of long-term treated PLHIV on more recently recommended cART regimens. Regarding 
possible mechanisms, consumption of clotting factors could play a role, as prothrombin 
concentrations were decreased with a concurrent increase in D-dimer in the total PLHIV 
group. Fibrinogen concentrations were similar across all groups, but fibrinogen is a well-
known acute phase protein and could therefore reflect inflammation rather than coagulation 
capacity 39. Furthermore, decreased production of (pro)coagulation factors was deemed less 
likely as other factors produced by the liver such as fibrinogen and protein S were similar 
across groups. 
More recent papers have used in silico TG as a proxy for plasmatic coagulation potential and 
showed that this calculated TG correlate with development of CVD40. Furthermore, in the SMART 
study, in silico TG was lower in PLHIV without ART and ongoing viral replication compared to 
cART treated PLHIV 41,42. While D-dimer mirrors coagulation and fibrinolysis in vivo, in vitro TG 
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Supplementary Table 2. Subgroup analysis of individuals aged 40 years and above
  PLHIV (n=173) HC (n=22) p
age (mean (SD)) 54.8 (7.7) 59.4 (10.3) 0.013
BMI (median [IQR]) 24.4 [22.4, 26.6] 24.5 [22.3, 26.9] 0.954
d.dimer  (median [IQR]) 233.7 [166.2, 339.6] 333.0 [187.0, 391.9] 0.167
Plasma vWf (median [IQR]) 4550 [3442, 6248] 3453 [2341, 3923] 0.003#
iFABP (median [IQR]) 521.0 [286.2, 748.9] 371.8 [317.0, 545.6] 0.132
hsCRP (median [IQR]) 1504 [608, 3099] 812.6 [382.2, 1671.0] 0.073
sCD14 (median [IQR]) 2207 [1787, 2659] 1952 [1741, 2134] 0.066
sCD163 (median [IQR]) 740.9 [540.6, 904.7] 516.8 [442.7, 684.2] 0.011#
Fibrinogen (median [IQR]) 3.4 [2.8, 4.0] 4.0 [3.0, 4.5] 0.074
Prothrombin (median [IQR]) 109.0 [88.1, 136.3] 161.5 [134.9, 180.2] <0.001#
Protein S (median [IQR]) 91.7 [81.7, 111.9] 83.7 [71.3, 118.0] 0.325
ETP (median [IQR]) 86.6 [78.7, 101.0] 98.6 [94.3, 105.5] 0.014#
LagT (median [IQR]) 2.0 [1.7, 2.3] 2.0 [1.7, 2.4] 0.707
TTP (median [IQR]) 4.3 [4.0, 5.0] 4.7 [3.7, 5.0] 0.938
Peak (median [IQR]) 82.5 [68.8, 95.8] 90.1 [80.1, 103.4] 0.1
VI (median [IQR]) 78.1 [56.0, 102.0] 90.2 [71.2, 108.8] 0.134
LagT_TM (median [IQR]) 1.7 [1.4, 2.0] 2.0 [1.7, 2.0] 0.165
TTP_TM (median [IQR]) 3.7 [3.3, 4.0] 4.0 [3.6, 4.0] 0.296
ETP_TM (median [IQR]) 41.1 [27.0, 51.7] 47.9 [41.0, 63.4] 0.066
PEAK_TM (median [IQR]) 50.1 [31.9, 61.8] 52.4 [46.2, 68.2] 0.241
VI_TM (median [IQR]) 59.6 [37.4, 82.3] 65.2 [55.6, 83.8] 0.207
ETP_TM_NSR (median [IQR]) 0.9 [0.7, 1.2] 0.9 [0.7, 1.3] 0.558
PEAK_TM_NSR (median [IQR]) 0.9 [0.8, 1.1] 0.9 [0.8, 1.2] 0.494
VI_TM_NSR (median [IQR]) 1.0 [0.9, 1.3] 1.0 [0.9, 1.3] 0.97
Markers of inflammation: High sensitive CRP (hsCRP), soluble CD14, soluble CD163. Marker of micriobial translocation: 
plasma IFABP. Marker of endothelial activation: plasma von willebrand factor (vWf). Calibrated thrombin generation  was 
triggered with 5 pM tissue factor, 4 μM phospholipids and in the presence and absence of 7 nM thrombomodulin (TM). Lag 
time (LagT), Time to peak (TTP), endogenous thrombin production (ETP). Normalized Protein C activity (NSR). Circulating 
factors and ETP as the primary outcome for TG were corrected for multiple testing using Benjamini-Hochberg procedure 
(FDR). All remaining TG parameters were treated as exploratory parameters # Significantly different between groups 
after FDR-correction.
Supplementary Table 1. Linear regression using age and sex as co-factors in multivariate analysis.
Coefficient (univariate) Coefficient(corrected for age-sex)
d-dimer 52.75 (3.73 to 101.77, p=0.035) 6.87 (-61.05 to 74.78, p=0.842)
iFABP 289.4 (123.5 to 455.3, p=0.001) 278.5 (95.3 to 461.6, p=0.003)
hsCRP 1595 (210 to 2981, p=0.024) 1863 (324 to 3402, p=0.018)
Fibrinogen 0.07 (-0.17 to 0.32, p=0.557) -0.07 (-0.43 to 0.29, p=0.707)
vWf 13207 (5679 to 20735, p=0.001) 7120 (-3965 to 18204 p=0.207)
sCD14 423.8 (213.3 to 634.5, p<0.001) 319.9 (886.8 to 551.2, p=0.007)
sCD163 215.4 (120.1 to 310.6, p<0.001) 152.74(49.3 to 256.2, p=0.004)
Prothrombin -21.39 (-37.29 to -5.49, p=0.009) -23.40 (-43.15 to -3.64, p=0.020)
ProteinS 6.55 (-1.70 to 14.80, p=0.119) -3.21 (-15.00 to 8.57, p=0.592)
ETP -6.37 (-11.06 to -1.68, p=0.008) -4.86 (-11.39 to 1.67, p=0.144)
LagT 0.06 (-0.06 to 0.18, p=0.336) -0.06 (-0.23 to 0.12, p=0.525)
TTP 0.25 (0.04 to 0.47, p=0.022) 0.06 (-0.24 to 0.36, p=0.708)
Peak -6.50 (-11.84 to -1.16, p=0.017) -2.25 (-9.60 to 5.10, p=0.547)
VI -19.30 (-28.72 to -9.87, p<0.001) -7.50 (-19.93 to 4.94, p=0.236)
LagT_TM 0.02 (-0.11 to 0.14, p=0.799) -0.07 (-0.25 to 0.11, p=0.454)
TTP_TM 0.08 (-0.06 to 0.22, p=0.270) -0.06 (-0.26 to 0.14, p=0.569)
ETP_TM -12.27 (-18.39 to -6.15, p<0.001) -5.36 (-13.50 to 2.79, p=0.196)
ETP_TM_NSR -0.20 (-0.30 to -0.09, p<0.001) -0.08 (-0.23 to 0.06, p=0.259)
PEAK_TM -12.18 (-18.97 to -5.38, p<0.001) -3.28 (-12.34 to 5.77, p=0.476)
VI_TM -20.94 (-31.16 to -10.72, p<0.001) -5.43 (-18.65 to 7.79, p=0.419)
PEAK_TM_NSR -0.15 (-0.23 to -0.08, p<0.001) -0.08 (-0.18 to 0.03, p=0.155)
VI_TM_NSR -0.01 (-0.07 to 0.06, p=0.883) 0.01 (-0.09 to 0.11, p=0.847)
Markers of inflammation: High sensitive CRP (hsCRP), soluble CD14, soluble CD163. Marker of micriobial translocation: 
plasma IFABP. Marker of endothelial activation: plasma von Willebrand factor (vWf). Calibrated thrombin generation  was 
triggered with 5 pM tissue factor, 4 μM phospholipids and in the presence and absence of 7 nM thrombomodulin (TM). Lag 
time (LagT), Time to peak (TTP), endogenous thrombin production (ETP). Normalized Protein C activity (NSR).
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Supplementary Table 4. Univariate and multivariate analysis of circulating markers
ETP
Univariate Model 1 (Age-sex) model (age-sex-sCD14)
Prothrombin 4.45 (0.79 to 8.11, p=0.018) 5.81 (1.92 to 9.70, p=0.004) 5.90 (2.02 to 9.79, p=0.003)
Fibrinogen -6.28 (-9.73 to -2.82, p<0.001) -6.56 (-10.26 to -2.87, p=0.001) -6.41 (-10.13 to -2.69, p=0.001)
sCD163 1.96 (-4.54 to 8.46, p=0.553) -2.56 (-10.29 to 5.17, p=0.513) -1.54 (-9.41 to 6.33, p=0.700)
sCD14 -1.90 (-11.49 to 7.69, p=0.697) -8.07 (-19.47 to 3.33, p=0.164) -8.07 (-19.47 to 3.33, p=0.164)
hsCRP 1.48 (-0.61 to 3.58, p=0.165) 0.43 (-1.99 to 2.84, p=0.727) 0.77 (-1.72 to 3.25, p=0.543)
iFABP -2.35 (-5.13 to 0.43, p=0.097) -2.87 (-5.98 to 0.24, p=0.071) -2.84 (-5.94 to 0.26, p=0.072)
PEAK
Prothrombin 1.03 (-3.32 to 5.39, p=0.640) 2.16 (-2.58 to 6.90, p=0.370) 2.28 (-2.47 to 7.02, p=0.345)
Fibrinogen -5.23 (-9.39 to -1.08, p=0.014) -6.15 (-10.65 to -1.65, p=0.008) -5.96 (-10.50 to -1.43, p=0.010)
sCD163 -4.71 (-12.30 to 2.87, p=0.222) -8.11 (-17.20 to 0.98, p=0.080) -7.18 (-16.45 to 2.09, p=0.128)
sCD14 -6.34 (-17.53 to 4.86, p=0.266) -9.07 (-22.58 to 4.45, p=0.187) -9.07 (-22.58 to 4.45, p=0.187)
hsCRP 0.48 (-2.00 to 2.97, p=0.701) -0.24 (-3.13 to 2.65, p=0.870) 0.18 (-2.79 to 3.15, p=0.906)
iFABP -2.99 (-6.23 to 0.26, p=0.071) -2.99 (-6.69 to 0.70, p=0.112) -2.97 (-6.65 to 0.72, p=0.114)
TTP
Prothrombin 0.10 (-0.08 to 0.29, p=0.283) 0.08 (-0.12 to 0.29, p=0.409) 0.08 (-0.12 to 0.27, p=0.457)
Fibrinogen 0.15 (-0.02 to 0.33, p=0.089) 0.23 (0.04 to 0.41, p=0.018) 0.21 (0.02 to 0.40, p=0.027)
sCD163 0.51 (0.20 to 0.82, p=0.001) 0.49 (0.12 to 0.86, p=0.010) 0.42 (0.04 to 0.79, p=0.029)
sCD14 0.69 (0.23 to 1.15, p=0.003) 0.63 (0.08 to 1.19, p=0.024) 0.63 (0.08 to 1.19, p=0.024)
hsCRP 0.12 (0.02 to 0.22, p=0.023) 0.09 (-0.02 to 0.21, p=0.114) 0.07 (-0.05 to 0.19, p=0.264)
iFABP 0.07 (-0.07 to 0.20, p=0.336) 0.06 (-0.09 to 0.22, p=0.420) 0.06 (-0.09 to 0.21, p=0.429)
LagTime
Prothrombin -0.00 (-0.11 to 0.10, p=0.933) -0.03 (-0.15 to 0.09, p=0.611) -0.04 (-0.15 to 0.07, p=0.501)
Fibrinogen 0.15 (0.05 to 0.25, p=0.004) 0.20 (0.09 to 0.30, p<0.001) 0.18 (0.08 to 0.28, p=0.001)
sCD163 0.25 (0.07 to 0.43, p=0.007) 0.17 (-0.04 to 0.39, p=0.119) 0.09 (-0.12 to 0.30, p=0.395)
sCD14 0.64 (0.38 to 0.90, p<0.001) 0.62 (0.32 to 0.93, p<0.001) 0.62 (0.32 to 0.93, p<0.001)
hsCRP 0.10 (0.05 to 0.16, p=0.001) 0.08 (0.02 to 0.15, p=0.015) 0.06 (-0.01 to 0.12, p=0.087)
iFABP 0.01 (-0.07 to 0.09, p=0.809) 0.02 (-0.07 to 0.11, p=0.704) 0.02 (-0.07 to 0.10, p=0.724)
nETPTMsr
Prothrombin -0.07 (-0.16 to 0.01, p=0.105) -0.07 (-0.16 to 0.01, p=0.096) -0.07 (-0.16 to 0.01, p=0.102)
Fibrinogen -0.06 (-0.16 to 0.03, p=0.188) -0.08 (-0.18 to 0.02, p=0.113) -0.08 (-0.18 to 0.02, p=0.111)
sCD163 -0.21 (-0.37 to -0.04, p=0.014) -0.20 (-0.38 to -0.02, p=0.032) -0.20 (-0.39 to -0.02, p=0.032)
sCD14 -0.19 (-0.43 to 0.05, p=0.118) -0.02 (-0.30 to 0.26, p=0.885) -0.02 (-0.30 to 0.26, p=0.885)
hsCRP -0.07 (-0.12 to -0.02, p=0.009) -0.06 (-0.11 to -0.00, p=0.033) -0.06 (-0.11 to -0.00, p=0.038)
iFABP -0.01 (-0.08 to 0.06, p=0.817) -0.01 (-0.08 to 0.06, p=0.802) -0.01 (-0.08 to 0.06, p=0.812)
Supplementary Table 3. Subgroup analysis restricting to males only
  PLHIV (n=190) HC (n=34 p
AGE (mean (SD)) 51.2 (11.0) 39.7 (17.7) <0.001
BMI (median [IQR]) 24.1 [22.0, 25.9] 23.9 [21.9, 25.4] 0.89
d.dimer (median [IQR]) 216.5 [158.0, 334.2] 166.9 [115.2, 275.4] 0.019#
Plasma vWf (median [IQR]) 42675 [31896, 58881] 31559 [26013, 45904] 0.011#
iFABP (median [IQR]) 478.1 [245.5, 694.7] 268.3 [134.6, 397.5] 0.003#
hsCRP (median [IQR]) 1451 [607, 2688] 675 [166, 1309] 0.003#
sCD14 (median [IQR]) 2139 [1779, 2630] 1851 [1614, 2172] 0.007#
sCD163 (median [IQR]) 700.2 [516.8, 900.0] 532.1 [418.3, 620.5] 0.002#
Fibrinogen (median [IQR]) 3.4 [2.8, 4.0] 3.3 [2.8, 4.0] 0.615
Prothrombin (median [IQR]) 109.1 [89.3, 136.7] 136.7 [110.6, 162.1] 0.003#
ProteinS (median [IQR]) 91.7 [80.3, 111.3] 99.7 [79.9, 133.6] 0.315
ETP (median [IQR]) 86.6 [78.6, 99.2] 86.8 [80.5, 98.7] 0.961
LagT (median [IQR]) 2.0 [1.7, 2.3] 2.0 [2.0, 2.3] 0.052
TTP (median [IQR]) 4.4 [4.0, 5.0] 4.7 [4.0, 5.0] 0.329
Peak (median [IQR]) 82.4 [68.7, 95.4] 78.4 [66.3, 96.8] 0.588
VI (median [IQR]) 76.8 [55.9, 100.7] 76.1 [56.2, 104.6] 0.813
LagT_TM (median [IQR]) 1.7 [1.4, 2.0] 2.0 [1.7, 2.0] 0.029
TTP_TM (median [IQR]) 3.7 [3.3, 4.0] 4.0 [3.7, 4.0] 0.082
ETP_TM (median [IQR]) 40.6 [27.7, 52.0] 43.5 [30.0, 50.5] 0.764
PEAK_TM (median [IQR]) 49.5 [31.8, 62.2] 49.9 [37.9, 62.2] 0.898
VI_TM (median [IQR]) 59.6 [38.2, 80.2] 60.2 [44.2, 81.7] 0.691
ETP_TM_NSR (median [IQR]) 0.9 [0.7, 1.2] 0.9 [0.7, 1.3] 0.594
PEAK_TM_NSR (median [IQR]) 0.9 [0.8, 1.1] 1.0 [0.8, 1.2] 0.347
VI_TM_NSR (median [IQR]) 1.1 [0.9, 1.2] 1.1 [0.9, 1.2] 0.711
Markers of inflammation: High sensitive CRP (hsCRP), soluble CD14, soluble CD163. Marker of micriobial translocation: 
plasma IFABP. Marker of endothelial activation: plasma von willebrand factor (vWf). Calibrated thrombin generation  was 
triggered with 5 pM tissue factor, 4 μM phospholipids and in the presence and absence of 7 nM thrombomodulin (TM). Lag 
time (LagT), Time to peak (TTP), endogenous thrombin production (ETP). Normalized Protein C activity (NSR). Circulating 
factors and ETP as the primary outcome for TG were corrected for multiple testing using Benjamini-Hochberg procedure 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Prothrombin 0.22 (0.03 to 0.41, p=0.026) 0.30 (0.10 to 0.49, p=0.003) 0.27 (0.08 to 0.46, p=0.006)
Fibrinogen -0.30 (-0.48 to -0.12, p=0.001) -0.31 (-0.49 to -0.12, p=0.001) -0.28 (-0.46 to -0.10, p=0.003)
sCD163 0.19 (-0.15 to 0.52, p=0.268) -0.06 (-0.45 to 0.32, p=0.754) 0.13 (-0.26 to 0.52, p=0.509)
sCD14 -0.07 (-0.57 to 0.42, p=0.779) -0.47 (-1.04 to 0.10, p=0.104) 0.42 (0.14 to 0.70, p=0.004)
hsCRP 0.11 (0.00 to 0.22, p=0.049) 0.04 (-0.08 to 0.16, p=0.466) 0.08 (-0.04 to 0.20, p=0.201)
iFABP -0.12 (-0.26 to 0.03, p=0.109) -0.15 (-0.30 to 0.01, p=0.066) -0.12 (-0.27 to 0.04, p=0.133)
Linear regression was used for analysis. Data shown as Beta with confidence interval and p-value. Model 1 includes age, 
time of inclusion and sex as covariates. Model 2 also includes sCD14 as a covariate. High sensitive CRP (hsCRP), soluble 
CD14, soluble CD163. Marker of micriobial translocation: plasma IFABP; IRT: inverse rank based normalization.
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Chapter 5 - Plasmatic coagulation capacity in HIV
Supplementary Table 6. Subgroup analysis restricting to PLHIV on a non-abacavir (ABC) containing regimen and 
healthy controls only.
PLHIV-no ABC (n=114) HC (n=56) p
AGE (mean (SD)) 52.3 (10.3) 39.9 (17.3) <0.001
BMI (median [IQR]) 24.2 [22.4, 26.0] 23.8 [21.5, 25.6] 0.395
Sex (%female) 13 (11.4) 22 (39.3) <0.001
iFABP (median [IQR]) 576.2 [287.4, 897.2] 242.5 [112.9, 376.9] <0.001#
hsCRP (median [IQR]) 1558 [624, 3285] 651.2 [205.9, 1179.2] <0.001#
sCD14 (median [IQR]) 2063 [1745, 2591] 1789 [1502, 2071] 0.001#
sCD163 (median [IQR]) 765.8 [581.6, 916.1] 517.3 [410.7, 578.1] <0.001#
Plasma vWf (median [IQR]) 42344.2 [31562.4, 61642.5] 32468.9 [2441.6, 43935.1] <0.001#
d.dimer (median [IQR]) 213.4 [158.6, 335.5] 170.5 [122.0, 307.2] 0.01#
Fibrinogen (median [IQR]) 3.4 [2.8, 4.0] 3.2 [2.8, 4.1] 0.589
Prothrombin (median [IQR]) 106.0 [87.1, 135.1] 135.1 [102.4, 162.5] <0.001#
ProteinS (median [IQR]) 91.7 [81.7, 109.4] 86.9 [72.7, 112.4] 0.163
ETP (median [IQR]) 83.7 [74.7, 97.6] 93.0 [83.3, 105.0] <0.001#
LagT (median [IQR]) 2.0 [1.7, 2.3] 2.0 [1.7, 2.0] 0.618
TTP (median [IQR]) 4.3 [4.0, 5.0] 4.3 [3.5, 5.0] 0.103
Peak (median [IQR]) 79.9 [65.2, 96.0] 88.1 [72.3, 101.5] 0.012
VI (median [IQR]) 76.4 [53.6, 102.5] 97.3 [64.0, 123.5] 0.002
LagT_TM (median [IQR]) 1.7 [1.4, 2.3] 1.7 [1.4, 2.0] 0.996
TTP_TM (median [IQR]) 3.7 [3.3, 4.0] 3.7 [3.3, 4.0] 0.687
ETP_TM (median [IQR]) 41.0 [28.0, 51.1] 50.1 [32.8, 76.2] 0.003
PEAK_TM (median [IQR]) 50.9 [33.2, 61.6] 57.1 [39.8, 82.5] 0.011
VI_TM (median [IQR]) 62.1 [39.8, 85.4] 71.9 [51.8, 112.5] 0.004
ETP_TM_NSR (median [IQR]) 0.9 [0.7, 1.2] 1.2 [0.8, 1.5] 0.012
PEAK_TM_NSR (median [IQR]) 1.0 [0.8, 1.1] 1.1 [0.9, 1.3] 0.003
Markers of inflammation: High sensitive CRP (hsCRP), soluble CD14, soluble CD163. Marker of micriobial translocation: 
plasma IFABP. Marker of endothelial activation: plasma von willebrand factor (vWf). Calibrated thrombin generation  was 
triggered with 5 pM tissue factor, 4 μM phospholipids and in the presence and absence of 7 nM thrombomodulin (TM). Lag 
time (LagT), Time to peak (TTP), endogenous thrombin production (ETP). Normalized Protein C activity (NSR). Circulating 
factors and ETP as the primary outcome for TG were corrected for multiple testing using Benjamini-Hochberg procedure 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Long-term treated HIV-infection 
is associated with platelet 
Mitochondrial dysfunction 
Wouter van der Heijden, Lisa Van de Wijer, Martin Jaeger, Karin Grintjes, Mihai Netea, Rolf 
Urbanus, Reinout van Crevel, Lambertus van den Heuvel, Maaike Brink, Richard Rodenburg, 
Philip de Groot, Andre van der Ven, Quirijn de Mast
Scientific reports 2021; 11(1): 6246.
167166
6
Chapter 6 - Platelet mitochondrial dysfunction in HIV
Background
Mitochondrial dysfunction is a well-known phenomenon in people living with HIV 
(PLHIV), which has been linked with the use of nucleoside reverse transcriptase inhibitors 
(NRTIs)1-5. The main mechanism underlying NRTI toxicity is inhibition of mitochondrial 
DNA polymerase γ and increased oxidative stress, resulting in mitochondrial DNA (mtDNA) 
depletion6-8, and mitochondrial dysfunction at the tissue level7,9. These adverse effects were 
greatly reduced when the older NRTIs stavudine, zidovudine (AZT) and didanosine were 
replaced by the newer NRTIs tenofovir (TDF) and abacavir (ABC). However, these newer 
NRTIs may still impair mitochondrial function, albeit to a lesser degree10-13. More recently, 
mitochondrial dysfunction has also been reported in people living with HIV (PLHIV) 
naive for combined antiretroviral therapy (cART)3,14-16, including in elite-controllers 17. The 
factors responsible for cART-independent mtDNA depletion are less well defined and may 
involve persistent immune activation18,19. Mitochondrial dysfunction has been suggested to 
contribute to non-AIDS related co-morbidities such as cardiovascular diseases, diabetes, 
cancer and dementia in PLHIV20,21. 
Platelets are the second most numerous blood cells that are, unlike red blood cells, equipped 
with mitochondria with mtDNA22,23. Human platelets lack a nucleus and mitochondria 
are essential in maintaining platelet health and lifespan, as recently reviewed23. MtDNA 
copy number is considered to reflect mitochondrial function24. Healthy platelets contain 
between 5 and 8 mitochondria, which serve important processes such as platelet activation, 
ATP production and platelet viability25-29. Platelets are traditionally known for their role in 
hemostasis, but an increasing body of evidence supports their role in key processes beyond 
hemostasis, including inflammation and immunoregulation23. With the importance of 
mitochondria in platelet metabolism, it is no surprise that the health consequences of 
abnormalities in platelet mitochondrial DNA and function has received increased attention, 
and platelet mtDNA has been proposed to serve as biomarker for different diseases22,30-32. Data 
on platelet function in PLHIV is contradictory, with some studies reporting increased 33-37, but 
other reduced agonist-induced platelet reactivity28,38,39. 
We hypothesized that mitochondrial dysfunction in PLHIV is associated with reduced 
platelet mtDNA copies and platelet dysfunction. Here, we show that platelet mtDNA copies 
are lower in PLHIV on long-term cART and this was validated in a subgroup of PLHIV using 
mitochondrial functional assays. 
Abstract
HIV infection and antiretroviral therapy have been linked to mitochondrial dysfunction. 
The role of platelet mitochondrial dysfunction in thrombosis, immunoregulation and 
age-related diseases is increasingly appreciated. Here, we studied platelet mitochondrial 
DNA content (mtDNA pl) and mitochondrial function in people living with HIV (PLHIV) and 
related this to platelet function. In a cohort of 208 treated PLHIV and 56 uninfected controls, 
mtDNApl was quantified, as well as platelet activation, platelet agonist-induced reactivity 
and inflammation by circulating factors and flow cytometry. In a subgroup of participants, 
the metabolic activity of platelets was further studied by mitochondrial function tests and 
the Seahorse Flux Analyzer. PLHIV had significantly lower mtDNApl compared to controls 
(8.5 copies/platelet (IQR:7.0-10.7) vs. 12.2 copies/platelet (IQR:9.5-16.6); p < 0.001), also after 
correction for age, sex and BMI. Prior zidovudine-use (n=46) was associated with a trend 
for lower mtDNApl. PLHIV also had reduced ex vivo platelet reactivity and mean platelet 
volume compared to controls. MtDNApl correlated positively with both platelet parameters 
and correlated negatively with inflammatory marker sCD163. Mitochondrial function tests 
in a subgroup of participants confirmed the presence of platelet mitochondrial respiration 
defects. Platelet mitochondrial function is disturbed in PLHIV, which may contribute to 
platelet dysfunction and subsequent complications. Interventions targeting the preservation 
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Table 1. Baseline characteristics 
Characteristics PLHIV (n=208) Healthy controls (n=56)
Sex (% Female) 17 (8.2) 22 (39.2)a
Age (years, median [IQR]) 52.0 [45.8, 59.0] 30.0 [25.8-53.0]b
BMI (median [IQR]) 24.1 [22.0, 26.0] 23.8 [21.5-25.6]
HIV infection duration (years, median [IQR]) 8.5 [5.0, 14.2]
Way of transmission (%)
   Heterosexual 8 (3.8)
   IDU 3 (1.4)
   MSM 158 (76.0)
   Other/unknown 39 (18.8)
CD4 nadir (median [IQR]) 250.0 [135.0, 362.5]
CD4 count (median [IQR]) 660.0 [480.0, 812.5]
Undetectable HIV load, n (%) 208 (100)
CD4/CD8 ratio (median [IQR]) 0.8 [0.6, 1.1]
cART duration (years; median [IQR]) 6.6 [4.1, 11.8]
cART regimen
NRTI-use (%) 200 (96.2)
NtRTI-use (%) 97 (46.6)
NNRTI-use (%) 61 (29.3)
PI-use (%) 32 (15.4)
Maraviroc-use (%) 3 (1.4)
INSTI-use (%) 140 (67.3)
ABC (%) 93 (44.7)
DTG (%) 86 (41.3)
EVG (%) 15 (7.2)
RAL (%) 38 (18.3)
Smoking (%) 59 (28.4)
Pack years (median [IQR]) 13.8 [0.0, 28.0]
Hypercholesterolemia (%) 56 (26.9)
Hypertension (%) 40 (19.2)
Diabetes Mellitus (%) 9 (4.3)
No cardiovascular risk factors (%) 50 (24.0)
Statins (%) 56 (26.9)
Aspirin (%) 18 (8.7)
Metformin (%) 9 (4.3)
BMI: body mass index. cART: combination antiretroviral therapy. NRTI: Nucleoside reverse transcriptase inhibitor. NRTI: 
nucleotide reverse transcriptase inhibitor. NNRTI: non-nucleoside reverse transcriptase inhibitor. PI: protease inhibitor. 




Between December 2016 and February 2017, a total of 208 virally suppressed PLHIV on long-
term cART and 56 healthy controls (sampled twice) were concurrently enrolled. Baseline 
characteristics are shown in Table 1. PLHIV were older compared to controls (52 years (IQR: 
45.8-59.0) vs 30 years (IQR: 25.8-53), respectively, p < 0.001). Median duration of cART use was 
6.6 yrs (IQR: 4.2-11.9). 
Platelet mtDNA copies are reduced in PLHIV
Platelet mtDNA copies (mtDNApl) were significantly lower in PLHIV compared to healthy 
controls (Figure 1A; median 8.5 copies/platelet (plt) (IQR 7.0-10.7) vs 12.2 copies/plt 
(IQR: 9.5-16.6), p < 0.001). mtDNApl copies correlated inversely with age (Figure 1B; Pearson’s 
R=-0.24, p < 0.001). MtDNApl remained significantly associated with HIV status after 
correction for age, sex and body-mass index (BMI) in a linear regression model (B=0.77 SE:0.14, 
P<0.0001). When analysis was restricted to individuals of 40 years and above (Supplemental 
Table S1; PLHIV: n=173 vs HC: n=22), mtDNApl remained significantly lower in PLHIV compared 
to controls (Supplemental Figure 1; PLHIV: 8.4 copies/plt (IQR: 6.6-10.2) vs HC: 10.5 copies/plt 
(IQR:8.9-14.7), p = 0.001).  Similarly, the differences in mtDNApl between PLHIV and controls 
remained when analysis was restricted to males only (Supplemental Table S2; PLHIV: 8.5 
copies/plt (IQR: 6.6-10.7) vs HC: 11.6 copies/plt (IQR:9.3-14.7), p < 0.001). MtDNApl levels were 
neither associated with duration of cART nor with current CD4 count, CD4 nadir or CD4/
CD8 ratio in univariate analysis (Supplemental Table S3). Furthermore, no differences in 
mtDNApl were found between PI, NNRTI and INSTI-based regimens (all p > 0.1; Supplemental 
Figure S2). 
Although abacavir (ABC)-use has been shown to affect platelet function40, current ABC use 
(p = 0.89) or cumulative ABC exposure (in days) were not associated with mtDNApl copies 
(Supplemental Figure S2). Conversely, PLHIV with prior zidovudine-use (prior AZT-use, 
n=46/184; 25%) showed a trend towards lower copies of mtDNApl (AZT-use: 7.8 copies/plt 
[IQR:6.0, 9.4] vs never-AZT: 8.6 copies/plt [IQR: 6.9, 10.8], p = 0.055). After correcting for age in 
a linear regression model, a non-significant negative correlation remained (B:-0.07 (-0.15 to 
0.01, p = 0.069). Neither cumulative days on AZT (median 2069 days; IQR 792-3180 days; R=-
0.2, p = 0.12), nor total NRTI exposure (median 4520 days; IQR: 2734-7955; R = 0.05) correlated 
with mtDNA-use. Use of metformin (p = 0.079) or antihypertensive drugs (p = 0.061) showed 
a tendency for a lower mtDNApl copies, whereas use of statins (p = 0.74) or acetylsalicylic acid 
(p = 0.21) did not (Supplemental Figure S3).
171170
6
Chapter 6 - Platelet mitochondrial dysfunction in HIV
ng/mL (IQR: 443-684), p = 0.01). sCD163 correlated negatively with mtDNApl copies 
(R = -0.23, p < 0.001, Figure 1c), whereas sCD14 (R = -0.073, p = 0.27) and hsCRP 
(R: -0.087, p = 0.2) did not (Supplemental Figure S4). 
Platelet mitochondrial dysfunction in PLHIV
Energy demand for platelet ATP production and other metabolic processes that are essential 
for platelet activation is met by the combined actions of glycolysis and mitochondrial 
OXPHOS42. To validate our findings that the lower platelet mtDNA content is associated 
with platelet mitochondrial dysfunction, and to investigate platelet glycolysis activity, we 
assessed the metabolic activity of washed platelets of five PLHIV and five age-sex matched 
controls to assess membrane potential (Δψm), mitochondrial superoxide production (ROSm) 
and real-time glycolysis and mitochondrial respiration using the Seahorse Extracellular 
Flux Analyzer42. Platelet Δψm, as assessed by Tetramethylrhodamine ethyl ester (TMRE) 
fluorescence, was lower in PLHIV compared to controls (1669 ΔMFI (IQR: 911-2233) vs. 4545 
ΔMFI (IQR: 2249-5168) respectively, p = 0.02; figure 2e, t-test). In line with reduced Δψm, there 
was a small increase in ROSm in PLHIV at basal conditions (figure 2f; 7654 MFI (IQR: 6777-7798) 
vs 4956 MFI (IQR: 3840-6284), p = 0.007, t-test).  Next, using the Seahorse Extracellular Flux 
Analyzer, mitochondrial respiration and glycolytic capacity were investigated by assessing 
the oxygen consumption rate (OCR; measure for mitochondrial respiration/OXPHOS) and the 
acidification rate (ECAR; measure for glycolysis). There was a trend towards lower baseline 
platelet mitochondrial respiration (OCR in pmol/min) in PLHIV compared to controls (Figure 
2d; 47.4 pmol/min (SD: 11.3) vs 55.1 pmol/min (SD: 12.2), p = 0.084). Additionally, PLHIV had 
a smaller increase in OCR after ex vivo platelet stimulation with both CRP-XL (108% (SD: 16) 
vs 119% (SD: 16), p = 0.056, Figure 2b and Supplemental Figure 5) and Thrombin receptor 
activating peptide (TRAP; 139% (SD: 14) vs 167% (SD: 13), p = 0.037; Figure 2a-c) compared to 
matched controls. 
The fraction of the maximal mitochondrial capacity (maximal OCR after stimulation with 
the uncoupling agent FCCP) used after ex vivo platelet stimulation with TRAP was high in 
both groups (Supplemental Figure S6d; p > 0.1). This suggests that maximal mitochondrial 
capacity is a limiting factor in platelet activation. Conversely, there was no difference 
between groups in ECAR (glycolysis) at baseline (Figure 2b; HIV: 16.0 mpH/min (SD: 3.4) vs 
HC: 14.7mpH/min (SD: 2.4), p > 0.1) or after ex vivo stimulation. The increase in mitochondrial 
respiration (OCR) after ex vivo stimulation significantly correlated with mtDNApl (R=0.77, 
p = 0.045, n=7, Figure 3a) and a similar trend was found for basal mitochondrial respiration 
of platelets (R=0.61, p = 0.14, n=7, Figure 3b). Taken together, our data suggest that the 
lower platelet mtDNA in PLHIV in associated with a concurrent reduction in mitochondrial 
respiration capacity (OXPHOS) without a compensatory increase in glycolysis.
Mitochondrial dysfunction is associated with inflammatory diseases such as 
atherosclerosis and sepsis in HIV-negative individuals 22. Hence, we explored the 
association of known markers of persisting immune activation, a known driver of non-
AIDS related comorbidities20,21, with mtDNApl copy number. Overall, we observed higher 
plasma concentrations of immune activation markers soluble CD14 (sCD14), soluble 
CD163 (sCD163) and high-sensitive CRP (hsCRP) in PLHIV than in controls (Table 2). 
Among participants older than 40 years, only sCD163 remained significantly different 
between groups (Supplemental table S1; HIV 741 ng/mL (IQR: 547-906) vs controls 517 
3
Vol.:(0123456789)
Scientific Reports |         (2021) 11:6246  | https://doi.org/10.1038/s41598-021-85775-5
www.nature.com/scientificreports/
vs 12.2 copies/plt (IQR: 9.5–16.6), p < 0.001).  mtDNApl copies correlated inversely with age (Fig. 1B; Pearson’s 
R = − 0.24, p < 0.001).  MtDNApl remained significantly associated with HIV status after correction for age, sex and 
body-mass index (BMI) in a linear regression model (B = 0.77 SE: 0.14, P < 0.0001). When analysis was restricted 
to individuals of 40 years and above (Supplemental Table S1; PLHIV: n = 173 vs HC: n = 22),  mtDNApl remained 
significantly lower in PLHIV compared to controls (Supplemental Fig. S1; PLHIV: 8.4 copies/plt (IQR: 6.6–10.2) 
vs HC: 10.5 copies/plt (IQR: 8.9–14.7), p = 0.001). Similarly, the differences in  mtDNApl between PLHIV and 
controls remained when analysis was restricted to males only (Supplemental Table S2; PLHIV: 8.5 copies/plt 
(IQR: 6.6–10.7) vs HC: 11.6 copies/plt (IQR: 9.3–14.7), p < 0.001).  MtDNApl levels were neither associated with 
duration of cART nor with current CD4 count, CD4 nadir or CD4/CD8 ratio in univariate analysis (Supple-
mental Table S3). Furthermore, no differences in  mtDNApl were found between PI, NNRTI and INSTI-based 
regimens (all p > 0.1; Supplemental Fig. S2).
Although abacavir (ABC)-use has been shown to affect platelet  function40, current ABC use (p = 0.89) or 
cumulative ABC exposure (in days) were not associated with  mtDNApl copies (Supplemental Fig. S2). Convers ly, 
PLHIV with prior zidovudine-use (prior AZT-use, n = 46/184; 25%) showed a trend towards lower copies of 
 mtDNApl (AZT-use: 7.8 copies/plt [IQR: 6.0, 9.4] vs never-AZT: 8.6 copies/plt [IQR: 6.9, 10.8], p = 0.055). After 
correcting for age in a linear regression model, a non-significant negative correlation remained (B: − 0.07 (− 0.15 
to 0.01, p = 0.069). Neither cumulative days on AZT (median 2069 days; IQR 792–3180 days; R = − 0.2, p = 0.12), 
nor total NRTI exposure (median 4520 days; IQR: 2734–7955; R = 0.05) correlated with mtDNA-use. Use of 
metformin (p = 0.079) or antihypertensive drugs (p = 0.061) showed a tendency for a lower  mtDNApl copies, 
whereas u e of stat ns (p = 0.74) or cetylsalicylic acid (p = 0.21) did ot (Supplemental Fig. S3).
Mitochondrial dysfunction is associated with inflammatory diseases such as atherosclerosis and sepsis in 
HIV-negative  individuals22. Hence, we explored the association of known markers of persisting immune activa-
tion, a known driver of non-AIDS related  comorbidities20,21, with  mtDNApl copy number. Overall, we observed 
higher plasma concentrations of immune activation markers soluble CD14 (sCD14), soluble CD163 (sCD163) 
and high-sensitive CRP (hsCRP) in PLHIV than in controls (Table 2). Among participants older than 40 years, 
only sCD163 remained significantly different between groups (Supplemental Table S1; HIV 741 ng/mL (IQR: 
547–906) vs controls 517 ng/mL (IQR: 443–684), p = 0.01). sCD163 correlated negatively with  mtDNApl copies 
(R = − 0.23, p < 0.001, Fig. 1C), whereas sCD14 (R = − 0.073, p = 0.27) and hsCRP (R: − 0.087, p = 0.2) did not 
(Supplemental Fig. S4).
Platelet mitochondrial dysfunction in PLHIV. Energy demand for platelet ATP production and other 
metabolic processes that are essential for platelet activation is met by the combined actions of glycolysis and 
mitochondrial  OXPHOS41. To validate our findings that the lower platelet mtDNA content is associated with 
platelet mitochondrial dysfunction, and to investigate platelet glycolysis activity, we assessed the metabolic activ-
ity of washed platelets of five PLHIV and five age-sex matched controls to assess membrane potential (Δψm), 
mitochondrial superoxide production  (ROSm) and real-time glycolysis and mitochondrial respiration using the 
Seahorse Extracellular Flux  Analyzer41. Platelet Δψm, as assessed by Tetramethylrhodamine ethyl ester (TMRE) 
fluorescence, was lower in PLHIV compared to controls (1669 ΔMFI (IQR: 911–2233) vs. 4545 ΔMFI (IQR: 
2249–5168) respectively, p = 0.02; Fig. 2E, t-test). In line with reduced Δψm, there was a small increase in  ROSm 
in PLHIV at basal conditions (Fig. 2F; 7654 MFI (IQR: 6777–7798) vs 4956 MFI (IQR: 3840–6284), p = 0.007, 



































































Figure 1.  Platelet mtDNA content. Mitochondrial DNA content in platelets  (mtDNApl) was determined using 
qPCR after normalization for platelet count in isolated platelets. (A) Dotplot showing mtDNA copies per platelet 
in people living with HIV (PLHIV) and controls (HC); the line indicates median and error bars the interquartile 
range (IQR). Student’s t-test was used after inverse rank-based normalization. (B) Normalized (inverse rank 
based)  mtDNApl versus age. (C) Normalized  mtDNApl versus soluble CD163 (a macrophage scavenger receptor). 
Correlations were analyzed using Pearson’s correlation coefficients.
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vs 12.2 copies/plt (IQR: 9.5–16.6), p < 0.001).  mtDNApl copies correlated inversely with age (Fig. 1B; Pearson’s 
R = − 0.24, p < 0.001).  MtDNApl remained significantly associated with HIV status after correction for age, sex and 
body-mass index (BMI) in a linear regression model (B = 0.77 SE: 0.14, P < 0.0001). When analysis was restricted 
to individuals of 40 years and above (Supplemental Table S1; PLHIV: n = 173 vs HC: n = 22),  mtDNApl remained 
significantly lower in PLHIV compared to controls (Supplemental Fig. S1; PLHIV: 8.4 copies/plt (IQR: 6.6–10.2) 
vs HC: 10.5 copies/plt (IQR: 8.9–14.7), p = 0.001). Similarly, the differences in  mtDNApl between PLHIV and 
controls remained when analysis was restricted to males only (Supplemental Table S2; PLHIV: 8.5 copies/plt 
(IQR: 6.6–10.7) vs HC: 11.6 copies/plt (IQR: 9.3–14.7), p < 0.001).  MtDNApl levels were neither associated with 
duration of cART nor with current CD4 count, CD4 nadir or CD4/CD8 ratio in univariate analysis (Supple-
mental Table S3). Furthermore, no differences in  mtDNApl were found between PI, NNRTI and INSTI-based 
regimens (all p > 0.1; Supplemental Fig. S2).
Although abacavir (ABC)-use has been shown to affect platelet  function40, current ABC use (p = 0.89) or 
cumulative ABC exposure (in days) were not associated with  mtDNApl copies (Supplemental Fig. S2). Conversely, 
PLHIV with prior zidovudine-use (prior AZT-use, n = 46/184; 25%) showed a trend towards lower copies of 
 mtDNApl (AZT-use: 7.8 copies/plt [IQR: 6.0, 9.4] vs never-AZT: 8.6 copies/plt [IQR: 6.9, 10.8], p = 0.055). After 
correcting for age in a linear regression model, a non-significant negative correlation remained (B: − 0.07 (− 0.15 
to 0.01, p = 0.069). Neither cumulative days on AZT (median 2069 days; IQR 792–3180 days; R = − 0.2, p = 0.12), 
nor total NRTI exposure (median 4520 days; IQR: 2734–7955; R = 0.05) correlated with mtDNA-use. Use of 
metformin (p = 0.079) or antihypertensive drugs (p = 0.061) showed a tendency for a lower  mtDNApl copies, 
whereas use of statins (p = 0.74) or acetylsalicylic acid (p = 0.21) did not (Supplemental Fig. S3).
Mitochondrial dysfunction is associated with inflammatory diseases such as atherosclerosis and sepsis in 
HIV-negative  individuals22. Hence, we explored the association of known markers of persisting immune activa-
tion, a known driver of non-AIDS related  comorbidities20,21, with  mtDNApl copy number. Overall, we observed 
higher plasma concentrations of immune activation markers soluble CD14 (sCD14), soluble CD163 (sCD163) 
and high-sensitive CRP (hsCRP) in PLHIV than in controls (Table 2). Among participants older than 40 years, 
only sCD163 remained significantly different between groups (Supplemental Table S1; HIV 741 ng/mL (IQR: 
547–906) vs controls 517 ng/mL (IQR: 443–684), p = 0.01). sCD163 correlated negatively with  mtDNApl copies 
(R = − 0.23, p < 0.001, Fig. 1C), whereas sCD14 (R = − 0.073, p = 0.27) and hsCRP (R: − 0.087, p = 0.2) did not 
(Supplemental Fig. S4).
Platelet mitochondrial dysfunction in PLHIV. Energy demand for platelet ATP production and other 
metabolic processes that are essential for platelet activation is met by the combined actions of glycolysis and 
mitochondrial  OXPHOS41. To validate our findings that the lower platelet mtDNA content is associated with 
platelet mitochondrial dysfunction, and to investigate platelet glycolysis activity, we assessed the metabolic activ-
ity of washed platelets of five PLHIV and five age-sex matched controls to assess membrane potential (Δψm), 
mitochondrial superoxide production  (ROSm) and real-time glycolysis and mitochondrial respiration using the 
Seahorse Extracellular Flux  Analyzer41. Platelet Δψm, as assessed by Tetramethylrhodamine ethyl ester (TMRE) 
fluorescence, was lower in PLHIV compared to controls (1669 ΔMFI (IQR: 911–2233) vs. 4545 ΔMFI (IQR: 
2249–5168) respectively, p = 0.02; Fig. 2E, t-test). In line with reduced Δψm, there was a small increase in  ROSm 
in PLHIV at basal conditions (Fig. 2F; 7654 MFI (IQR: 6777–7798) vs 4956 MFI (IQR: 3840–6284), p = 0.007, 



































































Figure 1.  Platelet mtDNA content. Mitochondrial DNA content in platelets  (mtDNApl) was determined using 
qPCR after normalization for platelet count in isolated platelets. (A) Dotplot showing mtDNA copies per platelet 
in people living with HIV (PLHIV) and controls (HC); the line indicates median and error bars the interquartil  
range (IQR). Student’s t-test was used after inverse rank-based normalization. (B) Normalized (inverse rank 
based)  mtDNApl versus age. (C) Normalized  mtDNApl versus soluble CD163 (a macrophage scavenger receptor). 
Correlations were analyzed using Pearson’s correlation coefficients.
Figure 1. Platelet mtDNA content. Mitochondrial 
DNA content in platelets (mtDNApl) was determined 
using qPCR after normalization for platelet count 
in isolated platelets. (A) Dotplot showing mtDNA 
copies per platelet in people living with HIV (PLHIV) 
and controls (HC); the line indicates median and error 
bars the interquartile range (IQR). Student’s t-test 
was used after inverse rank-based normalization. 
(B) normalized (inverse rank based) mtDNApl versus 
age. (C) Normalized mtDNApl versus soluble CD163 (a 
macrophage scavenger receptor). Correlations were 
analyzed using Pearson’s correlation coefficients.
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Chapter 6 - Platelet mitochondrial dysfunction in HIV
HIV infection is associated with platelet dysfunction
Next, we explored the possible consequences of lower mtDNApl and mitochondrial dysfunction 
for platelet parameters and function. Platelet counts were similar between PLHIV and healthy 
controls (Table 2), but PLHIV had smaller platelets (mean platelet volume: PLHIV:10.1 fL (IQR: 
9.7:10.7) vs 10.8 fL (IQR: 10.3-11.3), p < 0.0001), as well as a lower immature platelet fraction (IPF; 
a marker for freshly released platelets from the bone marrow) compared to controls (Table 2; 
3.3% (IQR: 2.5-4.6) vs 3.7% (IQR: 2.8-5.9) respectively, p = 0.018). Platelet size (mean platelet 
volume) correlated positively with mtDNApl (Figure 5c). 
Next, platelet activation and function and function were determined using multiple methods. 
First, plasma markers of in vivo platelet activation (chemokines released from alpha-granules; 
CCL5, CXCL4, CXCL7) were comparable between PLHIV and controls (Table 2). Second, using 
flow cytometry, the activation status of circulating platelets, as well as their reactivity to ex 
vivo stimulation by platelet agonists was assessed. In unstimulated platelets, the expression 
of the alpha-granule marker P-selectin (measure of platelet degranulation) and the binding of 
fibrinogen to the activated integrin αIIbβ3 (measure of aggregation; Table 2) were also similar 
across groups. When analysis was restricted to individuals above 40 years of age or male only, 
unstimulated platelet activation was lower in PLHIV compared to controls (Supplemental Table 
S1-2). In line with this observation, fibrinogen binding to αIIbβ3 in response to stimulation by 
adenosine diphosphate (ADP)- and collagen related peptide (CRP-XL) was reduced in PLHIV-
induced) (Figure 4a). Differences in P-selectin reactivity across the groups were smaller with 
only a significant difference with a high dose (125µM) of ADP stimulation showed a significant 
difference between PLHIV and controls (Figure 4b). We observed no correlations with cART 
regimens containing either NNRTI, PI or INSTI-use as well as ABC and platelet reactivity indices 
(all P>0.15). In addition, persistent immune activation did not correlate with platelet indices in 
this cohort (Supplemental Table S4). In summary, these data show that platelet reactivity, and 
especially αIIbβ3 activation is reduced in PLHIV.
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Figure 2.  Platelet energy phenotype determined by the Seahorse extracellular flux analyzer and mitochondrial 
membrane potential and ROS production. Samples were measured with five replicates, 1 ×  107 washed 
platelets per well. Five age-and sex-matched donors per group. (A) Real-time mitochondrial respiration 
depicted as oxygen consumption rate (OCR) at 18 timepoints. Four agonists or inhibitors were added in the 
following order: (1) Thrombin Receptor Activator Peptide-6 (TRAP-6; 50 µM) or medium causing platelet 
activation; (2) Oligomycin which inhibits cellular ATP production; (3) Carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP), an uncoupling agent causing maximum oxygen consumption through complex 
IV, and (4) Antimycin A which inhibits all mitochondrial respiration (CRP-XL can be found in Supplemental 
Fig. 9). (B) Energymap showing the change in mitochondrial respiration (as change in OCR) and glycolysis 
(extracellular acidification rate (ECAR) from basal conditions after ex vivo stimulation with platelet agonists. 
((A)) Depicts the real-time ECAR after (1) medium or TRAP-6 (2) oligomycine, (3) FCCP and (4) antimycin 
A. Samples were measured with five replicates, 1 ×  107 washed platelets per well. Five age-and sex-matched 
donors per group. (D) Basal OCR as mean of first three measurements. (E) Membrane potential was determined 
using Tetramethylrhodamine ethyl ester (TMRE) staining with the uncoupler FCCP disrupting mitochondrial 
membrane potential as a negative control for every sample. Data depicted as delta geometric mean fluorescence 
intensity (MFI). (F) Mitochondrial ROS production with MitoSox staining in MFI. Data are depicted as 
mean ± standard error of the mean (SEM) and analyzed using the unpaired student’s T-test.
Figure 2. Platelet energy phenotype determined by the Seahorse extracellular flux analyzer and mitochondrial 
membrane pote tial a d ROS production. Samples w re m asured with five replicates, 1.10^7 d platelets per well. 
Five age-and sex-matched donors per group. (A) Real-time mitochondrial respiration depicted as oxygen consumption 
rate (OCR) at 18 timepoints. Four agonists or inhibitors w re added in the following order: 1) Thrombin Receptor Activator 
Peptide-6 (TRAP-6; 50µM) or medium causing platelet activation; 2) Oligomycin which inhibits cellular ATP production; 
3) Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP), an uncoupling agent causing maximum oxygen 
consumpt on through complex IV, a d 4) Antimycin A which inhibits all mitochondrial respiration (CRP-XL can be found 
in supplemental figure 9). (B) Energymap showing the change in mitochondrial respiration (as change in OCR) and 
glycolysis (extracellular acidification rate (ECAR) from basal conditions after ex vivo stimulation with platelet agonists. 
(C) Depicts the real-time ECAR after 1) medium or TRAP-6 2) oligo ycine, 3) FCCP and 4) antimycin A. Samples were 
measured with five replicates, 1.10^7 washed platelets per well. Five age-and sex-matched donors per group. (D) Basal 
OCR as mean of first three measurements. (E) Membra e potential was determined using T tramethylrhodamine ethyl 
ester (TMRE) staining with the uncoupler FCCP disrupting mitochondrial membrane potential as a negative control for 
every sample. Data depicted as delta geometric mean fluorescence intensity (MFI). (F) Mitochondrial ROS production 




Chapter 6 - Platelet mitochondrial dysfunction in HIV
Association of mtDNApl with platelet function
Next, given the role of platelet mitochondria in platelet function, we assessed associations of 
mtDNApl with platelet reactivity in PLHIV and controls. MtDNApl copies did neither correlate 
with ADP-induced P-selectin expression, nor with binding of fibrinogen to platelets or mean 
platelet volume (MPV) in PLHIV (Figure 5a-b). In controls, MtDNApl copies were significantly 
correlated with MPV (Figure 5c) and a positive trend was observed with fibrinogen binding 
(Figure 5d).
To further explore the link between platelet reactivity and platelet activation, we performed 
a principal component analysis (PCA) to summarize both platelet activation (plasma markers 
of platelet activation and unstimulated P-selectin expression and fibrinogen binding) and 
platelet reactivity (P-selectin expression and fibrinogen binding after ex vivo ADP and CRP-
XL stimulation). This PCA showed that Principal component (PC) 1 mainly represented 
platelet reactivity (P-selectin expression and fibrinogen binding after stimulation) whereas 
PC2 mainly represented in vivo platelet activation (plasma markers and unstimulated 
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mean platelet volume (MPV) in PLHIV (Fig. 5A,B). In controls,  MtDNApl copies were significantly correlated 
with MPV (Fig. 5C) and a positive trend was observed with fibrinogen binding (Fig. 5D).
To further explore the link between platelet reactivity and platelet activation, we performed a principal 
component analysis (PCA) to summarize both platelet activation (plasma markers of platelet activation and 
unstimulated P-selectin expression and fibrinogen binding) and platelet reactivity (P-selectin expression and 
fibrinogen binding after ex vivo ADP and CRP-XL stimulation). This PCA showed that Principal component (PC) 
1 mainly represented platelet reactivity (P-selectin expression and fibrinogen binding after stimulation) whereas 
PC2 mainly represented in vivo platelet activation (plasma markers and unstimulated P-selectin expression 
and fibrinogen binding; Supplemental Fig. S7a,b). We used these derivatives to correlate  mtDNApl with platelet 
reactivity (coordinates on PC1) and platelet activation (coordinates on PC2).  mtDNApl correlated with platelet 
reactivity (Supplemental Fig. S7c; PC1 of platelet parameters vs  mtDNApl, R = 0.14, p = P = 0.024), but not with 
in vivo platelet activation (Supplemental Fig. S7d; PC2 of platelet parameters vs  mtDNApl, R = 0.05, P = 0.41). 
These data suggest that mtDNA depletion is associated with platelet dysfunction with a reduced platelet reactivity 
capacity, but not with increased platelet activation status.
Whereas mitochondrial dysfunction can result in platelet dysfunction, platelet activation itself may also con-
tribute to loss of mitochondria from platelets through the formation of platelet microparticles (PMP)  formation42. 
We therefore studied PMP in a subgroup of 20 PLHIV and age-sex matched controls. No differences in total PMP 
number (Supplemental Fig. S8a), nor PMPs containing mitochondria (Supplemental Fig. S8b) were observed 
across both groups.
Discussion
The present data show that PLHIV on long-term cART have reduced platelet mitochondrial content  (mtDNApl) 
which was associated with platelet mitochondrial dysfunction and reduced energy supply. Platelet mitochondria 
play a key role in platelet metabolism, ATP production and platelet activation and lifespan, and we propose that 
the observed abnormalities in  mtDNApl and platelet mitochondrial function contribute to platelet dysfunction 
in PLHIV.
The literature on platelet function in cART treated individuals is contradictory, with some studies reporting 
increased platelet  reactivity33–37, while others reporting reduced  reactivity28,38,39. This heterogeneity in study 
results may be partly explained by differences in the characteristics of study participants, including the enrol-
ment of PLHIV with detectable plasma HIV-RNA, the degree of persistent immune activation, cART regimens 
and timing of treatment initiation, factors that all have changed considerably over the years. In accordance with 
our present findings, Mesquita et al.28 recently reported decreased platelet reactivity and platelet mitochondrial 
dysfunction in 36 PLHIV on stable cART. In contrast to our findings, platelets in the PLHIV in their cohort 
exhibited increased P-selectin expression. In the present study, not only platelet P-selectin expression, but also 
soluble markers of platelet activation were similar in PLHIV and controls. In addition, PLHIV exhibited a lower 
immature platelet fraction and a similar number of mitochondria-containing platelet microparticles. Together, 
these findings argue against excessive platelet activation being primarily responsible for reduced platelet reactivity 
Figure 3.  Platelet mitochondrial DNA vs mitochondrial respiration measured by Oxygen consumption 
rate (OCR in pmol/min). (A) Correlation plot showing platelet mitochondrial DNA (mtDNA) with change 
in oxygen consumption rate (mitochondrial respiration) measured by Seahorse extracellular flux analyzer 
after ex vivo stimulation with thrombin (TRAP 50 μM). mtDNA was normalized using inverse rank-based 
transformation and Pearson’s correlation coefficient is shown. (B) mtDNA in platelets vs basal OCR in pmol/
min (an average of first three measurements). OCR was measured in triplo and for 5 PLHIV and 2 controls both 
mtDNA in platelets and real-time measurements of mitochondrial respiration were available and included in the 
analysis.
Figure 3. Platelet mitochondrial DNA vs mitoch ndrial respiration measure   consumption rate (OCR in 
pmol/min). (A) Correlation plot showing platelet mitochondrial DNA (mtDNA) with change in oxygen consumption rate 
(mitochondrial respiration) measured by Seahorse extracellular flux analyzer after ex vivo stimulation with thrombin 
(TRAP 50uM). m DNA was normalized us ng inverse rank-based transformation nd Pearson’s correlation coefficient is 
shown. (B) mtDNA in platelets vs basal OCR in pmol/min (an average of first three measurements). OCR was measured in 
triplo and for 5 PLHIV and 2 controls both mtDNA in platelets and real-time measurements of mitochondrial respiration 
were available and included in the analysis.
Table 2
Platelet indices PLHIV  
(n=208)
Healthy controls  
(n=56)
p -value
Platelet count (10^9/L) 260 [200, 310] 270 [210, 320] 0.126
MPV (fL) 10.1 [9.7, 10.7] 10.8 [10.3, 11.3] <0.001
IPF (%) 3.3 [2.5, 4.6] 3.7 [2.8, 5.9] 0.018
Unstimulated fibrinogen binding (MFI) 2.0 [1.6, 2.2] 2.1 [1.6, 2.4] 0.072
Unstimulated P- electin expression (MFI) 2.7 [2.1, 3.2] 2.6 [2.2, 3.0] 0.158
Plasma CCL5 (ng/ml) 2.66 [1.64, 4.29] 2.61 [1.69, 4.18] 0.841
Plasma CXCL4 (ng/ml) 570.0 [290.0, 723.3] 492.9 [306.1, 839.5] 0.201
Plasma CXCL7 (ng/ml) 289.4 [180.3, 465.1] 306.6 [194.2, 609.8] 0.192
sCD14 (ng/ml) 2139.6 [1778.2, 2661.5] 1789.0 [1502.7, 2071.6] <0.001
sCD163 (ng/ml) 716.5 [528.7, 899.4] 517.3 [410.7, 578.1] <0.001
hsCRP (ng/ml) 1423.3 [608.8, 2726.3] 651.2 [205.9, 1179.2] <0.001
MPV: mean platelet volume. IPF: immature platelet fraction as a percentage of platelet count (Sysmex, Kobe, Japan). 
unstimulated platel t aggregation measur d as Fibrin ge  bin ing by flowcytometry in median fluorescence intensity 
(MFI). Unstimulated platelet degranulation measured as P-selectin expression by flow cytometry by MFI. sCD14: Serum 
levels of CD14, a marker of monocyte activation. sCD163: Serum levels of CD163, a monocyte- and macrophage-specific 
scavenger receptor. hsCRP: high sensi ive C-reactive pr tein
Figure 4. Platelet reactivity after collagen 
(CRP-XL) and ADP stimulation. (A) Platelet 
fibrinogen binding is depicted as mean 
fluorescence intensity (MFI) after ex vivo 
stimulation with platelet agonist collagen-
related peptide (CRP-XL; 33ng/mL; 625ng/
mL) and adenosine diphosphate (ADP; 
1.2uM, 125uM). (B) Platelet degranulation 
measured by P-selectin expression is depicted 
as mean fluorescence intensity (MFI) after 
ex vivo stimulation with CRP-XL (33ng/mL; 
625ng/mL) and ADP (1.2uM, 125uM). Data are 
shown as dotplot with error bars median and 
interquartile range (IQR).  Data were analyzed 
using unpaired Student’s T-test. People living 
with HIV (PLHIV); healthy controls (HC).
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in PLHIV. Whet er mitochondrial depletion contributes to the observed platelet dysfunction in PLHIV remains 
uncertain. A recent study reported that chemotherapy-associated platelet hyporeactivity was caused by mito-
chondrial dysfunction and subsequent reduction in mitochondrial  respiration27. Consistent with these observa-
tions, the lower platelet mtDNA content in PLHIV was associated with a reduction in mitochondrial respiration 
capacity, which may negatively impact platelet reactivity. In our study, however,  mtDNApl levels in PLHIV did 
not correlate with ex vivo platelet reactivity, whereas a positive trend was observed in HIV uninfected controls. 
The fa t that all PLHIV exhibited reduced  mtDNApl with little variation in the absolute values may explain the 
absence of a correlation with platelet reactivity measures. Future studies focusing on platelet dysfunction should 
incorporate mitochondrial dysfunction to corroborate our findings.
Ag , history of zidovudine (AZT)-use and in ate immune activation were all associated with decreased 
 mtDNApl. NRTI-use is a well-known cause of mitochondrial dysfunction and mtDNA  depletion6–8. We found 
that prior AZT-use was a possible risk factor for reduced  mtDNApl, a trend that remained after correcting for 
age and CD4 nadir, whereas total duration of cART-use o  duration of HIV infection were not. As platelets re 
short-lived, it is conceivable that mitochondrial mass is reduced during thrombopoiesis and that the known bone 
marrow toxicity of AZT 1 is still present even after switching to newer NRTIs such as TDF or ABC. Even though 
these NRTIs are known to have lower mitochondrial  toxicity1, it is unclear whether long-term treatment does 
not exert any cumulative reduction in  mtDNApl too. While ABC-use has been linked to platelet perturbations 
in multiple  studies43–45, others could not confirm ABC associated platelet  dysfunction35,46. In our study, neither 
 mtDNApl content nor platelet function were associated with current or prior ABC-use. Unfortunately, we could 
not dissect the link between the  mtDNApl, overall NRTI exposure and duration of HIV infection itself, as expo-
sure to NRTIs was high in the total study group. Still, as  mtDNApl content was lower in PLHIV than in controls, 
it is plausible that both NRTIs and HIV itself exert long-term changes in mitochondrial  function2. This possible 
long-term NRTI effect on mitochondrial function in platelets supports recent efforts to implement NRTI sparing 
regimens as viable treatment options for long-term HIV  treatment47. It would be interesting to assess  mtDNApl 
content, as well as platelet function, in PLHIV who are switched to a NRTI sparing regimen.
Figure 4.  Platelet reactivity after collagen (CRP-XL) and ADP stimulation. (A) Platelet fibrinogen binding is 
depicted as mean fluorescence intensity (MFI) after ex vivo stimulation with platelet agonist collagen-related 
peptide (CRP-XL; 33 ng/mL; 625 ng/mL) and adenosine diphosphate (ADP; 1.2 μM, 125 μM). (B) Platelet 
degranulation measured by P-selectin expression is depicted as mean fluorescence intensity (MFI) after ex vivo 
stimulation with CRP-XL (33 ng/mL; 625 ng/mL) and ADP (1.2 μM, 125 μM). Dat  are hown as dotplot with 
error bars median and interquartile range (IQR). Data were analyzed using unpaired Student’s T-test. People 
living with HIV (PLHIV); healthy controls (HC).
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Discussion
The present data show that PLHIV on long-term cART have reduced platelet mitochondrial 
content (mtDNApl) which was associated with platelet mitochondrial dysfunction and 
reduced energy supply. Platelet mitochondria play a key role in platelet metabolism, 
ATP production and platelet activation and lifespan, and we propose that the observed 
abnormalities in mtDNApl and platelet mitochondrial function contribute to platelet 
dysfunction in PLHIV. 
The literature on platelet function in cART treated individuals is contradictory, with 
some studies reporting increased platelet reactivity33-37, while others reporting reduced 
reactivity.28,38,39 This heterogeneity in study results may be partly explained by differences in 
the characteristics of study participants, including the enrolment of PLHIV with detectable 
plasma HIV-RNA, the degree of persistent immune activation, cART regimens and  timing of 
treatment initiation, factors that all have changed considerably over the years. In accordance 
with our present findings, Mesquita et al. 28 recently reported decreased platelet reactivity 
and platelet mitochondrial dysfunction in 36 PLHIV on stable cART. In contrast to our 
findings, platelets in the PLHIV in their cohort exhibited increased P-selectin expression. In 
the present study, not only platelet P-selectin expression, but also soluble markers of platelet 
activation were similar in PLHIV and controls. In addition, PLHIV exhibited a lower immature 
platelet fraction and a similar number of mitochondria-containing platelet microparticles. 
Together, these findings argue against excessive platelet activation being primarily 
responsible for reduced platelet reactivity in PLHIV. Whether mitochondrial depletion 
contributes to the observed platelet dysfunction in PLHIV remains uncertain. A recent study 
reported that chemotherapy-associated platelet hyporeactivity was caused by mitochondrial 
dysfunction and subsequent reduction in mitochondrial respiration27. Consistent with these 
observations, the lower platelet mtDNA content in PLHIV was associated with a reduction in 
mitochondrial respiration capacity, which may negatively impact platelet reactivity. In our 
study, however, mtDNApl levels in PLHIV did not correlate with ex vivo platelet reactivity, 
whereas a positive trend was observed in HIV uninfected controls. The fact that all PLHIV 
exhibited reduced mtDNApl with little variation in the absolute values may explain the 
absence of a correlation with platelet reactivity measures.  Future studies focusing on platelet 
dysfunction should incorporate mitochondrial dysfunction to corroborate our findings.
Age, history of zidovudine (AZT)-use and innate immune activation were all associated 
with decreased mtDNApl. NRTI-use is a well-known cause of mitochondrial dysfunction 
and mtDNA depletion6-8. We found that prior AZT-use was a possible risk factor for reduced 
mtDNApl, a trend that remained after correcting for age and CD4 nadir, whereas total 
P-selectin expression and fibrinogen binding; Supplemental Figure S7a-b). We used these 
derivatives to correlate mtDNApl with platelet reactivity (coordinates on PC1) and platelet 
activation (coordinates on PC2). mtDNApl correlated with platelet reactivity (Supplemental 
Figure S7c; PC1 of platelet parameters vs mtDNApl, R=0.14, p=P=0.024), but not with in vivo 
platelet activation (Supplemental Figure S7d; PC2 of platelet parameters vs mtDNApl, R=0.05, 
P=0.41). These data suggest that mtDNA depletion is associated with platelet dysfunction 
with a reduced platelet reactivity capacity, but not with increased platelet activation status.
Whereas mitochondrial dysfunction can result in platelet dysfunction, platelet activation 
itself may also contribute to loss of mitochondria from platelets through the formation of 
platelet microparticles (PMP) formation.41 We therefore studied PMP in a subgroup of 20 
PLHIV and age-sex matched controls. No differences in total PMP number (Supplemental 
Figure S8a), nor PMPs containing mitochondria (Supplemental Figure S8b) were observed 
across both groups. 
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Mitochondrial dysfunction and depletion have been associated with many diseases such as dementia, neu-
ropsychiatric diseases, and cardiovascular  diseases22,23,30,48. In PLHIV, these (non-AIDS related) co-morbidities 
have also been linked to persistent  inflammation20,21. In our cohort, we indeed found increased levels of hsCRP, 
sCD14 and sCD163, but only the latter parameter was associated with mtDNA levels in platelets. Importantly, 
sCD163 was shown to be independently correlated with overall mortality in PLHIV and the incidence of non-
AIDS related  comorbidities49,50.
Targeting mitochondrial dysfunction and inflammation may help reduce excess mortality and morbidity 
that is associated with HIV infection, even when treated successfully with cART 22,27. Reducing inflammation, 
besides reducing NRTI exposure, could indirectly reduce oxidative stress and mitochondrial dysfunction while 
treatment with ROS scavengers may also have beneficial effects in reducing non-AIDS related co-morbidities.
Multiple methods of mtDNA quantification have been used in whole blood or peripheral blood mononuclear 
cell (PBMC) fractions in HIV and other  diseases14,32. However, different methods of quantification, and hetero-
geneity of the cell composition of whole blood or PBMCs may hamper its  interpretation32,51. It is conceivable 
that platelet mtDNA content could mirror mitochondrial toxicity in other cell types as well. As a single cell-type 
source of mtDNA, platelet mtDNA may indeed serve as a possible biomarker for mitochondrial toxicity and 
non-AIDS related comorbidities associated with mitochondrial dysfunction, such as neurocognitive impairment 
and cardiovascular  disease22.
Our study has limitations associated with its cross-sectional design. Even though sample size was large 
enough to explore the link between inflammation, cART-use,  mtDNApl and platelet function, it lacked power 
to confirm a possible link between  mtDNApl levels and clinical outcomes such as non-AIDS co-morbidities and 
NRTI-related adverse events. Although we observed reduced oxygen consumption in individuals with reduced 
 mtDNApl, the overall reduction of  mtDNApl in PLHIV prevented to investigate functional consequences of 
 mtDNApl depletion in PLHIV. Furthermore, we did not perform immunofluorescence confocal or transmission 
electron microscopy experiments in the current study. In addition, age and sex differed substantially between 
cohorts, with an effect of age on mtDNA content in the uninfected cohort. We explored multiple methods to 
account for these differences using adjusted models and subgroup analyses. The subgroup of above > 40 years 
revealed a significant difference between PLHIV and controls supporting the independent correlation of HIV 
infection in the age-sex adjusted model. Finally, our study included mostly Caucasian men limiting generaliza-
tion of the findings to women and non-Caucasians.
In conclusion, PLHIV under long-term cART have reduced platelet mtDNA content and abnormalities in 
platelet mitochondrial respiration, which may possibly contribute to platelet dysfunction. Given the key role of 
Figure 5.  Association of platelet mitochondrial DNA with platelet reactivity and mean platelet volume (MPV). 
(A, B) correlation of normalized mitochondrial DNA content in platelets  (mtDNApl) and the binding of 
fibrinogen to the activated integrin αIIbβ3 after ex vivo platelet stimulation with ADP (125uM) in PLHIV (A) 
and healthy controls (B). (C, D) correlation of normalized mitochondrial DNA content in platelets  (mtDNApl) 
and MPV in PLHIV (C) and healthy controls (D). All correlations were analyzed using Pearson’s correlation 
coefficients.
Figure 5.  Association of platelet mitochondrial DNA with platelet reactivity and mean platel t volume (MPV). 
(A and B) correlation of normalized mit ch ndrial DNA conten  in platelets (mtDNApl ) and he binding of fibrinogen to 
the activated integrin αIIbβ3 after ex vivo platelet st mulation with ADP (125uM) n PLHIV (A) and heal hy controls (B). 
(C and D) correlation of normalized mitochondrial DNA content in platelets ( tDNApl ) and MPV in PLHIV (C) and 
healthy controls (D). All correlations were analyzed using Pearson’s correlation coefficients
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Our study has limitations associated with its cross-sectional design. Even though sample 
size was large enough to explore the link between inflammation, cART-use, mtDNApl 
and platelet function, it lacked power to confirm a possible link between mtDNApl levels 
and clinical outcomes such as non-AIDS co-morbidities and NRTI-related adverse events. 
Although we observed reduced oxygen consumption in individuals with reduced mtDNApl, 
the overall reduction of mtDNApl in PLHIV prevented to investigate functional consequences 
of mtDNApl depletion in PLHIV.  Furthermore, we did not perform immunofluorescence 
confocal or transmission electron microscopy experiments in the current study. In addition, 
age and sex differed substantially between cohorts, with an effect of age on mtDNA content 
in the uninfected cohort. We explored multiple methods to account for these differences 
using adjusted models and subgroup analyses. The subgroup of above >40 yrs revealed a 
significant difference between PLHIV and controls supporting the independent correlation 
of HIV infection in the age-sex adjusted model. Finally, our study included mostly Caucasian 
men limiting generalization of the findings to women and non-Caucasians.
In conclusion, PLHIV under long-term cART have reduced platelet mtDNA content and 
abnormalities in platelet mitochondrial respiration, which may possibly contribute to 
platelet dysfunction. Given the key role of platelets and mitochondria in the pathophysiology 
of long-term complications of HIV, interventions targeting platelet mitochondria, such as 
introducing NRTI sparing regimens, should be considered. 
Methods
Patient selection
This cross-sectional, single center, prospective study was performed at the Radboud 
university medical center, a tertiary teaching hospital in The Netherlands. This study is part 
of the Human Functional Genomics Project (HFGP; www.humanfunctionalgenomicsproject.
org) and was conducted in accordance with the Declaration of Helsinki after approval of the 
ethics committee (CMO Arnhem-Nijmegen, The Netherlands; NL42561.091.12, 2012/550). No 
animal experiments were performed in the current study. Adult HIV-1-infected individuals 
receiving cART for at least six months were included after providing written informed 
consent. Other inclusion criteria were a suppressed viral load (<200 copies/mL). Exclusion 
criteria included, use of P2Y12 receptor antagonists (platelet inhibitor), an active hepatitis B 
or C infection and/or signs of other active intercurrent infection other than HIV-1 (e.g. fever 
in last week or antibiotic-use in last 4 weeks). Healthy controls were concurrently included 
throughout the duration of inclusion of PLHIV. Exclusion criteria were use of medication 
(excluding oral contraceptives or paracetamol) and/or signs of an active infection in the last 
month. Clinical data was collected by extracting data from electronic medical record (Epic 
duration of cART-use or duration of HIV infection were not. As platelets are short-lived, it is 
conceivable that mitochondrial mass is reduced during thrombopoiesis and that the known 
bone marrow toxicity of AZT 1 is still present even after switching to newer NRTIs such as 
TDF or ABC. Even though these NRTIs are known to have lower mitochondrial toxicity 1, it is 
unclear whether long-term treatment does not exert any cumulative reduction in mtDNApl 
too. While ABC-use has been linked to platelet perturbations in multiple studies43-45, others 
could not confirm ABC associated platelet dysfunction35,46. In our study, neither mtDNApl 
content nor platelet function were associated with current or prior ABC-use. Unfortunately, 
we could not dissect the link between the mtDNApl, overall NRTI exposure and duration of 
HIV infection itself, as exposure to NRTIs was high in the total study group. Still, as mtDNApl 
content was lower in PLHIV than in controls, it is plausible that both NRTIs and HIV itself 
exert long-term changes in mitochondrial function2. This possible long-term NRTI effect 
on mitochondrial function in platelets supports recent efforts to implement NRTI sparing 
regimens as viable treatment options for long-term HIV treatment47 It would be interesting 
to assess mtDNApl content, as well as platelet function, in PLHIV who are switched to a NRTI 
sparing regimen. 
Mitochondrial dysfunction and depletion have been associated with many diseases such as 
dementia, neuropsychiatric diseases, and cardiovascular diseases22,23,30,48. In PLHIV, these 
(non-AIDS related) co-morbidities have also been linked to persistent inflammation20,21. In 
our cohort, we indeed found increased levels of hsCRP, sCD14 and sCD163, but only the latter 
parameter was associated with mtDNA levels in platelets. Importantly, sCD163 was shown 
to be independently correlated with overall mortality in PLHIV and the incidence of non-
AIDS related comorbidities 49,50. Targeting mitochondrial dysfunction and inflammation may 
help reduce excess mortality and morbidity that is associated with HIV infection, even when 
treated successfully with cART22,27. Reducing inflammation, besides reducing NRTI exposure, 
could indirectly reduce oxidative stress and mitochondrial dysfunction while treatment 
with ROS scavengers may also have beneficial effects in reducing non-AIDS related 
co-morbidities. 
Multiple methods of mtDNA quantification have been used in whole blood or peripheral 
blood mononuclear cell (PBMC) fractions in HIV and other diseases14,32. However, different 
methods of quantification, and heterogeneity of the cell composition of whole blood or 
PBMCs may hamper its interpretation 32,51. It is conceivable that platelet mtDNA content 
could mirror mitochondrial toxicity in other cell types as well. As a single cell-type source of 
mtDNA, platelet mtDNA may indeed serve as a possible biomarker for mitochondrial toxicity 
and non-AIDS related comorbidities associated with mitochondrial dysfunction, such as 
neurocognitive impairment and cardiovascular disease22. 
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anti-CD61, anti-CD62p, Annexin-V (all Biolegend), anti-CD45 and anti-CD41 (both Beckman 
Coulter). MPs were analyzed using a Cytoflex flow cytometer (Beckman Coulter) including 
the sensitive violet Side Scatter (405nM; VSSC) and FSC for detection of ultrasmall particles 
(1µm).54 Platelet MPs (PMPs) were selected based on aforementioned markers. Counting 
beads (Sphero Nano fluorescent, Spherotech, Fulda, Germany) of different sizes were 
included for reference to correct for concentration and size. All solutions for PMP isolation 
and staining were centrifuged at 20.000g for 20 min to remove (fluorescent) aggregates. A 
gating strategy is provided in Supplemental Figure 2.
mtDNA quantification and mitochondrial function
After platelet count measurement of every PRP sample, 500µL PRP was pelleted by 
centrifugation (2000g, 10min at RT without brake) and lysed using Triton –X100 0.1% 
for mtDNA quantification. MtDNApl was measured by real time Quantitative PCR using 
Mitotox Quickscan (Primagen, Amsterdam, Netherlands), Advanced SYBR green Super mix 
(Bio-rad, Hercules, CA, USA) and CFX96 Real time Detection System (Bio-Rad) according 
to manufacturer’s instructions. The kit includes primers and calibrators for quantification. 
A calibration curve with known mtDNA concentration was concurrently measured on 
every plate to ensure stability and quantification. A dilution curve with PRP showed a high 
correlation coefficient for mtDNA and platelet concentration. mtDNA copies per platelet 
(mtDNApl) are calculated by dividing mtDNA copy number per well by platelet count in 500µl 
of PRP. Contamination of leukocyte and erythrocyte was low <1:10.000. Samples with low 
platelet counts in PRP (below 50.10^12/mL) and erythrocyte/leukocyte contamination were 
excluded (n=2).  Mitochondrial respiration was quantified using the 96-well format Seahorse 
extracellular flux analyzer (Agilent, MA, USA). Washed platelets were plated to 60.000 
platelets/μL and seeded onto Cell-Tak coated XF96 microplates (Corning, Corning, NY, 
USA). A mitochondrial stress test was performed as described eslewhere42 using oligomycin 
(1μM, ATP synthase inhibitor (complex V), reducing mitochondrial respiration), Carbonyl 
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP;1μM, uncoupling agent causing 
maximum mitochondrial respiration), antimycin A (2.5 μM, Complex III inhibitor inhibiting 
mitochondrial respiration ) and 2-deoxy-D-glucose (2DG; 40mM, inhibits glycolysis)  after ex 
vivo stimulation (all Sigma). Oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) were determined before and after injection of platelet agonists. Samples were 
measured in five replicates with three measurements after every injection. For mitochondrial 
respiration measurements using Seahorse extracellular flux analyzer, significant outliers 
were excluded from analysis if measurement was 2x SD below the mean value in every 
timepoint with a maximum of one of the five replicates. 
Systems, Verona, WI, USA).  History of cART use was extracted from the Dutch HIV registry 
(Stichting HIV-monitoring). In a separate validation experiment for mitochondrial function, 
five virally suppressed male PLHIV (45-60yrs) who were not using statins or acetylsalicylic 
acid (ASA), were enrolled together with five age and sex matched controls.  
Platelet count and function
Platelet count and parameters were determined using an automated hematology analyzer 
(Sysmex, Kobe, Japan). Platelet reactivity was determined in citrated whole blood (3.2% 
sodium citrate, Becton Dickinson, Franklin Lakes, NJ, USA) using a flow cytometry based assay 
as previously described between 1-3 hours after blood collection 52. Platelets were ex vivo 
stimulated with ADP (1.2 and 125uM; Sigma-Aldrich, Zwijndrecht, The Netherlands) and CRP-
XL (a kind gift from Prof. Farndale, Cambridge, UK) for 20 min at room temperature. Platelets 
were stained using anti-CD61 (Beckman Coulter, Brea. CA, USA), anti-P-selectin (Biolegend, 
San Diego, CA, USA) and anti-fibrinogen (DAKO, Santa Clara, CA) antibodies and fixated in 
0.2% paraformaldehyde. Platelets were identified based on Size (FSC), granularity (SSC) 
and their expression of CD61. Degranulation was determined as the membrane expression 
of α-granule protein P-selectin and platelet aggregation was quantified as the amount of 
fibrinogen binding to the activated integrin αIIbβ3. Platelet reactivity was measured on a 
FC500 flow cytometer (Beckman Coulter, Brea, USA). Data were extracted using Kaluza 2.1 
(Beckman Coulter), normalized against quality controls to ensure measurement stability 
and are expressed as median fluorescence intensity (MFI). A gating strategy is provided in 
Supplemental Figure 1.
Platelet isolation
Platelet rich plasma (PRP) was obtained from citrated plasma (Vacutainer, Beckton-
Dickinson) after centrifugation 156g for 15min without brake at room temperature (RT). 
Samples were processed within 2 hours of blood collection. Platelet count in PRP was 
measured using an automated hematology analyser (Sysmex, Kobe, Japan). Washed 
platelets were obtained as previously described. 53 In short, PRP was supplemented with acid 
citrate dextrose (10%) and prostaglandin I2 and washed twice with Hepes tyrode’s buffer 
using centrifugation (330g, 20min). 
Platelet microparticles
Peripheral blood was centrifuged at 1000g for 5 min. Plasma was then centrifuged at 1500g 
for 20 min to obtain platelet poor plasma (PPP). 1ml of PPP was centrifuged for 30 min at 
20.000g to pellet microparticles (MPs). The MP pellet washed once in 500 µL calcium-free 
HBS complemented with 0.2% bovine serum albumin (pH 7.3) by 45 min centrifugation 
at 20.000g. MPs were labeled with MitoTracker Deep Red (200 nM; Invitrogen, Breda, The 
Netherlands) in HBS at room temperature containing calcium and subsequently stained with 
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Supplementary Table 3. Pearson’s correlation coefficient between platelet mtDNA and clinical parameters.
Platelet mtDNA content
R p-value
CD4 NADIR 0.005 0.95
CD4 COUNT -0.02 0.76
CD4/CD8 ratio 0.03 0.68
cART duration -0.03 0.63
HIV infection duration -0.086 0.23
mtDNA was normalized using inverse rank-based transformation.
Supplementary Table 4. Pearson’s correlations between Principal component 1 and Principal component 2 with 
clinical variables and inflammation. 
Principal component 1 Principal component 2
R p-value R p-value
CD4 NADIR 0.13 0.095 0.09 0.24
CD4 COUNT 0.05 0.56 0.07 0.34
CD4/CD8 ratio 0.09 0.26 -0.02 0.79
cART duration -0.09 0.24 0 0.96
HIV infection duration -0.04 0.56 0.02 0.83
sCD14 -0.05 0.43 0.02 0.81
sCD163 -0.1 0.15 -0.09 0.2
hsCRP -0.04 0.53 0.01 0.88
Supplementary Table 1. Platelet hematology indices, platelet activation parameters and markers of inflammation in 







Platelet count (10^9/L) 2.6 [2.0, 3.1] 2.8 [2.4, 3.0] 0.483
MPV (fL) 10.1 [9.7, 10.5] 10.9 [10.3, 11.4] 0.007
IPF (%) 3.2 [2.4, 4.5] 5.9 [3.4, 9.4] 0.008
Baseline fibrinogen binding (MFI) 2.0 [1.6, 2.2] 2.2 [2.1, 2.3] 0.002
Baseline P-selectin expression (MFI) 2.6 [2.0, 3.2] 2.9 [2.8, 3.1] 0.028
CCL5 (ng/ml) 2.66 [1.63, 4.23] 2.07 [1.60, 3.19] 0.245
Platelet factor 4 (ng/ml) 452.5 [294.5, 715.2] 324.0 [258.3, 462.4] 0.164
CXCL7 (ng/ml) 288.3 [180.9, 455.1] 213.9 [189.1, 260.3] 0.173
sCD14 (ng/ml) 2207.4 [1787.8, 2677.2] 1952.2 [1741.9, 2134.7] 0.062
sCD163 (ng/ml) 741.6 [547.3, 905.6] 516.8 [442.7, 684.2] 0.01
hsCRP (ng/ml) 1493.4 [608.4, 3051.2] 812.6 [382.2, 1671.0] 0.073
MPV: mean platelet volume. IPF: immature platelet fraction as a percentage of platelet count. (Sysmex, Kobe, Japan). 
Baseline platelet aggregation measured as Fibrinogen binding by flowcytometry in median fluorescence intensity (MFI). 
Baseline platelet degranulation measured as P-selectin expression by flow cytometry by MFI. sCD14: Serum levels of 
CD14, a marker of monocyte activation. sCD163: Serum levels of CD163, a monocyte- and macrophage-specific scavenger 
receptor, hsCRP: high sensitive C-reactive protein. Data depicted as median [interquartile range] and analyzed using 
Mann–Whitney
Supplementary Table 2. Platelet hematology indices, platelet activation parameters and markers of inflammation 







Platelet count (10^9/L) 260 [200, 310] 260 [220, 310] 0.483
MPV (fL) 10.1 [9.7, 10.5] 10.9 [10.3, 11.4] 0.007
IPF (%) 3.3 [2.6, 4.7] 5.0 [3.2, 7.0] 0.007
Baseline fibrinogen binding (MFI) 2.0 [1.6, 2.2] 2.2 [2.0, 2.4] <0.001
Baseline P-selectin expression (MFI) 2.7 [2.1, 3.2] 3.0 [2.8, 3.2] 0.008
CCL5 (ng/ml) 2.66 [1.63, 4.23] 2.07 [1.60, 3.19] 0.503
Platelet factor 4 (ng/ml) 458.4 [295.3, 726.1] 494.0 [333.1, 858.2] 0.39
CXCL7 (ng/ml) 290.4 [187.0, 452.8] 317.1 [214.4, 542.5] 0.466
sCD14 (ng/ml) 2155.2 [1780.7, 2672.7] 1851.0 [1614.1, 2172.7] 0.006
sCD163 (ng/ml) 700.2 [523.9, 900.0] 532.1 [418.3, 620.5] 0.002
hsCRP (ng/ml) 1451.7 [608.4, 2702.7] 675.9 [166.5, 1309.3] 0.003
MPV: mean platelet volume. IPF: immature platelet fraction as a percentage of platelet count. (Sysmex, Kobe, Japan). 
Baseline platelet aggregation measured as Fibrinogen binding by flowcytometry in median fluorescence intensity (MFI). 
Baseline platelet degranulation measured as P-selectin expression by flow cytometry by MFI. sCD14: Serum levels of 
CD14, a marker of monocyte activation. sCD163: Serum levels of CD163, a monocyte- and macrophage-specific scavenger 
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Supplementary figure 2. Platelet mtDNA levels as copies/platelet. (A) abacavir-use (B) Integrase inhibitor use (INSTI) 
(C) non-nucleoside reverse transcriptase inhibitor use (NNRTI) (D) Protease inhibitor use (PI). (E) History of Zidovudine 
(AZT) use. Data were analyzed using Mann–Whitney.
Supplementary figure 1. Platelet mtDNA levels as copies/platelet. Subgroup analysis of individuals Age >40 years 
(people living with HIV (PLHIV): n=173, healthy controls (HC): n=22). Data are shown as dotplot with error bars median 






Supplementary table 3 Pearson’s correlation coefficient between platelet mtDNA and clinical 
parameters. 
 
Platelet mtDNA content  
R p-value 
CD4 NADIR 0.005 0.95 
CD4 COUNT -0.02 0.76 
CD4/CD8 ratio 0.03 0.68 
cART duration -0.03 0.63 
HIV infection duration -0.086 0.23 




Supplementary table 4 Pearson’s correlations between Principal component 1 and Principal 
component 2 with clinical variables and inflammation.  
 Principal component 1  Principal component 2 
 R p-value  R p-value 
CD4 NADIR 0.13 0.095 
 
0.09 0.24 
CD4 COUNT 0.05 0.56 
 
0.07 0.34 
CD4/CD8 ratio 0.09 0.26 
 
-0.02 0.79 
cART duration -0.09 0.24 
 
0 0.96 
HIV infection duration -0.04 0.56 
 
0.02 0.83 
sCD14 -0.05 0.43 
 
0.02 0.81 
sCD163 -0.1 0.15 
 
-0.09 0.2 







Supplementary figure 1; Platelet mtDNA lev ls as copies/ latelet. 
Subgroup analysis of individuals Age >40 years (people living with HIV (PLHIV): n=173, healthy controls (HC): 
n=22). Data are shown as dotplot with error bars median and interquartile range (IQR).  Data were analyzed 








Supplementary figure 2; Platelet mtDNA levels as copies/platelet.  
(A) abacavir-use (B) Integrase inhibitor use (INSTI) (C) non-nucleoside reverse transcriptase inhibitor use (NNRTI) 
























































































Chapter 6 - Platelet mitochondrial dysfunction in HIV
Supplementary figure 4. Correlation between inflammation and platelet mtDNA. (A) soluble CD14, a marker of in vivo 
monocyte activation (B) high-sensitive C-reactive Protein (hsCRP). sCD14 and hsCRP were log-transformed. mtDNA/pl 
were transformed using an inverse rank-based normalization. Data were analyzed using Pearson’s coefficient.
Supplementary figure 5. Platelet energy phenotype determined by the Seahorse extracellular flux analyzer after 
CRP-XL stimulation. Samples were measured with five replicates, 1.10^7 washed platelets per well. Five age-and sex-
matched donors per group. Real-time mitochondrial respiration depicted as oxygen consumption rate (OCR) at 18 
timepoints. Four agonists or inhibitors were added in the following order: 1) collagen-related peptide (CRP-XL; 50ng/
mL or medium causing platelet activation 2) Oligomycin which inhibits cellular ATP production 3) Carbonyl cyanide-
4-(trifluoromethoxy) phenylhydrazone (FCCP), an uncoupling agent causing maximum oxygen consumption through 
complex IV and 4) Antimycin A which inhibits all mitochondrial respiration (C) real-time glycolysis as extracellular 
acidification rate (ECAR).
Supplementary figure 3. Platelet mtDNA levels stratified by use of co-medication. (A) antihypertensive drugs (eg. 
ACE-inhibitor, diuretics) (B) low-dose Acetylsalicylic acid (80mg/day; ASA; Aspirin) (C) Cholesterol lowering drug class 






Supplementary figure 3;  Platelet mtDNA levels stratified by use of co-medication.  
(A) antihyperte sive drugs (eg. ACE-inhibitor, diuretics) (B) low-dose Acetylsalicylic acid (80mg/day; ASA; Aspirin) 
(C) Cholesterol lowering drug class statins (D) Anti-di betics dru  etformin. Data were analyzed using Mann–
Whitney. 
 
Supplementary figure 4;  Correlation between inflammation and platelet mtDNA.  
(A) soluble CD14, a marker of in vivo monocyte activation (B) high-sensitive C-reactive Protein (hsCRP). sCD14 and 
hsCRP were log-transformed. mtDNA/pl were transformed using an inverse rank-based normalization. Data were 
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Supplementary figure 3;  Platelet mtDNA levels stratified by use of co-medication.  
(A) antihypertensive drugs (eg. ACE-inhibitor, diuretics) (B) low-dose Acetylsalicylic acid (80mg/day; ASA; Aspirin) 
(C) Cholesterol lowering drug class statins (D) Anti-diabetics drug Metformin. Data were analyzed using Mann–
Whitney. 
 
Supplementary figure 4;  Correlation between inflammation and platelet mtDNA.  
(A) soluble CD14, a marker of in vivo monocyte activation (B) high-sensitive C-reactive Protein (hsCRP). sCD14 and 
hsCRP were log-transformed. mtDNA/pl were transformed using an inverse rank-based normalization. Data were 
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Supplementary figure 5;  Platelet energy phenotype determined by the Seahorse extracellular flux 
analyzer after CRP-XL stimulation.  
Samples were measured with five replicates, 1.10^7 washed platelets per well. Five age-and sex-matched donors 
per group. Real-time mitochondrial respiration depicted as oxygen consumption rate (OCR) at 18 timepoints. Four 
agonists or inhibitors were added in the following order: 1) collagen-related peptide (CRP-XL; 50ng/mL or medium 
causing platelet activation 2) Oligomycin which inhibits cellular ATP production 3) Carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP), an uncoupling agent causing maximum oxygen consumption through 
complex IV and 4) Antimycin A which inhibits all mitochondrial respiration (C) real-time glycolysis as extracellular 
acidification rate (ECAR). 
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Supplementary figure 7.  Principal component analysis (PCA) of platelet activation and reactivity markers. (A) 
Coordinates of individuals on PC1 (x-axis) and PC2 (y-axis). All platelet activation markers (plasma levels of CCL5, CXCL7 
and PF4; unstimulated P-selectin expression and unstimulated fibrinogen binding) and platelet reactivity markers 
(P-selectin expression and fibrinogen binding after ex vivo stimulation) were used in this PCA. (B) Figure shows the 
direction of the used variables. Adenosine diphosphate (ADP), Fibrinogen binding (Fibro), P-selectin (CD62p). (C-
D) correlation between PC1/PC2 and mtDNA/pl. Platelet mtDNA (Y-axis) was normalized using inverse rank-based 
transformation.
Supplementary figure 6. Platelet energy phenotype after ex vivo stimulation. Platelet energy phenotype was 
determined using a Seahorse XFe96 Analyzer. (A) baseline Oxygen consumption rate (OCR) in pmol/min and extracellular 
acidification rate (ECAR) in mpH/min at baseline. (B) Change in OCR and ECAR after ex vivo stimulation with Trombin 
(TRAP; 50uM), Collagen-related peptide (CRP-XL; 50ng/mL) or unstimulated. (C) Maximal mitochondrial respiration 
capacity after FCCP (1μM) stimulation and maximal glycolysis capacity after oligomycin (1μM). (D) Percentage used after 






Supplementary figure 6; Platelet n rgy ph type aft r ex vivo stimulation  
Platelet energy phenotype was determined using a Seahorse XFe96 Analyzer. (A) baseline Oxygen consumption 
rate (OCR) in pmol/min and extracellular acidification rate (ECAR) in mpH/min at baseline. (B) Change in OCR and 
ECAR after ex vivo stimulation with Trombin (TRAP; 50uM), Collagen-related peptide (CRP-XL; 50ng/mL) or 
unstimulated. (C) Maximal mitochondrial respiration capacity after FCCP (1μM) stimulation and maximal 
glycolysis capacity after oligomycin (1μM). (D) Percentage used after ex vivo stimulation of total energy capacity. 
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Supplementary figure 7  Principal component analysis (PCA) of platelet activation and reactivity 
markers. 
(A) Coordinates of individuals on PC1 (x-axis) and PC2 (y-axis). All platelet activation markers (plasma levels of 
CCL5, CXCL7 and PF4; unstimulated P-selectin expression and unstimulated fibrinogen binding) and platelet 
reactivity markers (P-selectin expression and fibrinogen binding after ex vivo stimulation) were used in this PCA. 
(B) Figure shows the direction of the used variables. Adenosine diphosphate (ADP), Fibrinogen binding (Fibro), P-
selectin (CD62p). (C-D) correlation between PC1/PC2 and mtDNA/pl. Platelet mtDNA (Y-axis) was normalized 
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Supplementary figure 10. Platelet microparticle (MP) gating strategy. MPs were labelled with MitoTracker Deep 
Red (200 nM; Invitrogen, Breda, The Netherlands) in HBS at room temperature containing calcium and subsequently 
stained with anti-CD41 (Beckman Coulter), anti-CD61 (Biolegend, San Diego, CA), anti-CD62p (Biolegend), Annexin-V 
(Biolegend) and anti-CD45 (Beckman Coulter). MPs were  analyzed using an Cytoflex flow cytometer (Beckman Coulter, 
Brea, CA) including the sensitive violet Side Scatter (405nM; VSSC) and FSC for detection of ultrasmall particles (1µm). 
Platelet MPs (PMPs) were selected based on aforementioned markers.
Supplementary figure 8. Platelet microparticles and platelet mitochondrial release. (A) Platelet microparticle (PMP) 
count were determined by CD61, CD41, P-selectin (CD62p) and Annexin V expression and normalized to beads count. (B) 
The percentage of mitochondria positive PMPs were measured using Mitotracker Green. 17 HIV infected individuals and 
matched controls were used for this experiment. No significant differences could be observed by using the student’s 
T-test. Data are depicted as mean ±standard deviation.
Supplementary figure 9. Gating strategy using Kaluza 2.1 (Beckman Coulter) for platelet reactivity. First platelets 
were gated based on size (Forward scatter), granularity (Sideward scatter) and CD61 positivity. Thereafter P-selectin 






Supplementary figure 8 Platelet microparticles and platelet mitochondrial release  
(A) Platelet microparticle (PMP) count were determine  by CD61, CD41, P-selectin (CD62p) and Annexin V 
expression and normalized to beads count. (B) The percentage of mitochondria positive PMPs were measured 
using Mitotracker Green. 17 HIV infected individuals and matched controls were used for this experiment. No 
significant differences could be observed by using the student’s T-test. Data are depicted as mean ±standard 
deviation. 
 
Supplementary figure 9; Gating strategy using Kaluza 2.1 (Beckman Coulter) for platelet reactivity. 
First platelets were gated based on size (Forward scatter), granularity (Sideward scatter) and CD61 positivity. 
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Introduction
Cardiovascular disease is a leading cause of morbidity and mortality in HIV-infected 
individuals1. Persistent inflammation is thought to be a major factor in this excess risk2. 
Mounting evidence supports that platelets are important regulators of inflammation and 
are involved in both onset and progression of atherosclerosis, next to acute cardiovascular 
events3,4. Activated platelets release a wide range of inflammatory mediators and form 
aggregates with leukocytes, most notably via platelet P-selectin4,5. Platelet-monocyte 
aggregation (PMA) is a sensitive marker of in vivo platelet activation6 and renders monocytes 
more pro-inflammatory7,8.
Different studies have shown that both antiretroviral naïve and treated HIV-infected 
individuals have more activated and reactive platelets and increased PMA compared to HIV-
uninfected individuals9-13, although other studies yielded opposite results14,15.  In addition, 
HIV-infected patients with an acute coronary syndrome had higher platelet reactivity 
and residual platelet hyper-reactivity on dual anti-platelet therapy compared with HIV-
uninfected patients16. Together, these data suggest that platelets are a potential target to 
reduce persistent inflammation and the excess CVD risk in HIV. 
Our group recently found in a cross-sectional study that individuals on a raltegravir (RAL)-
based regimen had reduced platelet reactivity and PMA compared to those on a non-
integrase inhibitor-based regimen12. Therefore we performed a  randomized controlled trial 
to study whether a switch to a RAL-based regimen leads to a reduction in platelet reactivity, 
platelet-leukocyte aggregation, inflammation and immune activation. 
Methods
This investigator initiated, single centre, prospective randomized open-label, blinded 
end-point trial (NCT02383355) was performed at the Radboud university medical centre, a 
tertiary teaching hospital in the Netherlands. This study was conducted in accordance with 
the Declaration of Helsinki after approval of the ethics committee (CMO Arnhem-Nijmegen, 
The Netherlands; NL5068109114). Adult HIV-1-infected individuals receiving a non-integrase 
inhibitor (INSTI) containing regimen with a standard backbone of two NRTIs for at least six 
months were included after providing written informed consent. Other inclusion criteria 
were a suppressed viral load (<50copies/mL) for at least 6 months and a CD4 cell count 
>300cells/mL. Exclusion criteria included the use of platelet inhibitors, signs of an active 
infection other than HIV-1, estimated glomerular filtration rate below 50 ml/min, liver 
enzyme abnormalities, known genotypic resistance to any current ART component, history 
Abstract
Platelet hyperreactivity and increased platelet-monocyte aggregation (PMA) are associated 
with increased cardiovascular risk and inflammation. In a previous cross-sectional study, 
individuals using a raltegravir (RAL)-based regimen were found to have reduced platelet 
reactivity and PMA compared with other antiretroviral regimens. Our aim was to investigate 
whether switching from a non-integrase inhibitor regimen to a RAL-based regimen reduces 
platelet reactivity or PMA. An investigator initiated, single-centre, prospective randomized, 
open-label, blinded endpoint trial. Forty HIV-infected adults using a non-integrase inhibitor 
containing regimen with undetectable viral load were randomized to either continue their 
regimen or switch to a RAL-based regimen for 10 weeks, continuing the same backbone. The 
primary outcome was the change in platelet reactivity at week 10, which was determined as 
the expression of the platelet activation marker P-selectin and binding of fibrinogen before 
and after ex-vivo stimulation with different platelet agonists. Secondary outcomes included 
PMA, plasma markers of platelet activation and markers of inflammation and immune cell 
activation. Twenty-one participants were enrolled in the continuation group and 19 in the RAL 
group. Baseline characteristics were comparable between groups. There were no differences in 
the change in platelet reactivity to either platelet agonist at week 10, nor in plasma markers 
of platelet activation. PMA, C-reactive protein, T-cell activation (CD38+HLA-DR+) and monocyte 
(CD14+CD16+) subsets. Switching a non-integrase inhibitor containing regimen to a RAL-based 
regimen does not reduce platelet reactivity, platelet-leukocyte aggregation, inflammation and 
immune activation in virologically suppressed HIV-infected individuals.
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Results
Patient recruitment started in March 2015 and the last patient completed the study in 
March 2016. A flow diagram of the study is presented in supplementary figure 3. Nineteen 
participants were randomized to switch to RAL without changing their NRTI backbone 
therapy (RAL-group) and 21 continued their current regimen (CONT-group). One patient 
started aspirin after informed consent, but before treatment allocation, and was therefore 
excluded. Thirty-eight subjects completed the total follow-up period of 10 weeks. Two 
subjects discontinued RAL at week 4 due to grade I adverse events (mild sleeplessness and 
headache) and this time point was included as the end-of-study (EoS) time point. Overall, 
treatment was well tolerated and no grade III-IV adverse events were recorded.
Baseline characteristics, which are presented in supplementary table 1, were similar between 
the groups. Overall, 97.5% of participants were male with a median age of 48yrs (IQR:43-54) 
in the RAL-group and 49yrs (IQR:42-61) in the CONT-group. The ART backbone consisted 
of TDF/FTC (RAL:13 (68,8%), CONT:17 (81%)) or ABC/3TC (RAL:5 (26.3%), CONT:3 (14.3%)). 
Seventy-nine percent of participants in the RAL-group were using a NNRTI-based regimen 
at enrolment. All subjects had an undetectable viral load (VL;<50 copies/mL) at baseline. Two 
subjects in the RAL-group had a detectable VL during follow-up: one subject had a VL of 90 
copies/mL at week 4 with undetectable VL at week 10; the second subject had a VL of 2000 
copies/mL at week 10 due to suboptimal adherence. 
Platelet reactivity at baseline, as measured by P-selectin expression and fibrinogen binding 
after ex vivo stimulation with ADP, CRP-XL and TRAP-6 was similar between groups (Figure 1a-
b). Additionally, there were no differences observed in platelet reactivity at baseline between 
subjects on abacavir or tenofovir as backbone therapy (supplementary table 2). At week 10, 
there was no difference between both groups in the primary outcome parameters, i.e. the 
change in platelet reactivity parameters (figure 1c-d). 
This was supported by results from the plasma markers. Plasma levels of the platelet 
activation markers beta-thromboglobulin/CXCL7 and PF4 were similar at baseline and 
did not change in either group at week 10 (figure 2a-b). Concentrations of the plasmatic 
coagulation marker thrombin antithrombin complexes and the inflammation marker hsCRP 
also remained unchanged at week 10 compared to baseline (figure 2a-b). 
of virological failure (RNA blips <500copies/mL with subsequent suppression were allowed) 
and pregnancy or breastfeeding. Randomisation was performed using a computer generated 
block randomization algorithm (CASTOREDC, The Netherlands). 
Participants were randomised 1:1 to either switch to RAL 400mg twice daily continuing their 
current backbone therapy (RAL-group) or continuing their current regimen (CONT-group). 
Participants were followed for ten weeks with study visits at week 4 and week 10. At study 
visits, blood was obtained for platelet and inflammation markers and adherence and adverse 
events were recorded. The primary outcome was the change in platelet reactivity between 
week 0 and 10. This was defined as the expression of the platelet activation marker P-selectin, 
a marker for platelet degranulation, and the binding of fibrinogen to the activated fibrinogen 
receptor (integrin αIIbβ3), a marker for platelet aggregation, following ex vivo stimulation. 
Secondary outcomes included changes in platelet-leukocyte aggregation, monocyte subsets, 
T-cell activation and soluble markers of inflammation, platelet activation and plasmatic 
coagulation. 
Platelet reactivity was determined in citrated whole blood using a flow-cytometry based 
assay as previously described12 (supplementary figure 1).  Platelet-leukocyte aggregation, 
monocyte subsets and T-cell activation were measured at baseline and after ten weeks in 
whole blood on a NAVIOS flow-cytometry as previously described17 (supplementary figure 
2). Plasma concentrations of platelet factor 4 (PF4), beta-thromboglobulin (beta-tg/CXCL7), 
high-sensitive C-reactive protein (hsCRP) and thrombin antithrombin complexes were 
measured using ELISA as previously described18. All laboratory procedures are described in 
detail in the supplementary information.
The primary outcome was analyzed by calculating the change in platelet reactivity from 
baseline to end-of-study time point (week 10) and comparing the groups using independent 
Student’s T-test. Secondary outcomes were analyzed by independent T-test or Mann-
Whitney test depending distribution. Intention-to-treat analysis was performed and data 
are expressed as mean with standard deviation (SD) or median with interquartile range (IQR) 
depending distribution. Sample size estimation was based on the data of previous cross-
sectional study12. We anticipated ADP-induced P-selectin expression in the RAL-group to 
decrease from a MFI of 19 to 14 (SD 5.2). Demonstrating this difference with a power of 80% 
and α=0,05 required 18 individuals per group.  Consequently, we have included 20 per group. 
SPSS Statistics 22 and Graphpad Prism 5 were used for analyses.
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Figure 2. Soluble markers and cellular markers of platelet activation, inflammation and immune activation.  A) 
Plasma concentrations of platelet activation markers (platelet factor 4 (PF4, ng/mL) and beta-thromboglobulin (beta-
tg/CXCL7, ng/mL)), plasmatic coagulation thrombin-antithrombin complexes (TAT, pM)) and high sensitive C-reactive 
protein (hsCRP, ug/mL)). Data are depicted as median with interquartile range (IQR). B)  Fold-change from baseline to 
end of study. Data depicted according to Tukey (median, IQR, range excluding outliers defined as 3/2 times outer quartile 
and outliers are depicted as dots). C) Platelet-leukocyte aggregates were measured by flow-cytometry and are quantified 
by percentage (%) CD41-positive events on CD14+ cells (monocytes), CD4+cells, CD8+cells, CD56+cells (NK-cells) and 
B-cells (CD19+cells). Data are shown per group as median with IQR. D) Fold-change in platelet-leukocyte aggregates 
from baseline to week 10. Data are depicted according to Tukey. E) Baseline values of T-cell activation were defined as 
the % of double positive (CD38+HLA-DR+) CD4 or CD8-cells of the total CD4+ or CD8+ population. Monocyte subsets are 
depicted as the % of the total CD14+ cells. Classical monocytes (CD14+CD16-), intermediate monocytes (CD14+CD16+) and 
non-classical monocytes (CD14dimCD16+). Data are depicted as median with IQR. F) Fold-change in T-cell activation and 
monocyte subsets from week 0 to week 10. Data are depicted according to Tukey. No statistical differences were found 
using Mann-Whitney-U test.
Figure 1. Platelet reactivity at baseline and end of study. Platelet reactivity was determined by measuring platelet 
P-selectin expression and fibrinogen binding in unstimulated samples and after ex vivo stimulation with three agonists 
at two concentrations. A-B) P-selectin expression and fibrinogen binding at baseline. Data depicted as mean and 
standard deviation (sd). C-D) Fold-change in P-selectin expression and fibrinogen binding from baseline to end of 
study. Data depicted according to Tukey (median, interquartile range, range excluding outliers defined as 3/2 times 
outer quartile and outliers are depicted as dots). No significant differences were found between both groups using 
independent Student’s T-test. Adenosine diphosphate (ADP; low: 7.8 µM and high 125 µM), Thrombin Receptor Activator 
for Peptide 6 (TRAP6; low: 9.8 µM and high: 156 µM) or cross-linked collagen-related-peptide (CRP-XL; low: 27.33ng/L or 
high: 655.7ng/L). 
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
proposed that RAL may reduce inflammation more
effectively than other treatment regimens [22,23]. Part of
the inflammatory effects of platelets is mediated by their
interaction with leukocytes [7,8]. Our data do not
support the notion that switching to RAL reduces
inflammation or immune activation. The effects of RAL
on inflammation and immune activation in the literature
are also controversial. In cART-intensification studies,
addition of RAL reduced levels of the monocyte
activation marker sCD14 [25] and D-dimer in some
studies [23], whereas no effect on innate immune
activation or coagulation was observed in others
[22,26,27]. In the study by Martinez et al. [21], switching
from a protease inhibitor-based to a RAL-based regimen
decreased hsCRP and IL-6 levels, while D-dimer and
soluble P-selectin levels remained similar. Conversely, a
study in treatment-naive participants showed no consis-
tent reduction of inflammation in RAL-treated patients
compared with treatment with boosted protease inhibi-
tors [28]. Abacavir has been shown to influence platelet
function [29]. We did not find significant differences in
platelet activation or reactivity between those on an
abacavir or tenofovir-based backbone at enrolment. Also,
the backbone was not changed during the trial,
minimizing the possible confounding effects of abacavir
on our outcome measures.
Our study has several limitations. Even though our study
was correctly powered for the primary outcome (platelet
reactivity), the sample size gave us limited statistical power
to explore all secondary objectives in detail and to include
subanalyses exploring possible confounders. Second, the
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Fig. 1. Platelet reactivity at baseline and end of study. Platelet reactivity was determined by measuring platelet P-selectin
expression and fibrinogen binding in unstimulated samples and after ex-vivo stimulation with three agonists at two
concentrations. (a and b) P-selectin express on and fibrinogen binding at baseline. Data dep cted as the mean  SD. (c and
d) Fold-change in P-selectin expression and fibrinogen binding from baseline to end of study. Data depicted according to Tukey
(median, interquartile range, range excluding outliers defined as 3/2 times outer quartile and outliers are depicted as dots). No
significant differences were found between both groups using an independent Student’s t test. ADP (low: 7.8mmol/l and high
125mmol/l), thrombin receptor activator for peptide 6 (low: 9.8mmol/l and high: 156mmol/l) or cross-linked collagen-related-
peptide-XL (low: 27.33 ng/l or high: 655.7 ng/l).
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Raltegravir and platelet reactivity van der Heijden et al. 2473
Fig. 2. Soluble markers and cellular markers of platelet activation, inflammation and immune activation. (a) Plasma con-
centrations of platelet activation markers [platelet factor 4 (ng/ml) and beta-thromboglobulin (CXCL7, ng/ml)], plasmatic
coagulation thrombin–antithrombin complexes (pmol/l) and high sensitive C-reactive protein (mg/ml). Data are depicted as
the median with the interquartile range. (b) Fold-change from baseline to end of study. Data depicted according to Tukey (median,
interquartile range, range excluding outliers defined as 3/2 times outer quartile and outliers are depicted as dots). (c) Platelet-
leukocyte aggregates were measured by flow-cyto etry and are quantified by percentage (%) CD41-positive events on CD14þ
cells (monocytes), CD4þ cells, CD8þ cells, CD56þcells (natural killer cells) and B-cells (CD19þcells). Data are shown per group as
the median with the interquartile range. (d) Fold-change in platelet-leukocyte aggregates from baseline to week 10. Data are
depicted according to Tukey. (e) Baseline values of T-cell activation were defined as the % of double positive (CD38þHLA-DRþ)
CD4þ or CD8þ cells of the total CD4þ or CD8þ population. Monocyte subsets are depicted as the % of the total CD14þ cells.
Classical mo ocytes (CD 4þCD16�), intermediate monocytes (CD14þCD16þ) and nonclassi al monocytes (CD14dimCD16þ).
Data are depicted as the median with the interquartile range. (f) Fold-change in T-cell activation and monocyte subsets from week
0 to 10. Data are depicted according to Tukey. No statistical differences were found using Mann–Whitney U test.
205204
7
Chapter 7 - Raltegravir does not lower platelet reactivity
do not support the notion that switching to RAL reduces inflammation or immune activation. 
The effects of RAL on inflammation and immune activation in the literature are also 
controversial. In cART-intensification studies, addition of RAL reduced levels of the monocyte 
activation marker sCD1425 and D-dimer in some studies23, whereas no effect on innate 
immune activation or coagulation was observed in others22,26,27. In the study by Martinez et 
al21, switching from a PI- to a RAL-based regimen decreased hsCRP and IL-6 levels, while 
D-dimer and soluble P-selectin levels remained similar. Conversely, a study in treatment-
naive participants showed no consistent reduction of inflammation in RAL-treated patients 
compared to treatment with boosted PIs28. Abacavir has been shown to influence platelet 
function29. We did not find significant differences in platelet activation or reactivity between 
those on an abacavir or tenofovir-based backbone at enrolment. Also, the backbone was not 
changed during the trial, minimizing the possible confounding effects of abacavir on our 
outcome measures.
Our study has several limitations. Even though our study was correctly powered for the 
primary outcome (platelet reactivity), the sample size gave us limited statistical power to 
explore all secondary objectives in detail and to include sub-analyses exploring possible 
confounders. Secondly, the inclusion of only long-term, virologically suppressed individuals 
could have masked the possible beneficial effects of RAL, but mirrors the current chronically 
infected HIV population. Finally, our study included mostly men limiting generalization of 
the findings to women. The same applies to generalizability of these data to other INSTIs.
In conclusion, this study shows that switching to a RAL-based regimen does not reduce 
platelet reactivity, platelet-leukocyte aggregation, inflammation and immune activation in 
virologically suppressed HIV-infected individuals. 
Platelet-leukocyte aggregation in our study was most prominent for platelet-monocyte 
aggregation (RAL:18.2% CD41+ of CD14+cells (IQR:9.2-43.26), CONT:18.6% (IQR:11.6-23.9)) 
compared to platelets aggregating with lymphocyte subsets (RAL:2.5% (IQR:1.5-5.8), CONT: 
2.8% (IQR:1.4-4.6)) (figure 2c). At baseline, no differences were observed between groups 
and platelet aggregation to monocyte and lymphocyte subsets did not differ significantly 
at week 10 (figure 2c-d). An increase in activated proinflammatory monocyte subsets 
(CD14+CD16+) is associated with cardiovascular disease19,20. Circulating classical monocytes 
(CD14+CD16-), intermediate (CD14+CD16+) and nonclassical monocytes (CD14dimCD16+) were 
similar at baseline and were not influenced by a switch to RAL in this study (figure 2e-f). 
T-cell activation measured by CD38 and HLA-DR co-expression was also not statistically 
different between the RAL-group and CONT-group at baseline or after 10 weeks of treatment 
(figure 2e-f). 
Discussion
This randomized controlled trial demonstrates that switching from a non-INSTI containing 
regimen to a RAL-based regimen in virologically suppressed HIV-infected individuals does 
not reduce platelet reactivity, platelet-leukocyte aggregation and markers of immune 
activation, such as activation of monocytes and T-lymphocytes and concentrations of CRP 
and TAT. These findings are in accordance with a study by Martinez et al21, which showed 
that switching from a boosted protease inhibitor (PI) to RAL for 48 weeks did not lead to a 
reduction of in vivo platelet activation measured by soluble P-selectin. Yet, it is in apparent 
contrast to previous findings from a cross-sectional study performed by our group showing 
that individuals on a RAL-based regimen had reduced platelet reactivity compared to those 
on a NNRTI or PI containing regimen12. This may be explained in different ways.  First, the 
follow-up period of 10 weeks in the present study is relatively short, whereas the majority 
of patients in the cross-sectional study were on the same cART longer than 3 months. 
Although, platelet life-span is short (<10 days) and RAL intensification has shown effects on 
viral replication and plasmatic coagulation within 3 months22,23, effects on megakaryocytes 
may take longer. Second, cross-sectional studies are prone for selection bias. The latter 
is especially relevant as available data on platelet reactivity in cART treated patients are 
contradictory, with some studies reporting increased platelet reactivity9-13 while others 
reporting reduced reactivity14,15. 
Platelets are increasingly recognized as key effector cells in inflammation4. In turn, 
inflammation may also influence platelet reactivity24. Some studies have proposed that RAL 
may reduce inflammation more effectively than other treatment regimens22,23. Part of the 
inflammatory effects of platelets is mediated by their interaction with leukocytes7,8. Our data 
207206
7
Chapter 7 - Raltegravir does not lower platelet reactivity
21 Martinez, E. et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted 
protease inhibitors to raltegravir. AIDS 26, 2315-2326, doi:10.1097/QAD.0b013e328359f29c (2012).
22 Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-
suppressed subjects. Nat Med 16, 460-465, doi:10.1038/nm.2111 (2010).
23 Hatano, H. et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification 
in patients with treated HIV infection: a randomized, placebo-controlled trial. The Journal of infectious diseases 208, 
1436-1442, doi:10.1093/infdis/jit453 (2013).
24 Rondina, M. T. et al. In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). Chest 
141, 1490-1495, doi:10.1378/chest.11-2860 (2012).
25 Massanella, M. et al. Dynamics of CD8 T-Cell Activation after Discontinuation of HIV Treatment Intensification. 
Journal of acquired immune deficiency syndromes 7, 7 (2013).
26 Massanella, M. et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-
suppressed individuals with poor CD4 T-cell recovery. AIDS 26, 2285-2293, doi:10.1097/QAD.0b013e328359f20f 
(2012).
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Supplementary Table 1. Baseline characteristics.
Patient characteristics RAL (n=19) CONT (n=21) p-value
Age (years), median (IQR) 48 (43-54) 49 (42-61) 0.486
Female sex, n (%) 1 (5.2%) 0 (0%) 0.287
Body mass index, mean (SD) (kg / m2) 26.3 (±4) 24.7 (±3) 0.164
Current smoker, n (%) 4 (21.1%) 6 (28.5%) 0.583
Diabetes mellitus, n (%) 0 (0%) 2 (9.5%) 0.168
Hypertension, n (%) 3 (15.8%) 3 (14.3%) 0.894
Statin use, n (%) 2 (10.5%) 5 (23.8%) 0.270
cART regimens

















Boosted PI, n (%) 3 (15.8%) 3 (14.3%) 0.894
NNRTI, n (%) 15 (79%) 18(85.7%) 0.574
Zidovudine, n (%) 1 (5.2%) 0 (0%) 0.287
Viral load(<50 copies/mL), n (%) 19 (100%) 21 (100%) NA
Nadir CD4 (106 cells/L), median (IQR) 290 (250-355) 280 (185-335) 0.707
CD4 count (106 cells/L), median (IQR) 760 (585-925) 650 (540-740) 0.175
eGFR, mean (SD) (ml/min /1.73m2) 81 (±12) 82 (±10) 0.668
HIV1 diagnosis (years), median (IQR) 10 (6-12) 9 (5-13) 0.333
cART exposure (years), median (IQR) 7 (5-10,5) 6 (5-11) 0.452
Data were analysed using independent T-test or Mann-Whitney-U test depending on distribution and no significant 
differences were observed defined as p-value <0.05. Interquartile range (IQR); standard deviation (sd); Estimated 
glomerular filtration rate (eGFR); Combination antiretroviral therapy (cART); nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs); tenofovir difumarate (TDF); emciterabine (FTC); abacavir (ABC); lamivudine (3TC); non-nucleoside 
reverse transcriptase inhibitor (NNRTI); boosted protease inhibitor (PI)
Supplementary methods
Laboratory procedures
Platelet reactivity was determined in citrated whole blood (3.2% sodium citrate, Becton 
Dickinson) using a flow-cytometry based assay as previously described 1. Whole blood was 
processed after a rest period of one hour and within three hours after collection to prevent 
iatrogenic platelet activation. In short, whole blood was added to saturating concentrations 
of anti-CD61 ( Beckman Coulter, Brea, USA), anti-fibrinogen (DAKO, Belgium) and anti-
CD62p (anti-P-selectin; BD Biosciences, San Jose, USA) and stimulated ex vivo with adenosine 
diphosphate (ADP; 7.8 and 125 µM; Sigma-Aldrich, The Netherlands), Thrombin Receptor 
Activator Peptide  (TRAP6; 9.8 and 156 µM; Sigma-Aldrich) or cross-linked collagen-related-
peptide (CRP-XL; 27.33ng/L and 655.7ng/L) and fixed after 20 minutes. CRP-XL was prepared 
as described previously2. Samples were directly measured on a FC500 (Beckman Coulter). 
Platelets were gated on size, granularity and CD61 positivity and the expression of CD62p and 
fibrinogen-binding on platelets were recorded using median-fluorescence intensity (MFI). A 
representative sample with gating strategy is shown in supplementary figure 1.
Platelet-leukocyte aggregation, monocyte subsets and T-cell activation were measured at 
baseline and after ten weeks in whole blood on a NAVIOS flow-cytometry (Beckman Coulter) 
as previously described3. Platelet-leukocyte aggregation was determined as the percentage 
of CD41 positive cells of specific leukocyte (CD45+) populations (monocytes: CD14+, CD4-cells: 
CD3+CD4+, CD8-cells: CD3+CD8+, B-cells: CD19+ and NK-cells: CD3-CD56+). T-cell activation was 
determined as the percentage of CD4 or CD8-cells double positive for CD38 and HLA-DR. 
Monocyte subsets were determined as classical (CD14+CD16-), intermediate (CD14+CD16+) 
and non-classical (CD14dimCD16+) monocytes. Scattergrams of a representative sample with 
gating strategy is shown in supplementary figure 2. Soluble plasma proteins and thrombin-
antithrombin (TAT) complexes, a marker for plasmatic coagulation, were measured in 
citrated platelet-poor-plasma (1500g centrifugation without brake, 10min, 20oC). Plasma 
concentrations of platelet factor 4 (PF4), beta-thromboglobulin (beta-tg/CXCL7), high-
sensitive C-reactive protein (hsCRP, all R&D Systems) and TAT (Affinity Biologicals, USA) were 
measured using ELISA as previously described4.
1. Tunjungputri RN, Van Der Ven AJ, Schonsberg A, Mathan TS, Koopmans P, Roest M, et al. Reduced platelet 
hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based 
regimen. AIDS. 2014;28(14):2091-6.
2. Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ. Integrin alpha 2 beta 1-independent activation of 
platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures 
are sufficient alone for alpha 2 beta 1-independent platelet reactivity. The Biochemical journal. 1995;306 ( Pt 2):337-
44.
3. Aguirre-Gamboa R, Joosten I, Urbano PC, van der Molen RG, van Rijssen E, van Cranenbroek B, et al. Differential 
Effects of Environmental and Genetic Factors on T and B Cell Immune Traits. Cell reports. 2016;17(9):2474-87.
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Supplementary figure 1. Representative scatter gram with gating strategy of platelet reactivity. Platelet are selected 
based on side scatter (SS), forward scatter (FS) and CD61-positivity. Afterwards the median fluorescence intensity (MFI) 
is calculated of Fibrinogen and P-selectin to determine platelet reactivity. A) unstimulated sample. B) TRAP-stimulated 
sample. A minimum of 6000 platelets (CD61+) were analysed per condition. 
Supplementary Table 2. Platelet reactivity at baseline comparing subjects on abacavir vs tenofovir. 
P-selectin expression
  Abacavir (n=8) Tenofovir (n=32) P-value
Stimulus 25% median 75% 25% median 75%  
ADP high 33.1 37.2 43.44 33.3 41.3 45.5 0.62
ADP low 27.7 34.5 38.5 29.9 36.9 42.8 0.41
CRP-XL high 81.7 87.3 97 75 83.4 90.3 0.37
CRP-XL low 34.5 43.9 61.4 29.1 61.2 73.6 0.41
TRAP high 7.2 46.4 57.2 8.57 31.2 60.59 0.72
TRAP low 64.2 73.5 77.9 70.7 74.1 81.4 0.55
unstimulated 3.65 4.72 5.12 3.75 4.45 5.2 0.97
Fibrinogen binding
Abacavir (n=8) Tenofovir (n=32) P-value
Stimulus 25% median 75% 25% median 75%  
ADP high 8.57 13.6 17.2 11.1 13.5 20.5 0.55
ADP low 6.34 13.7 15.9 10.3 14.6 17.7 0.41
CRP-XL high 15.3 18.4 20.5 16.5 19.9 21.4 0.45
CRP-XL low 7.53 9.62 15 8.5 12.8 17.1 0.32
TRAP high 3.43 6.42 12.3 3.44 6.84 10.7 0.89
TRAP low 7.92 12.8 16.1 9.46 12 15.1 0.84
unstimulated 2.11 2.94 3.22 2.22 2.52 3.44 0.81
Platelet reactivity was determined by measuring platelet P-selectin expression and fibrinogen binding in unstimulated 
samples and after ex vivo stimulation with three agonists at two concentrations. Adenosine diphosphate (ADP; low: 
7.8 µM and high 125 µM), Thrombin Receptor Activator for Peptide 6 (TRAP6; low: 9.8 µM and high: 156 µM) or cross-
linked collagen-related-peptide (CRP-XL; low: 27.33ng/L or high: 655.7ng/L). Mann-Whitney U test was used for statistical 
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Supplementary figure 3. Screening and enrolment flow diagram (CONSORT). 38 subjects completed the total follow-
up period of 10 weeks. *Use of platelet inhibitor (aspirin), previous use of RAL **Two subjects discontinued raltegravir at 
week 4 because of grade I adverse events (mild sleeplessness and headache). In these subjects a measurement at week 
4 was included as the end of study (EoS/week 10) for the primary outcome. 
Supplementary figure 2. Representative scatter grams and gating strategy for platelet-leukocyte aggregates. Gating 
strategy for monocyte subsets and platelet-monocyte aggregates (A) are shown in the upper graphs. Monocytes are 
gated based on side scatter (SS), forward scatter (FS) and CD14-positivity. Platelet-monocyte interaction is the the 
percentage of CD14+cells, positive for CD41. Gating strategy for lymphocyte subsets (B) (CD4, CD8, CD56 and CD19) are 
shown in the lower panels. Platelet lymphocyte aggregates are the percentage of cells positive for CD41. A minimum of 






Supplementary figure 2. Representative scatter grams and gating strategy for platelet-leukocyte 
aggregates.  
Gating strategy for mon cyte subsets and platelet-mon c te aggregates (A) are shown in the upper graphs. 
Monocytes are gated based on side scat r (SS), forward scatter (FS) and CD14-positivity. Platelet-monocyte 
interaction is the the percentage of CD14+cells, positive for CD41. Gating strategy for lymphocyte subsets (B) (CD4, 
CD8, CD56 and CD19) are shown in the lower panels. Platelet lymphocyte aggregates are the percentage of cells 









Supplementary figure 3. Screening and enrolment flow diagram (CONSORT).   
38 subjects complet d th  otal fo low-up period of 10 weeks. *Use of platelet inhibi or (aspirin), previous use of 
RAL **Two subject  discontinued raltegravir at week 4 because of grade I adverse events (mild sleeplessness and 
headache). In these subjects a measurement at week 4 was included as the end of study (EoS/week 10) for the 
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Introduction
Although platelets are well known to be critical for hemostasis, it is becoming increasingly 
clear that platelets can actively modulate immune responses1,2. Upon activation, platelets 
release chemokines,
cytokines1, and plasma membrane platelet-derived microparticles (PMPs) into the 
circulation3. PMPs are in the submicron range, are involved in hemostasis, and expose the 
lipid phosphatidylserine and molecules specific for platelets3. They have the ability to 
transfer membrane receptors4 and microRNA5 to other cells and play a role in the regulation 
of immunity3,6. 
Forkhead box P3 (FOXP3)+ regulatory T cells (Tregs) are fundamental for immune 
homeostasis. Naturally occurring FOXP3+, CD25high, and CD127low/- Tregs comprise ;5% of the 
human peripheral blood CD4+ T cells7. FOXP3 gene hyper demethylation is key to high and 
constitutive FOXP3 expression, which in turn is crucial for Treg suppressor function8 and Treg 
stability7. We and others have shown that upon activation, CD4+CD25highFOXP3+ Tregs can lose 
FOXP3 and differentiate into interleukin 17 (IL-17)- and interferon γ (IFN-γ)-producing cells9-13. 
Although proinflammatory cytokine-producing Tregs may reveal reduced suppressive 
capacity, a subset of IL-17-producing cells was shown to retain both FOXP3 expression and 
suppressive function9,11,14,15. Of note, Wang et al showed that in rheumatoid arthritis patients, 
peripheral blood IL-17-producing Tregs were suppressive, whereas their synovial fluid 
counterparts lost suppressive capacity15. The notion that this plasticity might have clinical 
implications was fuelled by a mouse study revealing that cytokine-producing Tregs induced 
autoimmunity16. In humans, increased numbers of proinflammatory cytokine-producing 
Tregs were found in patients with multiple sclerosis17, Crohn disease18, and psoriasis19, where 
we identified IL-17-producing Tregs in the inflamed skin19. 
The ability of PMPs to influence cells of the immune system under inflammatory conditions 
that can also affect Treg phenotype led us to investigate the direct effect of PMPs in Tregs. 
Here, we show that PMPs inhibit the differentiation of highly purified human peripheral 
blood  Tregs into IL-17- and IFN-γ–producing cells. The binding of PMPs to Tregs, and the 
subsequent inhibition of Treg differentiation, appeared to be P-selectin and partly CXCR3 
dependent. Prior to and during Treg activation and subsequent differentiation, PMPs 
selectively bound a specific subset of memory-like Tregs expressing CCR6 and HLA-DR, 
known to bring forth IL-17-producing cells10,20. In the circulation, we found that;8% of Tregs 
are CD41 and P-selectin double positive. The finding that PMPs affect Treg proliferation 
provides a possible mechanism by which PMP binding to the memory-like Treg subset 
affects their IL-17-producing capacity. These findings open the exciting possibility that PMPs 
Abstract
Self-tolerance and immune homeostasis are orchestrated by FOXP3+ regulatory T cells 
(Tregs). Recent data have revealed that upon stimulation, Tregs may exhibit plasticity toward 
a proinflammatory phenotype, producing interleukin 17 (IL-17) and/or interferon γ (IFN-γ). 
Such deregulation of Tregs may contribute to the perpetuation of inflammatory processes, 
including graft-versus-host disease. Thus, it is important to identify immunomodulatory 
factors influencing Treg stability. Platelet-derived microparticles (PMPs) are involved in 
hemostasis and vascular health and have recently been shown to be intimately involved in 
(pathogenic) immune responses. Therefore, we investigated whether PMPs have the ability 
to affect Treg plasticity. PMPs were cocultured with healthy donor peripheral blood–derived 
Tregs that were stimulated with anti-CD3/CD28 monoclonal antibodies in the presence of IL-
2, IL-15, and IL-1β. PMPs prevented the differentiation of peripheral blood-derived Tregs into 
IL-17- and IFN-γ-producing cells, even in the presence of the IL-17-driving proinflammatory 
cytokine IL-1β. The mechanism of action by which PMPs prevent Treg plasticity consisted of 
rapid and selective P-selectin–dependent binding of PMPs to aCCR6+HLA-DR+memory-like 
Treg subset and their ability to inhibit Treg proliferation, in part through CXCR3 engagement. 
The findings that ∼8% of Tregs in the circulation of healthy individuals are CD41+P-selectin+ 
and that distinct binding of patient plasma PMPs to Tregs was observed support in vivo 
relevance. These findings open the exciting possibility that PMPs actively regulate the 
immune response at sites of (vascular) inflammation, where they are known to accumulate 
and interact with leukocytes, consolidating the (vascular) healing process.
219218
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Cell isolation, culture, and anti-CXCR3 and anti-CD40 mAb neutralization
Peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient centrifugation 
(Lymphoprep; Nycomed-Pharma AS, Oslo, Norway) of buffy coats obtained from healthy 
donors upon written informed consent according to the Declaration of Helsinki. CD4+ T cells 
were purified from PBMCs by magnetic bead sorting using CD4 MicroBeads (Miltenyi Biotec, 
Leiden, The Netherlands) according to the manufacturer’s instructions. Purified CD4+ T cells 
were labelled with anti-CD4–fluorescein isothiocyanate (FITC) (MT310; DAKO, Glostrup, 
Denmark) and anti-CD25-PE (MA251; BD Biosciences, Erembodegem, Belgium) monoclonal 
antibodies (mAbs), after which CD4+CD25high cells (Tregs) were isolated by high-purity (>99%) 
flowcytometric cell sorting using an Aria cell sorter (Beckman Coulter).
Cells (2.5 x 104/well) were cultured in culture medium (RPMI-1640 with Glutamax 
supplemented with 0.02 mM pyruvate, 100 U/mL penicillin, 100mg/mL streptomycin [Gibco, 
Paisley, United Kingdom], and 10% human pooled serum) at 37°C, 95% humidity, and 5% 
CO2 in 96-well round-bottom plates (Greiner, Frickenhausen, Germany). Anti-CD3/anti-
CD28 mAb-coated beads (1:10; Invitrogen, Breda, The Netherlands) and recombinant human 
cytokines IL-2 (25 U/mL; Cetus, Amsterdam, The Netherlands), IL-15 (10 ng/mL), and IL-1β 
(50 ng/mL) (Biosource, Etten-Leur, The Netherlands) were added at the start of the cultures, 
in the presence or absence of PMPs. The suppression assay, transwell assay, and CD40 and 
CXCR3 neutralization are described in supplemental Methods.
Flow cytometry and antibodies
Cells were phenotypically characterized using the Navios flow cytometer (Beckman Coulter) 
and conjugated mAbs supplied in supplemental Methods. In order to study cell proliferation, 
Pacific Blue succinimidyl ester (Invitrogen) labelling (0.012 mg/mL) of Tregs prior to culture 
was performed. Intracellular analysis was performed after fixation and permeabilization 
using Fixation/Permeabilization reagent (eBioscience, Uithoorn, The Netherlands). Before 
intracellular cytokine measurements, the cells were stimulated for 4 hours with phorbol 
12-myristate 13-acetate (PMA;12.5 ng/mL) plus ionomycin (500 ng/mL) in the presence of 
Brefeldin A (5 mg/mL; Sigma-Aldrich, Zwijndrecht, The Netherlands). Peripheral blood 
staining is described in supplemental Methods. All flow cytometry data were analyzed using 
Kaluza software (Beckman Coulter). Proliferation Platform of FlowJo 7.6 was employed to 
assess proliferation.
Confocal laser scanning microscopy and FOXP3 gene methylation
See supplemental Methods.
actively regulate the immune response at sites of (vascular) injury, where PMPs are known to 
accumulate21.
Methods
HIV-infected adults, acute coronary syndrome patients, and healthy volunteers
Peripheral blood (EDTA) was obtained from patients and healthy volunteers. HIV-infected 
adults on stable combination antiretroviral therapy with undetectable viral load (<50 copies/
mL) and CD4 counts <300 cells/mm3 were eligible for enrolment. Exclusion criteria were 
the use of platelet inhibitors or an active concomitant infection (e.g. hepatitis C or B). The 
study protocol was approved by the medical ethical committee Arnhem-Nijmegen (Radboud 
University Medical Center). Patients with a diagnosis of acute coronary syndrome (ACS; ST-
elevation myocardial infarction and non–ST-elevation myocardial infarction). Blood samples 
were collected 4 to 12 hours from the start of chest pain. Patients with evidence of infectious 
diseases, malignancies, hematologic or immunologic disorders, treatment with anti-
inflammatory drugs other than aspirin, and an ejection fraction ,40 were excluded. The study 
was approved by the local research ethics committee (St. George’s, University of London). 
Both studies adhered to the Declaration of Helsinki. Signed informed consent was obtained 
from all patients and healthy volunteers.
PMP isolation, storage, and anti–P-selectin monoclonal antibody neutralization
Single donor platelet-rich plasma (PRP) was collected from 3 healthy donors by apheresis 
upon written informed consent according to the Declaration of Helsinki. Using a component 
collection system (MCS1; Haemonetics, Braintree,MA) in combination with acid citrate 
dextrose solutionA, 3003109 leukoreduced (<1 X 106 leukocytes/U) platelets were collected 
in 300 mL plasma and stored in a lateral shaking device at 22°C 6 2°C for 7 days. At day 7 of 
storage (the maximum storage period in The Netherlands), PMPs were isolated from the PRP 
product under sterile conditions using differential centrifugation as previously described22. 
The PRP was centrifuged at 2000g for 15 minutes to remove platelets and cell debris. The 
supernatant was aliquoted, centrifuged for 45 minutes at 20 000g to pellet PMPs, and 
washed with 0.22mm filtered calcium-free Ringer’s solution (125mM NaCl, 5mM KCl, 1mM 
MgSO4, 32mM HEPES, 5mM glucose, and 0.2% bovine serum albumin [pH 7.4]). The PMPs 
were resuspended in calcium-free Ringer’s solution, snapfrozen with liquid N2, and stored at 
280°C. PMP purity/quantity was assessed using a Gallios flow cytometer (Beckman Coulter, 
Brea, CA) as described in supplemental Methods. PMP-associated P-selectin neutralization 
and washed platelet isolation, activation, and subsequent PMP generation are described 
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(Figure 1E-F). PMPs isolated from 2-day–stored platelet apheresis products also inhibited 
the generation of IL-17–producing cells (supplemental Figure 6), indicating that there are no 
major qualitative storage period–associated differences in this regard.
To examine whether the effects of PMPs on Treg differentiation are stored-platelet specific 
or can be attributed to other sources and causes of PMP production, we used freshly 
isolated washed platelets activated with thrombin receptor activator peptide 6 (TRAP) in 
the presence of calcium and shear stress for optimal PMP generation. The PMPs formed by 
these TRAP-activated washed platelets had similar effects on Treg differentiation as PMPs 
isolated from stored platelet units, including reduced induction of IL-17 and IFN-γ production 
(supplemental Figure 7). These data underscore the potential of both platelet apheresis unit–
derived, as well as activated platelet-derived, PMPs to promote Treg stability. In addition, we 
also observed a reduction in IL-17 production when culturing Tregs in the presence of TRAP-
activated washed platelets themselves (supplemental Figure 8). 
P-selectin and CXCR3 mediate PMP inhibitory effects on Treg differentiation
Subsequently, the question arose which molecular component(s) of the PMPs were 
responsible for the inhibitory effect observed. Using a transwell setup with intracellular IL-
17 expression as a readout (Figure 2A), we observed that Treg differentiation was contact 
dependent. This ruled out the possibility of cytokine scavenging or release by the PMPs 
significantly affecting Treg differentiation.
As we observed clear staining for the platelet-specific marker CD41 on Tregs cocultured with 
PMPs (Figure 2B), even after repeated washing steps, we proposed that PMPs firmly bind 
to these cells and postulated that adhesion molecules, several of which are present on the 
PMP membrane3, might be involved in this PMP–Treg contact-dependent interaction. Upon 
activation, platelets typically expose the adhesion molecule P-selectin, which they can pass 
onto the PMPs they generate29. Like their parental cells, PMPs are able to bind immune cells 
expressing the P-selectin ligand P-selectin glycoprotein ligand-1 (PSGL-1)30. This led us to 
investigate whether P-selectin is involved in the observed PMP adhesion to Tregs and/or the 
inhibition of their differentiation. 
Statistics
Repeated-measures 1-way (plus Tukey’s post-test) or 2-way (plus Bonferroni post-test) 
ANOVAs were used for statistical analysis. The reported (2-sided) P values of <.05 were 
considered significant and are indicated with an asterisk(*). Data in the text are presented as 
mean 6 ± standard deviation.
Results
PMPs inhibit CD25highFOXP31 Treg differentiation into IL-17–producing cells
We reasoned that PMPs, with their arsenal of immune-mediating molecules3, and their 
ability to interact with cells of the immune system6,23, might affect the differentiation of 
Treg into IL-17–producing T cells9. To obtain large amounts of PMPs, we used PMPs isolated 
from 7-day-stored platelet apheresis products of healthy donors, known to accumulate PMPs 
during storage24. PMP purity, size, and number were assessed by flow cytometry, based on 
exposure of phosphatidylserine (PS) and CD41 (Figure1A and supplemental Figure 1).Over 
99% of all measured events were smaller than 1 µm in diameter, and more than 90% stained 
positive for CD41 and PS. Stored platelets and their PMPs were further characterized for 
exposure of PS, CD40, CD41, and activation markers P-selectin and CD63 (supplemental 
Figure 2).
PMPs were then cocultured with highly purified CD4+CD25highCD27+CD127low/-FOXP3+ 
Treg isolated from PBMCs by fluorescence-activated cell sorting (supplemental Figure 3). 
Typically, anti-CD3/CD28 mAb stimulation of this population in the presence of IL-2, IL-15, 
and IL-1β leads to a substantial number of IL-17–producing cells, with concomitant loss of 
FOXP39.
The addition of PMPs to the freshly isolated Tregs at ratios of 2.4,12, or 60 PMPs per cell 
inhibited the induction of IL-17 and IFN-γ production in a dose-dependent manner (Figure 
1B-C,E-F). Similarly, the loss of FOXP3 expression was inhibited (Figure 1D-F), and a higher 
level of CpG demethylation in the Treg-specific demethylation region of theFOXP3genewas 
detected (supplemental Figure 4). Interestingly, of the few cells that managed to acquire 
IL-17–producing capacity in the presence of PMPs, most still expressed FOXP3 (Figure 1D), 
suggesting that the differentiation process was partially hampered. Furthermore, PMP 
binding was higher in IL-17+FOXP3+ cells than in IL-17+FOXP3- cells (supplemental Figure 
5). Previous studies have revealed that CD4+CD25+ Tregs expressing CD27 and/or CD62L 
constitute highly suppressive Treg subsets25,26. Similar to the expression of FOXP3, loss of 
CD27 and CD62L was also prevented, whereas PMPs inhibited the percentage of cells that 
acquired the TH1727 and memory-associated28 chemokine receptor CCR6 during culture 
223222
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Figure 3. CXCR3 neutralization leads to partial loss of PMP-mediated inhibition of IL-17 production by Treg. Treg were 
isolated from healthy donors and cultured for 7 days with anti-CD3/anti-CD28-mAb-coated beads and recombinant 
human IL-2, IL-15, and IL-1β in the presence or absence of 1.5×106 allogeneic PMPs isolated from platelet apheresis 
units of three healthy donors. Flow cytometry analyses of intracellular cytokines were performed after stimulation 
with PMA and ionomycin, in the presence of Brefeldin A. (A) Example dot plots of day 7 CXCR3 expression on Treg. 
(B) CXCR3 expression on Treg throughout culture. (C) CXCR3+ Treg present in the CD41- and CD41+ subpopulations in 
time. (D) Day 7 intracellular staining of IL-17 on Treg cultured with or without PMPs in the absence or presence of isotype 
or antagonistic anti-CXCR3 mAb. The percent PMP-mediated inhibition of IL-17-expressing Treg is displayed in the 
graph. Results for three Treg donors are shown. Mean and SD are shown. *P<0.05.
First, we established that the majority of PMPs (86.3% 6 2.4%) indeed expressed P-selectin 
(Figure 2C) and that Tregs expressed P-selectin ligand PSGL-1 at day 0 (Figure 2D). 
Subsequently, we performed neutralization experiments. Prior to coculture with Tregs, PMPs 
were incubated with an FITC-conjugated antagonistic anti–P-selectin mAb, an isotype control 
mAb, or in buffer only and subsequently washed. Although isotype mAb did not bind to the 
PMPs (0.4 6 0.1%), PMPs were effectively bound by the anti–P-selectin mAb (80.6%64.4%). 
The anti–P-selectin mAb was still present on the PMPs at day 7 of culture with Treg (77.4% 
6 7.1%). Notably, the neutralization of P-selectin not only abrogated (CD411) PMP adhesion 
to the Treg (Figure 2E) but also greatly blunted their inhibitory effect on Treg differentiation 
into IL-17–producing cells and loss of the Treg marker CD27 (Figure 2E). Neutralization of 
P-selectin also restored the loss of FOXP3 and CD62L and the increase in IFN-γ expression by 
Tregs during culture (supplemental Figure 9).
Confocal laser scanning microscopy of Tregs cocultured with PMPs confirmed the binding of 
CD41+PMPs to the cell membrane of part of the Treg (Figure 2F). The majority of these PMPs 
had a diameter of 0.5 mm or less, whereas some were larger PMPs and/or PMP aggregates. In 
addition, adherent P-selectin+ PMPs colocalized with PSGL-1 on the Treg membrane (Figure 2G).
Then, we focused attention on platelet-associated immune signalling molecules. Because 
CD40-CD40L costimulation has been implicated in PMP-mediated signaling23, we 
investigated the involvement of this pathway. However, neutralization of CD40 in culture 
with an antagonistic anti-CD40 mAb did not reduce the inhibitory effect of PMPs on Tregs 
(supplemental Figure 10).
Platelet factor 4 (PF4/CXCL4), predominantly expressed by platelets, is a CXCR3 ligand 
and triggers CXCR3-mediated signalling in activated T cells31 leading to inhibition of 
proliferation and IFN-γ secretion32. Moreover, PF4 was found to be a negative regulator of 
Th17 differentiation33. We therefore assessed CXCR3 expression on Tregs during culture 
and performed CXCR3 neutralization experiments. CXCR3 expression increased upon 
Treg activation (Figure 3A-C), and CXCR3 neutralization using an antagonistic CXCR3 mAb 
reduced the inhibitory effect of PMPs on the generation of IL-17–producing cells (Figure 3D).
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PMPs selectively target CCR61HLA-DR1 memory-like and IL-17–producing Tregs
Only a subset of peripheral blood–derived Tregs produces IL-17 upon stimulation9-13. Insight 
into the features of this subset might guide us in the characterization and regulation of these 
cells. Sparked by the observation that the PMPs only associated with a subset of the Tregs 
(Figure 2B), while inhibiting IL-17 production, we argued that we might use this characteristic 
to pinpoint the IL-17 precursors within the whole Treg population.
To establish the identity of the Treg subset(s) targeted by the PMPs, and to determine 
whether this interaction occurs before Treg differentiation progresses, we followed PMP 
binding to Treg in time during a 7-day culture (Figure 4). Binding of PMPs to Tregs already 
occurred within 1 day of culture (Figure 4A). Concomitantly, an increase in the expression of 
the P-selectin ligand PSGL-1 was observed (Figure 4A). 
CCR6-positive Tregs constitute a memory-like phenotype28 that was found to harbor the 
majority of Tregs with potential IL-17–producing capacity9,10,20. Therefore, we assessed 
CD41 and CCR6 expression on the Tregs over time, combined with HLA-DR, which defines 
an activated Treg subset12,34. Strikingly, a strong binding preference of PMPs was observed 
for CCR6+HLA-DR+ double-positive, but not single-positive, Tregs throughout days 1 to 7 of 
culture (Figure 4B-C). IL-17–producing cells were positive for both CCR6 and HLA-DR and 
expressed the TH17-associated transcription factor RORγT (supplemental Figure 11). Further 
phenotyping of the CD41+Treg revealed that the majority expressed the functional Treg 
marker CD3935 and contained a higher proportion of CD161+ cells (data not shown), associated 
with potential IL-17–producing capacity36. Coculture of Tregs with PMPs reduced Treg 
proliferation, particularly in CCR6+HLA-DR+Tregs (Figure 4D). 
This provides a potential mechanism by which CCR6+HLA-DR+Treg differentiation into IL-17-
producing cells is inhibited. Finally, sorted CCR6+ and CCR6- Treg populations were cultured 
with and without PMPs (supplemental Figure 12). As expected, IL-17- and IFN-γ-producing 
Tregs were predominantly found in the CCR6+ Treg population (supplemental Figure 12B). 
Coculture of CCR6+ Treg with PMPs effectively inhibited the generation of IL-17- and IFN-γ-
producing Tregs (supplemental Figure 12B), prevented the loss of FOXP3, and secured the 
suppressive capacity (supplemental Figure 12C-D).Figure 4. PMPs selectively target CCR6+HLA-DR+ Treg prior to, and during, activation. Treg were isolated from healthy 
donors and cultured for 7 days with anti-CD3/anti-CD28-mAb-coated beads, recombinant human IL-2, IL-15, IL-1β and 
1.5×106 allogeneic PMPs isolated from platelet apheresis units of three healthy donors. Treg were stained for surface 
markers and analyzed by flow cytometry at day 0, 1, 4 and 7. (A) CD41+ PMP-bound Treg (n=5 Treg donors), and the 
expression level of PSGL-1 on the Treg (n=3 PMP donors). (B) CCR6+HLA-DR+ Treg present in the CD41- and CD41+ 
subpopulations. (C) Example CCR6/HLA-DR dot plots of PMP-negative (CD41 ) and PMP-positive (CD41+) Treg. Mean 
and SD for three PMP donors are shown. *P<0.05. Results representaive for five Treg donors are shown. (D) Day 7 cell 
proliferation of PBSE-labeled Treg co-cultured with and without PMPs was assessed. The division index, proliferation 
index and percentage of divided cells were determined for total Treg and CCR6+HLA-DR+ Treg using FlowJo 7.6. Results 
are shown for Treg cultured alone and Treg co-cultured with PMPs of three different PMP donors.
231230
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Evidence for CD41+P-selectin+ Tregs in the circulation
To provide evidence for human in vivo relevance of Treg/PMP interaction, we investigated the 
presence of PMP-bound Tregs in the circulation. We established that ~8% of the peripheral 
blood Tregs from healthy individuals (n=17) were CD41 and P-selectin double positive (Figure 
5). Subsequently, we examined PMP-Treg binding in patients known to exhibit enhanced 
platelet activation and PMP formation in the circulation29,37-39, ie, HIV-infected adults on 
stable combination antiretroviral therapy (n=20) and patients with ACS (n=10).We confirmed 
higher numbers of (PS+CD41+P-selectin+) PMPs in plasma of ACS patients (1.17x107± 0.93x107/
mL) and HIV-infected individuals (6.2 x 107 ± 3.16 x 107/mL) compared with healthy volunteers 
(0.35 x 107 ± 0.36 x 107/mL). Notwithstanding the higher patient PMP levels, we found similar 
percentages of PMP-bound Tregs in peripheral blood compared with healthy individuals 
(Figure 5B). However, we did observe significantly less binding of HIV patient plasma PMPs 
to healthy control Tregs (Figure 6), whereas binding of PMPs from healthy individuals to 
Tregs of HIV-infected adults was comparable to their binding to Tregs of healthy volunteers 
(supplemental Figure 13). This suggests altered PMP binding capacity in these patients.
Discussion
Tregs constitute an essential component in the maintenance of tissue homeostasis and the 
prevention of (auto)inflammatory processes. Dysregulation of Treg function is associated 
with a myriad of pathologies (e.g. psoriasis, multiple sclerosis, rheumatoid arthritis, and graft-
versus-host disease)7,8,40. We and others have shown that Tregs may produce IFN-γ and IL-17 
when stimulated under proinflammatory conditions9-13 and that these differentiated cells are 
found at sites of inflammation19,41. 
In our search for immunomodulatory components that influence the Treg differentiation 
process, we hypothesized that PMPs might constitute a relevant force. Like their parental cells, 
PMPs are involved in hemostasis, maintenance of vascular health, and immunity3,6,21,23,29,30,42.
Here, we report that PMPs have the capacity to prevent the differentiation of Tregs into 
IL-17- and IFN-γ-producing cells, even in the presence of proinflammatory cytokines. The 
mechanism of action consists of rapid and selective P-selectin-dependent binding of PMPs to 
a specialized CCR6+HLA-DR+ memory-like Treg subset that is known to contain the majority of 
progenitor Th17-like cells10,20, disrupting their proliferation and eventual differentiation into IL-
17 producers. The few Tregs with bound PMPs that did acquire IL-17-producing capacity, were 
in a FOXP3+IL-17+ transitory state, likely due to the inhibitory effect of the PMPs. In addition, 
we found evidence for PMP-bound human Tregs in the circulation, suggesting a physiological 
function of this process.
Figure 5. Detection of CD41+P-selectin+ Treg in peripheral blood of healthy volunteers, HIV-infected adults and 
patients with acute coronary syndrome. Flow cytometry analyses of peripheral blood obtained from patients with 
acute coronary syndrome (ACS, n=10), HIV-infected adults on stable combination antiretroviral therapy (n=20) and 
healthy volunteers (HV, n=17) for surface CD4, CD127, CD25, CD41, P-selectin and intracellular FOXP3 expression. 
(A) Representative example of CD4+CD25highCD127lowFOXP3+ Treg gating and their exposure of CD41 and P-selectin in 
peripheral blood of a healthy volunteer. (B) Percentage of CD41 and P-selectin double positive Treg in peripheral blood 
of ACS patients, HIV-infected adults and healthy volunteers.
Figure 6. Reduced binding of plasma-derived PMPs from HIV-infected adults to Treg. Treg isolated from five healthy 
donors were cultured for 16 hours with recombinant human IL-2 in the presence or absence of total microparticle 
fractions isolated by differential centrifugation from platelet poor plasma of patients with acute coronary syndrome 
(ACS, n=3), HIV-infected adults on stable combination antiretroviral therapy (HIV, n=3) and healthy volunteers (HV, 
n=3). Treg were stained for surface CD4, CD25, CD41, P-selectin and intracellular FOXP3 and analyzed by flow cytometry. 
(A) Dot plots show the percentage of CD41 and P-selectin double positive CD4+CD25highFOXP3+ Treg. The dot plots were 
generated using merged data of three plasma microparticle donors. (B) The percentage of CD41 and P-selectin double 
positive Treg (n=3 plasma microparticle donors). Representative results are shown. *P<0.05
233232
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platelets, triggers CXCR3-mediated signalling in activated T cells31, leading to inhibition 
of proliferation and IFN-γ secretion32, and was found to be a negative regulator of Th17 
differentiation33. Other possibilities include the transfer of genetic information from PMPs 
to Tregs5 or the initiation of Treg–Treg signalling by PMPs binding to multiple Tregs30. The 
involvement of other adhesion molecules should also be considered, as exemplified by the 
ability of CD18 to keep Treg differentiation into IL-17–producing cells in check51.
Most PMPs in the circulation do not originate from platelets but are produced by 
megakaryocytes in the bone marrow52,53. These megakaryocyte-derived microparticles are 
abundant in healthy individuals3, whereas PMPs, identified by the expression of platelet 
activation markers P-selectin and/or CD63, are only observed during disease29,42. This implies 
that although megakaryocyte-derived microparticles have a more systemic function, PMPs may 
act locally at sites of platelet activation and that each has its own distinct role in homeostasis.
Apparently, different platelet activation stimuli can yield regulatory PMPs, as we observed that 
PMPs formed by TRAP-activated washed platelets were as able as stored platelet concentrate–
derived PMPs to curb Treg differentiation. We started out by using platelet apheresis units as 
the main source for our PMPs, because they are known to generate relatively large quantities 
of PMPs in a controlled and sterile environment24. The majority of the isolated PMPs was 
P-selectin positive and thus originated from activated platelets in the concentrates. Therefore, 
our findings also add to the understanding of PMPs in platelet transfusion medicine, of which 
little is known thus far54.
Platelets55 and their microparticles6 have been reported to exert a proinflammatory function 
in the autoimmune diseases lupus and rheumatoid arthritis, respectively. However, a recent 
study shows that platelets can exert either a pro- or anti-inflammatory effect, depending on the 
type of inflammatory response they encounter2. This observation, together with the alternative 
origin of the PMPs and a distinct cellular target (Tregs), could explain why we observe an anti-
inflammatory effect instead. Of interest is our finding that binding of plasma-derived PMPs 
from HIV-infected individuals to Tregs was diminished in vitro. This suggests altered PMP 
binding, which although not directly obvious in peripheral blood, may be of relevance in the 
local tissue environment. Of note, increased IL-17 production by classical and nonclassical T 
cells is an increasingly recognized feature in HIV patients56,57.
In conclusion, we have identified a novel function of PMPs to selectively bind a specialized 
subset of Th17-like progenitor cells in the Treg compartment and inhibit their differentiation 
into potentially pathogenic effector cells. The direct involvement of the cell adhesion molecule 
P-selectin and its ligand PSGL-1 in this process suggests a role for PMPs in wound healing by 
participating in the regulation of the required inflammatory response.
Leukocytes play a central role in wound repair and are recruited after coagulation and the 
resulting vascular inflammation have been initiated43. PSGL-1 is expressed on most leukocytes 
and mediates
their recruitment to inflamed endothelium by binding P- and E-selectin on activated 
endothelial cells44. P-selectin exposure by adherent activated platelets further assists leukocyte 
recruitment to the inflamed tissue1. Moreover, activated platelets release P-selectin+PMPs29, 
which also accumulate at sites of (vascular) injury21, and are able to bind PSGL-1+ leukocytes30. 
We show that PMPs can bind peripheral PSGL-1+memory-like Tregs through P-selectin-
mediated adhesion, possibly participating in their recruitment to sites of injury. Tregs were 
indeed found to be involved in local tissue repair by restricting the proinflammatory response 
in a lung injury mouse model45. In patients with systemic vasculitis, vascular infiltration of 
Th17 and Th1 cells was enhanced, and fewer Tregs were observed in the lesions46. Interestingly, 
FOXP3+ cells were shown to contribute to the IL-17 production in vascular lesions of these 
patients41. Our observations raise the tantalizing possibility that PMPs might assist in the 
control and eventual resolution of inflammation during tissue repair by stabilizing the Treg 
phenotype and preventing their differentiation into Th1 or Th17-like cells in a proinflammatory 
microenvironment. One could argue that PMPs can easily enter inflamed tissue due to their 
small size and ability to interact with leukocytes, allowing them to hitchhike to the site of 
inflammation to exert their regulatory function. Increased PSGL-1 expression was observed 
on all Tregs, concomitantly with PMP binding upon Treg activation. Nevertheless, the PMPs 
showed a high preference for CCR6+HLA-DR+Tregs, suggesting additional requirements 
for effective PMP binding. A possible explanation for this differential binding is that 
glycosyltransferases required to modify PSGL-1 to its active binding state are upregulated only 
upon T-cell activation47.
PSGL-1 engagement induces downstream signalling events that affect T-cell phenotype and 
function44. Deletion of PSGL-1 increased T-cell proliferation and exacerbated inflammation in 
vivo48. We also show that PMPs affect Treg proliferation, in particular within the CCR6+HLA-
DR+ subpopulation that was preferentially targeted by PMPs. Thus, cell proliferation may 
be one of the mechanisms by which PMPs prevent IL-17 production by Tregs, which requires 
sufficient proliferation9. Previously, activated washed platelets were shown to attenuate T-cell 
proliferation49,50; in our coculture system, we show that TRAP-activated washed platelets can 
inhibit proinflammatory cytokine production by Tregs. This might be due, at least in part, 
to PMP formation during coculture. Other scenarios that might explain the inhibitory effect 
include the involvement of additional signalling pathways next to PSGL-1.
Our finding that CXCR3 signalling may be involved to a certain extent validates this line of 
thinking and deserves further attention, particularly because PF4, primarily expressed by 
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Transwell assay and CD40 and CXCR3 neutralization
CD40 and CXCR3 neutralization on Treg was performed by the addition of an antagonistic 
anti-CD40 mAb kindly provided by Dr. M. de Boer (1 µg/mL; Tanox Pharma B.V., Amsterdam, 
The Netherlands) or an antagonistic anti-CXCR3(Ab89255) mAb (1 µg/mL; Abcam, Cambridge, 
UK) 1 hour before the addition of PMPs. ThinCerts™ cell culture inserts (0.4 µm; Greiner Bio-
one, Wemmel, Belgium) for 24-well flat-bottom plates were used for the transwell assay, 
with the cells and the PMPs placed in the upper and the lower compartments, respectively.
Confocal laser scanning microscopy
Treg co-cultured with PMPs for 16 hours in the presence of anti-CD3/anti-CD28-coated-beads 
and recombinant human IL-2 were stained with CD41(P2)-FITC or anti-P-selectin(AK-4)-FITC 
and CD25(M-A251)-APC or PSGL-1(FLEG)-APC mAb antibodies, resuspended in HBS buffer 
pH 7.4 (10 mM HEPES, 135 mM NaCl, 5 mM KCl, 5 mM MgCl2, 1.8 mM CaCl2) and plated in 
8-well microscopy chambers (Nunc, Wiesbaden, Germany). Images were acquired with a 
TCS SP5 confocal microscope (Leica Microsystems, Mannheim, Germany) equipped with a 
HCX-PL-APO 63×1.2 water immersion lens while cells were maintained at 37°C. Leica LAS AF 
acquisition software was used.
FOXP3 gene methylation
Genomic DNA was isolated from Treg using the QIAamp DNABlood Mini kit (Qiagen, Hilden, 
Germany), treated by the EpiTect Bisulfite kit (Qiagen) and amplified using bisulfite-specific 
polymerase chain reaction (PCR) (forward 5’ TGGATATTTGGTTAGAGTTAAGAAT 3’ and reverse 
5’ ACCTAACACTCTCAAAACTTCAAAC 3’). The purified PCR product was labeled using BigDye 
Terminator version 1.1 Cycle Sequencing (Life Technologies, Carlsbad, Germany), purified 
using Sephadex G-50 FineDNA Grade (GE Healthcare, Little Chalfont, United Kingdom), 
sequenced on an ABI 3130 Genetic Analyzer (Life Technologies), and analyzed using 
Sequencing Analysis version 5.4 software (Life Technologies).
Washed platelet isolation and activation
Washed platelets (WP) were obtained from freshly collected whole blood of healthy donors 
anticoagulated with 3.2% sodium citrate (Becton Dickinson, Franklin Lakes, NJ) upon written 
informed consent. Whole blood was centrifuged for 15 min at 156g without brake to obtain 
platelet-rich-plasma (PRP). PRP was supplemented with 10% acid citrate dextrose (ACD) 
and centrifuged twice at 330g without brake for 20 min. The pellets were resuspended 
in 0.22 μm filtered HEPES tyrode (HT) buffer (NaCl 145mM, KCl 5mM, Na2HPO4 0.5mM, 
MgSO4 1mM, HEPES 10mM, Glucose 5mM, pH 7.3). Prostacyclin (10ng/ml; PGI2, Cayman 
Chemical, Ann Arbor, MI) was added after the first wash step to prevent platelet activation 
during centrifugation. After isolation washed platelets were rested for 60 min at 37°C. WP 
(100×109/L) were activated for 30 min with Thrombin Receptor Activator Peptide 6 (100μM; 
Supplementary methods
Antibodies
The following conjugated mAbs were used for flow cytometry of Treg: 
Surface - CD4(MT310)-FITC, CD27(M-T271)-FITC (DAKO), CD25(M-A251)-PE or APC, CCR6(11A9)-
PE, CXCR3(1C6/CXR3)-PE-Cy5 (BD Biosciences), CXCR3(G025H7)-APC-Cy7, CD27(O323)-APC-
Cy7, CD39(A1)-BV421, CD41(HIP8)-PerCP-Cy5.5 (BioLegend, San Diego, CA), PSGL-1(FLEG)-
APC, CD25(BC96)-PE-Cy7, CD127(eBioRDR5)-PE-Cy7 (eBioscience, Uithoorn, The Netherland), 
CD4(SFCI12T4D11)-ECD, PE-Cy7 or PB, CD27(1A4CD27)-PE-Cy5.5, CD41(P2)-FITC or PE, 
CD62L(DREG56)-ECD, CD127(R34.34)-APC-AlexaFluor700, HLA-DR(Immu-357)-ECD (Beckman 
Coulter) and CD161(191B8)-APC (Miltenyi).
Intracellular - FOXP3(PCH101)-FITC or eFluor660, IL-17A(EBIO64DEC17)-AlexaFluor647 or 
APC-eFluor780, IFN-γ(4S.B3)-PE-Cy7, RORγt(AFKJS-9)-APC (eBioscience) and T-bet(4B10)-PE 
(Santa Cruz Biotechnology, Santa Cruz, CA).
PMP analysis using state-of-the-art flow cytometry
PMP purity/quantity was assessed using an optimized microparticle detection protocol (see 
Figure S1) on the GalliosTM flow cytometer (Beckman Coulter) adapted from a widely used 
method of Lacroix, Dignat-George and colleagues  . Combined Annexin V-FLUOS (Roche, 
Basel, Switzerland) or Annexin V-AlexaFluor647 (Invitrogen) and anti-CD41(P2)-FITC, PE 
(Beckman Coulter) or anti-CD41(HIP8)-PerCP-Cy5.5 (BioLegend) mAb staining was used to 
identify PMPs. Additional mAbs used for PMP characterization were: P-selectin(AK-4)-FITC 
mAb (eBioscience), CD40(5C3)-PE (BD Biosciences) and CD63(H5C6)-PE-Cy7 (BioLegend). 
All staining solutions were centrifuged at 20.000g and 4ºC for 20 min prior to use to remove 
fluorescent aggregates. Matched isotype controls were used to assess aspecific staining.
Size exclusion gating for PMPs was based on measurements using G100, G250, G500 Fluoro-
Max Dyed Green Aqueous Fluorescent Particles (100, 250 and 500 nm; Duke Scientific Corp, 
Palo Alto, CA) and sulfate latex microspheres (900 nm; Invitrogen). Noise was excluded 
and washed Flow-Count Fluorospheres (~10 µm; Beckman Coulter) were added for PMP 
quantification (identified based on size and fluorescence). 
PMP-associated P-selectin neutralization
P-selectin neutralization was performed by incubating PMPs for 30 min at room temperature 
in calcium-free Ringer’s solution containing anti-P-selectin(AK-4)-FITC mAb (eBioscience), 
which is known to neutralize P-selectin (Li et al, J.Surg.Res. 1996;61:543-548). PMPs were 
pelleted by centrifugation and washed with calcium-free Ringer’s solution.
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for 20 min to obtain platelet poor plasma (PPP). The PPP was divided in 1 mL aliquots and 
centrifuged for 20 min at 20.000g to pellet microparticles. The microparticle pellet was then 
resuspended in ~10 µL PPP, snap-frozen with liquid N2, and stored at -80°C. Upon thawing 
microparticles were washed with 0.22 µm filtered calcium-free Ringer’s solution and 
analyzed as described for PMPs above.
For co-culture with Treg, microparticles were thawed and washed once with culture medium, 
before being cultured for 16h with Treg in culture medium containing recombinant human 
IL-2. PMP (CD41+P-selectin+) binding to Treg was assessed as described in Methods.
TRAP; Sigma-Aldrich, Zwijndrecht, The Netherlands). After stimulation WP were diluted and 
resuspended in culture medium.
PMP generation by washed platelets
For PMP generation from freshly isolated WP, 2.5 mM calcium was added to WP (100×109/L) 
together with TRAP (100μM) in 0.22 μm filtered HT buffer and stimulated for 1 hour on a 
rolling device (shear stress) for optimal PMP generation. Subsequently, WP were diluted in 
0.22μm filtered HT-buffer and PMPs were isolated as described earlier and washed using 
0.22μm filtered calcium-free Ringer’s solution. The TRAP generated PMPs were resuspended 
in filtered calcium-free Ringer’s solution, snap-frozen with liquid N2 and stored at -80°C until 
use. Microparticle purity and quantity were assessed by flow cytometry as described earlier.
Suppression assay
The suppressor capacity of regulatory cells was studied in a co-culture suppression assay. 
FACS sorted CCR6+ Treg cultured with and without PMPs for 7 days (as described in Methods) 
were washed and rested overnight in fresh culture medium containing 25 U/mL recombinant 
human IL-2. Autologous CD4+CD25- T cells (2.5×104, from frozen) were stimulated with 
anti-CD3/anti-CD28-coated beads (Invitrogen, Breda, The Netherlands) in a bead:cell ratio 
of 1:5, in the absence or presence of increasing numbers of Tregs. T cell proliferation was 
analyzed by [3H]-thymidine incorporation using a Gas Scintillation Counter (Matrix-96 Beta-
counter; Canberra-Packard, Meriden, CT). To this end, 0.037 MBq (1 Ci) [3H]-thymidine (ICN-
Pharmaceuticals, Irvine, CA) was added to each well, cells were harvested after 8 hours of 
culture, and [3H]-thymidine incorporation was measured. The [3H]- thymidine incorporation 
is expressed as mean plus or minus SD counts per 5 minutes of at least triplicate 
measurements.
Peripheral blood staining
The following conjugated mAbs were used: CD4(RPA-T4)-APC-H7, CD25-BB515 (BD 
Biosciences), CD41(HIP8)-PE-Cy7, CD127(eBioRDR5)-PerCP-Cy5.5, FOXP3(PCH101)-eFluor660 
(eBioscience) and P-selectin(AK-4)-PE (BioLegend). In brief, 200 μL blood was incubated with 
antibodies for 40 min. Intracellular staining for FOXP3 was performed after simultaneous 
red blood cells lysis and leukocyte fixation/permeabilization using 1 mL Fix/Perm reagent 
(eBioscience). Cells were then analyzed within 2 hours using the NaviosTM (Beckman 
Coulter) or LSRII (BD Biosciences) flow cytometers.
Plasma-derived microparticle isolation and co-culture with Treg
Plasma-derived microparticles were isolated from patient and healthy volunteer peripheral 
blood (EDTA) under sterile conditions using differential centrifugation. In brief, the 
peripheral blood was centrifuged at 1000g for 5 min. Plasma was then centrifuged at 1500g 
243242
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Chapter 8 - Platelet microparticles inhibit treg plasticity
Figure S5. PMPs are enriched on IL-17+FOXP3+ compared to IL-17+FOXP3-cells. Treg were isolated from six healthy 
donors and cultured for 7 days with anti-CD3/anti-CD28-mAb-coated beads and recombinant human IL-2, IL-15, and IL-
1β in the presence or absence of 1.5×106 allogeneic PMPs isolated from platelet apheresis units of three healthy donors. 
Surface CD41 staining and intracellular FOXP3, IL-17 and IFN-γ staining was performed after stimulation with PMA and 
ionomycin, in the presence of Brefeldin A. Example IL-17/FOXP3 density plots of all cells and CD41- and CD41+ Treg are 
shown. A density plot of Treg cultured without PMPs is shown as reference. Each donor’s Tregs are plotted as a separate 
data series (line) representing the mean response of those Tregs to the three different donor’s PMPs. *P<0.05
Figure S3. CD4+CD25highCD27+CD127lowFOXP3+ Treg cell sorting. After CD4+ T cell isolation from PBMCs by magnetic 
bead sorting, CD4+CD25high T cells were purified by fluorescence-activated cell sorting. The sorted cells were checked for 
surface CD4, CD25, CD27, CD62L, CD127, CCR6, and intracellular FOXP3 expression. A representative example of the flow 
cytometry analyses of these cells is shown. 
Figure S4. PMPs prohibit CpG methylation in the Treg cell-specific demethylation region of the FOXP3 gene. CpG 
methylation in the Treg cell-specific demethylation region of the FOXP3 gene in freshly isolated Treg (n=3 donors) and Treg that 
were cultured for 7 days with anti-CD3/anti-CD28-coated beads and recombinant human IL-2, IL-15, and IL-1β in the presence or 
absence of 1.5×106 allogeneic PMPs isolated from platelet apheresis units of three healthy donors (n=3 PMP donors).
247246
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Figure S8. Activated washed platelets also inhibit IL-17 production by Treg. Tregs were isolated from three healthy 
donors and cultured for 7 days with anti-CD3/anti-CD28-coated beads and recombinant human IL-2, IL-15 and IL-1β 
in the presence or absence of 1.5×106 allogeneic resting (WP) or TRAP-activated washed platelets (act WP) from three 
healthy donors. Flow cytometry analyses of surface CCR6, CD27 and intracellular IL-17 and IFN-γ were performed after 
stimulation with PMA and ionomycin in the presence of Brefeldin A. Each donor’s Tregs are plotted as a separate data 
series (line) with each data point representing the mean response of those Tregs to the three different donor’s platelets. 
*P<0.05
Figure S9. PMP inhibition of Treg differentiation is P-selectin-dependent. Treg were isolated from two healthy donors 
and cultured for 7 days with anti-CD3/anti-CD28-mAb-coated beads and recombinant human IL-2, IL-15, and IL-1β in the 
presence of allogeneic untreated or anti-P-selectin mAb-blocked PMPs isolated from platelet apheresis units of three 
healthy donors. Flow cytometry analyses of surface CCR6 and CD62L and intracellular FOXP3 and IFN-γ were performed 
after stimulation with PMA and ionomycin in the presence of Brefeldin A. Mean and SD from a representative Treg donor 
are shown. *P<0.05. 
Figure S6. PMPs from fresh platelet apheresis units also inhibit IL-17 and IFN-γ production by Treg. Tregs were isolated 
from three healthy donors and cultured for 7 days with anti-CD3/anti-CD28-coated beads and recombinant human IL-2, 
IL-15 and IL-1β in the presence or absence of 1.5×106 allogeneic PMPs isolated from two-day (fresh) or seven-day stored 
platelet apheresis units from three healthy donors. Flow cytometry analyses of surface CCR6, CD27 and intracellular IL-17 
and IFN-γ were performed after stimulation with PMA and ionomycin in the presence of Brefeldin A. Each donor’s Tregs 
are plotted as a separate data series (line) with each data point representing the mean response of those Tregs to the 
three different donor’s PMPs.
Figure S7. PMPs produced by TRAP-activated platelets also inhibit IL-17 production by Treg. Tregs were isolated from 
three healthy donors and cultured for 7 days with anti-CD3/anti-CD28-coated beads and recombinant human IL-2, IL-15 
and IL-1β in the presence or absence of 1.5×106 allogeneic PMPs isolated from a stored platelet apheresis concentrate or 
from TRAP-activated washed platelets from three healthy donors. Flow cytometry analyses of surface CCR6, CD27 and 
intracellular IL-17 and IFN-γ were performed after stimulation with PMA and ionomycin in the presence of Brefeldin A. 
Each donor’s Tregs are plotted as a separate data series (line) with each data point representing the mean response of 
those Tregs to the three different donor’s PMPs. *P<0.05
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Figure S11. IL-17-producing cells co-express CCR6 and HLA-DR. Treg were isolated from five healthy donors and 
cultured for 7 days with anti-CD3/anti-CD28-mAb-coated beads and recombinant human IL-2, IL-15, and IL-1β. Flow 
cytometry analyses of surface CCR6 and HLA-DR and intracellular IL-17, IFN-γ, FOXP3, RORγt and T-bet were performed 
after stimulation with PMA and ionomycin in the presence of Brefeldin A. (A) Density plots showing the CCR6 and HLA-
DR expression of IL-17-negative and IL-17-positive cells. (B) Density plots showing IL-17, RORγt, FOXP3, IFN-γ and T-bet 
expression. Representative results are shown.
Figure S10. CD40 neutralization does not affect PMP inhibition of Treg differentiation. Treg were isolated from two 
healthy donors and cultured for 7 days with anti-CD3/anti-CD28-mAb-coated beads, recombinant human IL-2, IL-15, and 
IL-1β and allogeneic PMPs isolated from platelet apheresis units of three healthy donors in the presence or absence of 
anti-CD40 antagonistic mAb. Flow cytometry analysis of intracellular IL-17 was performed after stimulation with PMA 
and ionomycin in the presence of Brefeldin A. Mean and SD from a representative Treg donor are shown.
251250
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Figure S13. Ex vivo PMP binding to Treg is not affected by HIV-infection. CD4+ T cells isolated from peripheral blood of 
HIV-infected adults on stable combination antiretroviral therapy (n=4) and of healthy volunteers (HV, n=5) were cultured 
for 16 hours with recombinant human IL-2 in the presence or absence of 1.5×106 allogeneic PMPs isolated from platelet 
apheresis units of three healthy donors. Flow cytometry analyses of CD4, CD127, CD25 and CD41 was performed. (A) 
Example of CD41+ (PMP bound) CD4+CD25highCD127low/- Treg gating. (B) Percentage of CD41+ Treg of HIV-infected adults 
and of healthy volunteers. Each patient’s and healthy volunteer’s Tregs are shown as a data point representing the mean 
response of those Tregs to the three different donor’s PMPs.
Figure S12. Suppression of T cell proliferation by CCR6+ Treg cultured with and without PMPs. CCR6+ and CCR6- FACS 
sorted Treg from two healthy donors were cultured for 7 days in the presence of anti-CD3/anti-CD28-coated-beads and 
recombinant human IL-2, IL-15 and IL-1β in the presence or absence of 1.5×106 allogeneic PMPs isolated from platelet 
apheresis units of three healthy donors. (A) CCR6 expression on CCR6+ and CCR6- sorted Treg on day 0. (B) Intracellular 
Treg expression of IL-17 and IFN-γ as assessed by flow cytometry on day 7. After 7 days the cultured CCR6+ Treg were 
washed and rested for a single day in fresh culture medium containing IL-2, after which a [3H]-thymidine-based Treg 
suppression assay was performed using autologous CD4+CD25- responder cells as described in Methods. (C) Mean and 
SD of percent suppression of responder cell proliferation by CCR6+ Treg cultured with and without PMPs (n=3 donors) 
is shown. (D) Intracellular expression of IL-17 and FOXP3 by cultured CCR6+ Treg as assessed by flow cytometry on day 
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Chapter 9 - Platelet inhibitors modulate systemic inflammation
Introduction
Platelet aggregation inhibitors are the pharmacological cornerstone in the primary and 
secondary prevention of cardiovascular events. In addition, it is increasingly recognized that 
platelets have potent immunomodulatory properties. Platelets respond to inflammatory 
stimuli by release of chemokines1, and expression of P-selectin and CD40 ligand, which 
are important regulators of platelet-leukocyte interactions2. The commonly used platelet 
aggregation inhibitors acetylsalicylic acid (ASA) and the P2Y12 receptor inhibitors (such as 
ticagrelor and clopidogrel) potentially interfere with these immunological effects and may 
thereby influence the clinical outcome of patients that encounter a severe infection. 
Several cohort studies have evaluated the association between acetylsalicylic acid treatment 
and outcome in patients with sepsis and pneumonia (summarized in Supplemental Table 
1). Acetylsalicylic acid (ASA) treatment has been associated with a reduced mortality in 
patients with sepsis admitted to the Intensive Care Unit (ICU) in four large cohort studies3-6. 
Furthermore, in a smaller study, the combination of ASA with macrolide treatment was 
associated with reduced mortality in patients with pneumosepsis7. Only one study did not 
identify an association of platelet inhibitory therapy with mortality in ICU patients with 
sepsis, but this study also included patients on alternative platelet inhibitors than ASA8. ASA 
treatment in patients with community acquired pneumonia has also been associated with a 
reduced need for ICU admission9 and mortality10.
Clinical data on the immunomodulatory effects of P2Y12 receptor inhibitors is sparse. 
Treatment with clopidogrel added to ASA is associated with attenuated inflammatory 
markers in patients following coronary interventions11,12 and other studies have demonstrated 
that clopidogrel use is associated with increased incidence of pneumonia13 and post-coronary 
artery bypass surgical site infections14. A post-hoc analysis of the Platelet inhibition and 
patient Outcomes (PLATO) trial suggested a reduced mortality after pulmonary infections 
and sepsis in patients treated with ticagrelor and ASA, compared to patients treated with 
clopidogrel and ASA15, although a beneficial effect on sepsis-related mortality of ticagrelor 
was not confirmed in a more recent randomized trial16. 
The immunomodulatory effects of platelet inhibitors have been investigated in more 
detail in experimental models of inflammation. Seemingly counterintuitive, inhibition of 
cyclooxygenase (COX) augmented cytokine release. A three day treatment with 650 mg ASA 
in healthy volunteers augmented the ex vivo cytokine response of whole blood stimulated 
with lipopolysaccharide (LPS)17, and treatment with COX inhibitors amplified the pro-
inflammatory response after in vivo LPS administration in mice18 and healthy volunteers19,20.
Abstract
The use of acetylsalicylic acid (ASA) is associated with improved outcome in patients with 
sepsis, and P2Y12 inhibitors have been suggested to also have immunomodulatory effects. 
Therefore, we evaluated the effects of clinically relevant combinations of antiplatelet 
therapy on the immune response in experimental endotoxemia in humans in vivo. 40 
healthy subjects were randomized to seven days of placebo, placebo with ASA, ticagrelor 
and ASA, or clopidogrel and ASA treatment. Systemic inflammation was elicited at day 
seven by intravenous administration of Escherichia coli endotoxin. ASA treatment profoundly 
augmented the plasma concentration of pro-inflammatory cytokines, but did not affect 
anti-inflammatory cytokines. Addition of either P2Y12 antagonist to ASA did not affect any of 
the circulating cytokines, except for an attenuation of the ASA-induced increase in TNFα by 
ticagrelor. Systemic inflammation increased plasma adenosine, without differences between 
groups, and although P2Y12 inhibition impaired platelet reactivity, there was no correlation 
with cytokine responses. 
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USA)). Endotoxin was administered as a bolus of 1 ng/kg, followed by continuous infusion at 1 
ng/kg/h for three hours. Blood was obtained before study treatment, immediately before LPS 
administration, and every hour until eight hours afterwards with an extra blood withdrawal 
at 1.5h after initiation of LPS administration.
Cytokine measurement
Plasma concentration of the cytokines TNFα, IL-6, IL-8, IL-10 and IL-1 receptor antagonist (IL-
1RA) and the chemokines macrophage inflammatory protein (MIP)-1α, MIP-1β and monocyte 
chemoattractant protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), 
were determined batchwise in Ethylenediaminetetraacetic-(EDTA) anticoagulated plasma 
by a multiplex immunoassay assay according to the manufacturer’s instructions (Bio-Plex, 
BioRad, Hercules, USA and Milliplex, Millipore, Billerica, USA). 
Plasma adenosine
Plasma adenosine levels were determined as previously described23 (see Supplemental 
Methods). 
Assessment of P2Y12 inhibition and platelet activation and responsiveness
Specific effectiveness of P2Y12 inhibition was determined by the level of phosphorylation 
of vasodilator-stimulated phosphoprotein (VASP) in citrated blood using an ELISA-based 
assay (CY-QUANT VASP/P2Y12, BioCytex, Marseille, France) according to manufacturer’s 
instructions. P2Y12 inhibition is expressed as platelet reactivity index (PRI%), with a value 
<50% considered as adequate platelet inhibition. Platelet activation and responsiveness 
were assessed in whole blood (see Supplemental Methods). Briefly, platelet responsiveness 
was assessed by ex vivo stimulation with either adenosine diphosphate (ADP, 3.4 or 125 μM) 
or crossed-linked collagen-related-peptide (CRP-XL, 39 or 625 ng/mL) and platelet expression 
of P-selectin, a measure of degranulation, was measured using flow cytometry. 
Platelet-leukocyte complexes
Platelet-leukocyte complex formation was determined using flow cytometry. Citrated whole 
blood was incubated with anti-CD61 (PC7; Beckman Coulter, Brea, CA, USA), anti-CD14 (ECD; 
DAKO, Heverlee, Belgium), anti-CD16 (FITC; Biolegend, San Diego, CA, USA) and anti-HLA-
DR (PC5; Beckman Coulter, Brea, CA, USA) within 2 hours after blood collection. Optilyse 
B (Beckman Coulter, Brea, CA, USA) was added after 20 minutes for fixation followed by 
distilled water for erythrocyte lysis. Monocytes and neutrophils were selected based on 
granularity (side-scatter, SS) and size (forward-scatter, FS) as well as their expression of CD16, 
CD14 and HLA-DR (see Supplemental Figure 1 for gating strategy). The platelet-monocyte and 
platelet-neutrophil complex formation were quantified based on the % of cells expressing 
the platelet marker CD61 on respectively monocytes (CD14-positive) and neutrophils 
In contrast, P2Y12 inhibitors exert anti-inflammatory effects. A single dose of ticagrelor in 
healthy volunteers mitigated ex vivo cytokine production by LPS-stimulated leukocytes21. 
Similarly, treatment with ticagrelor or clopidogrel attenuated circulating levels of pro-
inflammatory mediators tumor necrosis factor (TNF)α, interleukin (IL)-6, and chemokine 
ligand 2 during human endotoxemia22. Importantly, in contrast to clinical practice, the P2Y12 
inhibitors were not combined with ASA treatment in this study.
Taken together, epidemiological data indicate that treatment with ASA is associated with a 
beneficial outcome after sepsis. For P2Y12-inhibitors, data shows less consistent effects. To 
gain more insight into the immunomodulating properties of the various antiplatelet agents 
that are used for cardiovascular prevention, we aim to study the effect of low-dose ASA alone 
and in combination with the P2Y12 inhibitors clopidogrel and ticagrelor in a well-validated 
human in vivo model of systemic inflammation. 
Materials and methods
Study design, subjects and study procedures
This prospective randomized open-label, blinded endpoint study was performed according 
to the declaration of Helsinki, and registered by clinicaltrials.gov identifier NCT01978158. 
After approval of the local ethics committee (CMO Arnhem-Nijmegen, the Netherlands), 
forty healthy male volunteers aged 18-35 years, provided written informed consent and were 
included after screening. All subjects had normal physical examination, electrocardiography 
and routine laboratory values. The main exclusion criteria were medication use, recent febrile 
illness and increased bleeding risk. 
Randomization was performed after inclusion by opening of a sealed opaque envelope, 
prepared by a research nurse not involved in the study. Subjects were randomized to one 
of four study arms, i.e. ticagrelor (AstraZeneca, London, UK) and ASA (Apotex, Leiden, The 
Netherlands) (TA-group, n=10), clopidogrel (Sandoz, Berleben, Germany) and ASA (CA-
group, n=10), dummy capsules (‘placebo’, Apotheek Radboudumc, Nijmegen, the Netherlands) 
and ASA (PA-group, n=10), or placebo only (P-group, n=10). A detailed description of the 
study protocol is provided in the Supplemental Methods. Briefly, subjects were treated 
for seven days after a loading dose on day one. Loading dosages were 180, 300, and 160 
mg, and maintenance dosing schedules were 90 mg b.i.d., 75 mg q.d and 80 mg q.d for 
ticagrelor, clopidogrel, and ASA, respectively. Drug adherence was monitored by pill counts. 
The seventh day of study treatment, systemic inflammation was elicited by administration 
of purified lipopolysaccharide (US Standard Reference Endotoxin, Escherichia Coli O:113, 
Pharmaceutical Development Section of the National Institutes of Health (Bethesda, MD, 
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using GraphPad Prism version 5.03 (GraphPad Software, San Diego, USA). A two-sided p value 
<0.05 was considered statistically significant. 
Results
Subject inclusion and follow up, drug safety, compliance, and subject 
characteristics
The forty subjects that were included all completed the study (see CONSORT [Consolidated 
Standards of Reporting Trials] flow chart in Supplemental Figure 2). Study treatment was well 
tolerated. One subject treated with clopidogrel-ASA reported a spontaneous haematoma 
and one subject treated with ticagrelor-ASA experienced three days of mild dyspnea with 
preserved exercise tolerance (both Grade I). Treatment compliance was 100%. Demographic 
characteristics are listed in Table 1.








Age [y] 22 [20-28] 21 [19-24] 22 [21-24] 21 [20-21]
Height [cm] 183 [175-187] 186 [183-190] 180 [177-186] 186 [181-191]
Weight [kg] 77 [66-84] 83 [80-88] 72 [68-77] 83 [77-91]
BMI [kg/m²] 23 [21-25] 24 [23-26] 22 [21-24] 24 [22-25]
Data is presented as median [interquartile range]. y: years, cm: centimeter, kg: kilogram, BMI: body mass index, m: meter. 
Cytokine and chemokine response
Plasma cytokine and chemokine concentrations were below the lower detection limit of 
the assay before administration of LPS. LPS administration resulted in an increased plasma 
concentration of the cytokines Tumor Necrosis Factor (TNF)α, Interleukin(IL)-6, IL-8, IL-10, 
IL-1 receptor antagonist (IL-1RA), monocyte chemoattractant protein(MCP)-1, macrophage 
inflammatory protein(MIP)-1α and MIP-1β in all subjects (Figure 1). To evaluate the effects 
of low dose acetylsalicylic acid, we compared the cytokine response of subjects treated with 
ASA to the placebo treated group. 
Plasma levels of TNFα,IL-6, IL-8 and MIP-1α were increased to a greater extent in ASA treated 
subjects compared with the placebo group, and there was a trend towards enhanced levels of 
MCP-1. To evaluate whether addition of ticagrelor or clopidogrel further affected the systemic 
inflammatory response, we compared the cytokine response of the ASA group with the 
ticagrelor-ASA group and the clopidogrel-ASA group. Only for TNFα, addition of ticagrelor 
(CD16high,CD14low, HLA-DR negative). It is known that the amount of PMC’s measured 
depend on the time window between blood withdrawal and analysis. Due to variation in time 
from blood withdrawal to analysis between time points, data are only suitable to compare 
groups per time point, and not to evaluate changes in time within groups. 
Plasma thromboxane
Plasma thromboxane B2 (the stable metabolites of thromboxane A2) was measured in 
citrated plasma in the placebo and placebo-ASA groups using an ELISA (Thromboxane B2 EIA 
Kit, Oxford Biomedical Research, Oxford, USA). 
Leukocyte and platelet counts
Platelet and leukocyte counts and differentiation were performed in EDTA-anticoagulated 
blood using routine analysis methods (Sysmex XE-5000, The Netherlands).
Ex vivo monocyte stimulation
Monocytes were isolated from buffy coats obtained from healthy donors after written 
informed consent (Sanquin Blood Bank, Nijmegen, The Netherlands) as previously 
described24 using both Ficoll-Paque and hyper-osmotic Percoll density gradient 
centrifugation and washing with warm PBS for purity and low platelet contamination. 
Washed platelets were isolated as previously described21,and pre-incubated with ASA (5 uM, 
Sigma) for 1 hour and washed to remove ASA. Supernatant and platelets were collected for co-
incubation with isolated and adhered monocytes. Adhered monocytes (1.105) were incubated 
for 24 hours with Escherichia coli LPS (10ng/mL; serotype 055:B5, Sigma), prostaglandin E2 
(0.1 uM or 1uM; Sigma), ASA (5-500uM), unexposed or ASA-exposed platelet supernatant (1:4 
dilution) and/or unexposed or ASA-exposed washed platelets (ratio 1:50 or 1:25). Hereafter, 
supernatants were collected and stored at -20 degrees. ELISA was used to determine TNFα.
Statistical analysis
Data are expressed as a mean ± SEM or as median [interquartile range], according to their 
distribution. Data were tested for normality using the Shapiro-Wilk test. To limit the number 
of statistical tests used, three hypotheses were hierarchically defined and sequentially tested 
by performing repeated measures two-way ANOVAs (interaction term of group and time) 
on specific pairs of groups: 1. To evaluate the effects of ASA, placebo-ASA was compared to 
placebo 2. To evaluate the effect of clopidogrel or ticagrelor added to ASA, clopidogrel-ASA 
and ticagrelor-ASA were compared to placebo-ASA. 3. In case of an effect of ticagrelor or 
clopidogrel added to ASA, a comparison of clopidogrel-ASA with ticagrelor-ASA was made 
to assess for differences between these P2Y12 inhibitors. In case no differences between 
groups were identified, no further statistical testing was performed. Statistical tests used 
are described in the figure legends and Supplement. All statistical analyses were performed 
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Plasma adenosine
As adenosine is known to have potent anti-inflammatory effects25, and ticagrelor has 
previously been shown to increase extracellular adenosine by blocking reuptake26, we 
evaluated the effect of the study treatments on plasma adenosine. Plasma adenosine levels 
were comparable at baseline between groups. Endotoxemia significantly increased 
adenosine levels to a similar degree in all groups (Figure 2), and there were no differences 
between groups.
Figure 2. Plasma adenosine. Plasma concentrations of adenosine before and 3h after initiation of endotoxin 
administration. Data are expressed as box and whiskers plots with median, minimal and maximal observed values. 
Baseline values were comparable between groups (Kruskal-Wallis test, p=0.13), and changes in adenosine after 3h were 
tested with the Wilcoxon signed rank test. * indicates p<0.05. 
Platelet P2Y12 receptor inhibition and platelet activation and responsiveness
To evaluate the specific inhibition of P2Y12, the level of phosphorylation of vasodilator-
stimulated phosphoprotein (VASP) was measured. There was no P2Y12 inhibition before the 
start of study treatment in any subject, and P2Y12 dependent platelet inhibition remained 
unaffected throughout the study in the placebo and placebo-ASA groups (Figure 3). Ticagrelor 
treatment resulted in a VASP-PRI% <50% in all subjects, whereas platelet inhibition varied 
largely in clopidogrel-treated subjects.
In vivo platelet activation, as measured by unstimulated platelet P-selectin expression, 
was low in all subjects and was not affected by study treatment or endotoxemia (Figure 
4A). Platelet responsiveness to low and high concentrations of adenosine diphosphate 
and cross-linked collagen-related peptide remained unaffected by both experimental 
to ASA mitigated the ASA-induced augmentation, addition of clopidogrel to ASA did not 
alter any of the ASA-mediated changes in cytokines. Comparison of the ASA-clopidogrel 
and ASA-ticagrelor group did not reveal any difference in TNFα levels between ticagrelor- or 
clopidogrel-treated subjects. None of the study treatments affected plasma concentrations 
of MIP-1β and the anti-inflammatory cytokines IL-10 and IL-1RA. 
Figure 1. Plasma cytokine concentrations. Plasma concentrations of (A) TNFα, (B) IL-6, (C) IL-8, (D) IL-10 and (E) IL-
1RA during endotoxemia. Data are expressed as means with SEM. Effects of study treatment on the cytokine response 
were evaluated using a two-way ANOVAs (interaction term of group and time) on group pairs. P-values of significant 
differences are displayed in the figure. P: placebo, PA: placebo and acetylsalicylic acid, TA: ticagrelor and acetylsalicylic 
acid, CA: clopidogrel and acetylsalicylic acid.
263262
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Figure 4. Platelet activation and responsiveness. Mean fluorescence intensity as a measure of platelet P-selectin 
expression before study treatment and during endotoxemia of unstimulated platelets (A), and after stimulation with low 
(B) and high (C) concentrations of adenosine diphosphate (ADP, 3.4 or 125 μM) and low (D) and high (E) concentrations 
of cross-linked collagen-related-peptide (CRP-XL, 39 or 625 ng/mL). Data are expressed as box and whiskers plots with 
median, minimal and maximal observed values. Effects of study treatment on platelet activation status and reactivation 
were evaluated using a two-way ANOVAs (interaction term of group and time) on group pairs. P-values of significant 
differences between groups are displayed in the figure. P: placebo, PA: placebo and acetylsalicylic acid, TA: ticagrelor 
and acetylsalicylic acid, CA: clopidogrel and acetylsalicylic acid.
Prostaglandins
To evaluate if COX-1 inhibition by ASA treatment was sufficient, plasma levels of 
thromboxane B2, the stable metabolite of the COX-1 product thromboxane A2, were 
determined. ASA treatment strongly reduced thromboxane B2 levels compared to placebo 
treatment (Figure 6).
endotoxemia and ASA treatment (Figure 4B-E). Treatment with P2Y12 inhibitors diminished 
adenosine diphosphate-induced P-selectin expression in clopidogrel- and ticagrelor-treated 
subjects similarly. P-selectin expression after stimulation with low concentration cross-
linked collagen-related peptide was reduced in clopidogrel- and ticagrelor-treated subjects 
similarly. However, stimulation with high concentration cross-linked collagen-related 
peptide fully surmounted the clopidogrel-, but not the ticagrelor-induced reduction in 
platelet responsiveness. Platelet responsiveness did not correlate with cytokine responses 
(Supplemental Figure 3).
Platelet-leukocyte complexes
To evaluate whether antiplatelet agents affect platelet-monocyte and platelet-neutrophil 
interactions, the percentage of platelet-monocyte and platelet neutrophil complexes (PMC 
and PNC) was determined. Due to the endotoxin-induced transient monocytopenia, platelet-
monocyte complexes were not measurable at 2 hours after onset of endotoxemia. Although 
there is a trend towards decreased PMC formation in the ticagrelor-ASA treated group at 4h, 
there were neither differences in formation of PMCs, nor of PNCs at any time point between 
groups (Figure 5). Again, there was no correlation between PMC and PNC formation and 
cytokine response (Supplemental Figure 4).  
Figure 3. VASP-P Platelet Reactivity Index. Platelet Reactivity Index (PRI), expressed as the percentage of 
phosphorylation of vasodilator-stimulated phosphoprotein (VASP-P). Data are expressed as box and whiskers plots with 
median, minimal and maximal observed values. Baseline values were comparable among groups (Kruskal-Wallis test, 
p=0.53). Treatment with PA and P did not alter PRI (Friedman test, p=0.20 and p=0.16 respectively), treatment with 
TA and CA decreased PRI (Friedman test with post-hoc Dunn’s Multiple Comparison Test p=0.0004 and p=0.006). * 
indicates a difference with baseline value.
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Hemodynamic parameters, temperature and symptoms
Endotoxemia resulted in a decrease of mean arterial blood pressure of approximately 15 
mmHg (Supplemental Figure 5A) and an increased heart rate with approximately 35 bpm 
(Supplemental Figure5B). Body temperature increased with 2.5°C (Supplemental Figure 5C). 
Endotoxin-related symptoms peaked at 3 hours and resided six hours after the start of 
endotoxin infusion (Supplemental Figure 5D). There were no differences in these parameters 
between groups.
Platelet and leukocyte count and differentiation
Platelet counts were comparable after study treatment (Supplemental Figure 6A) and 
endotoxemia resulted in a typical neutrophilia, and a transient thrombo-, mono- and 
lymphocytopenia (Supplemental Figure 6B-D), which were similar between groups. 
Ex vivo monocyte stimulation
In order to evaluate whether the ASA-induced augmentation of the inflammatory 
response is platelet-dependent, isolated, adhered monocytes were stimulated with LPS in 
different conditions. Incremental concentrations of ASA did not affect TNFα production 
upon LPS stimulation, whereas PGE2 attenuated TNFα production (Figure 7A).Therefore, 
we hypothesized that platelets mediated the ASA-induced pro-inflammatory response. 
Correspondingly, platelets pre-exposed to ASA augmented LPS-stimulated monocytic TNFα 
production, (Figure 7B), and similarly the supernatant of ASA-exposed platelets augments 
monocytic TNFα response (Figure 7C). These effects were abrogated in the presence of PGE2. 
Figure 5. Platelet-leukocyte complexes. Percentage of platelet-monoycte complexes (A) and platelet-neutrophil 
complexes (B) during endotoxemia. Data are expressed as mean with SEM. Differences between study treatment 
groups were evaluated using a one-way ANOVA, there were no significant differences between groups. P: placebo, PA: 
placebo and acetylsalicylic acid, TA: ticagrelor and acetylsalicylic acid, CA: clopidogrel and acetylsalicylic acid.
Figure 6. Thromboxane B. Plasma concentration of thromboxane B before and after treatment with placebo (P) or 
placebo with acetylsalicylic acid (PA). Data are expressed as box and whiskers plots with median, minimal and maximal 
values. Baseline values were comparable among groups (Mann-Whitney test, p=0.80).Treatment with ASA mitigated 
plasma thromboxane B (Friedman test with post-hoc Dunn’s Multiple Comparison Test p=0.004). Endotoxemia did not 
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Discussion
We evaluated the effects of clinically relevant dosages of ASA, ticagrelor, and clopidogrel 
on systemic inflammation during human endotoxemia. A seven day course of low-dose 
ASA profoundly enhanced the pro-inflammatory response. Although the addition of 
ticagrelor attenuated the ASA-induced increase in TNFα levels, it did not affect the ASA-
induced augmentation of other pro-inflammatory cytokines and chemokines. Furthermore, 
clopidogrel added to ASA did not affect the ASA-enhanced pro-inflammatory response 
during endotoxemia. There were no significant differences in immunomodulating effects 
between ticagrelor and clopidogrel added to ASA. 
The pro-inflammatory effects of low-dose ASA observed in this study mirror results from 
previous experimental studies on COX-inhibitors in humans. Single or multiple high 
dose(650 mg) treatment with a ASA augmented LPS-induced pro-inflammatory cytokine 
production ex vivo17,27 and treatment with the COX-inhibitor ibuprofen showed similar 
results during human endotoxemia19,20. Accordingly, ASA was shown to enhance plasma 
TNFα upon Salmonella typhi vaccination in healthy volunteers28. Interestingly, the timing of 
ASA treatment appears to be of importance, as a single dose of 1000 mg of ASA just before 
LPS administration did not affect the inflammatory response18. ASA, as a COX-inhibitor, 
abrogates the production of PGE2, and we and others have shown that PGE2 attenuates 
cytokine production29. Furthermore, the addition of exogenous PGE2 dose-dependently 
prevents the pro-inflammatory of ASA30. As such, ASA prevents PGE2 production and thereby 
abrogate it’s inhibitory effect on cytokine production. Of note, low dose ASA and ibuprofen 
treatment both have shown to attenuate the production of PGE2 during human endotoxemia 
in vivo31. Of note, the studies that assessed the effect of COX-inhibition on LPS-induced 
cytokine production were performed in whole blood or in vivo, and therefore in the presence 
of platelets17,27.
To investigate whether the ASA-induced anti-inflammatory effect depends on a direct 
effect on myeloid cells or is platelet dependent, we performed ex vivo experiments on 
human isolated monocytes and platelets. The data shows that that the ASA induced pro-
inflammatory effect is mediated by platelets. This is in correspondence with previous 
evidence obtained from experiments with murine bone marrow derived macrophages 
(BMDM), in which it was demonstrated that TNFα production of BMDM was shown to 
be attenuated in the presence of platelets or platelet supernatant32. Analogous to our 
experiments , pretreatment with ASA of platelets abolishes the anti-inflammatory effects. 
These authors further demonstrate that platelets exert anti-inflammatory effects through 
the activation of the COX-1-PGE2 pathway32. 
Figure 7. Ex vivo experiments with isolated monocytes, acetylsalicylic acid, prostaglandin E2 and platelets. TNFα 
production of LPS-stimulated monocytes with incremental dosages of ASA and/or PGE2 (A). Treatment with ASA did 
not affect TNFα production (Wilcoxon signed rank test, p=NS), whereas PGE2 attenuated TNFα production compared 
to the condition without PGE2 (Wilcoxon signed rank test, * indicates p<0.05, n=9). TNFα production of LPS-stimulated 
monocytes in the presence of unexposed or ASA-exposed platelets (n=9) (B) or the supernatant of these platelets 
(n=12) and PGE2 (1 uM) (C). Treatment of platelets with ASA augmented TNFα production (Wilcoxon signed rank test, * 
indicates p<0.05), PGE2 abrogated this ASA-platelet mediated effect. Data are expressed as box and whisker plots with 
median, minimal and maximal values. TNFα; Tumor Necrosis Factor-α
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therapy8. In patients with community acquired pneumonia, pretreatment with ASA 
has been associated with a reduced need for ICU admission9 and mortality10. So, clinical 
data consistently support the association of ASA with beneficial outcomes in sepsis and 
pneumonia. However, due to the observational nature of these studies, no cause-effect 
relationships can be identified. Therefore, these associations instigate the development 
of hypothesis concerning how anti-platelet therapy could contribute to these observed 
beneficial effects in sepsis. Two hypothesis on how the immune-enhancing effects of ASA 
may contribute to any survival benefit in patients with sepsis may be put forward. First, the 
augmented pro-inflammation caused by low-dose ASA may result in a more effective early 
clearance of bacteria, resulting in improved survival compared to patients with an initial less 
pronounced cytokine response43. Alternatively, the here described immune-enhancing effects 
of ASA could also explain the observed beneficial outcomes in sepsis if ASA counteracts 
sepsis-induced immunoparalysis. Sepsis-induced immunoparalysis is a phenomenon 
receiving increasing attention, characterized by the inability to clear pathogens and an 
increased susceptibility to secondary (opportunistic) infections44. The immune-stimulating 
properties of ASA may partially compensate this immune refractant state. 
Second, as platelets are increasingly recognized as mediators in inflammation, modulating 
the immune response with anti-platelet therapy may represent a novel strategy to treat 
patients with sepsis. Although it is recognized that imbalances in the immune response 
itself result in the clinical syndrome of sepsis and sepsis-related mortality, until now, anti-
inflammatory therapies have failed to improve outcome45. The host response in sepsis 
is complex, with interindividual differences in the inflammatory balance over time. 
Nevertheless, it is conceivable that modulating the immune response, depending on the 
inflammatory state, may be of clinical benefit45. Although randomized controlled trials have 
not shown beneficial effects of ibuprofen46 and lornoxicam47 in sepsis, this may be due to 
small sample sizes, patient selection and timing of treatment45. Currently, a randomized trial 
is recruiting patients to evaluate the effects of ASA in patients with severe sepsis or septic 
shock (Clinical Trials.gov identifier NCT02612480). Alternatively, the observed improved 
survival of ASA users in sepsis may be based on non-immunologic mechanisms, or despite 
efforts to correct for baseline differences between ASA and non-ASA users, even be related 
to other patient characteristics or chance. Therefore, the questions if and how ASA affects 
outcome in patients with sepsis still require definitive answers. 
In this study, we evaluated the effect of clinically relevant antiplatelet treatment schedules 
on systemic inflammation in a highly reproducible human model. In contrast to bolus 
administration in previous studies22, systemic inflammation was elicited with continuous 
infusion of endotoxin, which resulted in a prolonged inflammatory state and may therefore 
be more representative of ongoing inflammation as encountered in patients. Although we 
Taken together, it is conceivable that the mechanism of the ASA-induced pro-inflammatory 
effects observed are caused by inhibition of PGE2 production by platelets. As a consequence, 
PGE2-induced dampening of pro-inflammatory cytokine responses is attenuated, ultimately 
resulting in increased cytokine levels.
Although the addition of ticagrelor to ASA significantly affected plasma TNFα levels during 
endotoxemia, it did not influence other cytokines or chemokines, and clopidogrel added 
to ASA did not affect the cytokine response at all. Furthermore, there were no statistical 
significant differences in cytokine responses between ticagrelor- and clopidogrel-treated 
subjects. Animal studies evaluating the role of P2Y12 inhibition in various models of 
inflammation are sparse and have yielded conflicting results, showing pro-inflammatory33, 
anti-inflammatory34,35, or no effects36. Our results are in contrast with the scarcely available 
human data, as a single dose of ticagrelor reduced platelet-leukocyte interaction and ex vivo 
cytokine responses21, and ticagrelor and clopidogrel reduced pro-inflammatory cytokine 
levels during human endotoxemia22. Importantly, subjects did not receive concomitant 
treatment with ASA in these studies. The anti-inflammatory effects observed in these 
studies were suggested to be caused by a reduction in platelet reactivity and reduced 
platelet-leukocyte interaction22. However, in our study, there were no differences between 
groups in platelet-leukocyte interactions. In addition, although ADP-dependent platelet 
responsiveness was reduced by P2Y12 inhibitors, the degree of responsiveness did not 
correlate with cytokine responses. Therefore, it is most likely that the pro-inflammatory 
potential of ASA overshadows the previously observed immunomodulating effects of P2Y12 
inhibitors. This is important, as most patients use a P2Y12 inhibitor in combination with 
ASA, and not as monotherapy. Various recent studies showed that ticagrelor increases 
the extracellular levels of endogenous adenosine37,38. Since adenosine is a potent anti-
inflammatory agent, it was proposed that this mechanism contributes to the beneficial 
effect of ticagrelor on endotoxemia, but adenosine levels were not measured in this study22.
We found no effects of ticagrelor on plasma adenosine, which is consistent with our previous 
finding that ticagrelor does not inhibit ENT transport at clinically relevant dosages39. In 
conclusion, our findings indicate that ticagrelor and clopidogrel do not relevantly modulate 
the immune response when they are combined with ASA treatment. This implies that that 
the beneficial effects of ticagrelor and ASA compared with clopidogrel and ASA on mortality 
after sepsis and pneumonia in the PLATO trial are unlikely caused by immunomodulation15. 
The putative immunomodulating effects of antiplatelet therapy are important for two 
reasons. First, use of anti-platelet therapy in the ICU population is very common, with 
estimates ranging from 17-43%6,40-42. ASA treatment has consistently been associated with 
reduced mortality in patients with sepsis in several studies3-7, with the exception of one 
smaller study, which evaluated not only treatment with ASA, but also other anti-platelet 
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for blood pressure monitoring and blood withdrawal. A venous cannula provided access for 
intravenous hydration and endotoxin administration. Heart rate was monitored by a three-
lead electrocardiogram and haemodynamic data was recorded from a Philips M50 monitor 
(Eindhoven, The Netherlands) with an interval of 30 seconds using an in-house developed 
system. Subjects were prehydrated with intravenous (i.v.) infusion of 1.5L glucose 2.5%/0.45% 
NaCl in one hour. Purified lipopolysaccharide (LPS, US Standard Escherichia Coli O:113 
endotoxin) was obtained from the Pharmaceutical Development Section of the National 
Institutes of Health (Bethesda, MD, USA). The lyophilized powder was reconstituted in 5 mL 
saline 0.9% for injection and vortex mixed for 20 min after reconstitution. An i.v. bolus of 
LPS was administered at a dose of 1 ng/kg at time point 0 hours, continued by a continuous 
infusion at a dose of 1 ng/kg/ h for 3 hours. Hydration was continued with a rate of 150 ml/h 
for 6 hours, and 75 ml/h for the rest of the experiment to ensure optimal hydration. Blood 
was drawn at several time points throughout the experiment. All samples were processed 
within 3 hours after collection. Temperature was measured using a tympanic thermometer 
(FirstTemp Genius 2; Covidien, Dublin, Ireland). Endotoxin induced flu-like symptoms 
(headache, nausea, shivering, muscle and back pain) were scored on a six-point scale (0 = no 
symptoms, 5 = worst ever experienced), resulting in a total symptom score of 0–25.
Cytokine measurement
Ethylenediaminetetraacetic-(EDTA) anticoagulated blood was immediately centrifuged 
after withdrawal at 2000 g,4°C for 10 minutes. The obtained plasma was stored at -80°C 
until further analysis. Plasma concentration of the cytokines Tumor Necrosis Factor (TNF)
α, Interleukin (IL)-6, IL-8, IL-10 and IL-1 receptor antagonist (IL-1RA) and the chemokines 
macrophage inflammatory protein (MIP)-1α, MIP-1β and monocyte chemoattractant 
protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), were determined 
batchwise in anticoagulated plasma by a multiplex immunoassay assay according to the 
manufacturer’s instructions (Bio-Plex, BioRad, Hercules, USA and Milliplex, Millipore, 
Billerica, USA). 
Plasma adenosine
Plasma adenosine levels were determined using an in-house developed method as 
described previously23. Blood was drawn with a special syringe system that immediately 
mixed the blood with a solution that consisted of pharmacological blockers of adenosine 
formation, transport and degradation at the tip of the syringe in a 1:1 ratio. Haematocrit 
values in the blocking solution-blood mixture and in whole blood were determined to 
correct for dilution. The mixture was centrifuged at 2000 g, 4°C for 10 minutes and stored at 
-80°C until further analysis. 
Supplemental Methods
Study design, subjects and study procedures 
This prospective randomized open-label, blinded endpoint (PROBE-design) study was 
performed according to the latest version of the declaration of Helsinki (2008), the Medical 
Research Involving Human Subjects Act (WMO) and Good Clinical Practice (GCP) and is 
registered at clinicaltrials.gov identifier NCT01978158. 
After approval of the local ethics committee from the Radboud university medical centre, 45 
males signed informed consent and were screened for eligibility. Forty healthy volunteers 
were included as they met all inclusion criteria and none of the exclusion criteria. Inclusion 
criteria were male sexe, age 18-35 years and no known current medical or psychiatric 
diseases. Exclusion criteria were history, signs or symptoms of cardiovascular disease, 
chronic obstructive pulmonary disease or asthma, hemorrhagic diathesis or disorders 
associated with increased risk of bleeding, pathological bleeding, history of intracranial 
haemorrhage, history of dyspepsia, quantitative bleeding assessment tool (BAT) score> 
350, immune deficiency, spontaneous vasovagal collapse, use of any medication, smoking, 
cardiac conduction abnormalities on electrocardiogram, hypertension (systolic blood 
pressure >160 mmHg or diastolic blood pressure >90 mmHg), hypotension (systolic blood 
pressure <100 mmHg or diastolic blood pressure < 50 mmHg), renal impairment (estimated 
glomerular filtration rate by Modification of Diet in Renal Disease formula < 60 ml/min), 
liver enzyme abnormalities (ALAT or ASAT > two times the upper limit of reference value), 
thrombocytopenia (thrombocytes < 150 x 109/L), anemia (heamoglobin < 8.0 mmol/L), febrile 
illness in the week before the endotoxin challenge, hypersensitivity to ticagrelor or any 
excipients and participation in another drug trial or donation for blood 3 months prior to, 
until 3 months after the planned endotoxin experiment. 
Subjects were randomized to one of four study arms, i.e. ticagrelor and ASA (TA), clopidogrel 
and ASA (CA), placebo and ASA (PA) or placebo. All subjects received a loading dose of the 
allocated treatment on day one, and continued with maintenance doses during the seven 
days preceding the endotoxemia experimental day. Ticagrelor loading dose was 180mg, with 
a maintenance dose of 90 mg twice daily, clopidogrel loading dose was 300 mg, and with a 
maintenance dose of 90 mg daily, ASA loading dose was 320 mg, with a maintenance dose of 
80 mg daily. 
Subjects refrained from alcohol, nicotine and caffeine for 24 hours, and fasted overnight prior 
to the endotoxemia experiment. After admission to the intensive care research department, 
an arterial cannula (Angiocath; Becton Dickinson, USA) was placed in the radial artery and 
connected to a blood pressure monitoring system (Edward Lifesciences, Irvine, CA, USA) 
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Coulter). Platelets were gated on forward-scatter (FS), side-scatter (SS) and CD61 positivity. 
Subsequently expression of CD62p, a measure of degranulation, and fibrinogen after ADP 
stimulation were expressed as median fluorescence intensity (MFI).
Leukocyte and platelet counts
Analyses of leukocyte counts, differentiation and thrombocyte counts were performed in 
EDTA anticoagulated blood using routine analysis methods also used for patient samples 
(flow cytometric analysis on a Sysmex XE-5000). 
Statistical analysis
Data are expressed as a mean ± SEM or as median [interquartile range], according to their 
distribution. Data were tested for normality using the Shapiro-Wilk test. To evaluate the 
effect of platelet inhibitors on cytokine responses, PRI and activity and responsiveness, 
repeated measures two-way ANOVAs (interaction term of group and time) were performed 
between specific pairs of groups: 1. To evaluate the effects of ASA, placebo-ASA was compared 
to placebo 2. To evaluate the effect of clopidogrel or ticagrelor added to ASA, placebo-ASA 
was compared to clopidogrel-ASA and ticagrelor-ASA. 3. In case of an effect of ticagrelor or 
clopidogrel added to ASA, a comparison of clopidogrel-ASA with ticagrelor-ASA was made to 
assess for differences between these P2Y12 inhibitors. 
Baseline values of prostaglandins, plasma adenosine and VASP-P platelet reactivity index 
were compared with Students t-test or Mann-Whitney test. Differences in changes over 
time were analyzed with Friedman test with post-hoc Dunn’s Multiple Comparison Test 
(thromboxane B and VASP-P) or Wilcoxon signed rank test (adenosine). Haemodynamic 
parameters, temperature, symptom scores, platelet and leukocyte counts were analyzed for 
differences between all four groups using a repeated measures two-way ANOVA (interaction 
term of group and time). Correlation between platelet responsiveness and plasma cytokine 
levels were calculated using Pearson’s correlation. All statistical analyses were performed 
using GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA, USA). A two-sided p 
value <0.05 was considered statistically significant.
The blocker solution consisted of 40 μM dipyridamole (adenosine transport inhibitor), 
10 μM erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) (adenosine deaminase inhibitor), 
10 μM iodotubericidine (ITU) (adenosine kinase inhibitor), 13.2 mM Na2EDTA (disodium 
ethylenediamine tetraacetate) (inhibits release from platelets and acts as a 5ʹ-nucleotidase 
inhibitor), 118 mM NaCl, and 5 mM KCl. Plasma adenosine concentrations were determined 
by high performance liquid chromatography (HPLC). In brief, 36 volumes of plasma were 
mixed with 1 volume of perchloric acid (70%) and 20 volumes of 0.5M trioctylamine in 
chloroform, followed by centrifugation (3 min, 13400rpm, RT). Four volumes of supernatant 
were mixed with 1 volume of chloroacetaldehyde (6x diluted in 1M acetate buffer, pH 4.5) 
followed by derivatization (60 min, 500rpm, 70 °C). Chloroform was added (3.3 volumes), the 
mixture was centrifuged (3 min, 13400 rpm, RT), the supernatant was transferred to a HPLC 
vial and injected. Adenosine was separated by HPLC system (Thermo Scientific, Rockford, 
USA) using a Polaris C18-A column (150 x 4.6 mm) with gradient elution using eluent A (50 
mM NH4H2PO4, 5 mM sodium 1-hexanesulfonate monohydrate [pH 3.0], and 2% MeOH) 
and eluent B (H2O: ACN: THF; 50:49:1). The retention time was approximately 10 min. 
Quantification was based on peak areas of the samples and reference standards measured 
with fluorescence (excitation: 280 nm; emission: 420 nm).
Assessment of P2Y12 inhibition
Specific effectiveness of P2Y12 inhibition was determined by the level of phosphorylation 
of vasodilator-stimulated phosphoprotein (VASP) in citrated blood (3,2% sodium citrate, 
Vacutainer, Becton Dickinson) whole blood using an ELISA-based assay (CY-QUANT VASP/
P2Y12, BioCytex, Marseille, France) according to manufacturer’s instructions. This test 
monitors the responsiveness to P2Y12 inhibitors, and P2Y12 inhibition is expressed as platelet 
reactivity index (PRI%), a value < 50% is considered as adequate platelet inhibition. 
Platelet activation and responsiveness 
Platelet activation and responsiveness was assessed in citrated (3.2% sodium citrate, 
Vacutainer, Becton Dickinson) whole blood using flow cytometry within 3 hours. Whole blood 
(5µL) was added to a mix of hepes-buffered saline, saturating concentrations of FITC-labeled 
anti-fibrinogen (DAKO, Heverlee Belgium), PE-labeled anti-CD62p (anti-P-selectin; BD 
Biosciences, San Jose, CA, USA) and PC7-labeled anti-CD61 (anti-glycoprotein IIIa; Beckman 
Coulter, Brea, CA, USA). Platelet reactivity was assessed by ex vivo stimulation with either 
platelet agonist adenosine diphosphate (ADP; 3.4 and 125 µM; Sigma-Aldrich, Zwijndrecht, 
The Netherlands) or cross-linked collagen-related-peptide (CRP-XL; 39ng/L or 625ng/L). 
CRP-XL was a generous gift from Prof. dr. R. Farndale (Cambridge, UK) and was prepared as 
described previously51. After incubation for 20 minutes at room temperature a 500µL fixative 
solution (0,4% formaldehyde) was added. Samples were directly measured on a FC500 flow 
cytometer (Beckman Coulter) and data were analyzed using Kaluza® software (Beckman 
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Supplemental Figure 1. Gating strategy platelet-leukocyte complexes. Gating strategy for platelet-monocyte and 
platelet-neutrophil complex formation in a representative sample. Monocytes (blue) were selected based on size 
(forward-scatter; FS), granularity (side-scatter; SS) and expression of CD16, CD14 and HLA-DR as shown in the upper 
scattergrams. Neutrophils were gated based on size (FS), granularity (SS) CD14, CD16 and HLA-DR as shown in the 
lower scattergrams. The markers were chosen to distinguish neutrophils and monocytes during experimental human 
endotoxemia. Platelet interaction was assessed using the % of CD61-positive events shown in the right overlay graph. 
An example of the different populations of monocytes (Blue) and neutrophils (green) are shown left in the scattergram. 
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Supplemental Figure 3. Correlations between tumor necrosis factor (TNF)α (A and B) and interleukin-6 (C and D) and 
platelet reactivity expressed as P-selectin expression upon stimulation with high doses of collagen related peptide (CRP-
XL) (A and C) or adenosine diphosphate (ADP) or at time of endotoxin administration. Cytokine production is expressed 
as the area under the concentration-time curve (ng/ml*h). Pearson’s correlation coefficients were not significant. ASA: 
acetylsalicylic acid.
Supplemental Figure 4. Correlations between tumor necrosis factor (TNF)α and interleukin-6 and platelet monocyte 
complexes (PMC) or platelet neutrophil complexes (PNC). Cytokine production is expressed as the area under the 
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Supplemental Figure 6. (A) platelet-, (B) neutrophil-, (C) monocyte-, and (D) lymphocyte counts during endotoxin-
elicited systemic inflammation. Endotoxin administration started at t=0 hours and continued until t=3 hours. Data are 
expressed in box plots with minimal and maximal observed values. Platelets, monocytes and lymphocytes decreased 
temporarily due to endotoxemia (1-way ANOVA in P group, p<0.0001 for all parameters), without any effect of study 
treatment on cell counts. P: placebo, PA: placebo and acetylsalicylic acid, TA: ticagrelor and acetylsalicylic acid, CA: 
clopidogrel and acetylsalicylic acid.
Supplemental Figure 5. (A) Mean arterial pressure (MAP), (B) heart rate, (C) temperature and (D) symptom score during 
endotoxin-elicited systemic inflammation. Endotoxin administration started at t=0 hours and continued until t=3 
hours. Data are expressed as mean and SEM. MAP decreased over time, with a concurrent increase in heart rate and 
temperature (1-way ANOVA in P group, p<0.0001 for all parameters). There was a small difference in MAP between 
groups (2-way ANOVA p=0.04), although post-hoc analysis did not point out what the discrepant group or time point 
was. There was no effect of study treatment on heart rate, temperature and symptom score. P: placebo, PA: placebo and 
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inflammasome related molecules (e.g., NLRP3, STAT1), cytokines (e.g., IL1B, CCL2, MMP9, 
IL1RN), and pattern-recognition receptors (e.g. TLR2, TLR4, TLR7 and NOD2), indicating the 
broad upregulation of inflammatory pathways in monocytes of PLHIV on stable cART. 
Monocytes are known to play a crucial role in the development of atherosclerosis18,19. 
Monocytes can be reprogrammed after exposure to endogenous and microbial structures 
by changes at the epigenetic level, a process termed “trained immunity”20,21. This trained 
immunity phenotype renders monocyte with a long-term enhanced functional state, showing 
a stronger proinflammatory response (e.g. IL-6 and IL-1β production) to a second stimulus22. 
Trained immunity is known to rely on epigenetic modifications such as histone modification 
and DNA methylation22-24 but also metabolic reprogramming25. Clinical implications of 
trained immunity have been shown in multiple diseases such as cardiovascular disease and 
diabetes26-29. Our data indicate a similar trained immunity phenotype in PLHIV with a stable 
increased cytokine production capacity with augmented pro-inflammatory pathways. 
A recent study by Bowman et al30 showed that monocyte-derived macrophages from PLHIV, 
were pro-atherogenic with pro-inflammatory transcriptional phenotypes and increased foam 
cell formation, both hallmarks of trained immunity19. This phenotype was induced through 
PLHIV serum and linked to lipid alteration, a further indication to trained immunity, as 
oxidized Low-density lipoprotein (LDL) is known to induce a trained immunity phenotype. 
Another strong inducer of trained immunity is (1→3)-β-D-glucan (β-glucan)24, a fungal cell 
wall product31. In this thesis we show that concentrations of β-glucan in serum are increased 
in PLHIV compared to controls32-34. Furthermore, we could associate the presence β-glucan 
in serum of PLHIV to a pro-inflammatory phenotype of monocytes. HIV is associated with 
impaired intestinal integrity35,36 and different studies have reported increased circulating LPS 
concentrations in PLHIV35,37.   Increased microbial translocation may also lead to increased 
plasma β-glucan concentrations32,34,38. The immune effects of LPS and β-glucan differ, as 
also shown by our in-vitro data. Whereas LPS exposure induces tolerance, even at very low 
concentrations, β-glucan induces a pro-inflammatory phenotype21,23,39. These observations 
warrant further study in PLHIV, focusing on gut barrier dysfunction and the gut mycobiome, a 
compartment of the microbiome, which is  overlooked in the general population, but also in 
special groups such as PLHIV40. 
The gastrointestinal tract is a crucial for HIV replication and possibly for persistence of 
the HIV reservoir41. Local disruption of the intestinal Th17 and regulatory T-cells (Tregs) 
balance may have major consequences for the maintenance of gut barrier integrity and 
function42. A disrupted intestinal mucosal barrier may Increase exposure to endogenous 
and microbial structures leading to epigenetic modification and resulting in trained 
immunity21. Pharmacological interventions targeting epigenetic modification have been 
Summary
The introduction of combination antiretroviral therapy (cART) has revolutionized HIV care 
by strikingly improving morbidity, mortality and transmission1-4. Although drug toxicity 
remains a concern, the clinical advantages of viral suppression are clear5. The extended 
choice of different antiretroviral drugs from nucleoside reverse transcriptase inhibitors 
(NRTI), protease inhibitors (PI), nonnucleoside reverse transcriptase inhibitors (NNRTI), and 
integrase inhibitors (INSTI) has increased possibilities for patients suffering from adverse 
effects of cART. These therapeutic options have transformed HIV from a deadly condition, 
into a chronic manageable disease6-8. Still, multi-morbidity is common6,7 and people living 
with HIV (PLHIV) remain at increased risk for non-AIDS related comorbidities such as 
cardiovascular disease and cancer6,9-11. The clinical necessity of tackling these comorbidities is 
important as HIV cure remains a distant prospect12. A better understanding of the persistent 
immune defects and inflammation is important as these are associated with increased risks 
for cancer and cardiovascular disease (CVD)11 as well as HIV persistence13-15. Furthermore, the 
complex interplay between inflammation and coagulation, is known to play a crucial role 
in the development of cardiovascular diseases16. This complex interplay has been termed 
thrombo-inflammation.
In this thesis, multiple aspects of thrombo-inflammation in PLHIV were studied. In 
Chapters 2-6, data generated from a Dutch HIV-cohort of 217 PLHIV with prolonged viral 
suppression are presented. This cohort is part of the Human Functional Genomics Project 
(HFGP)17. In Chapters 7-9, additional studies are described to better understand thrombo-
inflammation in PLHIV. This final chapter covers a summary of our findings and an 
elaboration on future perspectives.
In Chapter 2, we showed the presence of persistent inflammation in PLHIV with prolonged 
viral suppression. Since PLHIV showed increased concentrations of circulating inflammatory 
markers compared to uninfected controls. By using an integrative approach of functional 
and transcriptional analyses, the functional phenotype of circulating immune cells were 
analyzed. We found that stimulation of circulating immune cells resulted in a sustained 
increased monocyte cytokine responsiveness, most notably for IL-1β, in PLHIV compared 
to uninfected controls. This increased responsiveness was associated with persistent 
inflammation, suggesting a functional link between changes in the innate immune cell 
function and systemic inflammation in PLHIV. The observed intrinsic pro-inflammatory 
phenotype of monocytes in PLHIV was stable over time and associated with upregulation 
of pro-inflammatory pathways, most notably the interleukin (IL)-1β pathway. This was 
confirmed using a second age-sex matched control group in which we also performed 
transcriptome analysis. Upregulated genes were intracellular signaling proteins and 
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cells and suppressive Tregs must remain balanced to preserve functional immunity. Altered 
ratios have been described in untreated HIV (lower Th17/Treg), autoimmune disease and 
cancer (higher Th17/ /Treg)59-61. In line with Th17 levels, PLHIV showed increased peripheral 
blood Th17/Treg ratios, which is apparent contrast to earlier reports of massive depletion 
of Th17 cells from the peripheral blood and the gut59, a process that is partially reversed by 
cART62,63. IL-1β and IL-6 are critical cytokines driving T-cell differentiation into Th17 cells64. 
Indeed, the pro-inflammatory phenotype (described in Chapter 2) correlated with Th17 
frequencies, as circulating IL-6 correlated with Th1y frequencies.
These changes in cell subsets also translated into functional changes in adaptive immunity 
with reduced interferon (IFN)-g levels upon stimulation with C. albicans and M. tuberculosis. 
While Th17-subsets were increased, we found no effect on ex vivo IL-17 and IL-22 production 
by peripheral blood mononuclear cells. Parameters of the HIV reservoir (e.g. cell associated 
HIV DNA and RNA) correlated with IFNy production and with several circulating immune 
cell subsets, most notably, inflammatory Treg subsets, Th17 cells, central memory CD4 cells 
and markers of T-cell expansion. Besides the reservoir, CMV co-infection, CD4 nadir, age, 
sex and smoking also contributed to the T-cell repertoire in PLHIV. This comprehensive 
overview of the peripheral immune cell composition showed a dysregulated immune profile 
in PLHIV. The observed link with the HIV reservoir will be combined with transcriptomic and 
proteomic analyses in the future to pinpoint new culprits in HIV persistence. Such hypothesis 
generating analyses could open new avenues in HIV cure research. 
Still, Th17 cells in the peripheral blood poorly reflect mucosal Th17 numbers 65. As such, 
we cannot exclude that altered Th17 recruitment leading to mucosal Th17 depletion is still 
present despite suppressive cART. This depletion could lead to an altered mucosal immunity 
and possibly lead to increased microbial translocation. Indeed, intestinal fatty acid binding 
protein (IFABP), a marker of intestinal integrity, was increased in our cohort and correlated 
with Th17 cell numbers. Furthermore, the gut homing chemokine (CCL20) correlated with 
Th17 cell frequencies, underlining the importance of gut immune homeostasis in PLHIV. 
Future studies are warranted to investigate the link between peripheral and mucosal Th17 
cells in long-term virally suppressed PLHIV. 
In Chapter 4, the occurrence of somatic mutations driving clonal hematopoiesis in PLHIV 
are described. Somatic mutations in HIV-uninfected individuals have been implicated in the 
risk and development of cardiovascular disease as well as hematological (pre)malignancies66. 
Targeted sequencing of known genes involved in clonal hematopoiesis in both the HIV-
cohort, in another HFGP cohort, namely a cohort of subjects at risk for CVD (300-OB) and 
uninfected population controls, enabled us to explore the occurrence of clonal hematopoiesis 
in PLHIV on stable cART. The prevalence of clonal hematopoiesis adjusted for age was 
used in PLHIV, especially in attempts to reduce the HIV reservoir and to achieve (functional) 
cure43. Treatment with these epigenetic modifying drugs such as histone deacetylase 
inhibitors (HDACi) reduces high-sensitivity C-reactive protein (hsCRP) and IL-1β expression 
in peripheral blood mononuclear cells (PBMCs)44 and reduces IL-1β production upon LPS 
stimulation in whole blood 45. However, these HDACi have not been used to broadly target 
persistent inflammation.
Besides HDACi, statins46-48, aspirin49 and other anti-inflammatory drugs have been used 
to reverse persistent inflammation with limited success9. In Chapter 2, we showed the 
importance of the  IL-1β pathway and thereby also as a possible therapeutic target for persistent 
inflammation in PLHIV and HIV-related cardiovascular disease and atherosclerosis50. The 
CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) trial, which that 
was carried out in non-HIV infected subjects with a recent cardiovascular event and residual 
inflammation showed that inhibition of IL-1β via subcutaneous injection was associated 
with a reduction in the incidence of subsequent cardiovascular events51.  A subsequent trial 
using the orally administered anti-inflammatory drug colchicine showed a similar reduction 
in cardiovascular events in patients with stable and recent coronary disease52. In contrast, 
the immunosuppressive drug methotrexate was not successful in reducing CVD, supporting 
thereby the importance of IL-1β in CVD53. In a pilot study, canakinumab reduced atherosclerotic 
inflammation, measured by Positron Emission Tomography (PET)-FDG scanning, in PLHIV at 
high-risk for CVD54 which further supports the importance of IL-1β pathway in HIV. 
In addition, an exploratory analysis of the CANTOS trial found a dose-dependent reduction in 
incident lung cancer and fatal lung cancer for IL-1β inhibition, with those with increased IL-6 
at highest risk55. Inflammation in the tumor microenvironment mediated by IL-1β is linked 
to cancer progression, and metastases56,57. Smokers and those with the most pronounced 
reduction in inflammation upon IL-1β inhibition gained the most benefit55. As cancer is 
another major cause of morbidity in long-term treated PLHIV5, IL-1β inhibition could provide 
an interesting target for immune based therapy. Orally administrated treatments that 
specifically inhibit the IL-1β pathway, such as inflammasome inhibitors or colchicine may 
form an attractive alternative to subcutaneous injections52,58. 
In Chapter 3, we focused on the circulating immune cell composition by examining 108 
different cell types in PLHIV and comparing these with healthy controls. Despite being on 
long-term suppressive cART, PLHIV exhibited an expansion of cluster differentiation (CD)8 
cells and lower proportions of CD4+ T cells and an immune cell profile characterized by an 
increase in proliferating memory and effector CD4 and CD8 T-cells. The number of circulating 
T-helper 17 cells (Th17) and pro-inflammatory Th17-like (CC chemokine receptor 6 (CCR6)+) 
regulatory (Treg) T-cells, were increased. The relationship between pro-inflammatory Th17 
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observed differences in transcriptional activity in CHDM carriers could , therefore, also be 
the result of modulation of these integration sites. Future studies on the effect of CHDMs on 
epigenetic marks and integration sites of  HIV-1 DNA are warranted. 
It has been suggested that clonal hematopoiesis increases cardiovascular risk through 
augmentation of inflammatory pathways. While, we found that CHDM-carriers had increased 
markers of coagulation compared to non-carriers, we did not observe such correlation for 
inflammation. Importantly, this procoagulant state in CHDM-carriers was independent of 
age and CD4 nadir. Therefore, clonal hematopoiesis could serve as a novel risk factor for non-
AIDS related comorbidities in PLHIV. 
Previous studies have shown that D-dimer concentrations are increased in PLHIV and are 
linked to mortality and the occurrence of cardiovascular disease76. D-dimer is a biomarker of 
in vivo coagulation, depending on coagulation factors and signals that provoke coagulation, 
such as inflammation and endothelial activation. To date, published data on coagulation 
capacity in PLHIV are conflicting77-79. The capacity of plasma to form thrombin is a critical 
determinant of in vivo plasmatic coagulation80. Thrombin generation can be measured 
ex vivo to determine coagulation capacity in a standardized setting and has been used 
as a diagnostic tool for hypo- and hypercoagulability states81. In Chapter 5, we describe 
thrombin generation capacity in our 200HIV cohort and explore factors associated with 
these functional coagulation assays. In line with earlier studies, D-dimer concentrations were 
increased in PLHIV compared to uninfected controls. At the same time, thrombin generation 
was slightly reduced in the PLHIV, after correction for age, sex and antiretroviral regimens. 
However, abacavir-use was independently associated with increased thrombin generation. 
This observation may shed light on the reported increase in thrombotic events during 
abacavir-use82,83. Furthermore, we showed that D-dimer concentrations were more associated 
with inflammation than plasmatic coagulation capacity. Overall, we concluded that the 
increased D-dimer concentrations found in PLHIV are most likely the result of increased 
exposure to triggers that propagate coagulation, such as inflammation and endothelial cell 
activation, rather than an intrinsic activation of the coagulation system.
The role of platelet mitochondrial dysfunction has been increasingly recognized in 
thrombosis, immunoregulation and age-related disease84. Mitochondrial toxicity is a well-
known complication of cART. The older generation NRTI’s, such as zidovudine and stavudine, 
were associated with profound mitochondrial toxicity, but mitochondrial toxicity may still 
occur with more recent NRTIs85. 
Mitochondria are essential in maintaining platelet health and lifespan, as recently 
reviewed86. Platelet dysfunction has been reported widely in PLHIV49,87-93, but the link 
increased and clone size was larger in PLHIV compared to population controls. Moreover, 
older age, low CD4 nadir and high CD4/CD8 ratio were associated with clonal hematopoiesis 
within PLHIV.  A recent study by Bick et al (not yet peer-reviewed) also reported increased 
clonal hematopoiesis in PLHIV67. Although an association with cART duration as well as with 
age and coronary artery disease, no correlations with other HIV-related parameters such as 
CD4 levels, HIV medication, HIV reservoir parameters were found.  Still, our studies suggest 
that that the risk for somatic mutations is increased PLHIV and that HIV-specific factors may 
play a role. 
Signature analysis of the found mutations showed a unique mutational signature in PLHIV 
which has been linked to reactive oxygen species (ROS) in cancer68. Although, sample size 
limited the ability to draw strong conclusions, PLHIV with prior exposure to zidovudine, a 
NRTI, were exclusively responsible for this ROS-associated mutational signature. Zidovudine 
is well-known for its hematological adverse effects.  Mitochondrial dysfunction is a hallmark 
of NRTI toxicity and leads to oxidative stress (i.e. ROS)69. Consequently, CHDMs with a ROS 
mutational signature could possibly be induced by NTRI exposure. The observation by Bick 
et al that cART duration is linked to clonal hematopoiesis could support this hypothesis67. 
However, future studies are warranted to study the effect of NRTIs on CHDM development. 
In virally suppressed PLHIV, the HIV-1 CA-DNA roughly equals total integrated parvoviral 
DNA, while HIV-1 CA-RNA is associated with HIV-1 transcriptional activity 70. The size of the 
reservoir measured by CA-DNA is associated with timing CD4 nadir and duration of cART 
treatment13. Although both parameters of the HIV reservoir strongly intercorrelate, HIV CA-
RNA was increased in CHDM carriers and HIV CA-DNA was not. This discrepancy between 
CA-RNA and CA-DNA suggests an effect on viral transcriptional activity70. Although the CA-
RNA difference disappeared after correction for CD4 nadir and age, the ratio of HIV-1 CA-RNA 
to CA-DNA, which represents viral transcription activity, was increased in CHDM carriers, 
independent of CD4 nadir, age and CD4/CD8 ratio.
HIV transcription is known to rely on epigenetic modifications such as DNA methylation71-73. 
Modulating transcriptional activity is a major field of research in HIV cure, especially those 
who pursue a shock-and-kill (or Kick-and-kill) strategy74. This strategy involves inducing HIV-1 
transcription and replication and thereby reversing latency (shock), followed by an immune-
mediated recognition and destruction of infected cells (kill). As CHDMs in the epigenetic 
regulators TET2 and DNMT3A have been linked to changes in DNA methylation75, increased 
HIV transcription activity in CHDM carriers could be a result of aberrant DNA methylation 
or altered gene expression linked to clonal hematopoiesis75. Recently, the integration site 
of HIV-1 DNA into the genome (e.g. distance to transcriptional start site and accessible 
chromatin marks)73 has been linked to spontaneous control in HIV elite controllers. The 
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Platelets may modulate immune function in several ways, among others by forming 
aggregates with immune cells, through P-selectin (on platelets) and P-selectin glycoprotein 
ligand (PSGL)-1 binding (on immune cells), thereby altering their function. Platelets are 
mostly considered pro-inflammatory, although binding to regulatory T-cells may also 
result in reduced inflammation. In Chapter 8, we show that platelet microparticles (PMP) 
can bind to a specialized subset of Th17-like progenitor cells in the Treg compartment and 
thereby inhibit their differentiation into potentially pathogenic effector cells. Compared to 
HIV-uninfected individuals, binding of plasma-derived microparticles from PLHIV to Tregs 
is decreased, suggesting reduced inhibition of differentiation of Tregs into IL-17 and IFN-γ 
producing cells. 
Various drugs have been used to inhibit and modulate platelet function for secondary 
cardiovascular prevention97. Low-dose acetyl salicylic acid (ASA or aspirin), commonly known 
as aspirin, is traditionally used for platelet inhibition, but this is increasingly combined or 
replaced by P2Y12 inhibitors, such as clopidogrel and ticagrelor 
98.  In Chapter 9, we evaluated 
the effects of clinically relevant dosages of aspirin, ticagrelor, and clopidogrel on systemic 
inflammation during human endotoxemia, a well-known model to study in vivo inflammation 
in humans99. While the effect of P2Y12 inhibition on inflammation was limited, a seven-day 
course of low-dose aspirin profoundly enhanced the pro-inflammatory response (e.g. TNFα), 
most likely through platelet-derived prostaglandin E2 via Cyclooxygenase (COX)-1 inhibition. 
Aspirin is generally known for its anti-inflammatory properties and has therefore been used 
to treat HIV-related persistent inflammation, although with limited success100. Our data 
offers an explanation why low-dose aspirin did not result in a detectable anti-inflammatory 
effect in earlier studies100 and may even increase inflammation in inflammatory conditions101. 
between platelet function and platelet mitochondria has received limited attention93. 
In Chapter 6, we show that platelets of PLHIV on long-term cART have reduced platelet 
mitochondrial content (mtDNApl). These lower mtDNApl levels were associated with platelet 
mitochondrial dysfunction and reduced energy supply. These mitochondrial perturbations 
were linked to reduced ex vivo platelet reactivity showing the functional consequences of 
HIV-associated mitochondrial dysfunction. This mitochondrial dysfunction was also linked to 
markers of persistent inflammation (e.g. sCD163).
Given the key role of platelets and mitochondria in the pathophysiology of cardiovascular 
events and other age-related conditions84,86, platelet mitochondria may be an attractive 
target to reduce long-term complications. Traditionally cART consists of a backbone of two 
NRTIs and one NNRTI, PI or INSTI. Recently, regimes with only one NRTI or even no NRTI have 
been introduced94. Future studies are needed to explore whether these new NRTI sparing 
regimens are associated with preserved platelet mtDNA and less platelet dysfunction.
The next chapters are focused on the role of platelets and thrombo-inflammation in HIV and 
were not performed within the HIV-cohort of the HFGP project. Mounting evidence supports 
the notion that platelets play an important role in inflammation16. 
A previous cross-sectional study from our group found that individuals on a raltegravir-
based regimen showed reduced platelet reactivity and platelet-monocyte complexes 
compared with those on a non-INSTI-based regimen90. Chapter 7 reports the results of a 
randomized controlled trial studying the effects of switching cART to a regimen based on 
the integrase inhibitor raltegravir. We show that switching PLHIV on a non-INSTI regimen 
to a raltegravir-based regimen for ten weeks did not reduce platelet reactivity, platelet-
leukocyte aggregation, monocyte activation or T-cell dysfunction. Different explanations 
for this difference can be considered. First, the follow-up period of ten weeks in the present 
study is relatively short, whereas most patients in the cross-sectional study were on the 
same cART longer than three months. Still, the life-span of platelets is short (<10 days) and 
several studies have shown effects of raltegravir intensification on viral replication and 
plasmatic coagulation within three months95,96. Nevertheless, platelets are produced by 
megakaryocytes and we cannot exclude an effect of cART on megakaryocytes, possibly via 
epigenetic modification or modifying mitochondrial function. Subsequent alterations in 
platelet reactivity may take longer and require a prolonged treatment switch. Second, cross-
sectional studies are prone for selection bias and confounders. Due to a relatively small 
sample size, the aforementioned cross-sectional study was not able to correct for possible 
confounders in a multivariate regression model or perform subgroup analyses. 
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in PLHIV, as found by us and reported by others32,33. Whether IL-17 disbalance contributes 
to development of cardiovascular disease is debated104. Our data suggest that normal 
T-cell renewal is disturbed in PLHIV with less naïve cells and an enrichment of terminally 
differentiated T cells with signals of clonal expansion. Correspondingly, we observed a 
reduction in ex vivo IFN-γ production capacity among PLHIV. This functional defect was 
associated with parameters of the HIV reservoir and could play a role in HIV persistence105,106 
and defective vaccination responses seen in PLHIV on stable cART107. 
Third, we describe different functional abnormalities in platelets and the plasmatic 
coagulation system. As mentioned above, the function of the coagulation and immune 
systems are tightly linked and both platelets and thrombin are not only important in 
bleeding and thrombosis, but also in the regulation of the different parts of the immune 
system16,108,109. 
A novel insight in this link is described in Chapter 7. We report that platelet microparticles 
inhibit further differentiation of Tregs into Th17 producing Tregs. Our finding that platelets 
microparticles from PLHIV showed reduced capacity to inhibit this process may underly 
the increased proportion of pro-inflammatory Th17-like CCR6+ Tregs that we found in 
PLHIV. Changes in platelet function may also contribute to thrombo-inflammation. In this 
thesis, we report that the mitochondrial content (mtDNApl) of platelets is reduced and that 
these lower mtDNApl levels are associated with platelet mitochondrial dysfunction and 
reduced energy supply. This mitochondrial dysfunction appeared to be long-lived as prior 
zidovudine users seemed to be more at risk for mitochondrial depletion. Since, platelets are 
short-lived (<10 days), an effect on megakaryocytes is plausible. Given that megakaryocytes 
produce the majority of circulating MPs110, mitochondrial alterations86 (and possibly 
epigenetic modifications111) of megakaryocytes could affect anti-inflammatory properties 
of microparticles in PLHIV. Regarding the plasmatic coagulation, thrombin generation was 
reduced in PLHIV despite increased plasma D-dimer concentrations. In summary, in our 
cohort of PLHIV on long-term cART, we did not find a procoagulant state in PLHIV. Although 
we corroborated multiple links between coagulation and inflammation in Chapters 4-6 and 
7-9, disturbances within the coagulation pathway itself seem to be limited compared to 
inflammatory processes. 
Developing directed therapies for these disturbances may improve the care for PLHIV. 
The next step is extrapolating our results towards the development of new treatment 
strategies. Currently HIV-care is shifting focus towards reducing AIDS and non-AIDS 
related comorbidities. Paramount is the early initiation of cART, mitigating most of the 
increased mortality associated with HIV5. However, this very early cART-strategy should be 
accompanied by efforts to minimize cART toxicity. 
General discussion and future perspectives
In this thesis immune and coagulation disturbances associated with HIV are described. 
Inflammation and coagulation are tightly linked and ‘thrombo-inflammation’ is increasingly 
recognized to play an important role in different conditions, including atherosclerosis and 
tumorigenesis18,102. These insights have provided a rationale for the development of anti-
inflammatory treatment strategies in the prevention of cardiovascular events as well as 
immune-based therapy for different malignancies. In line with this reasoning, the novel 
insights described in this thesis do not only increase our understanding of HIV pathobiology 
but may also provide leads for the development of immune-based therapies to prevent the 
long-term complications of HIV. 
This thesis shows that the regulation of the immune and coagulation system in long-term 
treated PLHIV is disturbed at several levels. First, within the innate immune compartment, 
monocyte responsiveness was increased with activation of the IL-1β pathway. Our data 
indicate a similar trained immunity phenotype in PLHIV with a stable increased cytokine 
production capacity with augmented pro-inflammatory pathways. Clinical implications 
of trained immunity have been shown in multiple diseases such as cardiovascular 
disease and diabetes26-29. Trained immunity is known to rely on epigenetic and metabolic 
reprogramming22-24 and can be induced by  infection, vaccines, pathogen-associated 
molecular patterns (PAMPs) but also cytokines and oxidized LDL22,103. HIV is frequently 
associated with impaired intestinal integrity and we postulate that leakage of β-glucan in 
the circulation, the most potent inducer of trained immunity known to date23, contributes to 
the trained immunity phenotype in PLHIV.  Serum concentrations of β-glucan were indeed 
increased in our PLHIV cohort, as also previously reported by others32-34. Future studies 
are warranted to investigate also the epigenetic and metabolic processes underlying the 
observed trained immunity phenotype in PLHIV.
Second, we found disturbances in the adaptive immune system, despite viral suppression. 
HIV primarily infects CD4+ T-cells and a lower proportion of CD4+ T cells alongside an 
expansion of CD8 cells were found in this cohort. Within CD4+ cells, we found higher levels of 
Th17 subsets with increased Th17/Treg ratios in PLHIV. Increased Th17/Treg ratios have been 
linked to cardiovascular disease and atherosclerosis60. Notably, the proportion of Th17-like 
CCR6+ Tregs was increased as well, further suggesting a pro-inflammatory state. In contrast, 
IL-17 production upon ex vivo stimulation was not different between PLHIV and controls, 
suggesting that the functional capacity of these cells is compromised. These cells may home 
to tissues, like the gut, where reduced number of Th17 cells are found in PLHIV, also during 
long-term cART42. Th17 cells are important to maintain intestinal integrity. Reduced mucosal 
immunity and increased intestinal permeability may contribute to the higher β-glucan levels 
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use is key in reducing morbidity in PLHIV112. At least 26 behavioural and 34 dietary 
supplement intervention studies have been registered to reduce HIV-related inflammation 
on clinicaltrials.gov. These lifestyle interventions should be accompanied by adequate 
cardiovascular risk management with regard to proper statin prescription and blood pressure 
control135. Reaching adequate LDL levels is important for cardiovascular risk management. 
Statins have also displayed pleiotropic effects on inflammation46 and were shown to 
modulate trained immunity in vitro136. Multiple intervention studies have shown beneficial 
effects of statin on inflammation - independent of cholesterol lowering46,137-140. The effect 
of the statin pitavastatin on clinical outcomes is currently evaluated in a large randomized 
controlled trial including 6500 PLHIV (REPRIEVE-trial; NCT02344290)137.  
Regarding possible platelet-directed therapies, aspirin is commonly prescribed for 
secondary prevention of CVD, with P2Y12 inhibition therapy for at least one year after 
myocardial infarction or stent insertion; monotherapy with P2Y12 inhibition is common 
practice after stroke141,142. However, long-term P2Y12 inhibition (e.g. clopidogrel) instead of 
aspirin for secondary prevention after myocardial infarction has received growing attention 
after favourable findings in recent meta-analyses143,144. Our finding that low-dose aspirin 
potentiates innate immune responses (Chapter 9), whereas P2Y12 inhibition does not or even 
may reduce inflammation. This supports the prioritization of studies including PLHIV for 
long-term P2Y12 inhibition instead of low-dose aspirin as secondary prevention. 
A strength of the current studies was the comprehensive use of a combination of ‘multi-
omics’ technologies with functional immune phenotyping, ex vivo validation experiments 
and the inclusion of validation cohorts. This offers a powerful tool to better understand the 
underlying biology associated with HIV infection.  However, several limitations need to be 
addressed. 
First, even though persistent inflammation has been extensively linked to non-AIDS related 
co-morbidities, we did not link these disturbances directly to clinical events. While linking 
these parameters to a clinical outcome is the golden standard, cardiac computed tomography 
(CT) for calcium scoring, PET imaging for vascular inflammation or intima-media thickness 
by ultrasound (IMT) could provide clinical intermediate outcomes. Nonetheless, the current 
set-up is still useful for hypothesis generation. These results could support the rationale for 
subsequent intervention studies to establish causality and evaluate clinical benefit. 
Second, the current PLHIV and control cohort differed in age and sex distribution. Hence, 
all analyses were corrected for these differences using multivariate analyses with sufficient 
sample size. Matching on age and sex is often preferred to reduce bias. Still, lifestyle factors, 
(e.g., smoking and substance-use) and co-medication may influence inflammation and 
Regarding this toxicity, the European AIDS Clinical Society (EACS) guidelines suggest to 
modify cART regimens in people at increased cardiovascular risk (10 year CVD risk >10%)112. 
These guidelines recommend replacing zidovudine and abacavir to other NRTIs or replacing 
a traditional cART regimen to a NRTI sparing regimen112. Abacavir has been linked to a 
higher risk for cardiovascular events82,113. We found that platelet reactivity was similar 
between abacavir users and non-abacavir users supporting findings of some researchers114,115 
but disputing findings of others114-118. A recent paper hypothesized that abacavir induces 
endothelial cell activation, which may lead to both platelet activation and increased 
plasmatic coagulation capacity115. Our present findings that abacavir is associated with 
increased thrombin generation support this hypothesis. 
In addition, NRTI-sparing regimens and avoiding zidovudine have been recommended to 
reduce mitochondrial dysfunction and limit oxidative stress85,94, which in turn may decrease 
the risk for cardiovascular disease86. Our present findings that mtDNApl is reduced in PLHIV 
and that clonal haematopoiesis, a known biomarker for CVD, is linked to reactive oxygen 
species in PLHIV support the importance of reducing oxidative stress and mitochondrial 
toxicity by cART modification. This may be achieved by replacing one or both NRTI that are 
presently the backbone of cART, by antiretroviral drugs from a different class. Currently, 
multiple studies with dual-drug regimens have shown non-inferiority compared to standard 
cART regimens for viral suppression119-121. Efforts to design and introduce NRTI sparing 
regimens should be given priority to mitigate NRTI associated toxitiy94. 
Persistent immune activation in thought to be a key factor in the long-term complications of 
HIV. Thus far, intervention studies with low-dose aspirin (COX-1 inhibition)100, COX-2 inhibition 
(NSAIDS)122,123, sevelamer124, methotrexate125,126, mesalamine127, (hydroxy)chloroquine128,129, 
rifaximin130, valganciclovir131, dipyramidole132 showed no or very modest effects on HIV-
related inflammation. IL-1β is a key pro-inflammatory cytokine in cardiovascular diseases 
and malignancies56,57,133. Therefore, modulating IL-1β and trained immunity may decrease 
the risk for cardiovascular disease and cancer in PLHIV51,54,55,134. Recently, panobinostat (a 
HDACi)44,45, a epigenetic modifier, and canakinumab (IL-1β  inhibition)54 showed potent 
anti-inflammatory properties in PLHIV. These findings are consistent with our findings in 
Chapter 2. Orally administrated treatments that specifically inhibit the IL-1β pathway, such 
as inflammasome inhibitors or colchicine may form an attractive alternative to subcutaneous 
injections52,58. However, the actual clinical benefit of the reduction in inflammation was not 
evaluated in these pilot-studies. In general, studies modulating inflammation in PLHIV with 
clinically relevant outcome parameters are scarce.
Besides cART modification and possible anti-inflammatory therapies, promoting a healthy 
lifestyle with a focus on smoking cessation, a healthy diet and reduction in substance-
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risk for cardiovascular disease as well. For example, HIV-uninfected men who have sex with 
men (MSM) showed increased inflammation and microbial translocation compared to non-
MSM145. Matching controls on all those factors is not feasible. Identifying subgroups and 
differences within PLHIV and providing sufficient information on those factors can overcome 
some of these issues and reduces the introduction of bias or overestimation of the effects of 
HIV itself.
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been performed previously146,147. Although a ‘multi-omics’ reduces the required sample size 
significantly17,148, the current sample size still limits our discovery rate. Finally, the inclusion 
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A larger and/or second multi-omics cohort would tackle most of these limitations. For that 
reason, a second cohort consisting of PLHIV are enrolled in four centers in the Netherlands 
(clinicaltrials.gov identifier: NCT03994835). This 2000HIV+ study will contain a discovery 
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In conclusion, HIV care has seen staggering advances over the last decades. Early and 
effective cART has transformed HIV from a deadly into a chronic condition with a near-
normal life expectancy7,8. Nonetheless, despite viral suppression there is ongoing immune 
dysfunction and inflammation, which may be an important target for therapy. In recent years, 
immune-directed and anti-inflammatory therapies are transforming cardiovascular risk 
management and treatment of malignancies. I hope the studies described in this thesis add 
to our understanding of immune and coagulation dysfunction in HIV and, as such, contribute 
to the identification of effective immune-based therapies for people living with HIV.
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Appendices - Nederlandse samenvatting
Factoren die van invloed zijn op de ontwikkeling van hart- en vaatziekten en kanker bij 
mensen met hiv zijn complex en omvatten de behandeling zelf, co-infecties (bijv. hepatitis 
C of CMV-infectie), voedingsstatus, levensstijlfactoren zoals roken en de timing van de start 
van behandeling. De onderliggende mechanismen zijn onvolledig begrepen. Het risico op 
deze aandoeningen wordt geassocieerd met ontsteking, onvolledig herstel van de afweer en 
verhoogde stollingsneiging. 
Het menselijk immuunsysteem kan worden onderverdeeld in een aangeboren en een 
verworven immuunsysteem. Het aangeboren immuunsysteem bestaat uit monocyten, 
macrofagen, dendritische cellen en bloedplaatjes. De aangeboren immuuncellen reageren 
niet-specifiek op externe stimuli en produceren ontstekingsmediatoren zoals cytokinen 
(IL-6, IL-1beta, TNF-alfa) en chemokinen (CCL5, RANTES) die (systemische) ontstekingen 
veroorzaken. Deze ontstekingsmediatoren zijn in verband gebracht met hart- en vaatziekten, 
kanker en het risico op overlijden bij mensen met hiv.
Het verworven immuunsysteem bestaat voornamelijk uit T- en B-cellen. Deze cellen zorgen 
voor een specifieke respons en herbergen een (klassiek) immunologisch geheugen. Ondanks 
antiretrovirale therapie, is het herstel van CD4+cel aantal na behandeling vaak onvolledig, 
wat leidt tot langdurige uitputting en veroudering van CD4+cellen. CD4-cellen zijn belangrijk 
voor de afweer van de darmen en daarom hebben deze veranderingen hebben ook negatieve 
effecten op de afweer van de darmen. B-cellen zijn belangrijk voor antistofproductie, en ondanks 
succesvolle behandeling van een hiv-infectie is er aanhoudende B-cel disfunctie en verminderde 
werking van vaccinaties bij mensen met hiv. Alle compartimenten van het immuunsysteem zijn 
door al deze verstoringen, ondanks succesvolle onderdrukking van het virus, niet meer in balans. 
Deze disbalans lijdt tot gezondheidsproblemen bij mensen met hiv. 
Het human functional genomics-project (HFGP) integreert deze grote hoeveelheid data 
(-omics) en heeft tot doel ons begrip van de variabiliteit van afweer en ontsteking in de 
menselijke populatie te begrijpen. Deze aanpak is al succesvol gebleken bij niet-hiv-
geïnfecteerde personen. Het leverde nieuwe inzichten op over de invloed van gastheer- en 
omgevingsfactoren, genetische factoren en darmflora op individuele afweerreacties. Een 
vergelijkbare benadering kan mogelijk de determinanten van aanhoudende ontsteking 
bij mensen met hiv ontrafelen en een basis bieden voor nieuwe interventies gericht op het 
verbeteren van de gezondheid van mensen met hiv. In dit proefschrift bieden we de eerste 
stappen van deze benadering door veranderingen in stolling, bloedplaatjesfunctie en 
afweerreactie bij mensen met hiv te onderzoeken. Integratie en koppeling van verschillende 
(patho)fysiologische processen kunnen de basis leggen voor grotere -omics-gebaseerde 
projecten die de nieuwe uitdagingen in de zorg en genezing van hiv aanpakken. 
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Het Humaan immunodeficiëntievirus 1 (HIV-1) werd in 1983 ontdekt als de veroorzaker van 
het verworven immuundeficiëntiesyndroom (AIDS). Hiv infecteert specifieke afweercellen 
die de clusterdifferentiatie (CD)4-receptor tot expressie brengen, waaronder T-cellen (CD4+ 
T-cellen), monocyten/macrofagen en dendritische cellen.
Een primaire hiv-infectie kan 2-4 weken na blootstelling worden waargenomen en 
presenteert zich meestal als een ‘griepachtig’ syndroom, hoewel sommige personen geen 
significante symptomen ervaren. Deze acute hiv-infectie wordt gevolgd door een periode van 
weinig klinische symptomen (latente fase) of chronische hiv-infectie gedurende 3-20 jaar. 
Tijdens deze fase nestelt het virus zich in het genetisch materiaal van onze afweercellen. Het 
virus nestelt zich daarmee levenslang in het menselijk lichaam en wordt het hiv-reservoir 
genoemd. Zonder behandeling veroorzaakt het natuurlijke verloop van hiv-infectie een 
daling van CD4+ T-cellen, wat leidt tot ernstige afweerstoornis.  Dit leidt tot de ontwikkeling 
van opportunistische infecties en specifieke vormen van kanker (bv. Kaposisarcoom). Dit 
syndroom werd AIDS genoemd in de jaren 80. AIDS ging destijds gepaard met een zeer 
slechte prognose met een levensverwachting tussen 6-12 maanden.
In 1987 werd de eerste antiretrovirale therapie (zidovudine) voor de behandeling van 
HIV goedgekeurd. Het aanvankelijke gebruik als monotherapie resulteerde in een snelle 
ontwikkeling van resistentie. Dit belemmerde een succesvolle behandeling op lange termijn. 
De introductie van meerdere andere antiretrovirale geneesmiddelen in het midden van de 
jaren negentig maakte de weg vrij voor de introductie van (zeer effectieve) antiretrovirale 
combinatietherapie (cART), die meestal bestond meestal uit 3 verschillende antiretrovirale 
middelen. Deze combinatie verhinderde de ontwikkeling van resistentie, waardoor de 
werkzaamheid van hiv-behandeling opmerkelijk toenam en de prognose van een hiv-
infectie sterk verbeterde. Ondanks deze grote vooruitgang hebben mensen met hiv een 
aanhoudend verhoogd risico op kanker en hart- en vaatziekten met bijbehorend lagere 
levensverwachting. Dit risico werd in verband gebracht met het laagste bereikte CD4-aantal 
(CD4-nadir) en reflecteert daarmee ernst van afweerstoornis voor start van behandeling. Dit 
suggereert blijvende schade bij het uitstellen van de hiv-behandeling. In 2015 toonde een 
belangrijke hiv-studie aan dat directe start inderdaad de levensverwachting sterk verbeterde. 
Deze resultaten verenigde de voordelen voor individuele patiënten met voordelen voor de 
volksgezondheid, aangezien virale onderdrukking als gevolg van antiretrovirale therapie 
ook het risico op overdracht van HIV tot bijna nul vermindert. Momenteel schat de 
Wereldgezondheidsorganisatie (WHO) dat 38 miljoen mensen met hiv leven, van wie 25,4 
miljoen met antiretrovirale therapie worden behandeld.
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In Hoofdstuk 4 rapporteren wij het optreden van somatische mutaties in ons DNA die leiden 
tot klonale hematopoëse in mensen met hiv. Hematopoëse is de productie van bloedcellen. 
Klonale hematopoëse is de aanwezigheid van een kloon van gemuteerde bloedcellen en 
komt voor bij gezonde individuen uit de algemene populatie. Het risico op een kloon neemt 
toe met de leeftijd. Deze klonen zijn geassocieerd met het risico op hart- en vaatziekten en 
hematologische maligniteiten in de algemene populatie. Wij toonden aan dat mensen met 
hiv meer klonale hematopoëse hebben en dat dit geassocieerd is met ernst van eerdere 
infectie (laagste CD4-getal), hiv-reservoir en leeftijd. Daarnaast was klonale hematopoëse 
ook geassocieerd met stollingsactiviteit in mensen met hiv.
Eerdere studies hebben aangetoond dat D-dimeer concentraties verhoogd zijn bij mensen 
met hiv en verband houden met mortaliteit en het optreden van hart- en vaatziekten. 
D-dimeer is een biomarker van stolling. Tot op heden zijn de gepubliceerde gegevens 
over de stollingscapaciteit bij mensen met hiv tegenstrijdig. Het vermogen van plasma 
om trombine te vormen is een belangrijke factor in stollingscascade. Trombine productie 
kan worden gemeten in een gestandaardiseerde setting. In Hoofdstuk 5 beschrijven 
wij trombine productie in ons 200HIV-cohort en toonden wij aan dat het gebruik van 
abacavir (een antiretroviraal middel) onafhankelijk geassocieerd was met een verhoogde 
stollingscapaciteit. Abacavir is in het verleden gelinkt aan hart- en vaatziekten. 
Bloedplaatjes spelen naast plasmafactoren ook een belangrijke rol in stolling en 
wondgenezing. Naast deze rol, spelen zij ook een belangrijke rol bij ontsteking en 
ontwikkeling van hart- en vaatziekten. Bloedplaatjes hebben geen kern maar beschikken over 
mitochondriaal DNA (mtDNA). Mitochondriën zijn belangrijk voor de energiehuishouding 
van alle cellen in ons lichaam. Mitochondriële toxiciteit is een belangrijk onderliggend 
mechanisme voor het optreden van de belangrijkste bijwerkingen bij bepaalde groep van 
antiretrovirale middelen (NRTI).  In Hoofdstuk 6 laten wij zien dat bloedplaatjes van mensen 
met hiv minder mtDNA bevatten. Deze verlaging is het meest uitgesproken bij mensen dien 
in het verleden zidovudine gebruikt hebben. Zidovudine is één van de eerste antiretrovirale 
middelen en is sterk gelinkt aan mitochondriële toxiciteit. Deze mitochondriële disfunctie 
leidt in bloedplaatjes tot een lager energieniveau en zorgt daarmee ook voor verminderde 
functie van bloedplaatjes. Mitochondriële disfunctie is geassocieerd met ontsteking. 
In Hoofdstuk 7-9 beschrijven we aanvullende studies om de mechanismen die 
bloedplaatjesfunctie koppelen aan ontsteking, afweer en antiretrovirale medicatie te 
onderzoeken. Een eerdere studie van onze groep suggereerde dat personen met een op 
raltegravir gebaseerd regime een verminderde bloedplaatjesfunctie hadden in vergelijking 
met personen met een ander antiretroviraal regime. 
In Hoofdstuk 2 hebben we de aanwezigheid van ontsteking bij mensen met hiv met 
langdurige virale onderdrukking aangetoond. We hebben daarnaast de functie van 
circulerende immuuncellen onderzocht.  We ontdekten dat stimulatie van circulerende 
immuuncellen resulteerde in een aanhoudende verhoogde productie van cytokines van 
monocyten (mn. IL-1β). Deze verhoogde productie is geassocieerd met aanhoudende 
ontsteking. Dit wijst op een verband tussen veranderingen in de monocyten functie en 
systemische ontsteking bij mensen met HIV. Deze veranderde functie van monocyten bleek 
stabiel in de tijd. Monocyten spelen een cruciale rol bij de ontwikkeling van atherosclerose 
(aderverkalking).  Deze cellen kunnen na blootstelling aan endogene en microbiële 
structuren opnieuw worden geprogrammeerd door veranderingen aan te brengen op 
epigenetisch (veranderingen aan de bereikbaarheid van het DNA) niveau. Dit proces wordt 
‘getrainde afweer of immuniteit’ genoemd. Het getrainde fenotype maakt monocyten met 
een langdurige verbeterde functionele toestand met een versterkte afweerreactie (bijv. IL-
6- en IL-1β-productie) op een tweede stimulus. Een bekende veroorzaker van deze getrainde 
afweer is β -glucan, een onderdeel van schimmels. We vonden dat β -glucan verhoogd was 
bij mensen met HIV en met name in de groep met meest pro-inflammatoire monocytfunctie. 
Klinische consequenties van getrainde afweer zijn aangetoond bij meerdere ziekten zoals 
hart- en vaatziekten en diabetes. Onze gegevens wijzen op een vergelijkbaar getraind afweer 
in mensen met hiv.
In Hoofdstuk 3 hebben we ons gericht op de samenstelling van de circulerende afweercellen 
door 108 verschillende celtypes bij mensen met hiv te onderzoeken en deze te vergelijken 
met gezonde controles. Ondanks langdurig antiretrovirale therapie, vertoonde mensen 
met hiv significante verandering in de verhouding van verschillende immuuncellen. 
De verhouding tussen pro-inflammatoire Th17-cellen (een specifieke CD4 T-cel) en 
onderdrukkende regulatoire T-cellen (Treg) moet in evenwicht blijven om functionele afweer 
te behouden. Veranderde verhoudingen zijn beschreven bij onbehandelde hiv-infectie 
(lagere Th17/Treg), auto-immuunziekte en kanker (hogere Th17//Treg). 
Deze veranderingen in immuuncel aantallen vertaalden zich ook in functionele 
veranderingen in de verworven afweer met verminderde cytokineproductie door T-cellen. 
Parameters van het hiv-reservoir correleerden met deze veranderingen en met verschillende 
circulerende afweercellen. Naast het hiv-reservoir droegen ook CMV-co-infectie (virus), ernst 
van ziekte bij start van behandeling, leeftijd, geslacht en roken bij aan de samenstelling van 
afweercellen in ons menselijk lichaam. Deze verstoringen kunnen een rol spelen bij het in 
stand houden van het hiv-reservoir. Vervolgonderzoek zal zich focussen op het moduleren 
van deze veranderingen om hiv-genezing dichterbij te brengen. 
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Interventiestudies met meerdere ontstekingsremmers, bloedverdunners, cholesterol-
verlagers of antivirale medicijnen lieten geen of zeer bescheiden effecten op hiv-
gerelateerde ontsteking zien. IL-1β is een belangrijke pro-inflammatoire cytokine bij hart- en 
vaatziekten en maligniteiten. Daarom kan het moduleren van IL-1β en getrainde immuniteit 
het risico op hart- en vaatziekten en kanker bij mensen met hiv mogelijk verminderen. 
Onlangs vertoonden panobinostat, een epigenetische modulator, en canakinumab (IL-
1β-remming) krachtige ontstekingsremmende eigenschappen bij mensen met HIV. Deze 
bevindingen komen overeen met onze bevindingen in Hoofdstuk 2. Oraal toegediende 
behandelingen die specifiek de IL-1β-route remmen, zoals anti-jicht medicijn colchicine, 
kunnen een aantrekkelijk alternatief vormen voor injecties. Het werkelijke klinische voordeel 
van de vermindering van ontsteking werd echter niet geëvalueerd in deze relatief kleine 
studies. Grote studies zijn hiervoor in de toekomst nodig. Het bevorderen van een gezonde 
levensstijl met een focus op stoppen met roken, een gezond dieet en vermindering van het 
middelengebruik zijn verder ook van cruciaal belang bij het verminderen van de morbiditeit 
bij mensen met hiv. 
De kracht van uitgebreide karakterisering van de afweer en ontstekingsreactie van mensen 
met hiv heeft in dit proefschrift geleidt tot nieuwe inzichten. Een vervolgstudie met 2000 
deelnemers is reeds gestart om onze bevindingen te bevestigen en nieuwe analyses toe te 
voegen met als doel om nieuwe invalshoeken te vinden ter verbetering van de zorg voor 
mensen met hiv. Dit tweede cohort, bestaande uit mensen met hiv ingeschreven in vier 
centra in Nederland, zal ons begrip van hiv verder verbeteren.
Samenvattend: de hiv-zorg heeft de afgelopen decennia enorme vooruitgang geboekt. Vroege 
en effectieve antiretrovirale therapie heeft hiv getransformeerd van een dodelijke ziekte naar 
een chronische aandoening met een bijna normale levensverwachting. Desalniettemin is er, 
ondanks virale onderdrukking, aanhoudende ontsteking en bijbehorende veranderingen in 
de afweer. Deze afwijkingen kunnen een belangrijk doelwit voor therapie zijn en daarmee 
ziekten zoals kanker en hart en vaatziekten voorkomen. In de afgelopen jaren hebben 
deze ontstekingsremmende therapieën het cardiovasculaire risico en de behandeling 
van maligniteiten getransformeerd. Ik hoop dat de studies die in dit proefschrift worden 
beschreven, bijdragen aan ons begrip van afweer en stollingsdisfunctie bij mensen met hiv 
en als zodanig bijdragen aan de identificatie van effectieve immuungebaseerde therapieën 
voor mensen die leven met hiv.
Hoofdstuk 7 rapporteert de resultaten van een gerandomiseerde gecontroleerde studie 
waarin de effecten zijn onderzocht van het overschakelen van hiv-behandeling naar een 
regime gebaseerd op de integraseremmer raltegravir. We laten zien dat het overschakelen 
naar raltegravir gedurende tien weken de bloedplaatjesfunctie niet veranderde. 
Bloedplaatjes moduleren ons immuunsysteem door direct contact met andere andere 
immuuncellen. In Hoofdstuk 8 hebben we het effect van bloedplaatjes op regulerende 
T-cellen (Treg) onderzocht. Deze anti-inflammatoire cellen kunnen ook pro-inflammatoire 
kenmerken ontwikkelen. Bloedplaatjes kunnen deze ontwikkeling remmen en voorkomen 
dat deze pro-inflammatoire eigenschappen ontwikkelen. Bloedplaatjes van mensen 
met hiv kunnen minder goed binden aan Tregs, wat zou kunnen leiden T-cellen die meer 
ontstekingsmediatoren produceren zoals IFN-gamma en IL-17.
Er zijn verschillende geneesmiddelen gebruikt om de bloedplaatjesfunctie te remmen 
en daarmee hart- en vaatziekten te voorkomen. Een lage dosis acetylsalicylzuur (ASA of 
aspirine) wordt traditioneel gebruikt voor de remming van bloedplaatjes. Aspirine wordt 
steeds vaker gecombineerd met of vervangen door P2Y12-remmers, zoals clopidogrel en 
ticagrelor. In Hoofdstuk 9 hebben we de effecten geëvalueerd van aspirine, ticagrelor en 
clopidogrel op ontsteking tijdens menselijke endotoxemie, een bekend model om ontsteking 
bij mensen te bestuderen. In dit model wordt in gezonde vrijwilligers een onderdeel van 
de celwand van een bacterie ingespoten waarbij er een (kortdurende) ontstekingsreactie 
ontstaat, vergelijkbaar met een bloedvergiftiging. Hoewel het effect van P2Y12-remming 
op ontsteking beperkt was, versterkte een zevendaagse kuur met een lage dosis aspirine 
de ontstekingsreactie (bijv. TNFα), hoogstwaarschijnlijk door het remmen van een enzym 
(COX-1) in bloedplaatjes. Aspirine staat algemeen bekend om zijn ontstekingsremmende 
eigenschappen en is daarom gebruikt voor de behandeling van aanhoudende hiv-
gerelateerde ontstekingen, zij het met beperkt succes. Onze gegevens bieden een verklaring 
waarom een  lage dosis aspirine in eerdere onderzoeken niet resulteerde in een detecteerbaar 
ontstekingsremmend effect en mogelijk zelfs de ontsteking bij ontstekingsziekten verhoogt.
Het ontwikkelen van gerichte behandeling voor aanhoudende ontsteking en afweerdisfunctie 
in mensen met hiv kan de zorg voor deze mensen sterk verbeteren. De volgende stap is het 
extrapoleren van onze resultaten naar de ontwikkeling van nieuwe behandelstrategieën. 
Vooralsnog is de belangrijkste stap de vroege start van antiretrovirale therapie, waardoor het 
grootste deel van de verhoogde mortaliteit geassocieerd met hiv wordt verminderd. Toch zal 
de laatste stap om de levensverwachting van mensen met hiv volledig te normaliseren ook 
gerichte therapie op immuundisfunctie moeten worden gericht.
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upon reasonable request. All left-over samples are stored at M379.01; freezer 9; rack 9 at -80 
degrees Celsius (with exact lay-out in folder: H:)\\umcfs073\aigdata$\ExpIntGnk\general\10 
storage databases\Freezers.  Furthermore, samples of the HFGP cohort are also stored at 
the Radboud biobank and available upon reasonable request. Data for Chapters 2-6 were 
analysed using R 3.6. Data from Chapters 7-10 were analysed with SPSS Version 22 (SPSS 
Inc.), Graphpad Prism 5 or Kaluza Software (Beckman-Coulter).
1 Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A et al. The FAIR Guiding Principles for 
scientific data management and stewardship. Sci Data 3, 160018, doi:10.1038/sdata.2016.18 (2016).
Research Data Management
The data obtained for this thesis are stored according to the FAIR principles to optimize 
Findability, Accessibility, Interoperability and Reusability1. Raw and processed data 
for Chapter 2-7 were stored digitally on a local server of the department of Internal 
Medicine (H:)\\umcfs073\aigdata$\ExpIntGnk\500FG_project, which is backed-up daily 
on the Radboudumc server. Accessibility was limited to researchers directly involved in the 
200HIV/500FG projects within the human functional genomics project (HFGP). For Chapter 
8 and 9, data of participants were stored (H:)\\umcfs073\aigdata$\ExpIntGnk\Employees\ 
WoutervanderHeijden\RAPID. Data for chapter 10 were stored (H:)\\umcfs073\aigdata$\
ExpIntGnk\Employees\ WoutervanderHeijden\TICA.  All human studies described in this 
thesis were conducted according to the principles of the declaration of Helsinki and were 
approved by the Medical Ethics Committee on Research Involving Human Subjects, region 
Arnhem Nijmegen, Nijmegen, The Netherlands. Prior to enrolment all participants gave 
written informed consent.  In chapter 2-7, participants received electronic questionnaires 
via Castor EDC (Amsterdam, The Netherlands).  Data management and monitoring 
were performed within Castor EDC for all studies involving human subjects. The data 
will be saved for 15 years after termination of the study as per informed consent in case of 
Chapter 2-7 (February 2032), Chapter 8-9 ( November 2029) and Chapter 10 (November 
2030). An independent Data Safety Monitoring Board was (DSMB) was established for 
the study described in Chapter 10 to perform safety  surveillance and interim analyses 
on safety data halfway through the study. Using these patient data in future research is 
only possible within the framework of the Human functional genomics project (www.
humanfunctionalgenomicsproject.org). If additional questions arise  a renewed informed 
consent should be obtained as recorded in the informed consent. Digital copies of the 
informed consent forms are stored at (H:)\\umcfs073\aigdata$\ExpIntGnk\ 500FG_project. 
Hard copies are stored in a locked closet (M379.01.152) to which only Wouter van der Heijden 
and Lisa Van de Wijer have access. The handling of subject data in all studies complied with 
the Dutch Personal Data Protection Act (in Dutch: De Wet Bescherming Persoonsgegevens, 
Wbp). The privacy of the participants was warranted by use of encrypted and unique 
individual subject codes. The coding information is stored digitally separately from data 
and informed consent forms which has been secured with a password known by Wouter 
van der Heijden and Lisa Van de Wijer. Data generated in this thesis are part of published 
articles. RNAseq data described in chapter 2 have been deposited in the public functional 
genomics data repository GEO database with accession number GSE160184. Immunological 
data (immunophenotyping and cytokine production) and neuropsychiatric symptom 
questionnaire data are deposited at the DANS EASY archive of the Radboud university 
which is certified with the CoreTrustSeal, identifier is available upon request from Wouter 
van der Heijden or Lisa Van de Wijer. and files are available from the corresponding author 
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TEACHING ACTIVITIES
Lecturing
Lecturer in bachelor course Severe Infectious Diseases 2015-2018 1.5
Lecturer in minor Global Health & Infectious Diseases 2017 0.5
Supervision of internships / other
Supervision Medical student (total 3 months) 2016 1.0
Supervision Biomedical sciences student (total 6 months) 2016 2.0
Supervision Biomedical sciences student (total 6 months) 2017 2.0
TOTAL 39.25
PhD Portfolio
Name PhD candidate: W.A. van der Heijden
Department: Internal Medicine
Graduate School: RIHS
PhD period: 01-10-2014 – 31-12-2020
Promotor(s): Prof. A.J.A.M. van der Ven
                                  Prof. dr. M.G. Netea




Radboudumc Introduction day 2014 0.5
RIHS specific introductory course 2015 1.0
BROK course  2015 2.0
Scientific integrity course 2016 1.0
Basic course in R, Erasmus MC 2016 2.5
BROK cursus (NFU) 2016 2.0
Academic writing course 2017 2.0
Post-CROI Conference 2019 0.25
Seminars & lectures
Radboud Research Rounds (monthly) 2015-2019 1.0
Cytokine meetings Internal Medicine (weekly; incl. 5 x oral) 2015-2019 4
NVHB meeting (oral) 2017 0.5
Symposia & congresses
EACS 2013, Brussels (Oral) 2013 1.0
Radboud Science Day Infectious Diseases (laptop) 2015 0.5
Retraite AMC-Radboudumc (laptop) 2016 1
International Platelet meeting 2016, Wellesley (Oral and Poster) 2016 2
ISLH conference, Milan (Oral) 2016 1.5
Summer Frontiers - Systems Biology of Innate Immunity (poster) 2016 1.5
New Frontiers Symposium on the Microbiome , Nijmegen 2017 1.0
Retraite AMC-Radboudumc (laptop) 2017 1
CROI Conference 2017, Seattle (Poster) 2017 2
Radboud Science Day Infectious Diseases (oral) 2018 0.5
Frontiers in Innate Immunity and Inflammation (Poster), Cluj 2018 1.5
 AIDS Conference 2020, San Francisco digital (poster) 2020 2
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